Specific conjugation of antibodies
The use of zinc amino complexes for selective disulfide bond reduction in antibodies achieves homogeneous ADCs with improved payload distribution and reduced toxicity, addressing the inefficiencies of current ADC preparation methods.
Patent Information
- Application Number
- JP2024526535
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2021-11-03
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for preparing antibody-drug conjugates (ADCs) face challenges such as dose-limiting toxicity, batch-to-batch inconsistency, and inefficient site-specific conjugation, leading to heterogeneous distribution of payloads within antibodies, which affects their pharmacokinetic properties and efficacy.
A method involving the use of transition metal cation-amino complexes, specifically zinc amino complexes, to selectively reduce disulfide bonds between the heavy and light chains of antibodies, followed by conjugation with a drug/linker complex, and subsequent oxidation and quenching steps to achieve homogeneous ADCs with improved payload distribution.
The method results in ADCs with over 80% payload conjugation to the Fab region, enhancing pharmacokinetic properties and reducing in vivo toxicity compared to conventional methods, while maintaining batch consistency and manufacturability.
Smart Images

Figure 2024541058000955 
Figure 2024541058000956 
Figure 2024541058000957
Abstract
Description
[Technical Field]
[0001] The present invention relates to a method for preparing homogeneous antibody or antibody-like protein molecule / agent conjugates via linkage of sulfur groups at specific cysteine sites in the antibody. The present invention also relates to a method for preparing the conjugates in a specific manner, including generating specific thiol groups on the antibody or antibody-like protein agent, followed by reaction with a drug / conjugate complex, or generating specific thiol groups on the antibody or antibody-like protein agent, and simultaneously synthesizing the conjugate-drug assembly and conjugating it to the protein in one pot. The present invention also relates to methods for using the homogeneous conjugates in the targeted prevention or treatment of cancer, infectious diseases, and immune disorders. [Background technology]
[0002] Currently, the pace of ADC development is accelerating, with the number of clinical trials increasing more than threefold over the past five years. Seven of the 12 commercially available ADCs have been approved by the U.S. FDA in the past two years, highlighting the enthusiasm for this transformative cancer treatment. Conjugation of the payload to the antibody via a conjugate is a critical aspect that determines the quality, safety, efficacy, and overall success of the ADC (Non-Patent Documents 1 and 2). A report published by the U.S. FDA stated that for most ADCs currently in clinical development, dose-limiting toxicity (DLT) appears to be unrelated to the target antigen but is driven by the payload / conjugate complex (Non-Patent Document 3). The conjugate and conjugation site of an ADC are also known to play an important role in determining the stability of the ADC during preparation and storage, as well as the severity of toxicity in the blood circulation in vivo (Non-Patent Document 4).
[0003] Therefore, one of the current research and development directions for ADC chemistry and design is the expansion of conjugation chemistry to address the issues of the linker-payload compartment and dose-limiting toxicity (DLT) of ADCs against target diseases (Non-Patent Documents 5 and 6). Currently, a major research and development effort is to establish the development of novel and reliable site-specific ADC conjugation methods that are expected to have longer circulating half-lives, higher therapeutic efficacy, reduced off-target toxicity, and narrower in vivo pharmacokinetic (PK) properties, as well as improved batch-to-batch consistency in the manufacturing process, in order to extend the therapeutic window (TW) of ADCs (Non-Patent Documents 6-13).
[0004] In recent years, several methods have been developed for site-selective preparation of ADCs (Non-Patent Document 14). These methods include the introduction of unpaired cysteines into antibodies, such as engineered reactive cysteine residues, called THIOMAB technology by Genentech (Non-Patent Documents 15 and 16, Patent Documents 1 to 5), and the use of Streptoverticillium These include genetic introduction of glutamine tags using mobaraense transglutaminase (mTG) (Non-Patent Documents 12 and 17, Patent Document 6) or microbial transglutaminase (MTGase) (Non-Patent Document 18, Patent Documents 7 and 8), introduction of thiol fucose (Non-Patent Document 19), introduction of unnatural amino acids by mutagenesis (Non-Patent Documents 20-23, Patent Documents 9-19), introduction of selenocysteine into antibodies (Non-Patent Document 24, Patent Document 20), conversion of cysteine located in the CXPXR consensus sequence to formylglycine (FGly) by formylglycine generating enzyme (FGE) (Non-Patent Document 25, Patent Documents 21-25), introduction of sialic acid by glycoengineering using galactosyl- and sialyltransferases (Non-Patent Document 26 and Patent Document 26), and introduction of cyclopropenes of lysine followed by Diels-Alder cycloaddition with tetrazine derivatives in conjugation to give 1,4-dihydropyridazines (Non-Patent Document 27). However, the above methods require reoptimization of antibody engineering processes and cell culture conditions, and usually suffer from problems such as reduced protein expression, low conjugate yield, and limited conjugation sites. Therefore, several simple homogeneous conjugation methods based on recombining the reduced interchain disulfide bonds of native antibodies have been investigated, such as the use of bromo- or dibromomaleimides (Non-Patent Document 28) or dibromopyridazinediones (Non-Patent Documents 29 and 30), called next-generation maleimides (NGMs), or the application of bis-alkylating reagents via a three-carbon atom bridge (Non-Patent Document 31, Patent Documents 27 and 28), or an arylenedipropiolonitrile (ADPN) molecule (Non-Patent Document 32).Recently, Coumans et al. used 2-(diphenylphosphine)-benzenesulfonic acid (diPPBS) as a reducing agent to reduce only the designed cysteines in antibodies without disrupting the interchain disulfide bonds for the preparation of ADCs (Non-Patent Document 33). Wuxi Biologics Co., Ltd. has developed a method to selectively control the reduction of cysteines in antibodies, which are then reacted with payloads containing maleimide conjugates, to improve the uniformity of ADC production. 2+ ions (ZnCl in buffer solution) were applied (Patent Document 29). However, most antibodies are stored in phosphate-based buffer solutions such as PBS buffer, and the solubility constant of zinc phosphate at neutral or basic pH is 9.1 × 10 -33 Therefore, zinc cations rapidly precipitate in phosphate buffer to form zinc phosphate (Martin, R. Bruce. "Solubility and Solubility Products (references 34 and 35)," Non-Patent Documents 36, 37 and 38). Therefore, when ZnCl2 is used for antibody reduction, the amount of phosphate anion and the pH of the buffer must be precisely controlled to avoid the formation of zinc phosphate precipitates. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] U.S. Patent No. 8,309,300 [Patent Document 2] U.S. Patent No. 7,855,275 [Patent Document 3] U.S. Patent No. 7,521,541 [Patent Document 4] U.S. Patent No. 7,723,485 [Patent Document 5] International Publication No. 2008 / 141044 [Patent Document 6] U.S. Patent No. 8,871,908 [Patent Document 7] U.S. Patent Application Publication No. 2013 / 0189287 [Patent Document 8] U.S. Patent No. 7,893,019 [Patent Document 9] U.S. Patent No. 8,778,631 [Patent Document 10] U.S. Patent Application Publication No. 2010 / 0184135 [Patent Document 11] International Publication No. 2010 / 081110 [Patent Document 12] International Publication No. 2006 / 069246 [Patent Document 13] International Publication No. 2007 / 059312 [Patent Document 14] U.S. Patent No. 7,332,571 [Patent Document 15] U.S. Patent No. 7,696,312 [Patent Document 16] U.S. Patent No. 7,638,299 [Patent Document 17] International Publication No. 2007 / 130453 [Patent Document 18] U.S. Patent No. 7,632,492 [Patent Document 19] U.S. Patent No. 7,829,659 [Patent Document 20] U.S. Patent No. 8,916,159 [Patent Document 21] U.S. Patent No. 7,985,783 [Patent Document 22] U.S. Patent No. 8,097,701 [Patent Document 23] U.S. Patent No. 8,349,910 [Patent Document 24] U.S. Patent Application Publication No. 2014 / 0141025 [Patent Document 25] U.S. Patent Application Publication No. 2010 / 0210543 [Patent Document 26] U.S. Patent Application Publication No. 2014 / 0294867 [Patent Document 27] International Publication No. 2013 / 190272 [Patent Document 28] International Publication No. 2014 / 064424 [Patent Document 29] International application No. PCT / CN2020 / 075162
Non-licensed literature
[0006]
Non-patent document 1
Non-patent document 2
Non-patent document 3
Non-patent document 4
Non-patented document 5
Non-patent document 6
Non-patent document 7
Non-patent document 8
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
Non-licensed Document 14
Non-licensed Document 15
Non-licensed Document 16
Non-licensed Document 17
Non-licensed Document 18
Non-licensed Document 19
Non-licensed Document 20
Non-patent document 21
Non-patent document 22
Non-patent document 23
Non-patent document 24
Non-patented document 25
Non-patent document 26
Non-patent document 27
Non-patent document 28
Non-patent document 29
Non-patent document 30
Non-patent document 31
[0007] We have disclosed several conjugation methods for re-crosslinking pairs of thiol groups from reduced interchain disulfides in native antibodies, such as using bromomaleimide and dibromomaleimide linkers ( WO 2014 / 009774 ), 2,3-disubstituted succinic acid / 2-monosubstituted / 2,3-disubstituted fumaric acid or maleic acid linkers ( WO 2015 / 155753 , WO 2016 / 596228 ), acetylenedicarboxyl linkers ( WO 2015 / 151080 , WO 2016 / 596228 ), hydrazine linkers ( WO 2015 / 151081 ), and acryloylpropyl linkers ( WO 2018 / 086139 ). In this application, we have expanded the scope of our earlier patent application to the preparation of more homogeneous conjugates through the controlled selective reduction of disulfide bonds between antibodies, followed by or simultaneously conjugation under the coordination of zinc amino complexes / chelate complexes. Zinc amino complexes offer significant advantages over ZnCl2 in coordinating the reduction of disulfide bonds in antibodies. First, zinc amino complexes are much bulkier than ZnCl2, allowing for more spatially selective insertion into specific positions (e.g., more specifically, the position of the disulfide bond between the heavy and light chains of an IgG1 antibody). Second, zinc amino complexes are more stable in aqueous solutions; for example, the stability constant of the zinc ammonia complex ion is 2.9 x 10 9(https: / / chempedia.info / info / stability / ), which slows precipitation in neutral pH phosphate buffer. More importantly, the use of zinc amino complexes reduces the disulfide bonds between the light and heavy chains of IgG antibodies in stoichiometric proportions without damaging the disulfide bonds between the heavy chains (hinge region) of the antibody. Our previous data (WO2016 / 059622) and other research results (S. Shao, et al., Bioorg Med Chem Lett. 2018, 28, 1363) have shown that bis-alkylation of two adjacent thiols proceeds more easily within the heavy chain of the hinge region than conjugation between interchain disulfide bonds. Therefore, bis-alkylation of two geometrically adjacent thiols can be achieved more specifically. In summary, the conjugation strategy of the present invention has robust manufacturability, enabling the production of high-yield, uniform ADCs without the need for antibody engineering, thereby resolving a key shortcoming of current ADC preparation methods. This conjugation strategy can be directly applied to other antibody-like proteins, and the resulting homogeneous ADCs exhibit improved pharmacokinetic properties, better efficacy, and reduced in vivo toxicity compared to conventional heterogeneous ADCs. [Means for solving the problem]
[0008] The present invention provides a conjugation method that improves the homogeneity of antibody conjugates or antibody-like protein conjugates, particularly antibody-drug conjugates (ADCs), in which 75% or more of the payload (drug) is specifically bound to the disulfide bond between the heavy and light chains of the antibody.
[0009] This homogeneous conjugation method involves three key steps: (a) providing an effective amount of a transition metal cation-amino chelate / complex (M(NR1R2R3)) to selectively reduce interchain disulfide bonds in the antibody or antibody-like protein to generate sulfhydryl groups; m1 m2+incubating an antibody or antibody-like protein, particularly an IgG antibody, in a buffer system (e.g., PBS, Mes, Bis-Tris, Bis-Tris propane, Pipes, Aces, Mopso, Bes, Mops, Hepes, Tes, Pipps, Dipso, Tapso, Heppso, Tris-up, Tris-HCl, Tricine, Hepps, Gly-Gly, Bicine, Taps, Hepee, acetate, histidine, citrate, MES, or borate) in the presence of a phosphate buffer solution (PBS), ... (b) adding an effective amount of a conjugate or payload / conjugate conjugate having a thiol-reactive group (e.g., a drug containing a maleimide terminus) to react with the sulfhydryl group generated in step (a); and (c) adding an effective amount of an oxidizing agent (e.g., dehydroascorbic acid) to reoxidize any unreacted sulfhydryl groups and then purifying the resulting conjugate; (d) Step (c) can be replaced by adding an effective amount of cystine or a related disulfide compound to quench any unreacted reducing agent, while generating cysteine from the reduction of cystine to quench excess conjugation of a conjugate or conjugate / payload complex containing a thiol-reactive group (e.g., maleimide).
[0010] The transition metal cation-amino chelate / complex is M(NR1R2R3) m1 m2+ where M is Zn 2+ , Cu 2+ , Fe 2+ , Cd 2+ , Ni 2+ , Cr 2+ , Cr 3+ , Ti 2+ , Ti 3+ , Co 2+ , Mn 2+ , Mn 3+ , Ag + , and Hg 2+
[0023] m1 is 1, 2, 3, 4, 5, 6, 7, or 8. m2 is 1, 2, 3, 4, 5, or 6. Preferably, M is Zn; m1 is 1, 2, 3, or 4; and m2 is 1, 2, 3, or 4.
[0024] m1 is 1, 2, 3, or 4; and m2 is 1, 2, 3, or 4.
[0025] m1 is 1, 2, 3, or 4; and m2 is 1, 2, 3, or 4.
[0026] m1 is 1, 2, 3, or 4; and m2 is 1, 2, 3, or 4.
[0027] m1 is 1, 2, 3, or 4; and m2 is 1, 2, 3, or 4.
[0028] m1 is 1, 2, 3, or 4; and m2 is 1, 2, 3, or 4. [0029 ...
[0011] In addition, (NR1R2R3) m1 can form dimers, trimers, tetramers, pentamers, or hexamers, and these polymers can be covalently linked between N, R1, R2, and / or R3 to form heterocyclic, carbocyclic, heterobicyclic, or carbobicyclic rings.
[0012] The transition metal cation-amino complex M(NR1R2R3) used in step (a) m1 m2+ The concentration of is 0.5 to 20 molar equivalents of protein, and can be added to the reaction solution together with a water-miscible organic solvent selected from ethanol, methanol, propanol, propanediol, DMA, DMSO, THF, or CH3CN.
[0013] The reducing agent is an organic phosphine, preferably selected from tris(2-carboxyethyl)phosphine (TECP) or tris(hydroxypropyl)phosphine, and is used in a concentration of 0.02 mM to 1.0 mM in the reaction solution or in an amount of 1.0 to 20 equivalents per mole of protein. The oxidizing agent added in step (c) is DHAA, Fe 3+ , I2, Cu 2+ , Mn 3+ , MnO2, or Fe 3+ / I -The oxidizing agent is used in the reaction solution at a concentration of 0.02 mM to 1.0 mM, or at 1 to 100 equivalents per mole of protein. The optimum pH for the conjugation reaction is usually about 5.0 to 8.0, preferably about 5.5 to 7.5. The optimum temperature for the conjugation reaction is usually about -5 to about 40°C, preferably about 0 to 37°C, more preferably about 2 to 8°C. The optimum time for the conjugation reaction is usually about 15 minutes to about 48 hours, preferably about 30 minutes to overnight (10 to 16 hours). The optimum reaction conditions (pH, temperature, buffer, reactant concentration, etc.) depend particularly on the antibody-like protein, payload / conjugate-linker complex, reducing agent, and / or M(NR1R2R3) used. m1 m2+ Depends on.
[0014] The antibody or antibody-like protein in the conjugation method can be any type of antibody or protein as long as it has two or more disulfide bonds in the protein for differentiation during reduction, and the payload / linker conjugate can be of any type or format as long as it has a thiol-reactive group.
[0015] In short, in contrast to conventional methods, where approximately 40% of the payload is in the Fab region of the antibody, and even using the method of International Publication No. WO 2020 / 164561, where approximately 70% of the payload is in the Fab region of the antibody, in ADCs prepared by the method of the present application, more than 80% of the payload is conjugated to the Fab region of the antibody. The advantages of the present application, along with improved conjugation methods for ADC homogeneity, will become more apparent from the following detailed description of several embodiments, experiments, and figures. [Brief explanation of the drawings]
[0016] [Figure 1] Proposed mechanism of coordination of zinc amino complexes for reduction of disulfide bonds in antibodies. [Figure 2]Mid-level characterization of ADCs after N-deglycosylation and reduction. (a) rpHPLC chromatographs of ADC fragments obtained after deglycosylation and DTT reduction: light chains (LC) with 0 or 1 drug molecule attached (L0 and L1) and heavy chains with 0, 1, 2, or 3 drug molecules attached (H0, H1, H2, and H3). (b) The table summarizes the quality and ratio of the various ADC fragments, as well as the average DAR measured from the peak area. The results indicate that the payload is primarily attached to the site between the light and heavy chains. [Figure 3] MS and MS / MS spectra of peptide-loaded drug / conjugate (C-408b). (a) [GEC]+1 payload and (b) [SCDK]+1 payload show that the payload is primarily linked at the site between the light and heavy chains. [Figure 4] The percentage of drug-loaded peptides generated from BCMA conjugate C-408b by hydrolase and analyzed by UPLC-MS. (a) The light chain (LC) peptide [GEC] conjugated zero or one drug molecule (DO and D1), (b) the heavy chain (HC) peptide [SCDK] conjugated zero or one drug molecule (DO and D1) in the arm region, and (c) the HC peptide [THTCPPCPAPELLXXXXXXXXXXX XX] conjugated zero, one, or two drug molecules (DO, D1, and D2) in the hinge region (where x represents an amino acid, as disclosed in a separate patent application). The results showed that the payload was primarily (over 85%) conjugated at the cysteine site between the light and heavy chains of the antibody. [Figure 5] HIC-HPLC analysis of BCMA antibody conjugate C-406 prepared by conventional conjugation (no adjustment with zinc amino complex, 2.2-4.0 equivalents of TCEP, pH 7.0-7.2). (5a): Room temperature, 6.0 equivalents of compound 406, 4 hours of conjugation, DAR=4.0, D4=41.96%; (5b): 4±2°C, 6.0 equivalents of compound 406, 5 hours of conjugation, DAR=4.2, D4=47.16%; (5c): 4±2°C, 6.5 equivalents of compound 406, 5 hours of conjugation, DAR=5.1, D4=40.03%. [Figure 6]HIC-HPLC analysis of BCMA antibody conjugate C-406 conditioned with 2.0-2.4 equivalents of zinc chloride at pH 7.2, 4±2°C for 15±2 hours. (6a): 2.0 equivalents of ZnCl2, 4.0 equivalents of TCEP, 6.0 equivalents of compound 406, DAR = 4.2, D4 = 68.15%; (6b): 2.2 equivalents of ZnCl2, 4.0 equivalents of TCEP, 6.5 equivalents of compound 406, DAR = 4.7, D4 = 68.39%; (6c): 2.4 equivalents of ZnCl2, 3.5 equivalents of TCEP, 6.5 equivalents of compound 406, DAR = 4.6, D4 = 62.53%; (6d): 2.4 equivalents of ZnCl2, 4.0 equivalents of TCEP, 6.5 equivalents of compound 406, DAR = 5.1, D4 = 65.16%. [Figure 7] HIC-HPLC analysis of BCMA antibody conjugate C-406 prepared using 2.4 equivalents of Z-11, 4.0 equivalents of TCEP, and 6.5 equivalents of compound 406 at pH 7.2, 4 ± 2°C for 5 hours; DAR = 4.6, D4 = 79.81%. [Figure 8] HIC-HPLC analysis of EGFR antibody conjugate C-038 prepared using 2.4 equivalents of Z-28, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 038 at pH 7.2, 4±2°C for 5 hours; DAR=4.2, D4=79.68%. [Figure 9] HIC-HPLC analysis of EGFR antibody conjugate C-111 prepared using 2.4 equivalents of Z-28, 3.4 equivalents of TCEP, and 6.0 equivalents of compound 111 at pH 7.2, 4±2°C for 5 hours; DAR=4.4, D4=80.39%. [Figure 10] HIC-HPLC analysis of EGFR antibody conjugate C-226 prepared using 2.4 equivalents of Z-28, 3.4 equivalents of TCEP, and 6.0 equivalents of compound 226 at pH 7.2, 4±2°C for 5 hours; DAR=4.4, D4=77.94%. [Figure 11] HIC-HPLC analysis of EGFR antibody conjugate C-227 prepared using 2.4 equivalents of Z-28, 3.4 equivalents of TCEP, and 6.0 equivalents of compound 038 at pH 7.2, 4±2°C for 5 hours; DAR=4.0, D4=78.73%. [Figure 12]HIC-HPLC analysis of BCMA antibody conjugate C-325 prepared using 2.4 equivalents of Z-28, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 325 at pH 7.2, 4±2°C for 5 hours; DAR=4.1, D4=80.11%. [Figure 13] HIC-HPLC analysis of Trop2 antibody conjugate C-334 prepared using 2.4 equivalents of Z-28, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 334 at pH 7.2, 4.2 ± 2°C for 5 hours; DAR = 4.2, D4 = 81.15%. [Figure 14] HIC-HPLC analysis of Her2 antibody conjugate C-334 prepared using 2.4 equivalents of Z-28, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 334 at pH 7.2, 4±2°C for 5 hours; DAR=4.4, D4=80.82%. [Figure 15] HIC-HPLC analysis of CD33 antibody conjugate C-334 prepared using 2.4 equivalents of Z-28, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 334 at pH 7.2, 4±2°C for 5 hours; DAR=4.4, D4=79.93%. [Figure 16] HIC-HPLC analysis of EGFR antibody conjugate C-379 prepared using 2.4 equivalents of Z-28, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 379 at pH 7.2, 4±2°C for 5 hours; DAR=4.4, D4=70.02%. [Figure 17] HIC-HPLC analysis of EGFR antibody conjugate C-385 prepared using 2.2 equivalents of Z-21, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 385 at pH 7.2, 4±2°C for 5 hours; DAR=3.8, D4=69.54%. [Figure 18] HIC-HPLC analysis of EGFR antibody conjugate C-387 prepared using 2.2 equivalents of Z-21, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 387 at pH 7.2, 4±2°C for 5 hours; DAR=4.1, D4=77.25%. [Figure 19]HIC-HPLC analysis of CD33 antibody conjugate C-413d prepared using 2.2 equivalents of Z-21, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 413d at pH 7.2, 4±2°C for 5 hours; DAR=4.1, D4=76.70%. [Figure 20] HIC-HPLC analysis of EGFR antibody conjugate C-422a prepared using 2.2 equivalents of Z-21, 3.4 equivalents of TCEP, and 6.0 equivalents of compound 422a at pH 7.2, 4±2°C, and 5 hours; DAR=4.2, D4=76.58%. [Figure 21] HIC-HPLC analysis of EGFR antibody conjugate C-431a prepared using 2.2 equivalents of Z-21, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 431a at pH 7.2, 4±2°C, and 5 hours; DAR=4.1, D4=77.97%. [Figure 22] HIC-HPLC analysis of Her2 antibody conjugate C-431a prepared using 2.2 equivalents of Z-21, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 431a at pH 7.2, 4±2°C, and 5 hours; DAR=4.2, D4=79.44%. [Figure 23] HIC-HPLC analysis of Steap1 antibody conjugate C-412c prepared using 2.2 equivalents of Z-21, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 412c at pH 7.2, 4±2°C, and 5 hours; DAR=4.4, D4=80.01%. [Figure 24] HIC-HPLC analysis of Steap1 antibody conjugate C-428c prepared using 2.2 equivalents of Z-21, 3.6 equivalents of TCEP, and 6.0 equivalents of compound 428c at pH 7.2, 4±2°C, and 5 hours; DAR=4.4, D4=79.83%. [Figure 25]Figure 1 shows a comparison of the antitumor effects of EGFR antibody conjugates C-031, C-038, C-066, C-071, C-093, C-111, C-118, C-208, C-214, and C-216 (all D4>75% except for C-066 and C-071, where D8>75%) prepared by the method of the present invention, paclitaxel + naked EGFR antibody, conjugate C-038 (D4=41%) prepared by a conventional conjugation method, and PBS buffer using a mouse model with human lung adenocarcinoma HCC-827 cells xenografted, at a dose of 6 mg / kg, administered intravenously once. This figure shows that all 10 conjugates have superior antitumor activity to paclitaxel plus naked EGFR antibody (6 mg / kg EGFR antibody and 10 mg / kg paclitaxel, 3×QW (weekly injections for 3 weeks) intravenous injection), and that conjugate C-038 prepared by the method of the present invention has better in vivo activity than conjugates prepared by conventional methods. [Figure 26] The figure shows a comparison of the antitumor activity of Trop2 antibody conjugates C-216, C-218, C-328, C-384, C-408b, C-412c, C-422a, C-425a, and C-431c prepared by the method of the present invention (all of which had D4 > 75% (78-83%) and DAR = 4.2-4.4) with conjugate C-408b prepared by a conventional conjugation method (D4 = 42%, DAR = 4.2) and PBS buffer using a mouse xenograft of human gastric cancer NCI-N87 cells at a dose of 6 mg / kg intravenously. This figure demonstrates that all nine conjugates exhibited antitumor activity, and that conjugate C-408b prepared by the method of the present invention exhibited better in vivo activity than the conjugate prepared by the conventional method. [Figure 27]The figure shows a comparison of the antitumor activity of BCMA antibody conjugates C-227, C-403a, C-403b, C-408b, C-412e, C-412f, C-428c, and C-431a prepared by the method of the present invention (all of which had D4 > 75% (78-83%) and DAR = 4.1-4.4) with conjugate C-408b prepared by a conventional conjugation method (D4 = 47%, DAR = 4.2) and PBS buffer using a human multiple myeloma NCI-H929 cell xenograft mouse model, administered intravenously at a dose of 6 mg / kg. The figure demonstrates that all nine conjugates exhibited antitumor activity, with conjugate C-408b prepared by the method of the present invention exhibiting better in vivo activity than the conjugate prepared by the conventional method. DETAILED DESCRIPTION OF THE INVENTION
[0017] definition
[0018] "Alkyl" refers to an aliphatic hydrocarbon group or monovalent group derived from an alkane by removing one or two hydrogen atoms from a carbon atom. It may be linear or branched, having C1 to C8 (1 to 8 carbon atoms) in the chain. "Branched" refers to a linear alkyl group having one or more lower C alkyl groups, such as methyl, ethyl, or propyl groups, attached to it. Specific examples of alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, octyl, nonyl, decyl, cyclopentyl, cyclohexyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 3,3-dimethylpentyl, 2,3,4-trimethylpentyl, 3-methylhexyl, 2,2-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 3,5-dimethylhexyl, 2,4-dimethylpentyl, 2-methylheptyl, 3-methylheptyl, n-heptyl, isoheptyl, n-octyl, and isooctyl. The C1-C8 alkyl group may be unsubstituted or substituted with one or more substituents (but is not limited to the following substituents). Examples of the substituent include -C1-C8 alkyl, -O-(C1-C8 alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH2, -C(O)NHR', -C(O)N(R')2, -NHC(O)R', -SR', -S(O)2R', -S(O)R', -OH, -halogen, -N3, -NH2, -NH(R'), -N(R')2, and -CN, where each R' is independently selected from C1-C8 alkyl and aryl.
[0019] "Halogen" refers to fluorine, chlorine, bromine, or iodine atoms, with fluorine and chlorine atoms being preferred.
[0020] "Heteroalkyl" refers to a C2-C8 alkyl in which one to four carbon atoms are independently replaced by a heteroatom selected from the group consisting of O, S, and N.
[0021] "Carbocycle" refers to a saturated or unsaturated monocyclic ring containing 3 to 8 carbon atoms or a bicyclic ring containing 7 to 13 carbon atoms. Monocyclic carbocycles have 3 to 6, more typically 5 or 6, ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms and are arranged as a [4,5], [5,5], [5,6], or [6,6] bicycle, or 9 to 10 ring atoms and are arranged as a [5,6] or [6,6] bicycle. Representative C3-C8 carbocycles include, but are not limited to, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclopentadienyl, -cyclohexyl, -cyclohexenyl, -1,3-cyclohexadienyl, -1,4-cyclohexadienyl, -cycloheptyl, -1,3-cycloheptadienyl, -1,3,5-cycloheptatrienyl, -cyclooctyl, and -cyclooctadienyl.
[0022] A C3-C8 carbocycle refers to a saturated or unsaturated non-aromatic hydrocarbon carbocyclic compound having 3, 4, 5, 6, 7, or 8 carbon atoms. A C3-C8 carbocycle can be unsubstituted or substituted with one or more substituents, including, but not limited to, -C1-C8 alkyl, -O-(C1-C8 alkyl), -aryl, -C(O)R', -OC(O)R', -C(O)OR', -C(O)NH2, -C(O)NHR', -C(O)N(R')2, -NHC(O)R', -SR', -S(O)R', -S(O)2R', -OH, -halogen, -N3, -NH2, -NH(R'), -N(R')2, and -CN, where each R' is independently selected from C1-C8 alkyl and aryl.
[0023] "Alkenyl" refers to an aliphatic hydrocarbon group having a carbon-carbon double bond, which may be straight-chained or branched, and has 2 to 8 carbon atoms in the chain. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, hexylenyl, heptenyl, and octenyl.
[0024] "Alkynyl" refers to an aliphatic hydrocarbon group having a carbon-carbon triple bond and may be straight or branched, having 2 to 8 carbon atoms in the chain. Examples of alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, 5-pentynyl, n-pentynyl, hexynyl, heptynyl, and octynyl.
[0025] "Alkylene" refers to a saturated, straight or branched chain or cyclic hydrocarbon group of 1 to 18 carbon atoms having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene groups include, but are not limited to, methylene (-CH-), 1,2-ethyl (-CHCH-), 1,3-propyl (-CHCHCH-), 1,4-butyl (-CHCHCHCH-), and the like.
[0026] "Alkenylene" refers to an unsaturated, straight or branched chain or cyclic hydrocarbon group of 2 to 18 carbon atoms having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. Typical alkenylene groups include, but are not limited to, 1,2-ethylene (-CH=CH-).
[0027] "Alkynylene" refers to an unsaturated, straight or branched chain or cyclic hydrocarbon group of 2 to 18 carbon atoms having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne. Typical alkynylene groups include, but are not limited to, acetylene, propargyl, and 4-pentynyl.
[0028] "Aryl" or Ar refers to an aromatic or heteroaromatic group consisting of one or several rings containing 3 to 14 carbon atoms, preferably 6 to 10 carbon atoms. The term "heteroaromatic group" refers to an aromatic group in which one or several carbons, preferably 1, 2, 3, or 4 carbon atoms, have been replaced by O, N, Si, Se, P, or S, preferably O, S, and N. The term aryl or Ar also refers to one or more H atoms independently replaced by -R', -halogen, -OR', or -SR', -NR'R'', -N=NR', -N=R', -NR'R'', -NO, -S(O)R', -S(O)R', -S(O)OR', -OS(O)OR', -PR'R'', -P(O)R'R'', -P(OR')(OR''), -P(O)(OR')(OR''), or -OP(O)(OR')(OR''), where R', R'' are independently H, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, arylalkyl, carbonyl, or a pharmaceutical salt.
[0029] "Heterocycle" refers to a ring system in which one to four ring carbon atoms are independently replaced with a heteroatom from the group O, N, S, Se, B, Si, and P. Preferred heteroatoms are O, N, and S. Heterocycles are described in The Handbook of Chemistry and Physics, 78th Edition, CRC Press, Inc., 1997-1998, pp. 225-226, the disclosure of which is incorporated herein by reference. Preferred non-aromatic heterocycles include, but are not limited to, epoxy, aziridinyl, thiiranyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxiranyl, tetrahydrofuranyl, dioxolanyl, tetrahydropyranyl, dioxanyl, dioxolanyl, piperidyl, piperazinyl, morpholinyl, pyranyl, imidazolinyl, pyrrolinyl, pyrazolinyl, thiazolidinyl, tetrahydropyranyl, dihydropyranyl, tetrahydropyridyl, dihydropyridyl, tetrahydropyrimidinyl, dihydrothiopyranyl, azepanyl, as well as fused systems resulting from condensation with a phenyl group.
[0030] The term "heteroaryl" or aromatic heterocycle refers to a 3- to 14-membered, preferably 5- to 10-membered, aromatic hetero, monocyclic, bicyclic, or polycyclic ring. Examples include pyrrolyl, pyridyl, pyrazolyl, thienyl, pyrimidinyl, pyrazinyl, tetrazolyl, indolyl, quinolinyl, purinyl, imidazolyl, thienyl, thiazolyl, benzothiazolyl, furanyl, benzofuranyl, 1,2,4-thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, carbazolyl, benzimidazolyl, isoxazolyl, pyridyl-N-oxide, and fused systems resulting from condensation with a phenyl group.
[0031] "Alkyl," "cycloalkyl," "alkenyl," "alkynyl," "aryl," "heteroaryl," "heterocyclic," and the like, also refer to the corresponding "alkylene," "cycloalkylene," "alkenylene," "alkynylene," "arylene," "heteroarylene," "heterocyclene," and the like, formed by removing two hydrogen atoms.
[0032] "Arylalkyl" refers to an alkyl group consisting of a carbon atom, typically a terminal or sp 3 It refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced with an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethene-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl, etc.
[0033] "Heteroarylalkyl" refers to a heteroaryl group consisting of a carbon atom, typically a terminal or sp 3 It refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced with a heteroaryl group. Typical heteroarylalkyl groups include, but are not limited to, 2-benzimidazolylmethyl, 2-furylethyl, and the like.
[0034] Examples of "hydroxy protecting groups" include, but are not limited to, methoxymethyl ether, 2-methoxyethoxymethyl ether, tetrahydropyranyl ether, benzyl ether, p-methoxybenzyl ether, trimethylsilyl ether, triethylsilyl ether, triisopropylsilyl ether, t-butyldimethylsilyl ether, triphenylmethylsilyl ether, acetate ester, substituted acetate ester, pivaloate, benzoate, methanesulfonate, and p-toluenesulfonate.
[0035] "Leaving group" refers to a functional group that can be replaced by another functional group. Such leaving groups are well known in the art and include, but are not limited to, halides (e.g., chloride, bromide, and iodide), methanesulfonyl (mesyl), p-toluenesulfonyl (tosyl), trifluoromethylsulfonyl (triflate), and trifluoromethylsulfonate. The leaving group is preferably selected from nitrophenol; N-hydroxysuccinimide (NHS); phenol; dinitrophenol; pentafluorophenol; tetrafluorophenol; difluorophenol; monofluorophenol; pentachlorophenol; triflate; imidazole; dichlorophenol; tetrachlorophenol; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate; acid anhydrides formed with themselves or other acid anhydrides (e.g., acetic anhydride, formic anhydride); or intermediates generated by condensation reagents for peptide coupling reactions or Mitsunobu reactions.
[0036] The following abbreviations may be used herein and have the definitions set forth below: Boc, tert-butoxycarbonyl; BroP, bromotrispirolizinophosphonium hexafluorophosphate; CDI, 1,1'-carbonyldiimidazole; DCC, dicyclohexylcarbodiimide; DCE, 1,2-dichloroethane; DCM, dichloromethane; DIAD, diisopropyl azodicarboxylate; DIBAL-H, diisobutylaluminum hydride; DIPEA, diisopropylethylamine; DEPC, diethylphosphoroanidinium; DMA, N,N-dimethylacetamide; DMAP, 4-(N,N-dimethylamino)pyridine; DMF, N,N-dimethylformamide; DMSO, dimethylsulfoxide; DTT, dithiothreitol EDC, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; ESI-MS, electrospray mass spectrometry; HATU, O-(7-azabenzotriazol-1-yl)-N,N,N'-N'-tetramethyluronium hexafluorophosphate; HOBt, 1-hydroxybenzotriazole; HPLC, high-pressure liquid chromatography; NHS, N-hydroxysuccinimide; MMP, 4-methylmorpholine; PAB, p-aminobenzyl; PBS, phosphate-buffered saline (pH 7.0-7.5); PEG, polyethylene glycol; SEC, size-exclusion chromatography; TCEP, tris(2-carboxyethyl)phosphine; TFA, trifluoroacetic acid; THF, tetrahydrofuran; Val, valine.
[0037] The "amino acid(s)" may be natural and / or unnatural amino acids, preferably α-amino acids. Natural amino acids are those encoded by the genetic code: alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, tryptophan, and valine. Unnatural amino acids are derived forms of protein-forming amino acids, including, for example, hydroxyproline, lanthionine, 2-aminoisobutyric acid, dehydroalanine, γ-aminobutyric acid (a neurotransmitter), ornithine, citrulline, β-alanine (3-aminopropanoic acid), γ-carboxyglutamate, selenocysteine (present in most eukaryotes but not directly encoded by DNA), pyrrolysine (found only in some archaea and one bacterium), N-formylmethionine (often the first amino acid in proteins in bacteria, mitochondria, and chloroplasts), 5-hydroxytryptophan, L-dihydroxyphenylalanine, triiodothyronine, L-3,4-dihydroxyphenylalanine (DOPA), and O-phosphoserine. The term amino acid also includes amino acid analogs and mimetics. Analogs are compounds that have the same general HN(R)CHCOH structure of a natural amino acid, except that the R group is not one found in a natural amino acid. Examples of analogs include homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Preferably, an amino acid mimetic is a compound that has a structure different from the general chemical structure of an α-amino acid, but functions similarly to it. The term "unnatural amino acid" is intended to refer to the "D" stereochemical form, whereas natural amino acids are in the "L" form. When 1 to 8 amino acids are used herein, the amino acid sequence is preferably a cleavage recognition sequence for a protease.Many cleavage recognition sequences are known in the art, see, e.g., Matayoshi et al. Science 247: 954 (1990); Dunn et al. Meth. Enzymol. 241: 254 (1994); Seidah et al. Meth. Enzymol. 244: 175 (1994); Thornberry, Meth. Enzymol. 244: 615 (1994); Weber et al. Meth. Enzymol. 244: 595 (1994); Smith et al. Meth. Enzymol. 244: 412 (1994); and Bouvier et al. Meth. Enzymol. 248: 614 (1995), the disclosures of which are incorporated herein by reference. In particular, the sequence is selected from the group consisting of Val-Cit, Ala-Val, Ala-Ala, Val-Val, Val-Ala-Val, Lys-Lys, Ala-Asn-Val, Val-Leu-Lys, Cit-Cit, Val-Lys, Ala-Ala-Asn, Lys, Cit, Ser, and Glu.
[0038] "Pharmaceutically" or "pharmaceutically acceptable" means that the corresponding compound or compound composition does not produce harmful, allergic or other adverse reactions when administered to animals or humans in a suitable manner.
[0039] A "pharmaceutically acceptable solvate" or "solvate" refers to an association of one or more solvent molecules with a disclosed compound. Examples of solvents that form pharmacologically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
[0040] Pharmaceutically acceptable auxiliary materials include all carriers, diluents, auxiliaries, or excipients, such as preservatives, antioxidants, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, solvents, dispersion media, coating agents, antibacterial agents, antifungal agents, isotonic agents, absorption delaying agents, etc. In the pharmaceutical field, it is common practice to add these auxiliary materials to active drug components. It is considered reasonable to add auxiliary materials to drug components unless the auxiliary materials are incompatible with the active drug components. To achieve better results, active auxiliary materials may be added to drug components.
[0041] In the present invention, the term "pharmaceutical salt" refers to a salt derivative of the compound of the present invention. By appropriate modification, the compound of the present invention can be converted into a corresponding acid or alkali salt. Pharmaceutical salts include commonly used non-toxic salts or quaternary ammonium salts, which can be prepared with the compound of the present invention using a corresponding non-toxic inorganic or organic acid. For example, inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, aminosulfonic acid, phosphoric acid, and nitric acid. Organic acids include acetic acid, propionic acid, succinic acid, tartaric acid, citric acid, methanesulfonic acid, benzenesulfonic acid, glucuronic acid, glutamic acid, benzoic acid, salicylic acid, toluenesulfonic acid, oxalic acid, fumaric acid, and lactic acid, which can be used to form pharmaceutically acceptable salts. Other salts include ammonium salts such as trometamol, meglumine, and pyrroleethanol, and metal salts such as sodium, potassium, calcium, zinc, and magnesium.
[0042] In the present invention, pharmaceutical salts can be prepared from parent compounds containing acidic or basic residues by conventional chemical methods. Generally, these salts can be obtained by reacting the free acid or free base form of these compounds with a stoichiometric amount of an appropriate base or acid in water, an organic solvent, or a mixture of the two. Generally, ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is preferred as a non-aqueous reaction solvent. A list of suitable salts can be found in "Remington's Pharmaceutical Sciences," 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is incorporated by reference.
[0043] "Administering" or "Administration" refers to any manner of transferring, delivering, introducing, or carrying a pharmaceutical or other agent to a subject. Such manners include oral administration, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, nasal, subcutaneous, or cavity administration. Also contemplated by the present invention is the use of a device or instrument in administering the agent. Such devices may utilize active or passive transport and may be slow-release or fast-release delivery devices.
[0044] The abbreviations and chemical names of biological buffers are as follows: ACES (N-(2-acetamido)-2-aminoethanesulfonic acid) is used for buffering at pH 6.1 to 7.5 (pKa = 6.88). ADA (N-(2-acetamido)iminodiacetic acid, N-(carbamoylmethyl)iminodiacetic acid) is useful for buffering at pH 6.0 to 7.2 (pKa = 6.65). AMPD (2-amino-2-methyl-1,3-propanediol) is useful for buffering pH values between 7.8 and 9.7. AMPSO (N-(1,1-dimethyl-2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid). BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid). Bicine (N,N-bis(2-hydroxyethyl)glycine), bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane) is used as a buffer at pH 5.8-7.2 (pKa=8.35). BisTris (bis-(2-hydroxyethyl)amino-tris(hydroxymethyl)methane). BisTrisBisTrispropane (1,3-bis[tris(hydroxymethyl)methylamino]propane). DIPSO (N,N-bis(2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid) is used as a buffer at pH 7.0 to 8.2. Gly-Gly (diglycine, glycyl-glycine) is used for buffering at pH 7.5 to 8.9 (pKa=8.30). HEBPS (N-(2-hydroxyethyl)piperazine-N'-(4-butanesulfonic acid) is a homologue of HEPES and EPPS with a higher pKa (pKa = 8.30) and is used as a buffer at pH 7.6-9.0. HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; 2-morpholinoethanesulfonic acid; 2-(4-morpholino)ethanesulfonic acid; 2-(N-morpholino)ethanesulfonic acid; morpholine-4-ethanesulfonic acid hydrate) is widely used for buffering pH values between 6.8 and 8.2, with a pKa of 7.45-7.65 at 20°C. HEPPS or EPPS (3-[4-(2-hydroxyethyl)-1-piperazinyl]propanesulfonic acid hydrate, 4-(2-hydroxyethyl)piperazine-1-(2-hydroxypropanesulfonic acid) hydrate) is used as a buffer at pH 7.3-8.7 (pKa=8.00 / piperazine ring). HEPPSO (4-(2-hydroxyethyl)piperazine-1-(2-hydroxypropanesulfonic acid) hydrate). MES (2-(N-morpholino)ethanesulfonic acid, monohydrate) is used as a buffer at pH 5.2 to 7.1 (pKa: 6.16). MOBS (4-morpholinebutanesulfonic acid; 3-(N-morpholino)butanesulfonic acid hemisodium salt) is a homologue of MES and MOPS with a higher pKa / pH and is used in buffer solutions with a pH range of 6.9 to 8.3 (pKa: 7.6). MOPS (4-morpholinepropanesulfonic acid sodium salt). MOPSO (β-hydroxy-4-morpholinepropanesulfonic acid, 3-morpholino-2-hydroxypropanesulfonic acid). PIPES (piperazine-1,4-bis(2-ethanesulfonic acid) is used to buffer at pH 6.1 to 7.5 (pKa = 6.80). POPSO (piperazine-1,4-bis(2-hydroxypropanesulfonic acid) dihydrate). TAPS ([(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]-1-propanesulfonic acid). TAPSO (2-hydroxy-3-[tris(hydroxymethyl)methylamino]-1-propanesulfonic acid). TES (2-[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino]ethanesulfonic acid). Tricine (piperazine-N,N'-bis[2-hydroxypropanesulfonic acid]) is used to buffer at pH 7.4-8.8 (pKa: 8.16).
[0045] The term "antibody" is used herein in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments and antibody-containing fusion proteins exhibiting desired antigen-binding activity, and other modified configurations of immunoglobulin molecules containing antigen recognition sites. Antibodies include antibodies of any class, such as IgG, IgA, or IgM (or their subclasses), and antibodies need not be of a specific class. Depending on the amino acid sequence of the constant region of the antibody's heavy chain, immunoglobulins can be assigned to various classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, several of which can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant regions corresponding to the various classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively. The subunit structures and three-dimensional configurations of the various classes of immunoglobulins are well known. An "antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and multispecific antibody fragments formed from antibody fragment(s). A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, with all or substantially all of the HVRs (e.g., CDRs) corresponding to those of a non-human antibody, and all or substantially all of the HVRs (e.g., CDRs) corresponding to the variable domains of the non-human antibody. Substantially all FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization. The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.The heavy and light chain variable domains (VH and VL, respectively) of natural antibodies generally have similar structures, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR) (e.g., Kindt et al., Kuby Immunology, 6). th (See, e.g., W.H. Freeman and Co., page 91 (2007)). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a specific antigen can be isolated using the VH or VL domain from an antibody that binds the antigen to screen a library of complementary VH or VL domains, respectively. See, e.g., Portolano et al., J. Immunol. 150: 880-887 (1993); Clarkson et al., Nature 352: 624-628 (1991).
[0046] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for minor naturally occurring mutations. Monoclonal antibodies are highly specific, acting specifically at a single antigenic site. The modifier "monoclonal" indicates that the antibody is obtained from a substantially homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies used in accordance with the present invention can be made using the hybridoma method first described by Kohler and Milstein, Nature 256:495, 1975, or by recombinant DNA methods such as those described in U.S. Pat. No. 4,816,567. Monoclonal antibodies can also be isolated from phage libraries generated using, for example, the techniques described in McCafferty et al., Nature 348:552-554, 1990.
[0047] As used herein, a "humanized" antibody refers to forms of non-human (e.g., murine) antibodies that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (such as Fv, Fab, Fab', F(ab')2, or other antigen binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. Preferably, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences, but are included to further refine and optimize antibody performance. Generally, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are of human immunoglobulin consensus sequences. A humanized antibody will optimally also comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Antibodies with modified Fc regions, as described in WO 99 / 58572, are preferred. Another form of humanized antibody has one or more CDRs (CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, or CDR H3) that are "derived from," or are referred to as one or more CDRs of, the original antibody, and that have been altered relative to the original antibody.
[0048] As used herein, "human antibody" means an antibody having an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human and / or an antibody made using any of the techniques for making human antibodies disclosed herein or known to those of skill in the art. This definition of a human antibody includes antibodies that comprise at least one human heavy chain polypeptide or at least one human light chain polypeptide. One such example is an antibody that comprises a murine light chain and a human heavy chain polypeptide. Human antibodies can be produced using a variety of techniques known in the art. In one embodiment, human antibodies are selected from phage libraries that express human antibodies (Vaughan et al., Nature Biotechnology, 14:309-314, 1996; Sheets et al., Proc. Natl. Acad. Sci (USA) 95:6157-6162, 1998; Hoogenboom and Winter, J. Mol. Biol., 227:381, 1991; Marks et al., J. Mol. Biol., 222:581, 1991). Human antibodies can also be produced by immunization of animals transgenic for endogenous loci with human immunoglobulin loci, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. This approach is described in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; and 5,633,425. Alternatively, human antibodies can be prepared by immortalizing human B lymphocytes that produce antibodies against the target antigen (such B lymphocytes can be recovered from an individual, or from single-cell cloning of cDNA, or immunized in vitro). See, e.g., Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77, 1985; Boerner et al., J. Immunol., 147 (1):86-95, 1991; and U.S. Patent No. 5,750,373.
[0049] The term "chimeric antibody" is intended to refer to an antibody in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, e.g., the variable region sequences are derived from a murine antibody and the constant region sequences are derived from a human antibody.
[0050] The terms "polypeptide," "oligopeptide," "peptide," and "protein" are used interchangeably herein and refer to chains of amino acids of any length, preferably relatively short (e.g., 10-100 amino acids). The chains may be linear or branched, may include modified amino acids, and / or may be interrupted by non-amino acids. The term also includes amino acid chains that have been modified, naturally or by intervention, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or other manipulations or modifications, such as conjugation with a labeling component. Also included within this definition are polypeptides containing, for example, one or more analogs of an amino acid (including, for example, unnatural amino acids), as well as other modifications known in the art. It is understood that polypeptides can exist as single chains or combined chains.
[0051] A "monovalent antibody" contains one antigen-binding site per molecule (e.g., IgG or Fab). In some cases, a monovalent antibody can have more than one antigen-binding site, but the binding sites are from different antigens.
[0052] A "monospecific antibody" contains two identical antigen-binding sites per molecule, such as two binding sites that bind to the same epitope on an antigen (e.g., IgG). Thus, they compete for binding to a single antigen molecule. Most naturally occurring antibodies are monospecific. In some cases, a monospecific antibody may be a monovalent antibody (e.g., Fab).
[0053] A "bivalent antibody" contains two antigen-binding sites per molecule (e.g., IgG). In some cases, the two binding sites may have the same antigen specificity. However, a bivalent antibody may be dual-specific.
[0054] A "bispecific" or "dual-specific" antibody is a hybrid antibody that has two different antigen-binding sites. The two antigen-binding sites of a bispecific antibody bind to two different epitopes located on the same or different protein targets.
[0055] A "bifunctional" antibody is an antibody that has the same antigen-binding site (ie, the same amino acid sequence) in both arms, but each arm can recognize two different antigens.
[0056] A "heteromultimer," "heteromultimeric complex," or "heteromultimeric polypeptide" is a molecule comprising at least a first polypeptide and a second polypeptide, where the second polypeptide differs in amino acid sequence from the first polypeptide by at least one amino acid residue. A heteromultimer may comprise a "heterodimer" formed by the first and second polypeptides, or may comprise a higher order tertiary structure formed when polypeptides in addition to the first and second polypeptides are present.
[0057] A "heterodimer," "heterodimeric protein," "heterodimeric complex," or "heterodimeric polypeptide" is a molecule comprising a first peptide and a second peptide, wherein the amino acid sequence of the second peptide differs from the amino acid sequence of the first peptide by at least one amino acid residue.
[0058] In this patent application, the terms "hinge region," "hinge sequence," and variants thereof include the meanings well known in the art, as set forth in, for example, Janeway et al., ImmunoBiology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999); Bloom et al., Protein Science (1997), 6:407-415; Humphreys et al., J. Immunol. Methods (1997), 209:193-202.
[0059] In this patent application, "immunoglobulin-like hinge region," "immunoglobulin-like hinge sequence," and variants thereof refer to the hinge region and hinge sequence of an immunoglobulin-like molecule or antibody-like molecule (e.g., an immunoadhesin). In some embodiments, the immunoglobulin-like hinge region can come from or be derived from any of the IgG1, IgG2, IgG3, or IgG4 subtypes, or from IgA, IgE, IgD, or IgM, including chimeric forms thereof, e.g., chimeric IgG1 / 2 hinge regions.
[0060] In this patent application, the term "immune effector cell" or "effector cell" refers to a cell within the natural cellular repertoire of the human immune system that can be activated to affect the viability of a target cell, including the cell's ability to survive, proliferate, and / or interact with other cells.
[0061] The antibodies of the present invention can be prepared by techniques well known in the art, such as recombinant techniques, phage display techniques, synthetic techniques, or a combination of these techniques with other techniques known in the art (see, for example, Jayasena, SD, Clin Chem., 45: 1628-50, 1999 and Fellouse, FA, et al., J. Mol. Biol., 373(4): 924-40, 2007).
[0062] In this patent application, the term "cytotoxic agent" refers to a substance that inhibits or prevents cellular function and / or causes cell death or destruction. Cytotoxic agents include radioactive isotopes (e.g., At211, I131, I125, Y90, In111, Re186, Re188, Sm153, Bi212, P32, Pb212, Zr89, F18, and radioactive isotopes of Lu, such as Lu177); chemotherapeutic agents or drugs (e.g., tubulysins, maytansines, auristatins, DNA minor groove binders (such as PBD dimers), ducarmysins, topoisomerase inhibitors, RNA polymerase inhibitors, DNA alkylating agents, melanoma inhibitors, and the like); growth inhibitory agents; enzymes and fragments thereof, such as nucleases; antibiotics; toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant, or animal origin (including fragments and / or variants thereof); and various anti-tumor or anti-cancer agents disclosed throughout this application.
[0063] "Linker" refers to a chemical moiety comprising a covalent bond or chain of atoms that covalently attaches an antibody to a drug moiety. In various embodiments, the linker includes a divalent radical such as alkyldiyl, aryldiyl, heteroaryldiyl, -(CR2) n O(CR2) n moieties such as -, repeating alkyloxy units (e.g., polyethyleneoxy, PEG, polymethyleneoxy), and alkylamino (e.g., polyethyleneamino); diacid esters and amides include succinate, succinamide, diglycolate, malonate, and caproamide. In various embodiments, the linker can include one or more amino acid residues such as valine, phenylalanine, lysine, and homolysine.
[0064] In this specification and claims, the terms "comprise," "comprising," "including," and "includes" are used to indicate the presence of features, integers, components, or steps, but do not exclude the presence or coexistence of one or more other features, integers, components, steps, or groups thereof. The novel conjugates disclosed herein use bridge linkers. Some suitable linkers and their synthetic examples are described in Examples 1-4681 of the present specification.
[0065] Conjugation Methods of the Invention
[0066] As disclosed above, a key element of the conjugation method of the present invention is the use of a transition metal cation-amino complex, M(NR1R2R3), which coordinates the selective reduction of a particular strand of a disulfide bond in a biomolecule. m1 m2+ Preferably, specific interchain disulfide bonds in antibodies. Previous studies using LC-MS have shown that interchain disulfide bonds in IgG antibodies are more susceptible to reduction than intrachain disulfide bonds, and that the disulfide bond between the light chain and the heavy chain is more susceptible to reduction than the disulfide bond between the two heavy chains. Of the two interheavy chain disulfide bonds in IgG antibodies, the upper disulfide bond is more susceptible than the lower one. Furthermore, the disulfide bond in the CH2 domain is the most susceptible to reduction. The disulfide bonds in the VL, CL, VH, and CH1 domains have similar and intermediate susceptibility, while the disulfide bond in the CH3 domain is the least susceptible to reduction (Liu, H, et al. Anal. Chem., 2010, 82, 5219-5226). To control the reduction of disulfide bonds in the IgG antibody of WO2020 / 164561, the use of ZnCl2 salt at low temperatures of 2-8°C actually enabled the above-mentioned discernible reduction. Here, the transition metal cation-amino complex, M(NR1R2R3), used in the conjugation method of the present invention m1 m2+is very bulky and not only can tune disulfide reduction, but also sterically hinders reducing agents (such as TCEP) from accessing the disulfide bond between the two heavy chains of IgG antibodies, demonstrating better selective reduction and subsequent conjugation with drug / conjugate complexes.
[0067] The transition metal cation-amino chelate / complex has the formula M(NR1R2R3) m1 m2+ where M is Zn 2+ , Cu 2+ , Fe 2+ , Cd 2+ , Ni 2+ , Cr 2+ , Cr 3+ , Ti 2+ , Ti 3+ , Co 2+ , Mn 2+ , Mn 3+ , Ag + , and Hg 2+ R1, R2 and R3 are each independently selected from C1-C8 alkyl, C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl. m1 is selected from 1, 2, 3, 4, 5, 6, 7, or 8. m2 is selected from 1, 2, 3, 4, 5, 6, or 7. Preferably, M is Zn 2+ wherein m1 is selected from 1, 2, 3, or 4, and m2 is 2, 3, or 4. More preferably, m1 is 2.
[0068] In addition, (NR1R2R3) m1 can form dimers, trimers, tetramers, pentamers, or hexamers, and these polymers are covalently linked between N, R1, R2, and / or R3. N, R1, R2, and / or R3 can themselves form a heterocycle, carbocycle, heterobicycle, or carbobicycle.
[0069] When the preferred M is Zn, the preferred M(NR1R2R3)m1 m2+ は、 is illustrated as follows: Zn(NH2CH3)2 2+ 、Zn(NH2CH2CH3)2 2+ 、Zn(NH2CH2CH2CH3)2 2+ 、Zn(NH2CH(CH3)2)2 2+ 、Zn(NH2C(CH3)3)2 2+ 、Zn(NH2CH2C(CH3)3)2 2+ 、Zn(NH(CH3)2)2 2+ 、Zn(NH(CH2CH3)2)2 2+ 、Zn(NH(CH(CH3)2)2)2 2+ 、Zn(NH(C(CH3)3)2)2 2+ 、Zn(NH(CH(CH2CH3)2)2)2 2+ 、Zn(NH(CH2C(CH3)3)2)2 2+ 、Zn(NH(CH2C(CH2CH3)3)2)2 2+ 、Zn(NH(CH2CH2C(CH3)3)2)2 2+ 、Zn(NH2CH2CH2OH)2 2+ 、Zn(NH(CH2CH2OH)2)2 2+ 、Zn(N(CH2CH2OH)3)2 2+ 、Zn(NH2CH2COOH)2 2+ 、Zn(NH2CH2CONH2)2 2+ 、Zn(NH2CH2COOCH3)2 2+ 、Zn(NH2CH2COOCH2CH3)2 2+ 、Zn(NH2CH2COOC(CH3)3)2 2+ 、Zn(NH2CH2COOCH(CH3)2)2 2+ 、Zn(NH2CH2CH2COOH)2 2+ 、Zn(NH(CH2COOH)2)2 2+ 、Zn(N(CH2CH2COOH)3)2 2+ 、Zn(NH2CH3)4 2+ 、Zn(NH2CH2CH3)4 2+ 、Zn(NH2CH2CH2CH3)4 2+ 、Zn(NH2CH(CH3)2)4 2+ 、Zn(NH2C(CH3)3)4 2+, Zn(NH2CH2C(CH3)3)4 2+ , Zn(NH(CH3)2)4 2+ , Zn(NH(CH2CH3)2)4 2+ , Zn(NH(CH(CH3)2)2)4 2+ , Zn(NH(C(CH3)3)2)4 2+ , Zn(NH(CH(CH2CH3)2)2)4 2+ , Zn(NH(CH2C(CH3)3)2)4 2+ , Zn(NH(CH2C(CH2CH3)3)2)4 2+ , Zn(NH(CH2CH2C(CH3)3)2)4 2+ , Zn(NH2CH2CH2OH)4 2+ , Zn(NH(CH2CH2OH)2)4 2+ , Zn(N(CH2CH2OH)3)4 2+ , Zn(NH2CH2COOH)4 2+ , Zn(NH2CH2CONH2)4 2+ , Zn(NH2CH2COOCH3)4 2+ , Zn(NH2CH2COOCH2CH3)4 2+ , Zn(NH2CH2COOC(CH3)3)4 2+ , Zn(NH2CH2COOCH(CH3)2)4 2+ , Zn(NH2CH2CH2COOH)4 2+ , Zn(NH(CH2COOH)2)4 2+ , Zn(N(CH2CH2COOH)3)4 2+ , [ka] TIFF2024541058000002.tif194170
[0070] All of the complex cations are Cl - , Br - , I - , SO4 2- , HSO4 - , NO3 - , PO4 3- , HPO4 2- , H2PO4 - , CO32- , HCO3 - , H.C.O.O. - , CH3COO - , F3CCOO - , Cl3CCOO - , FCH2COO - , ClCH2COO - , F2CHCOO - , Cl2CHCOO - , BF4 - , SO3 2- , HSO3 - , CH3SO3 - , C6H5CH2SO3 - , C6H5SO3 - , C6H5COO - , C6H5CH2COO - , C6F5O - , C6H4(OH)COO - , C6H2F3O - , C6H4(NO2)O - , and C6H2(NO2)3O - They can be formed as salts with anions selected from, but not limited to:
[0071] The amount of the transition metal cation-amino complex in the reaction solution is 0.5 to 20 equivalents relative to the antibody, preferably 1.0 to 5.0 equivalents relative to the antibody. The transition metal cation-amino complex may be added to the reaction solution together with a water-miscible organic solvent selected from, but not limited to, ethanol, methanol, propanol, propanediol, DMA, DMF, DMSO, THF, and CHCN.
[0072] The reducing agent used in the reduction solution with transition metal cation-amino complexes is tris(hydroxypropyl)-phosphine (P(CH2CH2CH2OH)3), P(CH2CH3), P(CH2CH2CH3), P(CH2CH2-CH2CH3), P(CH(CH3)2), P(CH2CH=CH2), P(CH2CH2CN), P(CH(CH3)2)2(CH2CH2NH2), P(CH2CH2CONH2), P(CH2CH2CONHCH3), P(CH2CH2CH2NHCOCH3), NaB(CN)H3, (CH6H 11 )2P(CH2)4P(C6H 11 )2, (C6H 11 )2P(CH2)3P-(CH 11 )2, dicyclohexyl(ethyl)phosphine, bis[2-(di-tert-butylphosphine)ethyl]amine, tricyclohexylphosphine, 1,2-ethyldiylbis[dicyclohexyl]-phosphine, bis[2-(dicyclohexylphosphine)ethyl]amine, tris[2-(diphenylphosphine)ethyl]-phosphine ([(CH)2PCH2CH2]3P), triphenylphosphine, sulfonated triphenylphosphines (2-(diphenylphosphine)benzenesulfonic acid (diPPBS), 3-(diphenylphosphine)benzenesulfonic acid, 4-(diphenylphosphinyl)benzenesulfonic acid, 3,3',3''-phosphoryltribenzenesulfonic acid). Preferably, the reducing agent is selected from TECP or P(CH2CH2CH2OH)3, more preferably TECP. The concentration of the reducing agent used in the reaction solution is 0.04 mM to 0.4 mM, or 1.0 to 10.0 equivalents of the antibody in the reaction solution. Preferably, the reducing agent is used in an amount of 2.0 to 4.0 equivalents of the antibody.
[0073] Suitable buffers for selective reduction include, but are not limited to, PBS, Mes, Bis-Tris, Bis-Tris propane, Pipes, Aces, Mopso, Bes, Mops, Hepes, Tes, Pipps, Dipso, Tapso, Heppso, Tris-up, Tris-HCl, Tricine, Hepps, Gly-Gly, Bicine, Taps, Hepee, acetate, histidine, citrate, MES, borate, or any combination thereof, and have a pH of 4.0-9.0, preferably 5.0-7.5, more preferably 5.5-7.5. The concentration of the buffer solution during the reaction is 0.02-1.0 M, preferably 20-200 mM, more preferably 20-100 mM; as a co-solvent, up to 30% of a water-miscible organic solvent selected from DMA, DMF, ethanol, methanol, acetone, acetonitrile, THF, isopropyl alcohol, dioxane, propylene glycol, or ethylene glycol may be added to the aqueous buffer solution.
[0074] The optimum temperature for the reduction reaction is usually controlled between about -5 and 40°C, and the reaction time is between 15 minutes and 48 hours. However, it is well understood in the art of protein conjugation that the reaction time and temperature can be determined by those skilled in the art based on the specific protein, particularly the antibody, being conjugated. For example, a preferred reduction reaction can usually be controlled between about -5 and 40°C, preferably between about 0 and 37°C, more preferably between about 2 and 8°C, and more precisely between 4±1°C. The conjugation method takes 15 minutes to 12 hours, more preferably at a temperature between about 2 and 8°C, and the process time is between about 30 minutes and 15 hours (overnight).
[0075] During or after reduction, the drug / linker complex / assembly is added directly to the reduction reaction solution for conjugation. The drug / linker complex / assembly has formula (I) or (II), represented as follows: [ka]
[0076] Lv1 and Lv2 are thiol reactive groups and are independently selected from: [ka] TIFF2024541058000005.tif248170TIFF2024541058000006.tif237170TIFF2024541058000007.tif248170TIFF2024541058000008.tif222170
[0077] In the formula, X1′ and X2 X' is independently F, Cl, Br, I, OTf, OMs, OC6H4(NO2), OC6H3(NO2)2, OC6F5, OC6HF4, or Lv3; X2 is O, NH, N(R1), or CH2; R3 and R5 are independently H, R1, an aromatic, heteroaromatic, or aromatic group, in which one or several H atoms are independently replaced by -R1, -halogen, -OR1, -SR1, -NR1R2, -NO2, -S(O)R1, -S(O)2R1, or -COOR1; Lv3 and Lv3' are independently F, Cl, Br, I, nitrophenoxyl, N-hydroxysuccinimide (NHS), phenoxyl , benzenethiol, dinitrophenoxyl, pentafluorophenoxyl, tetrafluorophenoxyl, difluorophenoxyl, monofluorophenoxyl, pentachlorophenoxyl, triflate, imidazole, dichlorophenoxyl, tetrachlorophenoxyl, 1-hydroxybenzotriazole, tosylate, mesylate, 2-ethyl-5-phenylisoxazolium-3′-sulfonate, anhydrides formed with themselves or other anhydrides, acetyl anhydride, formyl anhydride, or an intermediate molecule generated with a condensation reagent for a peptide coupling reaction or a Mitsunobu reaction.
[0078] In formula (II) and formula (III), [ka] can be selected from the following:
[0079] [ka] TIFF2024541058000011.tif244170TIFF2024541058000012.tif232170TIFF2024541058000013.tif216170TIFF2024541058000014.tif198170
[0080] In the formula, Lv3, Lv3', X1', and X2' are as defined above. The bond in the middle of the two atoms [ka] means that it can bond to either of the two atoms.
[0081] L1 and L2 are the same or different and each independently represent O, NH, S, NHNH, N(R3), N(R3)N(R3'), or a group of the formula (OCH2CH2) p OR3, (OCH2CH(CH3)) p OR3, NH(CH2CH2O) p OR3, NH(CH2CH(CH3)O)pR3 p OR3, N[(CH2CH2O) p R3][(CH2CH2O) p’ R 3’ , (OCH2CH2) p COOR3, or CH2CH2(OCH2CH2) p COOR3 polyethyleneoxy units, where p and p' are independently an integer selected from 0 to about 1000, or a combination thereof; C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; 3’are independently H, C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, aryl of heterocycloalkyl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, or amide having 1 to 8 carbon atoms; or one to eight natural or unnatural amino acids as described in the definitions; or a group of formula (OCH2CH2) p or (OCH2CH(CH3)) p where p is an integer from 0 to about 1000, or a combination thereof.
[0082] L1 or L2 may comprise a self-immolative or non-self-immolative moiety, a peptidyl unit, a hydrazone bond, a disulfide, an ester, an oxime, an amide, or a thioether bond, wherein the self-immolative unit comprises aromatic compounds electronically similar to a para-aminobenzylcarbamoyl (PAB) group, including 2-aminoimidazole-5-methanol derivatives, heterocyclic PAB analogs, β-glucuronides, and ortho- or para-aminobenzyl acetals.
[0083] Preferably, the self-immolative linker moiety has one of the following structures: [ka]
[0084] In the formula, ( * Atoms labeled with X are points of attachment to additional spacers, releasable linker units, cytotoxic agents, and / or cell binding molecules (CBAs); 1 , Y 1 , Z 2 , and Z 3 are independently NH, O or S; Z 1 are independently H, NH, O, or S; v is 0 or 1; U 1 are independently H, OH, C1-C6 alkyl, (OCH2CH2) n , F, Cl, Br, I, OR5, SR5, NR5R 5’, N=NR5, N=R5, NR5R 5’ , NO2, SOR5R 5’ , SO2R5, SO3R5, OSO3R5, PR5R 5’ , POR5R 5’ , PO2R5R 5’ , OPO(OR5)(OR 5’ ), or OCH2PO(OR5)(OR 5’ ) wherein R5 and R 5’ are as defined above; preferably R and R 5’ are independently selected from H, C1-C8 alkyl; C2-C8 alkenyl, alkynyl, heteroalkyl; C3-C8 aryl, heterocycle, carbocycle, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or a medicinal cationic salt.
[0085] The non-self-immolative linker moiety has one of the following structures: [ka] TIFF2024541058000018.tif160170
[0086] In the formula, ( * Atoms labeled with X are points of attachment to additional spacers R, releasable linker units, cytotoxic agents, and / or binding molecules; 1 , Y 1 , U 1 , R5, R 5’ is as defined above; r is 0 to 100; m and n are independently 0 to 6;
[0087] More preferably, L1 or L2 may be comprised of one or more linker moieties that are 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP"), valine-citrulline ("val-cit" or "vc"), alanine-phenylalanine ("ala-phe" or "af"), p-aminobenzyloxycarbonyl ("PAB"), 4-thiopentanoic acid ("SPP"), 4-(N-maleimidomethyl)cyclohexane-1 carboxylate ("MCC"), (4-acetyl)aminobenzoic acid ("SIAB"), 4-thiobutyric acid (SPDB), 4-thio-2-hydroxysulfonylbutyric acid (2-sulfo-SPDB), or a natural or unnatural peptide having 1 to 8 natural or unnatural amino acid units.
[0088] More preferably, L1 or L2 may be a releasable linker. The term releasable linker refers to a linker that contains at least one bond that can be broken down under physiological conditions, such as pH-labile, acid-labile, base-labile, oxidatively labile, metabolically labile, biochemically labile, or enzymatically labile. Physiological conditions that cause such bond breakdown do not necessarily involve biological or metabolic processes, but instead may involve standard chemical reactions, such as hydrolysis or substitution reactions, e.g., disulfide bond exchange reactions with intracellular thiols, such as glutathione, which is abundant in the millimolar range in endosomes, which have a pH lower than the cytosolic pH, and / or in malignant cells.
[0089] Examples of the releasable linkers (L, L1 or L2) include, but are not limited to: -(CR5R6) m (Aa) r (CR7R8) n (OCH2CH2) t -, -(CR5R6) m (CR7R8) n (Aa) r (OCH2CH2) t -, -(Aa) r -(CR5R6) m (CR7R8) n (OCH2CH2) t-、-(CR5R6) m (CR7R8) n (OCH2CH2) r (Aa) t -、-(CR5R6) m -(CR7=CR8)(CR9R 10 ) n (Aa) t (OCH2CH2) r -、-(CR5R6) m (NR 11 CO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -、-(CR5R6) m (Aa) t (NR 11 CO)(CR9R 10 ) n (OCH2CH2) r -、-(CR5R6) m (OCO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -、-(CR5R6) m (OCNR7)(Aa) t (CR9R 10 ) n (OCH2CH2) r -、-(CR5R6) m (CO)(Aa) t -(CR9R 10 ) n (OCH2CH2) r -、-(CR5R6) m (NR 11 CO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -、-(CR5R6) m -(OCO)(Aa) t (CR9R 10 ) n -(OCH2CH2) r -、-(CR5R6) m (OCNR7)(Aa) t (CR9R 10 )n (OCH2CH2) r -, -(CR5R6) m (CO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -, -(CR5R6) m -phenyl-(CO)(Aa) t (CR7R8) n -, -(CR5R6) m -Frill-(CO)(Aa) t (CR7R8) n -, -(CR5R6) m -oxazolyl-(CO)(Aa) t (CR7R8) n -, -(CR5R6) m -thiazolyl-(CO)(Aa) t (CR7R8) n -, -(CR5R6) t -Thienyl-(CO)(CR7R8) n -, -(CR5R6) t -Imidazolyl-(CO)(CR7R8) n -, -(CR5R6) t -morpholino-(CO)(Aa) t (CR7R8) n -, -(CR5R6) t -piperazino-(CO)(Aa) t (CR7R8) n -, -(CR5R6) t -N-methylpiperazine-(CO)(Aa) t (CR7R8) n -, -(CR5R6) m -(Aa) t Phenyl-, -(CR5R6) m -(Aa) t Frill-,-(CR5R6) m -oxazolyl (Aa) t -, -(CR5R6) m -Thiazolyl (Aa) t -, -(CR5R6) m -Thienyl (Aa) t -, -(CR5R6) m -Imidazolyl (Aa)t -、-(CR5R6) m -モルホリノ-(Aa) t -、-(CR5R6) m -ピペラジノ-(Aa) t -、-(CR5R6) m -N-メチルピペラジノ-(Aa) t -、-K(CR5R6) m (Aa) r (CR7R8) n (OCH2CH2) t -、-K(CR5R6) m (CR7R8) n (Aa) r (OCH2CH2) t -、-K(Aa) r (CR5R6) m (CR7R8) n (OCH2CH2) t -、-K(CR5R6) m (CR7R8) n (OCH2CH2) r (Aa) t -、-K(CR5R6) m (CR7=R8)(CR9R 10 ) n (Aa) t (OCH2CH2) r -、-K(CR5R6) m (NR 11 CO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -、-K(CR5R6) m (Aa) t (NR 11 CO)(CR9R 10 ) n (OCH2CH2) r -、-K(CR5R6) m (OCO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -、-K(CR5R6) m (OCNR7)(Aa) t (CR9R 10 ) n(OCH2CH2) r -, -K(CR5R6) m (CO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -, -K(CR5R6) m (NR 11 CO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -, -K(CR5R6) m (OCO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -, -K(CR5R6) m (OCNR7)(Aa) t (CR9R 10 ) n (OCH2CH2) r -, -K(CR5R6) m (CO)(Aa) t (CR9R 10 ) n (OCH2CH2) r -, -K(CR5R6) m -phenyl-(CO)(Aa) t (CR7R8) n -, -K(CR5R6) m -Frill-(CO)(Aa) t (CR7R8) n -, -K(CR5R6) m -oxazolyl-(CO)(Aa) t (CR7R8) n -, -K(CR5R6) m -thiazolyl-(CO)(Aa) t (CR7R8) n -, -K(CR5R6) t -Thienyl-(CO)(CR7R8) n -, -K(CR5R6) t -Imidazolyl-(CO)(CR7R8) n -, -K(CR5R6) t -morpholino-(CO)(Aa) t (CR7R8)n -, -K(CR5R6) t -piperazino-(CO)(Aa) t (CR7R8) n -, -K(CR5R6) t -N-methylpiperazine-(CO)(Aa) t (CR7R8) n -, -K(CR5R6) m -(Aa) t Phenyl-, -K(CR5R6) m -(Aa) t Frill-, -K(CR5R6) m -oxazolyl (Aa) t -, -K(CR5R6) m -Thiazolyl (Aa) t -, -K(CR5R6) m -Thienyl (Aa) t -, -K(CR5R6) m -Imidazolyl (Aa) t -, -K(CR5R6) m -Morpholino-(Aa) t -, -K(CR5R6) m -Piperazino-(Aa) t G-, -K(CR5R6) m -N-methylpiperazino-(Aa) t .
[0090] wherein m, Aa, m, n, R3, R4, and R5 are as defined above; t and r are independently 0 to 100; R6, R7, and R8 are independently selected from H; halide; C1-C8 alkyl, aryl, alkenyl, alkynyl, ether, ester, amine, or amide, and include one or more of halide, CN, NRR, CF, OR, aryl, heterocycle, S(O)R, SO2R, -CO2H, -SO3H, -OR, -CO2R, -CONR, -PO2R1R 12 , -PO3H, or P(O)R1R2R 3’and K is NR1, -SS-, -C(=O)-, -C(=O)NH-, -C(=O)O-, -C=NH-O-, -C=N-NH-, -C(=O)NH-NH-, O, S, Se, B, or a C3-C6 heteroaromatic ring.
[0091] The structures of the linkers L1 and L2 can be the following structures or combinations thereof: [ka] TIFF2024541058000020.tif238170TIFF2024541058000021.tif242170TIFF2024541058000022.tif251170 TIFF2024541058000023.tif238170TIFF2024541058000024.tif235170TIFF2024541058000025.tif145170
[0092] In the formula, X2, X3, X4, X5, or X6 independently represent NH, NHNH; N(R 12 );N(R 12 )N(R 12’ );O;S;C1-C6 alkyl;C2-C6 heteroalkyl, alkylcycloalkyl, heterocycloalkyl;C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl;CH2OR 12 , CH2SR 12 , CH2NHR 12 or 1 to 8 amino acids; 12 and R 12’ are independently H; C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, or amide having 1 to 8 carbon atoms; or a group of the formula (OCH2CH2) p or (OCH2CH(CH3))p where p is an integer from 0 to about 100; or a combination thereof.
[0093] Furthermore, L1, L2, X1, X2, X3, X 1’ , X 2’ , and X 3’ may not exist independently.
[0094] E1 is a linking group that connects the two thiol-reactive groups of Lv1 and Lv2, and E1 is CH, CH2, NH, NHNH, N(R3), N(R3)N(R 3’ ), N=N, NN, P, P(=O), S, Si, C2-C8 alkyl, heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; a peptide comprising 1 to 4 units of an amino acid, preferably aspartic acid, glutamic acid, arginine, histidine, lysine, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, tyrosine, phenylalanine, glycine, proline, tryptophan, or alanine; or any of the following structures:
[0095] [ka] TIFF2024541058000027.tif53170
[0096] wherein D is a cytotoxic agent, a therapeutic agent, an immunotherapeutic short antibody-like protein, or a functional molecule for enhancing the binding or stability of a cell-binding antibody-like protein agent, a cell surface receptor-binding ligand, an antibody fragment, an siRNA, or a DNA molecule.
[0097] The cytotoxic agent is selected from, but not limited to:
[0098] 1) Chemotherapeutic agents: a) alkylating agents selected from the group consisting of: nitrogen mustards: chlorambucil, chlornaphazine, cyclophosphamide, dacarbazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, mannomustine, mitobronitol, melphalan, mitolactol, pipobroman, nobembitine, phenesterine, prednimustine, thiotepa, trofosfamide, uracil mustard; CC-1065 and synthetic analogs of adozelesin, carzelesin, and bizelesin; duocarmycin and its synthetic analogs KW-2189 and CBI-TMI; benzodiazepine dimers or pyrrolobenzodiazepine (PBD) dimers, tomaymycin dimers, indolinobenzodiazepine dimers nitrosourea compounds including carmustine, lomustine, chlorozotocin, fotemustine, nimustine, ranimustine; alkylsulfonates including busulfan, treosulfan, improsulfan, and piposulfan; triazenes or dacarbazine; platinum-containing compounds including carboplatin, cisplatin, and oxaliplatin; aziridines, benzodopa, carboquone, metledopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramine, and trimethylolomelamine; b) plant alkaloids selected from the group consisting of: vinca alkaloids including vincristine, vinblastine, vindesine, vinorelbine, and navelbine; taxoids including paclitaxel and docetaxel and analogs thereof; maytansinoids including DM1, DM2, DM3, DM4, DM5, DM6, DM7, maytansine, and ansamitocin and analogs thereof; cryptophycins including the cryptophycin 1 and cryptophycin 8 groups; epothilones, eleutherobin, discodermolide, bryostatins, dolostatins, auristatins, tubulysins, and cephalostatins; pancratistatin; sarcodictyin; and spongistatin. c) DNA topoisomerase inhibitors selected from the following: epipodophyllins, including 9-aminocamptothecin, camptothecin, crisnatol, daunomycin, etoposide, etoposide phosphate, irinotecan, mitoxantrone, novantrone, retinoic acid (retinolic acid), teniposide, topotecan, 9-nitrocamptothecin, or RFS 2000; and mitomycins, and analogs thereof; d) Antimetabolites: {[Antifolates: (DHFR inhibitors: including methotrexate, trimetrexate, denopterin, pteropterin, aminopterin (4-aminopteroic acid), or other folic acid analogs); IMP dehydrogenase inhibitors (including mycophenolic acid, tiazofurin, ribavirin, EICAR); Ribonucleotide reductase inhibitors (including hydroxyurea, deferoxamine)]; [Pyrimidine analogs: uracil uridine analogs (including ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, 5-fluorouracil, floxuridine, raltitrexed); cytosine analogs (including cytarabine, cytosine arabinoside, fludarabine); purine analogs (including azathioprine, fludarabine, mercaptopurine, thiamiprine, thioguanine); folic acid supplements such as folinic acid; e) Hormonal Therapy: Receptor Antagonists: [Antiestrogens: (including megestrol, raloxifene, tamoxifen); LHRH Agonists: (including goserelin, leuprolide acetate); Antiandrogens: (bicalutamide, flutamide, calsterone, dromostanolone propionate, epithiostanol, goserelin, leuprolide, mepitiostane, nilutamide, testolactone, trilostane, and other similar androgen inhibitors] retinoids / deltoids: [vitamin D3 analogs: (including CB1093, EB1089, KH1060, cholecalciferol, ergocalciferol); photodynamic therapy agents: (including verteporfin, phthalocyanines, photosensitizer Pc4, demethoxyhypocrelin A); cytokines: (including interferon alpha, interferon gamma, tumor necrosis factor (TNF), TNF domain-containing human proteins)]}; f) Kinase inhibitors: selected from the group consisting of BIBW2992 (anti-EGFR / Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib, vandetanib, E7080 (anti-VEGFR2), mubritinib, ponatinib, bafetinib, bosutinib, cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, trastuzumab, ranibizumab, panitumumab, and ispinesib; g) a poly(ADP-ribose) polymerase (PARP) inhibitor selected from the group consisting of olaparib, niraparib, iniparib, talazoparib, veliparib, CEP9722 (Cephalon), E7016 (Eisai), BGB-290 (Beigene), or 3-aminobenzamide; h) enediyne antibiotics (selected from the group consisting of calicheamicins, calicheamicin gamma 1, delta 1, alpha 1, or beta 1; dynemicins including dynemicin A and deoxydynemicin; esperamicin, kedarcidin, C-1027, maduropeptin, or neocarzinostatin chromophores and related chromoprotein enediyne antibiotic chromophores), aclacinomycins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin; chromomycins, dactinomycin, daunomycin, antibiotics selected from rubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin, epirubicin, eribulin, esorubicin, idarubicin, marcellomycin, nitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfilomycin, puromycin, queramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; i) Polyketides (acetogenins), bullatacin and bullatacinone; gemcitabine, epoxomicins and carfilzomib, bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allovectin-7, Zygeba, Provenge, Elvoy, isoprenylation inhibitors and lovastatin, dopaminergic neurotoxins and 1-methyl-4-phenyl Pyridine ion, cell cycle inhibitors (including staurosporine), actinomycins (including actinomycin D and dactinomycin), amanitins, bleomycins (including bleomycin A2, bleomycin B2, and peplomycin), anthracyclines (including daunorubicin, doxorubicin (adriamycin), idarubicin, epirubicin, pirarubicin, and zorubicin), mitoxantrone, MDR inhibitors or verapamil, Ca 2+ATP inhibitors or thapsigargin, histone deacetylase inhibitors (including vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat (MGCD0103), belinostat, PCI-24781, entinostat, SB939, resminostat, gibinostat, AR-42, CUDC-101, sulforaphane, and trichostatin A); thapsigargin, celecoxib, glitazones, epigallocatechin gallate, disulfiram, salinosporamide A, antiadrenal drugs (selected from the group consisting of aminoglutethimide, mitotane, and trilostanol); aceglatone; aldophosphamide glicoside; aminolevulinic acid; amsacrine; arabinoside, Bestravsil; and Bisant Len; edatrexate; defofamine; demecolcine; diaziquone; elfornithine (DFMO), elfomitine; elliptinium acetate; etocluside, gallium nitrate, gacytosine, hydroxyurea; ibandronate, lentinan; lonidamine; mitoguazone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllic acid; 2-ethylhydrazide; procarbazine; PSK (registered trademark); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes (including T2 toxin, verrucarin A, roridin A, and anguidine); urethane, siRNA, antisense drugs, nucleases;
[0099] 2) Anti-autoimmune disease drugs: cyclosporine, cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, corticoids (including amcinonide, betamethasone, budesonide, hydrocortisone, flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, triamcinolone acetonide, and beclomethasone dipropionate), DHEA, etanercept, hydroxychloroquine, infliximab, meloxicam, methotrexate, mofetil, mycophenolate, prednisone, sirolimus, and tacrolimus;
[0100] 3) Anti-infectives (including but not limited to): a) Aminoglycosides: amikacin, astromycin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin (amikacin, arbekacin, bekanamycin, dibekacin, tobramycin), neomycin (framycin, paromomycin, ribostamycin), netilmicin, spectinomycin, streptomycin, tobramycin, verdamycin; b) Amphenicols: azidamphenicol, chloramphenicol, florfenicol, thiamphenicol; c) Ansamycins: geldanamycin, herbimycin; d) Carbapenems: biapenem, doripenem, ertapenem, imipenem, cilastatin, meropenem, panipenem; e) Cephems: carbacephem (loracarbef), cephacetrile, cefaclor, cephradine, cefadroxil, cephalonium, cephaloridine, cephalothin or cephalothin, cephalexin, cephaloglycin, cefamandole, cephapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefbuperazone, cefcapene, cefdaloxime, cefepime, cefminox, cefoxitin, cefprozil, cefroxadine, ceftezole, cefuroxime, cefixime, cefdinir, cefditoren, cefepime, fetamet, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefprozil, cefquinome, cefsulodin, ceftazidime, cefteram, ceftibuten, ceftiolene, ceftizoxime, ceftobiprol, ceftriaxone, cefuroxime, cefuzonam, cephamycins (including cefoxitin, cefotetan, cefmetazole), oxacephems (flomoxef, latamoxef); f) Glycopeptides: bleomycin, vancomycin (including oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin; g) Glycylcyclines: Tigecycline; h) β-lactamase inhibitors: penams (sulbactam, tazobactam), clavams (clavulanic acid); i) Lincosamides: clindamycin, lincomycin; j) Lipopeptides: daptomycin, A54145, calcium-dependent antibiotics (CDA); k) Macrolides: azithromycin, cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolides (telithromycin, cethromycin), midecamycin, miokamycin, oleandomycin, rifamycins (rifampicin, rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin, tacrolimus (FK506), troleandomycin, telithromycin; l) Monobactams: aztreonam, tigemonam; m) Oxazolidinones: Linezolid; n) Penicillins: amoxicillin, ampicillin, pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin, azidocillin, azlocillin, benzylpenicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, clometocillin, procaine benzylpenicillin, carbenicillin (carindacillin), cloxacillin, dicloxacillin, epicillin, flucloxacillin, mecillinam (pivmecillinam), mezlocillin, methicillin, nafcillin, oxacillin, penamecillin, penicillin, phenethicillin, phenoxymethylpenicillin, piperacillin, propicillin, sulbenicillin, temocillin, ticarcillin; o) Polypeptides: bacitracin, colistin, polymyxin B; p) Quinolones: alatrofloxacin, balofloxacin, ciprofloxacin, clinafloxacin, danofloxacin, difloxacin, enoxacin, enrofloxacin, floxin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, canotrovafloxacin, levofloxacin, lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, orbifloxacin, ofloxacin, pefloxacin, trovafloxacin, grepafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, trovafloxacin; q) Streptogramins: Pristinamycin, quinupristin / dalfopristin; r) Sulfonamides: mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole (co-trimoxazole); s) Steroidal antibacterial agents: fusidic acid, etc.; t) Tetracyclines: doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline, meclocycline, methacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, glycylcyclines (tigecycline, etc.); u) Other antibiotics: annonacin, arsphenamine, bactoprenol inhibitors (bacitracin), DADAL / AR inhibitors (cycloserine), dictyostatin, discodermolide, eleutherobin, epothilone, ethambutol, etoposide, faropenem, fusidic acid, furazolidone, isoniazid, laulimalide, metronidazole, mupirocin, mycolactone, NAM synthesis inhibitors (fosfomycin), nitrofurantoin, paclitaxel, platensimycin, pyrazinamide, quinupristin / dalfopristin, rifampicin (rifampin), tazobactamcinidazole, uvaricin;
[0101] 4) Antiviral drugs: a) Entry / fusion inhibitors: aplaviroc, maraviroc, vicriviroc, gp41 (enfuvirtide), PRO140, CD4 (ibalizumab); b) Integrase inhibitors: Raltegravir, Elvitegravir, Globoidnan A; c) Maturation inhibitors: Bevirimat, Vivecon; d)Neuraminidase inhibitors: oseltamivir, zanamivir, peramivir; e) Nucleosides and Nucleotides: Abacavir, Acyclovir, Adefovir, Amdoxovir, Apricitabine, Brivudine, Cidofovir, Clevudine, Dexerbucitabine, Didanosine (DDI), Elvucitabine, Emtricitabine (FTC), Entecavir, Famciclovir, Fluorouracil (5-FU), 3'-Fluoro-substituted 2',3'-deoxynucleoside analogues (e.g., 3'-fluoro-2',3'-dideoxythymidine (FLT) and 3'-fluoro-2',3'- dideoxyguanosine (FLG), fomivirsen, ganciclovir, idoxuridine, lamivudine (3TC), L-nucleosides (e.g., β-L-thymidine and β-L-2'-deoxycytidine), penciclovir, rasvir, ribavirin, stampidine, stavudine (d4T), taribavirin (viramidine), telbivudine, tenofovir, trifluridine, valacyclovir, valganciclovir, zalcitabine (ddC), zidovudine (AZT); f) Non-nucleosides: amantadine, ateviridin, capravirine, diarylpyrimidines (etravirine, rilpivirine), delavirdine, docosanol, emivirine, efavirenz, foscarnet (phosphoryl formate), imiquimod, interferon alpha, loviride, rhodenosine, methisazone, nevirapine, NOV-205, peginterferon alpha, podophyllotoxin, rifampicin, rimantadine, resiquimod (R-848), tromantadine; g) Protease inhibitors: amprenavir, atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, pleconaril, ritonavir, saquinavir, telaprevir (VX-950), tipranavir; h) Other antiviral drugs: Abzyme, arbidol, calanolide A, ceragenin, cyanovirin-N, diarylpyrimidine, epigallocatechin gallate (EGCG), foscarnet, griffithsin, taribavirin (viramidine), hydroxyurea, KP-1461, miltefosine, pleconaril, portmanteau inhibitors, ribavirin, seliciclib;
[0102] 5) Drugs used in the bridged conjugates of the present invention also include radioisotopes. Examples of radioisotopes (radionuclides) include: 3 H, 11 C. 14 C. 18 F, 32 P, 35 S, 64 Cu, 68 Ga, 86 Y, 99 Tc, 111 In, 123 I, 124 I, 125 I, 131 I, 133 Xe, 177 Lu, 211 At, or 213 Radioisotope-labeled antibodies are useful for receptor-targeted imaging experiments or can be used for targeted therapy using the antibody-drug conjugates of the present invention (Wu et al. (2005) Nature Biotechnology 23(9): 1137-46). Cell-binding molecules, such as antibodies, can be labeled with ligand reagents via the bridge linkers of this patent that bind, chelate, or complex to radioisotopes using the techniques described in Current Protocols in Immunology, Volumes 1 and 2, Coligen et al., Ed. Wiley-Interscience, New York, Pubs. (1991). Chelating ligands that can complex with metal ions include DOTA, DOTP, DOTMA, DTPA, and TETA (Macrocyclics, Dallas, Texas, USA).
[0103] 6) Pharmaceutically acceptable salts, acids, or derivatives of any of the above drugs.
[0104] In another embodiment, drug D can be a chromophoric molecule for detecting, monitoring, or studying the interaction of a cell-binding molecule with a target cell. Chromophoric molecules capable of absorbing UV light, fluorescent light, IR light, near-IR light, or visible light; xanthophores, erythrophores, iridophores, leucophores, melanophores, and cerebrophores; a class or subclass of fluorescent molecules, which are fluorescent chemicals that re-emit light with light; a class or subclass of visual light-sensitive molecules; a class or subclass of luminescent molecules; a class or subclass of luminescent molecules; and a class or subclass of luciferin compounds.
[0105] Chromophore molecules include, but are not limited to, the following non-protein organic fluorophores: xanthene derivatives (including fluorescein, rhodamine, Oregon Green, eosin, and Texas Red); cyanine derivatives (including cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, and merocyanine); squalene derivatives and ring-substituted squaraines (including Seta, SeTau, and Square dyes); naphthalene derivatives (including dansyl and prodan derivatives); coumarin derivatives; oxadiazole derivatives (including pyridyloxazole, nitrobenzoxadiazole, and benzoxadiazole); anthracene derivatives (including anthraquinones, including DRAQ5, DRAQ7, and CyTRAK Orange); pyrene derivatives (Cascade Blue); oxazine derivatives (including Nile Red, Nile Blue, cresyl violet, and oxazine 170); acridine derivatives (including proflavine, acridine orange, and acridine yellow); and arylmethine derivatives (including auramine, crystal violet, and malachite green). It can be selected from tetrapyrrole derivatives (including porphines, phthalocyanines, bilirubins).
[0106] Alternatively, the chromophore molecule can be selected from analogs and derivatives of the following fluorophore compounds: CF dyes (Biotium), DRAQ and CyTRAK probes (BioStatus), BODIPY (Invitrogen), Alexa Fluor (Invitrogen), DyLight Fluor (Thermo Scientific, Pierce), Atto and Trancy (Sigma Aldrich), FluoProbes (Interchim), Abberior dyes (Abberior), DY and MegaStokes dyes (Dyomics), SulfoCy dyes (SETA BioMedicals), HiLyte Fluor (Biosearch Technologies), Seta, SeTau and Square dyes (SETA BioMedicals), Quasar and Cal Flour dyes (Biosearch Technologies), SureLight dyes (APC, RPEPerCP, Phycobilisome) (Columbia Biosciences), APC, APCXL, RPE, BPE.
[0107] Examples of widely used fluorophore compounds that are reactive or conjugable with the conjugates of the present invention include: allophycocyanin (APC), aminocoumarin, APC-Cy7 conjugate, BODIPY-FL, Cascade Blue, Cy2, Cy3, Cy3.5, Cy3B, Cy5, Cy5.5, Cy7, fluorescein, FluorX, hydroxycoumarin, Lissamine rhodamine B, Lucifer Yellow, methoxycoumarin, NBD, Pacific Blue, Pacific Orange, PE-Cy5 conjugate, PE-Cy7 conjugate, PerCP, R-phycoerythrin (PE), Red 613, Seta-555-azide, Seta-555-DBCO, Seta-555-NHS, Seta-580-NHS, Seta-680-NHS, Seta-780-NHS, Seta-APC-780, Seta-PerCP-680, Seta-R-PE-670, SeTau380-NHS, SeTau405-maleimide, SeTau405-NHS, SeTau425-NHS, SeTau647-NHS, Texas Red, TRITC, TruRed, and X-rhodamine.
[0108] For the study of nucleic acids or proteins, fluorophore compounds that can be attached to the conjugates of the invention are selected from the following compounds or their derivatives: 7-AAD (7-aminoactinomycin D, CG selective), acridine orange, chromomycin A3, CyTRAK orange (red excitation dark), DAPI, DRAQ5, DRAQ7, ethidium bromide, Hoechst 33258, Hoechst 33342, LDS751, mithramycin, propidium iodide (PI), SYTOX Blue, SYTOX Green, S YTOX Orange, Thiazole Orange, TO-PRO: Cyanine monomer, TOTO-1, TO-PRO-1, TOTO-3, TO-PRO-3, YOseta-1, YOYO-1; fluorescent dyes containing the following compounds or their derivatives: DCFH (2'7'-dichlorodihydrofluorescein, oxidized form), DHR (dihydrorhodamine 123, oxidized form, photocatalytic oxidation), Fluo-3 (AM ester, pH > 6), Fluo-4 (AM ester, pH 7.2), Indo-1 (AM ester, low / high calcium (Ca 2+)), SNARF (pH 6 / 9), allophycocyanin (APC), AmCyan1 (tetramer, Clontech), AsRed2 (tetramer, Clontech), Azami Green (monomer), azurite, B-phycoerythrin (BPE), cerulean, CyPet, DsRed monomer (Clontech), DsRed2 ("RFP"), EBFP, EBFP2, ECFP, EGFP (weak dimer), emerald (weak dimer), EYFP (weak dimer), GFP (S65A mutant), GFP (S65C mutant), GFP (S65L mutant), GFP (S65T mutant), GFP (Y66F mutant), GFP (Y66H mutant), GFP (Y66W mutant), GFP uv , HcRed1, J-Red, Katyusha, Kusabira Orange (monomer, MBL), mCFP, mCherry, mCitrine, Midoriishi Cyan (dimer, MBL), mKate (TagFP635, monomer), mKeima-Red (monomer), mKO, mOrange, mPlum, mRaspberry, mRFP1 (monomer), mStrawberry, mTFP1, mTurquoise2, P3 (phycobilisome complex), Peridinin Chlorophyll (PerCP), R-phycoerythrin (RPE), T-Sapphire, TagCFP (dimer), TagGFP (dimer), TagRFP (dimer), TagYFP (dimer), tdTomato (tandem dimer), Topaz, TurboFP602 (dimer), TurboFP635 (dimer), TurboGFP (dimer), TurboRFP (dimer), TurboYFP635 (dimer), Venus, native GFP, YPet, Zs Green 1 (tetramer), Zs Yellow 1 (tetramer), and their derivatives.
[0109] In another embodiment, drug D can be a polyalkylene glycol used to extend the half-life of a cell-binding antibody or antibody-like protein molecule when administered to a mammal. Polyalkylene glycols include, but are not limited to, polyalkylene glycols selected from poly(ethylene glycol) (PEG), poly(propylene glycol), and copolymers of ethylene oxide and propylene oxide; particularly preferred is PEG, and even more particularly preferred is monofunctionally activated hydroxyPEG (e.g., hydroxyPEG activated at one end, including hydroxyPEG-monocarboxylic acid, hydroxyPEG-monoaldehyde, hydroxyPEG-monoamine, hydroxyPEG-monohydrazide, hydroxyPEG-monocarbazide, hydroxyPEG-monoiodoacetamide, hydroxyPEG-monomaleimide, hydroxyPEG-orthopyridine disulfide, hydroxyPEG-monoxime, hydroxyPEG-monophenylcarbonate, hydroxyPEG-monophenylglyoxal, hydroxyPEG-monothiazolidine-2-thione, hydroxyPEG-monothioester, hydroxyPEG-monothiol, hydroxyPEG-monotriazine, and hydroxyPEG-monovinylsulfone).
[0110] In certain such embodiments, the polyalkylene glycol has a molecular weight of about 10 daltons to about 200 kDa, preferably about 88 Da to about 40 kDa; two branches each having a molecular weight of about 88 Da to about 40 kDa; and more preferably, two branches each having a molecular weight of about 88 Da to about 20 kDa. In one particular embodiment, the polyalkylene glycol is poly(ethylene) glycol and has a molecular weight of about 10 kDa; about 20 kDa; or about 40 kDa. In certain embodiments, the PEG is PEG 10 kDa (linear or branched), PEG 20 kDa (linear or branched), or PEG 40 kDa (linear or branched). Many U.S. patents, such as U.S. Patent Nos. 5,428,128; 5,621,039; 5,622,986; 5,643,575; 5,728,560; 5,730,990; 5,738,846; 5,811,076; 5,824,701; 5,840,900; 5,880,131; 5,900,402; 5,902,588; 5,919,455; 5,951,974; 5,965,119; 5,965,566; 5,969,040; 5,981,709; 6,011,042; 6,042,822; Nos. 6,113,906; 6,127,355; 6,132,713; 6,177,087; and 6,180,095 disclose the preparation of linear or branched "non-antigenic" PEG polymers and their derivatives or conjugates.
[0111] In yet another embodiment, D is more preferably a potent cytotoxic agent, such as tubulysin and analogs thereof, maytansine and analogs thereof, taxanes and analogs thereof, CC-1065 and analogs thereof, daunorubicin or doxorubicin and analogs thereof, amatoxin and analogs thereof, benzodiazepine dimers (dimers of pyrrolobenzodiazepines (PBD), tomaymycin, anthramycin, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidinobenzodiazepines) and analogs thereof, calicheamicin, and enediyne antibiotic analogs, actinomycin and its analogs, azaserine and its analogs, bleomycin and its analogs, epirubicin and its analogs, tamoxifen and its analogs, idarubicin and its analogs, dolastatins and their analogs, auristatins (including monomethyl auristatin (MMAE), MMAF, auristatin PYE, auristatin TP, auristatin 2-AQ, 6-AQ, EB (AEB), and EFP (AEFP)) and their analogs, combretastatins, duocarmycins and their analogs and analogs thereof, camptothecin and analogs thereof, geldanamycin and analogs thereof, methotrexate and analogs thereof, thiotepa and analogs thereof, vindesine and analogs thereof, vincristine and analogs thereof, hemiasterin and analogs thereof, nazmamide and analogs thereof, spliceostatin, pladienolide, microginin and analogs thereof, radiosumin and analogs thereof, alterobactin and analogs thereof, microsclerodermin and analogs thereof, theonellamide and analogs thereof, The agent is selected from esperamycin and its analogs, PNU-159682 and its analogs, protein kinase inhibitors, MEK inhibitors, KSP inhibitors, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, immunotoxins, specific cell receptor agonists, cell stimulatory molecules or intracellular signaling molecules, one or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA), as well as stereoisomers, equivalents, analogs, or derivatives of the aforementioned drugs.
[0112] Tubulysin and its analogs are well known in the art and can be isolated from natural sources according to known methods or prepared synthetically according to known methods (e.g., Balasubramanian, R., et al. J. Med. Chem., 2009, 52, 238-40; Wipf, P., et al. Org. Lett., 2004, 6, 4057-60; Pando, O., et al. J. Am. Chem. Soc., 2011, 133, 7692-5; Reddy, J. A., et al. Mol. Pharmaceutics, 2009, 6, 1518-25; Raghavan, B., et al. J. Med. Chem., 2008, 51, 1530-33; Patterson, A. W., et al. J. Org. Chem., 2008, 73, 4362-9; Pando, O., et al. Org. Lett., 2009, 11 (24), 5567-9; Wipf, P., et al. Org. Lett., 2007, 9 (8), 1605-7; Friestad, GK, Org. Lett., 2004, 6, 3249-52; Peltier, HM et al., J. Am. Chem. Soc., 2006, 128, 16018-9; Chandrasekhar, S., et al. J. Org. Chem., 2009, 74, 9531-4; Liu, Y., et al. Mol. Pharmaceutics, 2012, 9, 168-75; Friestad, GK, et al Org. Lett., 2009, 11, 1095-8; Kubicek, K., et al., Angew Chem Int Ed Engl, 2010.49: 4809-12; Chai, Y., et al., Chem Biol, 2010, 17 : 296-309; Ullrich, A., et al.,Angew Chem Int Ed Engl, 2009, 48, 4422-5; Sani, M., et al., Angew Chem Int Ed Engl, 2007, 46, 3526-9. Domling, A., et al., Angew Chem Int Ed Engl, 2006, 45, 7235-9; Patent applications: Zanda, M., et al., Canadian Patent Application CA 2710693 (2011); Chai, Y., et al., European Patent Application 2174947 (2010), WO 2010034724; Leamon, C., et al., WO2010033733, WO2009002993; Ellman, J., et al., PCT WO2009134279; WO 2009012958, US Applications 20110263650, 20110021568; Matschiner, G., et al., WO2009095447; Vlahov, I., et al., WO2009055562, WO2008112873; Low, P., et al., WO2009026177; Richter W., WO2008138561; Kjems, J., et al., WO 2008125116; Davis, M., et al., WO2008076333; Diener, J., et al., U.S. Patent Application No. 20070041901, WO2006096754; Matschiner, G., et al., WO2006056464; Vaghefi, F., et al., WO2006033913; Doemling, A., German Patent Application DE102004030227, WO2004005327, WO2004005326, WO2004005269; Stanton, M., et al, US Patent No. 20040249130; Hoefle, G., et al, Ger. OffenDE10254439, DE10241152, DE10008089; Leung, D., et al. al, WO2002077036; Reichenbach, H., et al, Ger. Offen. DE19638870; Wolfgang, R., US20120129779; Chen, H. Preferred structures of tubulysins for conjugation with cell-binding molecules according to the methods of the present patent application are described in patent application PCT / IB2012 / 053554.
[0113] A tubulysin analog having the following formula (IV): or a pharmaceutically acceptable salt, hydrate, or hydrated salt; or a polymorphic crystalline structure; or an optical isomer, racemate, diastereomer, or enantiomer thereof: [ka]
[0114] During the ceremony, [ka] are independently binding sites that bind to L1 and / or L2.
[0115] R 1 , R 2 , R 3 , and R 4 are independently H, C1-C8 alkyl; C2-C8 heteroalkyl, or heterocycle; C3-C8 aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl; or R 1 R 2 , R 1 R 3 , R 2 R 3 , R 3 R 4 , R 5 R 6 , R 11 R 12 , or R 13 R 14 form a 3- to 7-membered carbocyclic, cycloalkyl, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system; when attached independently or simultaneously to L1 or L2, R 1 and R2 may be absent independently; Y 1 is N or CH.
[0116] In the formula, R 5 , R 6 , R 8 , R 10 , and R 11 is independently H, or C1-C4 alkyl or heteroalkyl.
[0117] In the formula, R 7 are independently H, R 14 , -R 14 C(=O)X 1 R 15 ; or -R 14 X 1 R 15 X 1 is O, S, SS, NH, CH2, or NR 14 is.
[0118] In the formula, R 9 are H, OH, -O-, =O, -OR 14 , -OC(=O)R 14 , -OC(=O)NHR 14 -, -OC(=O)R 14 SSR 15 -, OP(=O)(OR 14 )-, -OC(=O)NR 14 R 15 , OP(=O)(OR 14 ), or OR 14 OP(=O)(OR 15 ) is selected.
[0119] In the formula, R 11 are independently H, R 14 , -R 14 C(=O)R 16 , -R 14 X 2 R 16 , -R 14 C(=O)X 2 wherein X 2 -O-, -S-, -NH-, -N(R 14 )-, -OR 14-, -SR 14 -, -S(=O)-R 14 - or -NHR 14 is.
[0120] In the formula, R 12 is R 15 , -OH, -SH, -NH2, NH, NHNH2, -NH(R 15 ), -OR 15 , -R 15 COR 16 , -R 15 COOR 16 , -R 15 C(O)NH2, -R 15 C(O)NHR 17 , -SR 16 , R 15 S(=O)R 16 , -R 15 P(=O)(OR 17 )2, -R 15 OP(=O)(OR 17 )2, -CH2OP(=O)(OR 17 )2, -R 15 SO2R 17 , -R 15 X 2 R 16 , -R 15 C(=O)X 2 wherein X 2 are -O-, OH, SH, -S-, NH2, -NH-, -N(R 15 )-, -OR 15 -, -SR 15 -, -S(=O)-R 15 -, CH2, or -NHR 15 -It is.
[0121] R 13 and R 14 are independently H, O, S, NH, N(R 15 ), NHNH, -OH, -SH, -NH2, NH, NHNH2, -NH(R 15 ), -OR 15 , CO, -COX 2 , -COX 2 R 16 , R 17 , F, Cl, Br, I, SR16 , N.R. 16 R 17 , N=NR 16 , N=R 16 , NO2, SOR 16 R 17 , SO2R 16 , SO3R 16 , OSO3R 16 , PR 16 R 17 , POR 16 R 17 , PO2R 16 R 17 , OP(O)(OR 17 )2, OCH2OP(O)(OR 17 )2, OC(O)R 17 ,OC(O)OP(O)(OR 17 )2, PO(OR 16 )(OR 17 ), OP(O)(OR 17 )OP(O)(OR 17 )2, OC(O)NHR 17 ;-O-(C4~C 12 Glycoside), -N-(C4~C 12 glycoside); C1-C8 alkyl, heteroalkyl; C2-C8 alkenyl, alkynyl, heteroalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, or ester, ether, or amide having 2 to 8 carbon atoms; or a peptide containing 1 to 8 amino acids (NH(Aa) 1~8 or CO(Aa) 1~8 (N-terminus or C-terminus (Aa) r , r=1 to 8 identical or different amino acid sequences), or the formula (OCH2CH2) p or (OCH2CH(CH3)) p where p is an integer from 0 to about 1000, or a combination of the above groups; X 2 are O, S, SS, NH, CH2, OH, SH, NH2, CHR 14 , or NR 14 is.
[0122] R 15 , R 16 , and R 17 are independently H, C1-C8 alkyl, heteroalkyl; C2-C8 alkenyl, alkynyl, heteroalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, alkylcarbonyl, or Na + , K. + , Cs + , Li + , Ca 2+ , Mg + , Zn 2+ , N + (R 1 )(R 2 )(R 3 )(R 4 ) or HN + (C2H5OH)3 salt.
[0123] Y 1 and Y 2 are independently N or CH; q is 0 or 1; when q=0, Y 3 does not exist, and Y 4 , Y 5 , Y 6 , and Y 7 are independently CH, N, NH, O, S, or N(R1), so that Y 2 , Y 4 , Y 5 , Y 6 , and Y 7 forms heteroaromatic rings of furan, pyrrole, thiophene, thiazole, oxazole, imidazole, pyrazole, triazole, tetrazole, thiadiazole; when q=1, Y 3 , Y 4 , Y 5 , Y 6 , and Y 7 are independently CH or N, so Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , and Y 7form aromatic rings in benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine, tetrazine, and pentazine.
[0124] In particular, tubulysin analogs have the structure shown below: [ka] TIFF2024541058000031.tif237170TIFF2024541058000032.tif247170TIFF20245410580 00033.tif253170TIFF2024541058000034.tif254170TIFF2024541058000035.tif247170 TIFF2024541058000036.tif252170TIFF2024541058000037.tif252170TIFF20245410580 00038.tif227170TIFF2024541058000039.tif222170TIFF2024541058000040.tif108170
[0125] In the formula, R 20 is H; C1-C8 straight or branched alkyl or heteroalkyl; C2-C8 straight or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 straight or branched aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 or a carboxylic acid salt, ester, ether, or amide having 1 to 8 carbon atoms; or an amino acid having 1 to 8 carbon atoms; or a compound of the formula (OCH2CH2) p or (OCH2CH(CH3)) p polyethyleneoxy units of the formula (where p is an integer from 0 to about 1000); or R 20 is absent and the oxygen atom forms a ketone, or a combination of the above;
[0126] Z 2 and Z 3 are independently H, OH, NH2, O, NH, COOH, COO, C(O), C(O), C(O)NH, C(O)NH2, R 18 , OCH2OP(O)(OR 18 )2, OC(O)OP(O)(OR 18 )2, OPO(OR 18 )2, NHPO(OR 18 )2, OP(O)(OR 18 )OP(O)(OR 18 )2, OC(O)R 18 , OC(O)NHR 18 , OSO2(OR 18 ), O-(C4~C 12 -glycoside), C1-C8 straight or branched alkyl or heteroalkyl; C2-C8 straight or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 straight or branched aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 )
[0127] R 17 and R 18 are independently H, straight or branched alkyl or heteroalkyl, C2-C8 straight or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 straight or branched aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ) is;
[0128] R 19 are H, OH, NH2, OSO2(OR 18 ), XCH2OP(O)(OR 18 )2, XPO(OR 18)2, XC(O)OP(O)(OR 18 )2, XC(O)R 18 , XC(O)NHR 18 , C1-C8 alkyl or carboxylate; C2-C8 alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl or alkylcarbonyl; or a pharmaceutical salt.
[0129] X is O, S, NH, NHNH, or CH2.
[0130] R7 is the same as defined above;
[0131] In the formula, the binding site in formulas (IV-01) to (IV-79) [ka] is the same as the binding site described in formula (IV).
[0132] Calicheamicin and related enediyne antibiotics are described in: Nicolaou, KC et al, Science 1992, 256, 1172-1178; Proc. Natl. Acad. Sci USA. 1993, 90, 5881-8), U.S. Patent Nos. 4, 970, 198; 5, 053, 394; 5, 108, 912; 5, 264, 586; 5, 384, 412; 5, 606, 040; 5, 712, 374; 5, 714, 586; 5, 739, 116; 5, 770, 701; 5, 770, 710; 5, 773, 001; 5, 877, 296; 6, 015, 562; 6, 124, 310; 8, 153, 768. Exemplary enediynes include, but are not limited to, calicheamicin, esperamicin, uncialamicin, dyneamicin, and derivatives thereof. The structure of calicheamicin is preferably the following formula: or an isotope of a chemical element, or a pharmaceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystalline structure, or an optical isomer, racemate, diastereomer, or enantiomer thereof:
[0133] [ka]
[0134] Geldanamycin is a benzoquinone ansamycin antibiotic that binds to Hsp90 (heat shock protein 90) and is used as an antitumor drug. Exemplary geldanamycins include, but are not limited to, 17-AAG (17-N-allylamino-17-demethoxygeldanamycin) and 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin).
[0135] Maytansine or its derivatives, maytansinoids, inhibit cell proliferation by inhibiting microtubule formation during mitosis through the inhibition of tubulin polymerization. See Remillard et al., Science 189:1002-1005 (1975). Exemplary maytansines and maytansinoids include, but are not limited to, mertansine (DM1, DM4), maytansinol and its derivatives, and ansamitocins. Maytansinoids are disclosed in U.S. Patents 4,256, 746, 4,361, 650, 4,307, 016, 4,294, 757, 4,294, 757, 4,371, 533, 4,424, 219, 4,331, 598, 4,450, 254, 4,364, 866, 4,313, 946, 4,315, 929, 4,362, 663, 4,322, 348, 4,371, 533, 4,424, 219, 5,208, 020, 5,416, 064, 5, Maytansinoids are described in: 208, 020; 5, 416, 064; 6, 333, 410; 6, 441, 163; 6, 716, 821, 7, 276, 497, 7, 301, 019, 7, 303, 749, 7, 368, 565, 7, 411, 063, 7, 851, 432, and 8, 163, 888. The structure of the maytansinoid is preferably represented by the following formula:
[0136] [ka]
[0137] Camptothecins (CPTs) and their derivatives are topoisomerase inhibitors that cause DNA damage that prevents DNA religation and thus triggers apoptosis. These inhibitors have been described in the following literature: Shang, XF et al., Med Res Rev. 2018, 38(3) 775-828; Botella, P. and Rivero-Buceta, EJ Control Release 2017, 247: 28-54; Martino, E. et al., Bioorg Med Chem Lett. 2017, 27(4):701-707; Lu, A., et al., Acta Pharmacol Sin 2007, 28(2): 307-314. Camptothecins include SN-38, topotecan, irinotecan (CPT-11), ciratecan (DB-67, AR-67), cositecan (BNP-1350), etirinotecan, exatecan, lurtotecan, gimatecan (ST1481), belotecan (CKD-602), rubitecan, and several others (Shang, XF et al, Med Res Rev. 2018, 38(3):775-828).To date, three CPT analogs, topotecan, irinotecan, and belotecan, have been approved and used in cancer chemotherapy (Palakurthi, S., Expert Opin Drug Deliv. 2015;12(12):1911-21; Shang, XF et al, Med Res Rev. 2018, 38(3):775-828), and both SN-38 and exatecan have been successfully used as payloads for ADC conjugates in clinical trials (Ocean, AJ et al, Cancer. 2017, 123(19): 3843-3854; Starodub, AN, et al, Clin Cancer Res. 2015, 21(17): 3870-8; Cardillo, TM, et al, Bioconjug Chem. 2015, 26(5): 919-31; Ogitani, Y . et al, Bioorg Med Chem Lett. 2016, 26(20): 5069-5072; Takekawa, N. et al, Int J Cancer. 2017 Oct 15;141(8):1682-1689. U.S. Patents 7, 591, 994; 7, 999, 083, 8, 080, 250, 8, 268, 317; U.S. Patent Applications 20130090458, 20140099258, 20150297748, 20160279259).
[0138] Camptothecin (CPT) has the structure shown in the following formula, or one or more isotopes of chemical elements, or a pharmaceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystalline structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer: [ka]
[0139] wherein R1, R2, and R4 are independently H, F, Cl, Br, CN, NO2, C1-C8 alkyl; O-C1-C8 alkyl; NH-C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or ester, ether, amide, carbonate, urea, or carboxylate having 2 to 8 carbon atoms. R3 is H, OH, NH2, C1-C8 alkyl; O-C1-C8 alkyl; NH-C1-C8 alkyl; C2-C8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; or an ester, ether, amide, carbonate, urea, or carbamate having 2 to 8 carbon atoms; or R1R2, R2R3, and R3R4 independently form a 5- to 7-membered carbocyclic, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system.
[0140] [ka] is an internal site to which L1 or L2 can bind.
[0141] The structure of camptothecin is preferably the following formula, or one or more isotopes of chemical elements, or a pharmaceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystalline structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer: [ka] TIFF2024541058000047.tif225170TIFF2024541058000048.tif252170TIFF2024541058000049.tif46170
[0142] During the ceremony, [ka] is the binding site for L1 or L2;
[0143] P 1 is H, OH, NH2, COOH, C(O)NH2, OCH2OP(O)(OR 18 )2, OC(O)OP(O)(OR 18 )2, OPO(OR 18 )2, NHPO(OR 18 )2, OC(O)R 18 , OP(O)(OR 18 )OP(O)(OR 18 )2, OC(O)NHR 18 , OC(O)N(C2H4)2NCH3, OSO2(OR 18 ), O-(C4-C 12 -glycoside), OC(O)N(C2H4)2CH2N(C2H4)2CH3, O-(C1-C8 linear or branched alkyl), C1-C8 linear or branched alkyl or heteroalkyl; C2-C8 linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 linear or branched aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 );R 17 and R 18 are independently H, linear or branched alkyl or heteroalkyl; C2-C8 linear or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 linear or branched aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 )
[0144] Combretastatins are naturally occurring phenols with intratumoral vascular disruption properties. Exemplary combretastatins and their derivatives include, but are not limited to, combretastatin A-4 (CA-4), CA4-βGal, CA-4PD, CA4-NPs, and ombrablein: [ka]
[0145] Taxanes, including the cytotoxic natural product paclitaxel (Taxol), the semisynthetic derivative docetaxel (Taxotere), and their analogs suitable for conjugation are described in K. C. Nicolaou et al., J. Am. Chem. Soc. 117, 2409-20, (1995); Ojima et al., J. Med. Chem. 39:3889-3896 (1996); 40:267-78 (1997); 45, 5620-3 (2002); Ojima et al., Proc. Natl. Acad. Sci., 96:4256-61 (1999); Kim et al., Bull. Korean Chem. Soc., 20, 1389-90 (1999); Miller, et al. J. Med. Chem., 47, 4802-5 (2004); U.S. Patent Nos. 5,475,011, 5,728,849, 5,811,452; 6,340,701; 6,372,738; 6,391,913, 6,436,931; 6,589,979; 6,596,757; 6,706,708; 7,008,942; 7,186,851; 7,217,819; 7,276,499; 7,598,290; and 7,667,054. The taxane structure is preferably of the formula: [ka]
[0146] During the ceremony, [ka] is the site of attachment to L1 or L2; Ar and Ar' are independently aryl or heteroaryl.
[0147] Anthracyclines are mammalian DNA topoisomerase II inhibitors that can induce DNA strand breaks and stabilize enzyme-DNA complexes covalently linked to antibody-like proteins. These anticancer drugs have played an important role in the treatment of many forms of solid tumors and acute leukemia for the past several decades. However, anthracyclines cause cardiovascular morbidity and mortality (Sagi, JC, et al, Pharmacogenomics. 2016, 17(9), 1075-87; McGowan, JV, et al, Cardiovasc Drugs Ther. 2017, 31(1), 63-75). Therefore, to increase the specific activity of such molecules while reducing cardiac toxicity, researchers have actively used conjugation of anthracyclines with cell-binding antibodies or antibody-like protein molecules as a general approach to improve the therapeutic index of these drugs (Mollaev, M. et al., Int J Pharm. 2018 Dec 29. pii: S0378-5173(18) 30991-8; Rossin, R., et al., Bioconjug Chem. 2016, 27(7):1697-706; Dal Corso, A,. et al., J Control Release. 2017, 264:211-218). Exemplary anthracyclines include, but are not limited to, daunorubicin, doxorubicin (i.e., adriamycin), epirubicin, idarubicin, valrubicin, and mitoxantrone. The structure of the anthracycline used in this application is preferably represented by the following formula:
[0148] [ka] TIFF2024541058000055.tif190170
[0149] Vinca alkaloids are a group of antimitotic and antimicrotubule alkaloids that act by inhibiting the ability of cancer cells to divide. Vinca alkaloids include vinblastine, vincristine, vindesine, leurosine, vinorelbine, catharanthine, vindoline, vincaminol, vineridine, minovincine, methoxyminovincine, minovincine, vincadifformine, desoxyvincaminol, vincamazine, vincamine, vinpocetine, and vinbrunin. The structures of vinca alkaloids are preferably vinblastine and vincristine, which have the following formula: [ka] TIFF2024541058000057.tif145170
[0150] Dolastatins and their peptide analogs and derivatives, the auristatins, are highly potent antimitotic agents that have been shown to have anticancer and antifungal activity (see, e.g., U.S. Patent No. 5,663,149 and Pettit et al., Antimicrob. Agents Chemother. 42:2961-2965, 1998). Exemplary dolastatins and auristatins include, but are not limited to, dolastatin 10, auristatin E (AE), auristatin EB (AEB), auristatin EFP (AEFP), MMAD (monomethyl auristatin D or monomethyl dolastatin 10), MMAF (monomethyl auristatin F or N-methylvaline-valine-dolaisoloiin-dolaproine-phenylalanine), MMAE (monomethyl auristatin E or N-methylvaline-valine-dolaisoloiin-dolaproine-norephedrine), 5-benzoylvaleric acid-AE ester (AEVB), auristatin F phenylenediamine (AFP), and other novel auristatins. Auristatins are described in Int. J. Oncol. 15: 367-72 (1999); Molecular Cancer Therapeutics, vol. 3, No. 8, pp. 921-32 (2004); U.S. Application Nos. 11134826, 20060074008, and 2006022925.U.S. Patent Numbers: 4414205, 4753894, 4764368, 4816444, 4879278, 4943628, 4978744, 5122368, 5165923, 5169774, 5286637, 5410024, 5521284, 5530097, 5554725, 5585089, 5599902, 5629197, 5635483, 5654399, 5663149, 5665860, 5708146, 5714586, 5741892, 5767236, 5767237, 5780588, 5821337, 5840699, 5965537, 600493 4, 6033876, 6034065, 6048720, 6054297, 6054561, 6124431, 6143721, 6162930, 6214345, 6239104, 6323315, 6342219, 6342221, 6407213, 6569834, 6620911, 6639055, 6884869, 6913748, 7090843, 7091186, 7097840, 7098305, 7098308, 749829 8, 7375078, 7462352, 7553816, 7659241, 7662387, 7745394, 7754681, 7829531, 7837980, 7837995, 7902338. The structure of the auristatin analog is preferably of the following formulae (Ih-01), (Ih-02), (Ih-03), (Ih-04), (Ih-05), (Ih-06), (Ih-07), (Ih-08), (Ih-09), (Ih-10), and (Ih-11), or one or more isotopes of chemical elements, or a pharmaceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystalline structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer:
[0151] [ka] TIFF2024541058000059.tif66170
[0152] In the formula, R 1 , R 2 , R 3 , R4 , and R 5 are independently H; C1 to C8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, amide, amine, heterocycloalkyl, or acyloxylamine; or a peptide containing 1 to 8 amino acids, or a group of the formula (OCH2CH2) p or (OCH2CH(CH3)) p (wherein p is an integer from 1 to about 5000); 1 R 2 , R 2 R 3 , R 1 R 3 , or R 3 R 4 may be taken together to form a 3- to 8-membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group.
[0153] Y1 and Y2 are attachment sites (independently attached to L1 and / or L2) [ka] and, when attached to, are independently O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R2), C(O)NHNHC(O), and C(O)NR1; or, [ka] When not bound to a , they are OH, NH, NHNH, NHR, SH, C(O)OH, C(O)NH, OC(O)NH, OC(O)OH, NHC(O)NH, NHC(O)SH, OC(O)NH(R), N(R)C(O)NH(R), C(O)NHNHC(O)OH, and C(O)NHR.
[0154] R 12 are OH, NH2, NHR1, NHNH2, NHNHCOOH, O-R1-COOH, NH-R1-COOH, NH-(Aa) n COOH, O(CH2CH2O) p CH2CH2OH, O(CH2CH2O) p CH2CH2NH2, NH(CH2CH2O) p CH2CH2NH2, NR1R 1’ , NHOH, NHOR1, O(CH2CH2O) p CH2CH2COOH, NH(CH2CH2O) p CH2CH2COOH, NH-Ar-COOH, NH-Ar-NH2, O(CH2CH2O) p CH2CH2NHSO3H, NH(CH2CH2O) p CH2CH2NHSO3H, R1-NHSO3H, NH-R1-NHSO3H, O(CH2CH2O) p CH2CH2NHPO3H2, NH(CH2CH2O) p CH2CH2NHPO3H2, OR1, R1-NHPO3H2, R1-OPO3H2, O(CH2CH2O) p CH2CH2OPO3H2, OR1-NHPO3H2, NH-R1-NHPO3H2, NH(CH2CH2NH) p CH2CH2NH2, NH(CH2CH2S) p CH2CH2NH2, NH(CH2CH2NH) p CH2CH2OH, NH(CH2CH2S) p CH2CH2OH, NH-R1-NH2, or NH(CH2CH2O) p CH2CH2NHPO3H2, where Aa is 1 to 8 identical or different amino acids; p is 1 to 5000;
[0155] R1, R2, R3, R4, R5, R 5’ , Z1, Z2, and n are the same as defined above.
[0156] Hemiasterin and its analogs (such as HTI-286) bind to tubulin, disrupt normal microtubule dynamics, and depolymerize microtubules in stoichiometric amounts. The structure of maytansinoids is preferably: [ka]
[0157] In the formula, R 1 , R 2 , R 3 , R 4 , and R 5 are independently H; C1-C8 straight chain or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, amide, amine, heterocycloalkyl, or acyloxylamine; or a peptide containing 1 to 8 amino acids, or a peptide of the formula (OCH2CH2) p or (OCH2CH(CH3)) p polyethyleneoxy units having the formula (wherein p is an integer of 1 to about 5000); R 2 R 3 can form a 3- to 8-membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group.
[0158] Eribulin binds primarily to a small number of high-affinity sites on the plus ends of pre-existing microtubules and has both cytotoxic and non-cytotoxic mechanisms of action. Its cytotoxic effects are related to its antimitotic activity, resulting in prolonged and irreversible inhibition of mitosis followed by the induction of apoptosis in cancer cells (Kuznetsov, G. et al., Cancer Research. 2004, 64 (16): 5760-6; Towle, M. J. et al., Cancer Research. 2010, 71 (2): 496-505). Preclinical studies in human breast cancer models have demonstrated that, in addition to its cytotoxic and antimitotic mechanisms, eribulin also exerts complex effects on the biology of surviving cancer cells and residual tumors that appear to be unrelated to its antimitotic effects. Eribulin has been approved by the U.S. FDA for the treatment of metastatic breast cancer that has received at least two chemotherapy regimens for advanced disease, including both anthracycline and taxane chemotherapy, and for the treatment of liposarcoma (a type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or has progressed (metastatic). Eribulin has been used as the payload in ADC conjugates (US20170252458). The structure of eribulin is preferably of the following formula Eb01:
[0159] [ka]
[0160] Nicotinamide phosphoribosyltransferase inhibitors (NAMPT) are potentially interesting ADC payloads due to their unique mechanism of potent activity (Sampath D, et al, Pharmacol Ther 2015; 151, 16-31). NAMPT regulates intracellular levels of nicotinamide adenine dinucleotide (NAD). NAD functions as an essential redox cofactor supporting energy and anabolic metabolism. NAD plays several important roles in metabolism: as a coenzyme in redox reactions, as a donor of the ADP-ribose moiety in ADP-ribosylation reactions, as a precursor to the second messenger molecule cyclic ADP-ribose, as well as a substrate for bacterial DNA ligase and NAD. + In addition to these metabolic functions, it also acts as a group of enzymes called sirtuins, which remove acetyl groups from proteins using NAD +NAMPT appears as an adenine nucleotide and is released from cells spontaneously or through regulated mechanisms (Smyth L. M, et al, J. Biol. Chem. 2004, 279 (47), 48893-903; Billington R. A, et al, Mol Med. 2006, 12, 324-7), and therefore may have important extracellular roles (Billington R. A, et al, Mol Med. 2006, 12, 324-7). In the presence of inhibitors of NAMPT, NAD levels fall below metabolic levels, creating an energy crisis and leading to cell death. To date, clinical NAMPT inhibitor candidates FK-866, CHS-828, and GMX-1777 have advanced to clinical trials, but all encountered dose-limiting toxicities before achieving objective responses (Holen K., et al., Invest New Drugs 2008, 26, 45-51; Hovstadius, P., et al., Clin Cancer Res 2002, 8, 2843-50; Pishvaian, MJ, et al., J Clin Oncol 2009, 27, 3581). Therefore, using ADCs for targeted delivery of NAMPT inhibitors may avoid systemic toxicity and achieve a broader therapeutic index. The structure of the NAMPT inhibitor is preferably of the following formula: NP01, NP02, NP03, NP04, NP05, NP06, NP07, NP08, and NP09, or an isotope of one or more chemical elements, or a pharmaceutically acceptable salt, hydrate, or hydrated salt, or a polymorphic crystal structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer:
[0161] [ka]
[0162] During the ceremony, [ka] is the same as above; X5 is F, Cl, Br, I, OH, OR1, R1, OPO3H2, OSO3H, NHR1, OCOR1, NHCOR1.
[0163] Benzodiazepine dimers and their analogs (e.g., pyrrolobenzodiazepine (PBD) or (tomaymycin) dimers, indolinobenzodiazepine (IGN) dimers, imidazobenzothiadiazepine dimers, or oxazolidinobenzodiazepine dimers) are antitumor agents containing one or more imine functional groups that bind to double-stranded DNA, or their equivalents. PBD and IGN molecules are based on the natural product athramycin and interact with DNA in a sequence-selective manner, with a preference for purine-guanine-purine sequences. Benzodiazepine dimers preferred in the present invention are exemplified by the following: U.S. Patents 8,153,627; 8,034,808; 7,834,005; 7,741,319; 7,704,924; 7,691,848; 7,678,787; 7,612,062; 7,608,615; 7,557,099; 7,528,128; 7,528,126; 7,511,032; 7,429,658; 7,407,951; 7,326,700; 7,312,210; 7,265,105; 7,202,239; 7,189,710; 7,173,026; 7,109,193; 7,067,511; 7,064,120; 7,056,913; 7,049,311; 7,022,699; 7,015,215; 6,979,684; 6,951,853; 6,884,799; 6,800,622; 6,747,144; 6,660,856; 6,608,192; 6,562,806; 6,977,254; 6,951,853; 6,909,006; 6,344,451; 5,880,122; 4,935,362; 4,764,616; 4,761,412; 4,723,007; 4,723,003; 4,683,230; 4,663,453; 4,508,647; 4,464,467; 4,427,587; 4,000,304; U.S. Patent Application Publications 20100203007, 20100316656, 20030195196.Exemplary structures of antibody-benzodiazepine dimer conjugates are shown below as PB01, PB02, PB03, PB04, PB05, PB06, PB07, PB08, PB09, PB10, PB11, PB12, PB13, PB14, PB15, and PB16.
[0164] [ka] TIFF2024541058000067.tif252170TIFF2024541058000068.tif81170 or isotopes of one or more chemical elements, or pharmaceutically acceptable salts, hydrates, or hydrated salts, or polymorphic crystalline structures of these compounds, or optical isomers, racemates, diastereomers, or enantiomers.
[0165] wherein X1, X2, Y1, Y2, Z1, Z2, and n are defined as above. Preferably, X1, X2, Y1, and Y2 are independently O, N, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R1), CH, C(O)NHNHC(O), and C(O)NR1.
[0166] R 1 , R 2 , R 3 , R 1’ , R 2’ , and R 3’ are independently H; F; Cl; ═O; ═S; OH; SH; C1-C8 linear or branched alkyl, aryl, alkenyl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester (COOR5 or -OC(O)R5), ester (OR5), amide (CONR5), carbamate (OCONR5), amine (NHR5, NR5R 5’ ), heterocycloalkyl, or acyloxylamine (—C(O)NHOH, —ONHC(O)R5); or a peptide containing 1 to 20 natural or unnatural amino acids, or a peptide of the formula (OCH2CH2) por (OCH2CH(CH3)) p where p is an integer from 1 to about 1000; two R:R 1 R 2 , R 2 R 3 , R 1 R 3 , R 1’ R 2’ , R 2’ R 3’ , or R 1’ R 3’ can independently form a 3- to 8-membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group.
[0167] X3 and Y3 are independently N, NH, CH, or CR1, or any one of X3 and Y3 may be absent;
[0168] R1 and R2 are C1-C8 linear or branched alkyl, heteroalkyl; C3-C8 aryl, heteroaryl, alkylcycloalkyl, acylosyl, alkylaryl, alkylaryloxyl, alkylarylamino, alkylarylthiol; or 1 to 6 identical or different amino acid / peptide sequences (Ar)r (r=1-6).
[0169] R4, R5, R 5’ , R6, R 12 , and R 12’ are independently H, OH, NH2, NH(CH3), NHNH2, COOH, SH, OZ3, SZ3, F, Cl, or C1-C8 straight chain or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxylamine.
[0170] Z3 is H, OP(O)(OM1)(OM2), OCH2OP(O)(OM1)(OM2), OSO3M1, or an O-glycoside (glucoside, galactoside, mannoside, glucuronoside / glucuronide, alloside, fructoside, etc.), NH-glycoside, S-glycoside, or CH2-glycoside; M1 and M2 are independently H, Na, K, Ca, Mg, NH4, or NR1R2R3;
[0171] X6 is CH, N, P(O)NH, P(O)NR1, CHC(O)NH, C3-C8 aryl, heteroaryl, alkylcycloalkyl, acyloxy, alkylaryl, alkylaryloxy, alkylarylamino, or Aa (an amino acid, preferably selected from Lys, Phe, Asp, Glu, Ser, Thr, His, Cys, Tyr, Trp, Gln, Asn, and Arg).
[0172] [ka] has the same definition as above.
[0173] CC-1065 analogs and duocarmycin analogs are also preferably used in the conjugation methods of the present invention. Examples of CC-1065 analogs and duocarmycin analogs, as well as their syntheses, are described in the following: Warpehoski, et al., J. Med. Chem. 31:590-603 (1988); D. Boger et al.,J. Org. Chem; 66; 6654-61, 2001; U.S. Patent Numbers: 4169888, 4391904, 4671958, 4816567, 4912227, 4923990, 4952394, 4975278, 4978757, 4994578, 5037993, 5070092, 5084468, 5101038, 5117006, 5137877, 5138059, 5147786, 5187186, 5223409, 5225539, 5288514 , 5324483, 5332740, 5332837, 5334528, 5403484, 5427908, 5475092, 5495009, 5530101, 5545806, 5547667, 5569825, 5571698, 5573922, 5580717, 5585089, 5585499, 5587161, 5595499, 5606017, 5622929, 562512 6, 5629430, 5633425, 5641780, 5660829, 5661016, 5686237, 5693762, 5703080, 5712374, 5714586, 5739116, 5739350, 5770429, 5773001, 5773435, 5786377, 5786486, 5789650, 5814318, 5846545, 5874299, 58772 96, 5877397, 5885793, 5939598, 5962216, 5969108, 5985908, 6060608, 6066742, 6075181, 6103236, 6114598, 6130237, 6132722, 6143901, 6150584, 6162963, 6172197, 6180370, 6194612, 6214345, 6262271, 6281 354, 6310209, 6329497, 6342480, 6486326, 6512101, 6521404, 6534660, 6544731, 6548530, 6555313, 6555693, 6566336, 6586618, 6593081, 6630579, 6756 397, 6759509, 6762179, 6884869, 6897034, 6946455, 7049316, 7087600, 7091186, 7115573, 7129261, 7214663, 7223837, 7304032, 7329507, 7,329,760, 7,388,026, 7,655,660, 7,655,661, 7,906,545, and 8,012,978. Exemplary structures of antibody-CC-1065 analog conjugates via the linkers of this patent are shown below as CC01, CC02, CC03, CC04, CC05, CC06, and CC07.
[0174] [ka] TIFF2024541058000071.tif39170
[0175] During the ceremony, X1, X2, Y1, and Y2 are connection sites [ka] and, when attached to, are independently O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R2), C(O)NHNHC(O), and C(O)NR1; or, [ka] When not bound to a , they are OH, NH, NHNH, NHR, SH, C(O)OH, C(O)NH, OC(O)NH, OC(O)OH, NHC(O)NH, NHC(O)SH, OC(O)NH(R), N(R)C(O)NH(R), C(O)NHNHC(O)OH, and C(O)NHR.
[0176] Z3 is H, PO(OM1)(OM2), SO3M1, CH2PO(OM1)(OM2), CH3N(CH2CH2)2NC(O)-, O(CH2CH2)2NC(O)-, R1, or a glycoside; R1, R2, R3, M1, M2, and n are as defined above.
[0177] Amatoxins and their analogues are a subgroup of at least 10 toxic compounds originally found in several genera of poisonous mushrooms, most notably Amanita phalloides, and several other mushrooms, and are preferred for use in the conjugates of this patent. These 10 amatoxins, i.e., α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanulin, amanurinic acid, amaninamide, and amanine, proamanitin, are rigid bicyclic peptides synthesized as precursors of proteins containing 35 amino acids, which are finally cleaved by eight amino acid prolyl oligopeptidases (Litten, W. 1975 Scientific American 232 (3): 90-101; H. E. Hallen, et al. 2007 Proc. Nat. Aca. Sci. USA 104, 19097-101; K. Baumann, et al. 1993 Biochemistry 32 (15): 4043-50; Karlson-Stiber C, Persson H. 2003 Toxicon 42 (4): 339-49; Horgen, PA et al. 1978 Arch. Microbio. 118 (3): 317-9). Amatoxins kill cells by inhibiting RNA polymerase II (Pol II), blocking gene transcription and protein synthesis (Brodner, OG and Wieland, T. 1976 Biochemistry, 15(16): 3480-4; Fiume, L., Curr Probl Clin Biochem, 1977, 7: 23-8; Karlson-Stiber C, Persson H. 2003 Toxicon 42(4): 339-49; Chafin, DR, Guo, H. & Price, DH 1995 J. Biol. Chem. 270 (32): 19114-19; Wieland (1983) Int. J. Pept. Protein Res. 22(3): 257-76). Amatoxins were collected from Amanita phalloides (Yocumulus RR).1978 Biochemistry 17(18): 3786-9; Zhang, P. et al., 2005, FEMS Microbiol. Lett.252(2), 223-8), or by fermentation using Basidiomycetes (Muraoka, S. and Shinozawa T., 2000 J. Biosci. Bioeng. 89(1): 73-6), or by fermentation using A. fissa (Guo, XW, et al., 2006 Wei Sheng Wu Xue Bao 46(3): 373-8), or by culturing A. cholera mushroom (WO / 1990 / 009799, JP11137291). However, the yields of these isolations and fermentations are quite low (less than 5 mg / L of culture). Over the past 30 years, several methods for preparing amatoxins and their analogues have been reported (W.E. Savige, A. Fontana, Chem. Commun. 1976, 600-1; Zanotti, G., et al., Int. J. Pept. Protein Res. 1981, 18(2): 162-8; Wieland, T., et al., Eur. J. Biochem. 1981, 117, 161-4; P.A. Bartlett, et al., Tetrahedron Lett. 1982, 23, 619-22; Zanotti, G., et al., Biochim. Biophys. Acta. 1986, 870(3): 454-62; Zanotti, G., et al., Int. J. Peptide. Protein Res. 1987, 30, 323-9; Zanotti, G., et al. al., Int. J. Peptide Protein Res. 1987, 30, 450-9; Zanotti, G., et al., Int J Pept Protein Res, 1988. 32(1): 9-20; G. Zanotti, T. et al, Int. J. Peptide Protein Res. 1989, 34, 222-8; Zanotti, G., et al. al., Int J Pept Protein Res, 1990. 35(3): 263-70; Mullersman, JE and JF Preston, 3rd, Int J Pept Protein Res, 1991. 37(6): 544-51; Mullersman, JE, et al, Int J Pept Protein Res, 1991. 38(5): 409-16; Zanotti, G., et al, Int J Pept Protein Res, 1992. 40(6): 551-8; Schmitt, W. et al, J. Am. Chem. Soc. 1996, 118, 4380-7; Anderson, M. O., et al, J. Org. Chem., 2005, 70(12): 4578-84; JP May, et al, J. Org. Chem. 2005, 70, 8424-30; F. Brueckner, P. Cramer, Nat. Struct. Mol. Biol. 2008, 15, 811-8; JP May, DM Perrin, Chem. Eur. J. 2008, 14, 3404-9; JP May, et al, Chem. Eur. J. 2008, 14, 3410-17; Q. Wang, et al, Eur. J. Org. Chem. 2002, 834-9; May, J.P. and D.M. Perrin, Biopolymers, 2007. 88(5): 714-24; May, J.P., et al., Chemistry, 2008. 14(11): 3410-7; S. De Lamo Marin, et al, Eur. J. Org. Chem. 2010, 3985-9; Pousse, G., et al., Org Lett, 2010. 12(16): 3582-5; Luo, H., et al., Chem Biol, 2014. 21(12): 1610-7; Zhao, L., et al., Chembiochem, 2015.16(10): 1420-5), most of which are partial synthetic methods. Due to their extremely potent efficacy and unique cytotoxic mechanism, amatoxins have been used as conjugate payloads (Fiume, L., Lancet, 1969. 2 (7625): 853-4; Barbanti-Brodano, G. and L. Fiume, Nat New Biol, 1973. 243(130): 281-3; Bonetti, E., M. et al., Arch Toxicol, 1976. 35(1): pp. 69-73; Davis, M.T., Preston, J.F. Science 1981. 213, 1385-1388; Preston, J.F. et al., Arch Biochem Biophys, 1981. 209(1): 63-71; H. Faulstich, et al., Biochemistry 1981. 20, 6498-504; Barak, L.S., et al., Proc Natl Acad Sci USA, 1981. 78(5): 3034-8; Faulstich, H. and L. Fiume, Methods Enzymol, 1985. 112: 225-37; Zhelev, Z., A. et al, Toxicon, 1987. 25(9): 981-7; Khalacheva, K., et al. al, Eksp Med Morfol, 1990. 29(3): 26-30; U. Bermbach, H. Faulstich, Biochemistry 1990, 29, 6839-45; Mullersman, JE and JF Preston, Int. J. Peptide Protein Res. 1991, 37, 544-51; Mullersman, JE and JF Preston, Biochem Cell Biol, 1991. 69(7): 418-27; J. Anderl, H. Echner, H. Faulstich, Beilstein J. Org. Chem. 2012, 8, 2072-84; Moldenhauer, G., et al, J. Natl. Cancer Inst. 2012, 104, 622-34; A. Moshnikova, et al; Biochemistry 2013, 52, 1171-8; Zhao, L., et al., Chembiochem, 2015. 16(10): 1420-5; Zhou, B., et al., Biosens Bioelectron, 2015. 68: 189-96; WO2014 / 043403, US20150218220, EP 1661584). We have been studying the conjugation of amatoxins for some time. The structures of the amatoxins applicable to the present invention are preferably the following Am01, Am02, and Am03, or isotopic substitutions of one or more chemical elements, or pharmaceutically acceptable salts, hydrates, or hydrated salts, or polycrystalline structures of these compounds, or optical isomers, racemates, diastereomers, or enantiomers:
[0178] [ka]
[0179] wherein X1 and Y1 are independently O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R1), CH2, CHNH, CHO, C(O)NHNHC(O), and C(O)NR1;
[0180] R7, R8, and R9 are independently H, OH, OR1, NH2, NHR1, C1-C6 alkyl, or absent;
[0181] Y2 is O, O2, NR1, NH, or absent;
[0182] R 10is CH2, O, NH, NR1, NHC(O), NHC(O)NH, NHC(O)O, OC(O)O, C(O), OC(O), OC(O)(NR1), (NR1)C(O)(NR1), C(O)R1, or lacking;
[0183] R 11 are OH, NH2, NHR1, NHNH2, NHNHCOOH, O-R1-COOH, NH-R1-COOH, NH-(Aa) r COOH, O(CH2CH2O) p CH2CH2OH, O(CH2CH2O) p CH2CH2NH2, NH(CH2CH2O) p CH2CH2NH2, NR1R2, O(CH2CH2O) p CH2CH2-COOH, NH(CH2CH2O) p CH2CH2COOH, NH-Ar-COOH, NH-Ar-NH2, O(CH2CH2O) p CH2CH2-NHSO3H, NH(CH2CH2O) p CH2CH2NHSO3H, R1-NHSO3H, NH-R1-NHSO3H, O(CH2CH2O) p -CH2CH2NHPO3H2, NH(CH2CH2O) p CH2CH2NHPO3H2, OR1, R1-NHPO3H2, R1-OPO3H2, O(CH2CH2O) p CH2CH2OPO3H2, OR1-NHPO3H2, NH-R1-NHPO3H2, or NH(CH2CH2O) p CH2-CH2NHPO3H2, where (Aa) r is 1 to 8 amino acids;
[0184] n and m1 are independently 1 to 20;
[0185] p is 1 to 5000;
[0186] R1, R2, Ar, and [ka] is the same as the definition above.
[0187] Spliceostatins and pladienolides are antitumor compounds that inhibit splicing and interact with the spliceosome SF3b. Examples of spliceostatins include, but are not limited to, spliceostatin A, FR901464, and (2S,3Z)-5-{[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,4R,5R,7S)-7-(2-hydrazinyl-2-oxoethyl)-4-hydroxy-1,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-1-yl-1}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate, which has the core structure of Sp-01:
[0188] [ka]
[0189] Examples of pladienolides include, but are not limited to, pladienolide B, pladienolide D, and E7107.
[0190] Protein kinase inhibitors, which block the action of enzymes that add phosphate groups (PO4) to serine, threonine, or tyrosine amino acids in antibody-like proteins, can modulate protein function. They can be used to treat diseases by modulating cellular function to overcome the overactivity of protein kinases (including mutant or overexpressed kinases) in cancer or other disease factors. The structures of protein kinase inhibitors are preferably those of the following formulae PK01 to PK40: adavosertib, afatinib, axitinib, bafetinib, bosutinib, cobimetinib, crizotinib, cabozantinib, dasatinib, entrectinib, erdafitinib, erlotinib, fostamatinib, gefitinib, ibrutinib, imatinib, lapatinib, lenvatinib, mubritinib, ni ... Lotinib, pazopanib, pegaptanib, ponatinib, revastinib, regorafenib, ruxolitinib, sorafenib, sunitinib, SU6656, tofacitinib, vandetanib, vemurafenib, entrectinib, palbociclib, ribociclib, abemaciclib, dacomitinib, neratinib, rociletinib (CO-1686), osimertinib, AZD3759, nazartinib (EGF816):
[0191] [ka] TIFF2024541058000078.tif254170TIFF2024541058000079.tif216170TIFF2024541058000080.tif232170 TIFF2024541058000081.tif230170TIFF2024541058000082.tif220170TIFF2024541058000083.tif128170
[0192] In the formula, Z5 and Z 5’is independently selected from O, NH, NHNH, NR, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R), N(R)C(O)N(R), C(O)NHNHC(O), and C(O)NR.
[0193] MEK inhibitors inhibit the mitogen-activated protein kinases MEK1 and / or MEK2, which are often overactivated in some cancers. MEK inhibitors are particularly used to treat BRAF-mutant melanoma, KRAS / BRAF-mutant colorectal cancer, breast cancer, and non-small cell lung cancer (NSCLC). MEK inhibitors are selected from PD0325901, selumetinib (AZD6244), cobimetinib (XL518), refametinib, trametinib (GSK1120212), pimasertib, binimetinib (MEK162), AZD8330, RO4987655, RO5126766, WX-554, E6201, GDC-0623, PD-325901, and TAK-733. Preferred MEK inhibitors are selected from trametinib (GSK1120212), cobimetinib (XL518), binimetinib (MEK162), selumetinib, which have the following formula:
[0194] [ka]
[0195] wherein Z5 is selected from O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R2), C(O)NHNHC(O), and C(O)NR1.
[0196] The protease inhibitor used as the payload of the conjugate is preferably selected from carfilzomib, clindamycin, retapamulin, and indibulin, which have the following structures:
[0197] [ka]
[0198] Immunotoxins are typically cytotoxic macromolecular drugs derived from bacterial or plant proteins, such as diphtheria toxin (DT), cholera toxin (CT), trichosanthin (TCS), dianthin, Pseudomonas exotoxin A (ETA), erythrogenic toxin, diphtheria toxin, AB toxin, and type III exotoxin. They may also be highly toxic bacterial pore-forming protoxins that require proteolytic treatment for activation. Examples of such protoxins include proerolysin and its genetically modified form, topsalicin. Topsalicin is a modified recombinant protein designed to be selectively activated by an enzyme present in the prostate gland, causing localized cell death and tissue destruction without damaging adjacent tissues and nerves. The immunotoxins of the present invention are preferably conjugated to an amino acid bearing a free amino, thiol, or carboxyl group, more preferably the N-terminal amino acid, by the methods of the present invention.
[0199] Additionally, cell receptor agonists, cell stimulatory molecules, or intracellular signaling molecules can be conjugated as drug D by the methods of the present invention.
[0200] The cell-binding ligand and receptor agonist are selected from the following: folic acid derivatives; glutamic acid urea derivatives; somatostatin and its analogs (selected from the group consisting of octreotide (sandostatin) and lanreotide (somatilin)); aromatic sulfonamides; pituitary adenylate cyclase-activating peptide (PACAP) (PAC1); vasoactive intestinal peptide (VIP / PACAP) (VPAC1, VPAC2); melanocyte-stimulating hormone (α-MSH); cholecystokinin (CCK) / gastrin receptor agonist, bombesin (Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp- Ala-Val-Gly-His-Leu-Met-NH2) / gastrin-releasing peptide (GRP); neurotensin receptor ligands (NTR1, NTR2, NTR3), substance P (NK1 receptor) ligands; neuropeptide Y (Y1-Y6); homing peptides including RGD (Arg-Gly-Asp), NGR (Asn-Gly-Arg), dimeric and multimeric cyclic RGD peptides (cRGDfV), TAASGVRSMH, and LTLRWVGLMS (chondroitin sulfate proteoglycan NG2 receptor ligand), and F3 peptide; cell membrane penetrating peptides (CPP);Luteinizing hormone-releasing hormone (LHRH) agonists and antagonists, and gonadotropin-releasing hormone (GnRH) agonists, which act by targeting follicle-stimulating hormone (FSH) and luteinizing hormone (LH), as well as testosterone production, include buserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-NHEt), gonadorelin (Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), gosselin (Gibberish, 2002), and gonadotropin-releasing hormone (GnRH) agonists. Histrelin (Pyr-His-Trp-Ser-)Tyr-D-Ser(OtBu)-Leu-Arg-Pro-AzGly-NH2), histrelin (Pyr-His-Trp-Ser-Tyr-D-His(N-benzyl)-Leu-Arg-Pro-NHEt), leuprolide (Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt), nafarelin (Pyr-His-Trp-Ser-Tyr-2Nal-Leu-Arg-Pro-Gly-NH2), triptorelin (Pyr-His s-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), nafarelin, deslorelin, abarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-(N-Me)Tyr-D-Asn-Leu-isopropylLys-Pro-DAla-NH2), cetrorelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2), degarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-4-aminoPhe(L-hydroorotyl)-D-4-aminoPhe(carbamoyl)-Leu-isopropyl-Lys-Pro-D-Ala-NH2), and ganirelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-(N9,N10-diethyl)-homoArg-Leu-(N9,N10-diethyl)-homoArg-Pro-D-Ala-NH2);Pattern recognition receptors (PRRs) selected from Toll-like receptor (TLR) ligands, C-type lectins, and Nodlike receptor (NLR) ligands; calcitonin receptor agonists; integrin receptors and their receptor subtypes (α; V β1, α V β3, α V β5, α V β6, α6β4, α7β1, α L β2, α IIb β3) agonists (selected from the group consisting of GRGDSPK, cyclo(RGDfV)(L1) and its derivatives [cyclo(-N(Me)R-GDfV), cyclo(R-Sar-DfV), cyclo(RG-N(Me)D-fV), cyclo(RGD-N(Me)fV), cyclo(RGDf-N(Me)V-) (cilengitide)]; anticalins (derivatives of lipocalins); adnectins (10th FN3 (fibronectin)); designed ankyrin repeat proteins (DARPins); avimers; EGF receptor or VEGF receptor agonists;
[0201] The cell binding molecule / ligand or cell receptor agonist is selected from the following: LB01 (folic acid), LB02 (PMSA ligand), LB03 (PMSA ligand), LB04 (PMSA ligand), LB05 (somatostatin), LB06 (somatostatin), LB07 (octreotide, somatostatin analog), LB08 (ramareotide, somatostatin analog), LB09 (vapreotide (sambar), somatostatin analog), LB10 (CAIX ligand), LB11 (CAIX ligand), LB12 (gastrin-releasing peptide receptor (GRPr), MBA), LB13 (luteinizing hormone-releasing hormone (LH-RH) ligand and GnRH), LB14 (luteinizing hormone-releasing hormone (LH-RH) and GnRH ligand), LB15 (GnRH antagonist, abarelix), LB16 (cobalamin, vitamin B12 analog), LB17 (cobalamin, vitamin B12 analog), LB18 (α vβ3 integrin receptor), LB19 (heterobivalent peptide ligand for VEGF receptor), LB20 (neuromedin B), LB21 (bombesin for G protein-coupled receptor), LB22 (TLR2 for toll-like receptor), LB23 (for androgen receptor), LB24 (α v Cilengitide / cyclo(-RGDfV-) for integrin receptors, LB23 (fludrocortisone), LB25 (rifabutin analog), LB26 (rifabutin analog), LB27 (rifabutin analog), LB28 (fludrocortisone), LB29 (dexamethasone), LB30 (fluticasone propionate), LB31 (beclomethasone dipropionate), LB32 (triamcinolone acetonide), LB33 (prednisone), LB34 (prednisolone), LB35 (methylprednisolone), LB36 (betamethasone), LB37 (irinotecan analog), LB3 8 (crizotinib analog), LB39 (bortezomib analog), LB40 (carfilzomib analog), LB41 (carfilzomib analog), LB42 (leuprolide analog), LB43 (triptorelin analog), LB44 (clindamycin), LB45 (liraglutide analog), LB46 (semaglutide analog), LB47 (retapamulin analog), LB48 (indibulin analog), LB49 (vinblastine analog), LB50 (lixisenatide analog), LB51 (osimertinib analog), LB52 (nucleoside analog), LB53 (erlotinib analog), or LB54 (lapatinib analog);
[0202] [ka] TIFF2024541058000087.tif237170TIFF2024541058000088.tif249170TIFF202 4541058000089.tif237170TIFF2024541058000090.tif246170TIFF2024541058 000091.tif248170TIFF2024541058000092.tif251170TIFF2024541058000093. tif237170TIFF2024541058000094.tif232170TIFF2024541058000095.tif63170
[0203] wherein X4 and Y1 are independently O, NH, NHNH, NR1, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R1), CH2, C(O)NHNHC(O), and C(O)NR1.
[0204] In another embodiment, one or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA) are conjugated as drugs by the methods of the present invention: [ka]
[0205] During the ceremony, [ka] is the binding site for the side chain linker of this patent. [ka] is a single- or double-stranded DNA, RNA, mRNA, siRNA, miRNA, or piRNA; X1 and Y are independently O, NH, NHNH, NR1, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R1), CH2, C(O)NHNHC(O), and C(O)NR1.
[0206] In some embodiments, an oxidizing agent can be added in step (c) of the method of the present invention (after the coupling reaction step) to reoxidize unreacted sulfhydryl groups, preferably selected from dehydroascorbic acid (DHAA), thereby reforming the disulfide bonds of the antibody or antibody-like protein and providing the antibody with a longer half-life. The concentration of the oxidizing agent in the reaction solution can be 0.01 mM to 1.0 mM.
[0207] Instead of adding DHAA in the method of the present invention, an excess amount of a disulfide compound such as cysteine can be added in step (c). Thus, the disulfide compound can be reduced by an excess of a reducing agent, such as TCEP in step (b), to form a thiol compound, which is simultaneously conjugated in excess with a linker or linker / payload conjugate containing a thiol-reactive group (e.g., maleic acid), and the resulting thiol-succinimide linker / payload conjugate is then removed by chromatography.
[0208] In some embodiments, specific thiols are introduced into an antibody or antibody-like protein by the conjugation method of the present invention (in the conjugation method of the present invention, when the antibody or antibody-like protein is an IgG antibody, it is likely that only the disulfide bond between the heavy and light chains is reduced to generate a thiol), and then the thiols independently react with formula (I), (II), or (III) simultaneously or sequentially in the conjugation reaction to form a conjugate of formula (V), (VI), or (VII) shown below:
[0209] [ka]
[0210] In the formula, n is 1 to 20; n' is 1 to 10; preferably, n is 1 to 8 and n' is 1 to 4; more preferably, n is 2 to 4 and n' is 1 to 2; D1, D2, L1, L2, and E1 are as defined above; S (sulfur) is generated by reduction of a specific disulfide bond in an antibody or antibody-like protein under the conditions of the method of the present invention; mAb is an antibody or antibody-like protein; Lv 1’ and Lv 2’ is the group obtained by reacting a thiol in the mAb with Lv1 and Lv2 in the above structure; Lv 1’ and Lv 2’ independently have the following structure:
[0211] [ka]
[0212] In the formula, X 2’ and R3 have the same definition as in claim 5.
[0213] In formula (VI) and formula (VII), [ka] can independently be selected from:
[0214] [ka] TIFF2024541058000103.tif238170TIFF2024541058000104.tif237170TIFF2024541058000105.tif153170
[0215] wherein R1, R2, and X2 have the same definitions as above; mAb is an antibody or antibody-like protein, preferably, when the antibody-like protein is an antibody, the conjugate specifically binds to the thiol between the heavy and light chains of the antibody.
[0216] In some embodiments, under the method of the present patent invention, a conjugate having formula (VIII), (IX), or (X) as shown below can be first reacted with a selectively reduced thiol in an antibody or antibody-like protein (typically the thiol between the heavy and light chain when the antibody or antibody-like protein is an IgG antibody), and then condensed with a cytotoxic agent or cytotoxic agent / conjugate to form a conjugate of formula (V), (VI), or (VII) as shown above: [ka]
[0217] wherein L1, L2, E1, Lv1, and Lv2 have the same definitions as above for formulas (I), (II), and (III).
[0218] Lv5 and Lv6 are independently selected from the following: [ka]
[0219] wherein X is F, Cl, Br, I, OTs (tosylate), OTf (triflate), OMs (mesylate), OC H (NO), OC H (NO), OC F, OC HF, or Lv; 2’ is O, NH, N(R1), or CH2; R3 and R5 are independently H, R1, aromatic, heteroaromatic, or an aromatic group in which one or several H atoms are independently replaced by -R1, -halogen, -OR1, -SR1, -NR1R2, -NO2, -S(O)R1, -S(O)2R1, or -COOR1; Lv3 and Lv 3’are independently a leaving group selected from F, Cl, Br, I, nitrophenoxyl; N-hydroxysuccinimide (NHS); phenoxyl; benzenethiol, dinitrophenoxyl; pentafluorophenoxyl; tetrafluorophenoxyl; difluorophenoxyl; monofluorophenoxyl; pentachlorophenoxyl; triflate; imidazole; dichlorophenoxyl; tetrachlorophenoxyl; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate, an anhydride formed with itself or with another anhydride selected from acetyl anhydride and formyl anhydride, or an intermediate molecule generated with a condensation reagent for a peptide coupling reaction or a Mitsunobu reaction; wherein functional groups Lv5 and / or Lv6 can also react with a thiol in a cytotoxic agent, so long as the reaction is at least one-fold faster or slower than the reaction between Lv1 or Lv2 and a thiol in an antibody or antibody-like protein.
[0220] In some embodiments, under the method of the present patent, a specific thiol is introduced into the antibody-like protein, typically generating a thiol between the heavy and light chains when the antibody or antibody-like protein is an IgG antibody, and then in a conjugation method, the thiol is reacted simultaneously or sequentially with a conjugate of formula (VIII), (IX), or (X) below to form a conjugate of formula (XI), (XII), or (XIII) below, which is subsequently reacted independently with a drug D1 or D2 to form a conjugate of formula (V), (VI), or (VII):
[0221] [ka] In the formula, Lv5, Lv6, L1, L2, E1, Lv 1’ , Lv 2’ , mAb, n, and n' are as defined above.
[0222] In some embodiments, under the method of the present invention, the conjugate of formula (VIII), (IX), or (X) above can be first reacted with a cytotoxic agent to form a cytotoxic agent / conjugate molecule of formula (I), (II), or (III), which can then be independently reacted with a reduced thiol in an antibody or antibody-like protein to form a conjugate of formula (V), (VI), or (VII). The first-step condensation reaction with the cytotoxic agent of formula (VIII), (IX), or (X) can be carried out in a separate pot, and the resulting cytotoxic agent / conjugate conjugate of formula (I), (II), or (III) can optionally be purified by chromatography, extraction, or precipitation before being conjugated with a reduced thiol in the antibody-like protein. The first step of specific reduction of disulfide bonds in the antibody-like protein and the conjugation reaction with formula (I), (II), or (III) are preferably carried out in the same pot without intermediate separation.
[0223] To distinguish between the reaction between Lv5 and / or Lv6 and the reaction between Lv1 and / or Lv2 and the thiol in the antibody-like protein, the reactions involving the conjugates of formula (VIII), (IX), or (X) can be carried out in the same or different reaction pods under different conditions. For example, a drug having an amino group can be condensed with a carboxyl group in the conjugate in the presence of a condensation reagent such as EDC, TBTU, or BroP to obtain a modified cytotoxic agent / conjugate conjugate of formula (I), (II), or (III) having an amide bond. This condensation reaction can proceed in a physiological buffer by activating the carboxyl group at one end of a linker of formula (VIII), (IX), or (X), which can react with a pharmaceutical having an amino group to produce a cytotoxic agent / linker conjugate of formula (I), (II), or (III), with n-hydroxyimide (NHS), pentafluorophenyl, dinitrophenyl ester, or carboxylic acid chloride, etc., and then simultaneously or sequentially conjugating it to a thiol of an antibody-like protein by the methods of the present invention to form a conjugate of formula (V), (VI), or (VII). In another embodiment, the thiol-reactive group (e.g., maleimide, vinylsulfonyl, haloacetyl, acryl, substituted propiolic) is present at one end, and the other end has a group capable of reacting with a drug (e.g., hydroxysuccinimidyl (NHS), pentafluorophenyl, dinitrophenyl ester, amino, alkyloxyamino, or a group capable of click chemistry (e.g., azide, alkyne, dibenzocyclooctyne, BCN ((1R,8S,9s)-bicyclo[6.1.0] The conjugate of formula (VIII), (IX), or (X), having both the hydroxyl group and the hydroxyl group (non-4-yn-9-ylmethanol) can be conjugated to a thiol of an antibody-like protein (preferably, an antibody) by the method of the present application in a buffer solution at pH 4.5 to 7.5 and 2°C to 40°C (preferably 2°C to 8°C), with or without the addition of 0 to 30% of a water-miscible (miscible) organic solvent, to independently obtain an antibody-like protein-conjugate conjugate of formula (XI), (XII), or (XIII), respectively.Next, drugs capable of reacting with the reactive groups in the antibody-like protein-conjugate conjugate of formula (XI), (XII), or (XIII) are added to the reaction solution sequentially or simultaneously to obtain the conjugate of formula (V), (VI), or (VII). Optionally, the antibody-like protein-conjugate conjugate of formula (XI), (XII), or (XIII) can be purified before condensation with the drug, and the condensation conditions in the second step can be modified, for example, by adjusting the pH to 6.5 to 8.5 and / or adjusting the temperature to 20 to 45°C.
[0224] In some embodiments, prior to conjugation with a drug during the conjugation methods of the invention, the antibody-like protein is conjugated to a compound selected from the group consisting of amine to sulfhydryl (succinimidyl (NHS) ester / maleimide, NHS ester / pyridyldithiol, NHS ester / haloacetyl) conjugates, diazirine (SDA) to sulfhydryl conjugates, azide to sulfhydryl conjugates, alkyne to sulfhydryl conjugates, sulfhydryl to carbohydrate (maleimide / hydrazide, pyridyl) conjugates, and the like. The hydroxyl to DNA (maleimide / psoralen, pyridyldithiol / psoralen, haloacetyl / psoralen), sulfhydryl to carboxyl (carbodiimide) linkers of formula (XI), (XII), or (XIII) may be modified by conjugation with a heterobifunctional bridge linker, such as a pyridyldithiol / hydrazide, haloacetyl / hydrazide linker, a hydroxyl to sulfhydryl (isocyanate / maleimide) linker, a sulfhydryl to DNA (maleimide / psoralen, pyridyldithiol / psoralen, haloacetyl / psoralen) linker, or a sulfhydryl to carboxyl (carbodiimide) linker.
[0225] The reactive group of the drug / cytotoxic agent that reacts with the modified antibody-conjugate complex of formula (XI), (XII), or (XIII) to give the final conjugate can be obtained by different methods. For example, conjugates linked via disulfide bonds can be obtained by first conjugating a conjugate of formula (VIII), (IX), or (X) to the antibody-like protein by reduction and conjugation according to the present invention at 2°C-8°C and pH 4.5-6.0, followed by disulfide exchange between the drug containing a free thiol group and the disulfide bond (e.g., a pyridyldithio moiety) in the conjugate bound to the modified antibody-like protein at pH 6.5-8.0 and 20°C-40°C. It is preferable to remove excess reducing agent (e.g., TCEP or tri(3-hydroxypropyl)phosphine) from the reaction vessel before adding the drug containing a free thiol for conjugation. The synthesis of thioether-linked conjugates is accomplished by first reacting a linker containing both thiol-reactive ends—maleimide, haloacetyl, ethylsulfonyl, or substituted propionyl groups—with a thiol in an antibody reduced by the methods of the present application at 2° C.-8° C. and pH 4.5-6.0 to produce an antibody-conjugate conjugate of formula (XI), (XII), or (XIII), followed by reaction with a thiol-containing drug at pH 6.5-8.0 and 20° C.-40° C. to yield a conjugate of formula (V), (VI), or (VII). When the same pH and / or temperature conditions are selected for the two-step reaction of the thioether-linked conjugate, the linker containing the reactive dual-terminated thiol is used in the conjugation at a four-fold or greater equivalent amount. It should be noted that the preferred method of synthesis of disulfide or thiol-ether bond conjugates is by first chemically synthesizing a drug-conjugate conjugate having a disulfide or thiol-ether bond of formula (I), (II), or (III), followed by reaction with a thiol in a protein (antibody) according to the methods of the present invention.Synthesis of conjugates with acid-labile hydrazone bonds can be achieved by reacting a carbonyl group with a hydrazide moiety in the linker by methods known in the art (e.g., P. Hamann et al., Cancer Res. 53, 3336-34, 1993; B. Laguzza et al., J. Med. Chem., 32; 548-55, 1959; P. Trail et al., Cancer Res., 57; 100-5, 1997). The synthesis of conjugates bearing a triazole bond can be achieved by reacting the 1-yne group of a drug with the azide moiety in the linker via click chemistry (Huisgen cycloaddition) (Lutz, JF. et al., 2008, Adv. Drug Del. Rev. 60, 958-70; Sletten, EM et al., 2011, Acc. Chem. Research 44, 666-76). The synthesis of conjugates linked via oxime is achieved by reacting a modified antibody-like protein containing a ketone or aldehyde with a drug containing an oxyamine group. Drugs bearing hydroxyl or thiol groups can be reacted with modified linkers of formula (XI), (XII), or (XIII) bearing a halogen, particularly an α-halide of a carboxylic acid, in the presence of a weak base, e.g., at pH 8.0-9.5, to yield modified drug / linker conjugates bearing an ether or thiol ether linkage of formula (I), (II), or (III). A drug containing a hydroxyl group is condensed with a linker of formula (XI), (XII), or (XIII) having a carboxyl group in the presence of a dehydrating agent such as EDC or DCC to form an ester bond, and the drug / linker conjugate is then conjugated to an antibody-like protein under the method of the present invention.Drugs containing an amino group can be condensed with NHS, imidazole, nitrophenoxyl carboxylic esters; N-hydroxysuccinimide (NHS); methylsulfonylphenoxyl; dinitrophenoxyl; pentafluorophenoxyl; tetrafluorophenoxyl; difluorophenoxyl; monofluorophenoxyl; pentachlorophenoxyl; triflate; imidazole; dichlorophenoxyl; tetrachlorophenoxyl; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3'-sulfonate on the antibody-like protein-conjugate of formula (VIII) or (XI) to give an amide bond conjugate of formula (V), (VI), or (VII).
[0226] In a further embodiment, the conjugates of formula (V), (VI), or (VII) obtained by the method of the present patent invention are conjugated at 75% or more of the cysteine residues between the heavy and light chains of an antibody, and at less than 15% of the cysteine residues (hinge region) between the heavy and heavy chains of the antibody. Typically, for formula (V) or (VII), when the drug / antibody ratio (DAR) is set to 4, the percentage distribution of the number of drugs in the antibody is as follows: D0<1%, D2<10%, D4>75%, D6<10%, D8<10%; for formula (VI), when the drug / antibody ratio (DAR) is set to 4, the percentage distribution of the number of drugs in the antibody is as follows: D0<1%, D1<10%, D2>75%, D3<10%, D4<10%.
[0227] The resulting conjugate can be purified by standard biochemical methods, such as gel filtration on a Sephadex G25 or Sephacryl S300 column, adsorption chromatography, ion (cation or anion) exchange, or dialysis (ultrafiltration or hyperfiltration (UF) and diafiltration (DF)). In some cases, when a small antibody-like protein (e.g., <10 KD) is conjugated with a small molecule drug as the cell-binding molecule, it can be purified by chromatography, such as HPLC, medium-pressure column chromatography, or ion-exchange chromatography.
[0228] Generally, conjugates of formula (V), (VI), or (VII) are preferably produced from drug / conjugate conjugates of formula (I), (XII), or (XIII) in a one-pot reaction. When a thiol reduced from an antibody-like protein reacts with a thiol-reactive group at the terminus of a drug / conjugate conjugate of formula (I), (XII), or (XIII), Ellman's reagent can optionally be used to monitor the efficient reduction of disulfide bonds and conjugation of thiols by measuring the number of free thiols in the reaction. UV spectroscopy at wavelengths ranging from 190 to 390 nm, preferably 240 to 380 nm, and more preferably 240 to 330 nm, is preferably used to support the reaction (through monitoring of conjugation). Thus, the conjugation reaction can be measured or performed in a quartz cell or Pyrex flask under temperature-controlled conditions. The drug-to-protein (antibody) ratio (DAR) of a conjugate can also be measured by calculating the drug and protein concentrations, by UV at wavelengths ranging from 240 to 380 nm, by measuring the integrated area of each drug / protein fragment, by hydrophobic interaction chromatography (HIC-HPLC), or by capillary electrophoresis (CE) and / or LC-MS, LC-MS / MS, or CE-MS (a combination of liquid chromatography (LC) or CE with mass spectrometry (MS) via measuring both the integrated area of LC or CE and the peak intensity of MS for each drug / protein fragment). In the conjugation method of the present invention, if the drug or drug / conjugate complex is not well soluble in the aqueous buffer, up to 30% of a water-miscible organic solvent, such as DMA, DMF, ethanol, methanol, acetone, acetonitrile, THF, isopropanol, dioxane, propylene glycol, or ethylenediol, can be added to the aqueous buffer as a cosolvent.
[0229] Aqueous solutions for modification of antibody-like proteins are buffered to a pH between 4 and 9, preferably between 6.0 and 7.5, and may contain non-nucleophilic buffer salts useful in these pH ranges. Representative buffers include phosphate, acetate, triethanolamine HCl, HEPES, and MOPS buffers, and may further contain additional components such as cyclodextrin, hydroxypropyl-β-cyclodextrin, polyethylene glycol, sucrose, and salts (e.g., NaCl, KCl). Other biological buffers useful in conjugation methods are listed in the definitions section. Reaction progress can be monitored by measuring the decrease in absorbance at 252 nm or the increase in absorbance at 280 nm, or changes at other appropriate wavelengths. After the reaction is complete, isolation of the modified cell-binding agent can be achieved by conventional methods, such as gel filtration chromatography, ion exchange chromatography, adsorption chromatography, or column chromatography on silica gel or alumina, crystallization, preparative thin-layer chromatography, ion exchange chromatography, or HPLC.
[0230] When disulfide exchange reactions are used to modify antibody-like proteins, the degree of modification can be assessed by measuring the absorbance of the emitted nitropyridinethione, dinitropyridinedithione, pyridinethione, carboxyamidopyridinedithione, and dicarboxyamidopyridinedithione groups via UV spectroscopy. For conjugates without chromophore groups, the modification or conjugation reaction can be monitored by LC-MS, preferably UPLC-QTOF mass spectrometry, or capillary electrophoresis (CEMS). The side-chain crosslinkers described herein have a variety of functional groups that can react with any drug, preferably a cytotoxic drug, bearing the appropriate substituent. For example, modified cell-binding molecules bearing amino or hydroxy substituents can react with drugs bearing N-hydroxysuccinimide (NHS) esters, and modified cell-binding molecules bearing thiol substituents can react with drugs bearing maleimide or haloacetyl groups. Furthermore, modified cell-binding molecules bearing carbonyl substituents (ketones or aldehydes) can react with drugs bearing hydrazides or alkyloxyamines. One of skill in the art can readily determine which linker to use based on the known reactivity of the available functional groups on the linker.
[0231] Examples of preferred conjugates of formulas (V), (VI), and (VII) that can be constructed according to the methods of the present invention to achieve greater than 80% of the total drug bound to the cysteines between the heavy chains of the antibody are those of the structures shown below, or one or more isotopes of the chemical elements, pharmaceutically acceptable salts, hydrates, or hydrated salts; or polymorphic crystal structures of these compounds; or optical isomers, racemates, diastereomers, or enantiomers:
[0232] [ka] TIFF2024541058000110.tif232170TIFF2024541058000111.tif248170TIFF2024541058000112.tif247170TIFF2024541058000113.tif232170TIFF2024541058000114.tif238170TIFF2024541058000115.tif247170TIFF2024541058000116.tif237170TIFF2024541058000117.tif254170TIFF2024541058000118.tif251170TIFF2024541058000119.tif237170TIFF2024541058000120.tif243170TIFF2024541058000121.tif253170TIFF2024541058000122.tif233170TIFF2024541058000123.tif196170TIFF2024541058000124.tif238170TIFF2024541058000125.tif253170TIFF2024541058000126.tif227170TIFF2024541058000127.tif227170TIFF2024541058000128.tif232170TIFF2024541058000129.tif232170TIFF2024541058000130.tif238170TIFF2024541058000131.tif202170TIFF2024541058000132.tif243170TIFF2024541058000133.tif228170TIFF2024541058000134.tif243170TIFF2024541058000135.tif243170TIFF2024541058000136.tif220170TIFF2024541058000137.tif202170TIFF2024541058000138.tif232170TIFF2024541058000139.tif212170TIFF2024541058000140.tif246170TIFF2024541058000141.tif253170TIFF2024541058000142.tif248170TIFF2024541058000143.tif232170TIFF2024541058000144.tif236170TIFF2024541058 000145.tif248170TIFF2024541058000146.tif242170TIFF2024541058000147.tif207170TIFF2024 541058000148.tif253170TIFF2024541058000149.tif222170TIFF2024541058000150.tif228170TI FF2024541058000151.tif208170TIFF2024541058000152.tif253170TIFF2024541058000153.tif24 8170TIFF2024541058000154.tif248170TIFF2024541058000155.tif252170TIFF202454105800015 6.tif222170TIFF2024541058000157.tif181170TIFF2024541058000158.tif247170TIFF202454105 8000159.tif248170TIFF2024541058000160.tif243170TIFF2024541058000161.tif237170TIFF202 4541058000162.tif252170TIFF2024541058000163.tif218170TIFF2024541058000164.tif247170.
[0233] In the formula, p, p1, p2, and p3 are independently an integer of 0 to 100. m, m1, and m2 are independently an integer of 0 to 20. n is an integer of 1 to 10.
[0234] P 1 is H, OH, NH2, COOH, C(O)NH2, OCH2OP(O)(OR 18 )2, OC(O)OP(O)(OR 18 )2, OPO(OR 18 )2, NHPO(OR 18 )2, OC(O)R 18 , OP(O)(OR18 )OP(O)(OR 18 )2, OC(O)NHR 18 , OC(O)N(C2H4)2NCH3, OSO2(OR 18 ), O-(C4-C 12 -glycoside), OC(O)N(C2H4)2CH2N(C2H4)2CH3, O-(C1-C8 straight or branched alkyl), C1-C8 straight or branched alkyl or heteroalkyl; C2-C8 straight or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 straight or branched aryl, arylalkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 );R 17 and R 18 are independently H, straight or branched alkyl or heteroalkyl; C2-C8 straight or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C3-C8 straight or branched aryl, arylalkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 )
[0235] R 1 , R 2 , R 3 , R 1’ , R 2’ , R 3’ , and R 4 are independently H, C1-C8 alkyl; C2-C8 heteroalkyl, or heterocycle; C3-C8 aryl, arylalkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl; or R 1 and R 2 , R 1 and R 3 , R 2and R 3 , R 3 and R 4 , R 1’ and R 2’ , R 1’ and R 3’ , or R 2’ and R 3’ form a 3- to 7-membered carbocyclic, cycloalkyl, heterocyclic, heterocycloalkyl, aromatic or heteroaromatic ring system.
[0236] R4, R5, R 5’ , and R 6 are independently H, C1-C8 straight or branched alkyl, C3-C8 aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxyamine, or (Ar)r, where r=1-6 (amino acids or peptides having the same or different amino acid sequences).
[0237] R7, R8, and R9 are independently H, OH, OR1, NH2, NHR1, C1-C6 alkyl, or absent.
[0238] R 10 is CH2, O, NH, NR1, NHC(O), NHC(O)NH, NHC(O)O, OC(O)O, C(O), OC(O), OC(O)(NR1), (NR1)C(O)(NR1), C(O)R1, or is absent.
[0239] R 11 is OH, NH2, NHR1, NHNH2, NHNHCOOH, O-R1-COOH, NH-R1-COOH, NH-(Aa)rCOOH, O(CH2CH2O) p CH2CH2OH, O(CH2CH2O) p CH2CH2NH2, NH(CH2CH2O) p CH2CH2NH2, NR1R2, O(CH2CH2O) p CH2CH2-COOH, NH(CH2CH2O) p CH2CH2COOH, NH-Ar-COOH, NH-Ar-NH2, O(CH2CH2O) p CH2CH2-NHSO3H, NH(CH2CH2O)p CH2CH2NHSO3H, R1-NHSO3H, NH-R1-NHSO3H, O(CH2CH2O) p -CH2CH2NHPO3H2, NH(CH2CH2O) p CH2CH2NHPO3H2, OR1, R1-NHPO3H2, R1-OPO3H2, O(CH2CH2O) p CH2CH2OPO3H2, OR1-NHPO3H2, NH-R1-NHPO3H2, or NH(CH2CH2O) p CH2-CH2NHPO3H2, where (Aa)r is 1 to 8 amino acids; n and m1 are independently 1 to 20. p is 1 to 1000. R1, R2, and Ar are as defined above in this application.
[0240] [ka] has the same definition as above.
[0241] R 12 and R 12’ are independently H, ═O, OR1, NH2, NH(CH3), NHNH2, COOH, SH, OZ3, SZ3, F, Cl, or C1-C8 linear or branched alkyl, C3-C8 aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, or acyloxyamine.
[0242] R 25 , R 26 , and R 25’ are independently H, Ac, R1, C(O)NHR1, C(O)R1, R1COOH, R1COOR2, R1OR2, R1CONHR2, CH2OAc, CH2NHAc, R1NH2, NR1R2, N + R1R2R3, CH2CONH(CH2) q1 COOH, CH2CONH(CH2) q1 COOR1, CH2CONH(CH2) q1 N + R1R2R3, or (Aa)r.
[0243] X1, X2, X4, Y1, and Y2 are binding sites [ka] are independently O, NH, NHNH, NR5, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R1), N(R1)C(O)N(R2), CH2, CHNH, CHO, C(O)NHNHC(O), OCH2C6H4NH, NHCH2C6H4NH, SCH2C6H4NH, and C(O)NR1 when attached to the binding site; or [ka] When not bound to S, Y is OH, NH, NHNH, NHR, SH, C(O)OH, C(O)NH, OC(O)NH, OC(O)OH, NHC(O)NH, NHC(O)SH, OC(O)NH(R), N(R)C(O)NH(R), C(O)NHNHC(O)OH, and C(O)NHR; further, when bound to S, Y may be O, O, NR, NH, or absent.
[0244] X3 and Y3 are independently N, NH, CH, CH2, or CR1, or one of X3 and Y3 may be absent, and R1 is C1 to C8 linear or branched alkyl, heteroalkyl; C3 to C8 aryl, heteroaryl, alkylcycloalkyl, acyloxy, alkylaryl, alkylaryloxy, alkylarylamino, alkylarylthiol; (Ar)r, r=1 to 6 (amino acids or peptides having the same or different amino acid sequences).
[0245] X3 is H, CH3, or X 1’ R 1’ and X 1’ is NH, N(CH), NHNH, O, or S, and R 1’is H, C1-C8 straight or branched alkyl, C3-C8 aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxyamine.
[0246] Z3 is OP(O)(OM1)(OM2), OCH2OP(O)(OM1)(OM2), OSO3M1, P(O)(OM1)(OM2), SO3M1, CH2P(O)(OM1)(OM2), CH3N(CH2CH2)2NC(O)O-, O(CH2CH2)2NC(O)O-, R1, or an O-glycoside (glucoside, galactoside, mannoside, glucuronoside / glucuronide, alloside, fructoside, etc.), NH-glycoside, S-glycoside, or CH2-glycoside. M1 and M2 are independently H, Na, K, Ca, Mg, NH4, or NR1R2R3.
[0247] Z3 is OP(O)(OM1)(OM2), OCH2OP(O)(OM1)(OM2), OSO3M1, P(O)(OM1)(OM2), SO3M1, CH2P(O)(OM1)(OM2), CH3N(CH2CH2)2NC(O)O-, O(CH2CH2)2NC(O)O-, R1, or an O-glycoside (glucoside, galactoside, mannoside, glucuronoside / glucuronide, alloside, fructoside, etc.), NH-glycoside, S-glycoside, or CH2-glycoside; M1 and M2 are independently H, Na, K, Ca, Mg, NH4, or NR1R2R3.
[0248] X5 is F, Cl, Br, I, OH, OR1, R1, OPO3H2, OSO3H, NHR1, OCOR1, NHCOR1, CN, or OCH2OP(O)(OM1)(OM2).
[0249] Y5 is NH, NHNH, NR1, O, OCH2C6H4NH, NHCH2C6H4NH, SCH2C6H4NH, R1, (Ar)r, r=1-6 (amino acids or peptides with the same or different amino acid sequences).
[0250] X6 and Y6 are independently CH, C(O), N, P(O)NH, P(O)NR1, CHC(O)NH, C1 to C8 straight-chain or branched alkyl, or C3 to C8 aryl, heteroaryl, alkylcycloalkyl, acyloxy, alkylaryl, alkylaryloxy, alkylarylamino, or Aa (amino acid, preferably Lys, Phe, Asp, Glu, Ser, Thr, His, Cys, Tyr, Trp, Gln, Asn, Arg).
[0251] Z5 and Z 5’ is independently selected from O, NH, NHNH, NR, S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R), N(R)C(O)N(R), C(O)NHNHC(O), or C(O)NR.
[0252] X8 is O, S, NH, NHNH, NHR1, SR 12 , SSR 12 , SSCH(CH3)R1, SSC(CH3)2R1, or R1.
[0253] wherein R1, R2, and R3 are independently H, C1-C8 linear or branched alkyl, C3-C8 aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, or acyloxyamine, unless otherwise defined in the structural formula.
[0254] Lv1 is the same as the leaving group defined above and is preferably selected from F, Cl, Br, I, OTs, OMS, OC6H3(NO2)2, OC6F5, OC6H4(NO2), OC6Cl5.
[0255] M1 and M2 are independently H, Na, K, Ca, Mg, NH4, or NR1R2R3.
[0256] [ka] has the same definition as above.
[0257] Examples of preferred drug / conjugate conjugates of Formulas (I), (II), and (III) that can be used in the methods of the present invention to achieve greater than 80% conjugation of the drug to cysteines between the heavy and light chains of the antibody are those having the structures shown below, or derivatives of these compounds containing one or more isotopes, pharmaceutically acceptable salts, hydrates, or hydrated salts of these compounds; or polymorphic crystal structures of these compounds; or optical isomers, racemates, diastereomers, or enantiomers of these compounds: [ka] TIFF2024541058000170.tif250170TIFF2024541058000171.tif243170TIFF2024541058000172.tif247170TIFF2024541058000173.tif253170TIFF2024541058000174.tif252170TIFF2024541058000175.tif217170TIFF2024541058000176.tif218170TIFF2024541058000177.tif223170TIFF2024541058000178.tif227170TIFF2024541058000179.tif223170TIFF2024541058000180.tif209170TIFF2024541058000181.tif214170TIFF2024541058000182.tif253170TIFF2024541058000183.tif217170TIFF2024541058000184.tif233170TIFF2024541058000185.tif251170TIFF2024541058000186.tif238170TIFF2024541058000187.tif232170TIFF2024541058000188.tif228170TIFF2024541058000189.tif228170TIFF2024541058000190.tif217170TIFF2024541058000191.tif235170TIFF2024541058000192.tif231170TIFF2024541058000193.tif215170TIFF2024541058000194.tif216170TIFF2024541058000195.tif221170TIFF2024541058000196.tif232170TIFF2024541058000197.tif237170TIFF2024541058000198.tif247170TIFF2024541058000199.tif231170TIFF2024541058000200.tif194170TIFF2024541058000201.tif251170TIFF2024541058000202.tif254170TIFF2024541058000203.tif226170TIFF2024541058000204.tif248170TIFF2024541058000205.tif228170TIFF2024541058000206.tif200170TIFF2024541058000207.tif243170TIFF2024541058000208.tif250170TIFF2024541058000209.tif218170TIFF2024541058000210.tif252170TIFF2024541058000211.tif236170TIFF2024541058000212.tif206170TIFF2024541058000213.tif206170TIFF2024541058000214.tif252170TIFF2024541058000215.tif252170TIFF2024541058000216.tif250170TIFF2024541058000217.tif251170TIFF2024541058000218.tif233170TIFF2024541058000219.tif186170TIFF2024541058000220.tif247170TIFF2024541058000221.tif243170TIFF2024541058000222.tif252170TIFF2024541058000223.tif248170TIFF2024541058000224.tif252170TIFF2024541058000225.tif227170TIFF2024541058000226.tif253170.
[0258] where m, m1, m2, n, P 1 , R 1 , R 2 , R 3 , R 4 , R 1’ , R 2’ , R 3’ , R1, R2, R3, R4, R5, R6, R 12 , R 12’ , R 25 , R 26 [[ID=25’ , X1, X2, X3, X5, X6, Y1, Y2, Y6, Z3, Z5, p, p1, p2, p3, q1, q2, Lv1, Aa, (Aa)r, Ar, and mAb have the same definitions as above.
[0259] antibody-like proteins
[0260] The antibody-like proteins used in the present conjugation methods are preferably cell-binding antibody-like protein molecules that bind to, complex with, or react with a portion of a cell population sought to be therapeutically or otherwise biologically modified.
[0261] For convenience in this section and elsewhere, unless the context requires otherwise, "antibody-like proteins" should be understood to include "antibody-like proteins and peptides." Suitable antibody-like proteins that may be present in the conjugates of the invention include, for example, peptides, polypeptides, antibodies, antibody fragments, enzymes, cytokines, chemokines, receptors, blood factors, peptide hormones, toxins, transcript antibody-like proteins, or multimeric antibody-like proteins structurally having interchain disulfide bonds.
[0262] Enzymes include carbohydrate-specific enzymes, proteolytic enzymes, and the like, including oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases, as disclosed in U.S. Patent No. 4,179,337. Particular enzymes of interest include asparaginase, arginase, adenosine deaminase, superoxide dismutase, catalase, chymotrypsin, lipase, uricase, bilirubin oxidase, glucose oxidase, glucuronidase, galactosidase, glucosulfurosidase, and glutaminase.
[0263] Blood antibody-like proteins include albumin, transferrin, Factor VII, Factor VIII or Factor IX, von Willebrand factor, insulin, ACTH, glucagen, somatostatin, somatotropin, thymosin, parathyroid hormone, chromohormones, somatomedin, erythropoietin, luteinizing hormone, hypothalamic releasing factor, antidiuretic hormone, prolactin, interleukins, interferons, e.g., IFN-α or IFN-β, colony-stimulating factors, hemoglobin, cytokines, antibodies, antibody fragments, chorionic gonadotropin, follicle-stimulating hormone, thyroid-stimulating hormone, and tissue plasminogen activator.
[0264] Other antibody-like proteins of interest are the allergenic antibody-like proteins disclosed in Dreborg et al. Crit. Rev. Therap. Drug Carrier Syst. (1990) 6 315-365 as being less allergenic when conjugated with polymers such as poly(alkylene oxide), and therefore suitable for use as tolerogens. Among the allergens disclosed are ragweed antigen E, honeybee venom, mite allergen, etc.
[0265] Glycopolypeptides such as immunoglobulins, ovalbumin, lipase, glucocerebrosidase, lectins, tissue plasminogen activator, and glycosylated interleukins, interferons, and colony-stimulating factors are of interest, as are immunoglobulins such as IgG, IgE, IgM, IgA, IgD, and fragments thereof. Of particular interest are receptor- and ligand-binding antibody-like proteins, antibodies, and antibody fragments used in clinical medicine for diagnostic and therapeutic purposes.
[0266] The antibody-like protein is preferably: (A): The group consisting of antibodies, antibody-like protein molecules, probodies, nanobodies, peptides, coated antibodies on polymeric micelles, antibody-liposomes, lipoprotein-based drug carriers, coated antibodies on nanoparticles, antibody dendrimers, and the above particles coated or conjugated with antibody-like proteins (antibodies), or combinations of the above; (B) antibody-like proteins, full-length antibodies (polyclonal antibodies, monoclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies, trispecific antibodies, or tetraspecific antibodies)); single-chain antibodies; antibody fragments that bind to target cells, monoclonal antibodies, single-chain monoclonal antibodies, monoclonal antibody fragments that bind to target cells, chimeric antibodies, chimeric antibody fragments that bind to target cells, domain antibodies, domain antibody fragments that bind to target cells, resurfaced antibodies, resurfaced single-chain antibodies, or resurfaced antibody fragments that bind to target cells, humanized antibodies or resurfaced antibodies, humanized single-chain antibodies, or humanized antibody fragments that bind to target cells Antibody fragments, anti-idiotype (anti-Id) antibodies, CDRs, diabodies, triabodies, tetrabodies, miniantibodies, probodies, probody fragments, small immune antibody-like proteins (SIPs), lymphokine antibody-like proteins, hormone-type antibody-like proteins, growth factor antibody-like proteins, colony-stimulating factor antibody-like proteins, nutrient transport antibody-like proteins, high molecular weight antibody-like proteins, fusion antibody-like proteins, kinase inhibitor antibody-like proteins, gene targeting antibody-like proteins, antibody-like proteins coated on nanoparticles or polymers modified with antibodies or high molecular weight antibody-like proteins.
[0267] Antibody fragments include epitope-binding fragments of Fab, Fab', F(ab')2, Fv [Parham, J. Immunol. 131, 2895-2902 (1983)], fragments obtained by Fab expression libraries, anti-idiotypic (anti-Id) antibodies, CDRs, bispecific antibodies, trispecific antibodies, cancer cell antigens, viral antigens, microbial antigens, or any of the above that immunospecifically bind to a protein generated by the immune system that is capable of recognizing, binding to a specific antigen, or exhibiting a desired biological activity (Miller et al. (2003) J. of Immunology 170:4854-61); interferons (e.g., types I, II, III); peptides; lymphokines, e.g., IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, GM-CSF, or interferon gamma (IFN-γ); hormones, e.g., insulin, TRH (thyrotropin-releasing hormone), MSH (melanocyte-stimulating hormone), or steroid hormones such as androgens, estrogens, or melanocyte-stimulating hormone (MSH); growth factors and colony-stimulating factors, e.g., epidermal growth factor (EFG), granulocyte-macrophage colony-stimulating factor (GM-CSF); transforming growth factors (TGF), e.g., TGFα, TGFβ; insulin and insulin-like growth factors (IGF-I, IGF-II), G-CSF, M-CSF, and GM-CSF [Burgess, Immunology Today, 5, 155-158 (1984)]; vaccine growth factor (VGF); fibroblast growth factor (FGF); small molecular weight proteins, polypeptides, peptides, and peptide hormones, such as bombesin, gastrin, and gastrin-releasing peptide; platelet-derived growth factor; interleukins and cytokines, such as interleukin-2 (IL-2), interleukin-6 (IL-6), leukemia inhibitory factor, granulocyte-macrophage colony-stimulating factor (GM-CSF); vitamins such as folic acid; apoproteins and glycoproteins, such as transferrin [O'Keefe et al, J. Bio. Chem.260, 932-927 (1985)]; carbohydrate-binding proteins or lipoproteins such as lectins; cellular nutrient transport molecules; and small molecule inhibitors, e.g., inhibitors of prostate-specific membrane antigen (PSMA), small molecule tyrosine kinase inhibitors (TKIs), non-peptides, or other cell-binding molecules or substances, such as bioactive polymers (Dhar, et al., Proc. Natl. Acad. Sci. 2008, 105, 17356-61), dendrimers (Lee, et al., Nat. Biotechnol. 2005, 23, 1517-26; Almutairi, et al., Proc. Natl. Acad. Sci. 2009, 106, 685-90), nanoparticles (Liong, et al., ACS Nano, 2008, 19, 1309-12; Medarova, et al. al, Nat. Med. 2007, 13, 372-7; Javier, et al, Bioconjugate Chem. 2008, 19, 1309-12), liposomes (Medinai, et al, Curr. Phar. Des. 2004, 10, 2981-9), and viral capsids (Flenniken, et al, Viruses Nanotechnol. 2009, 327, 71-93).
[0268] Generally, monoclonal antibodies are preferred as cell surface binding molecules, provided that suitable monoclonal antibodies are available. Antibodies may be murine, human, humanized, chimeric, or of other species origin.
[0269] The production of antibodies used in the present invention can involve in vivo or in vitro production processes, or a combination thereof. Methods for preparing anti-receptor peptide polyclonal antibodies are well known, as shown, for example, in U.S. Patent No. 4,493,795 (Nestor et al.). A typical method for preparing monoclonal antibodies involves fusing mouse spleen cells isolated from mice immunized with a specific antigen with myeloma cells (Kohler, G; Milstein, C. 1975. Nature 256:495-497). Detailed procedures are described in "Antibodies—A Laboratory Manual," Harlow and Lane, eds., Cold Spring Harbor Laboratory Press, New York (1988), the contents of which are incorporated herein by reference. In particular, monoclonal antibodies can be obtained by immunizing mice, rats, hamsters, or other mammals with the antigen of interest, which can be, for example, intact target cells, antigens isolated from target cells, whole viruses, weakened whole viruses, or viral proteins. Spleen cells are fused with myeloma cells using PEG 6000. The resulting hybridomas are screened for their sensitivity to HAT (hypoxanthine-aminopterin-thymine). Hybridomas producing monoclonal antibodies useful in the practice of the present invention are identified by immunoreaction with or inhibition of receptor activity of specific target cell receptors.
[0270] The monoclonal antibodies used in the present invention can be obtained by initiating the culture of monoclonal hybridoma cells in a nutrient medium containing hybridoma cells secreting antibodies with the appropriate antigen specificity. The culture must be maintained for a time and under conditions sufficient for the hybridoma cells to secrete the antibodies into the culture medium. After collecting the antibody-containing culture supernatant, the antibodies can be isolated by well-known techniques, such as protein A affinity chromatography; anion exchange chromatography, cation exchange chromatography, hydrophobic interaction chromatography, and molecular sieve chromatography (particularly affinity chromatography and molecular sieve chromatography using antigen-crosslinked protein A); centrifugation, precipitation, or other standard methods for purifying proteins.
[0271] Media useful for preparing these compositions are well known in the art and commercially available, including synthetic media. An exemplary synthetic medium is Dulbecco's Minimum Essential Medium (DMEM; Dulbecco et al., Virol. 8:396 (1959)) supplemented with 4.5 g / L glucose, 0-20 mM glutamine, 0-20% fetal bovine serum, ppm amounts of several heavy metals (e.g., Cu, Mn, Fe, or Zn) or / and heavy metals added in salt form, and an antifoaming agent (e.g., polyoxyethylene-polyoxypropylene block copolymer).
[0272] In addition to cell fusion techniques, cell lines for producing antibodies can also be constructed by the following methods: direct transformation of B lymphocytes with oncogenic DNA or transfection with oncogenic viruses, such as Epstein-Barr virus (EBV, also known as human herpesvirus 4 (HHV-4)) or Kaposi's sarcoma-associated virus (KSHV) (see U.S. Patent Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,451,570; 4,466,917; 4,472,500; 4,491,632; 4,493,890 for details). Monoclonal antibodies can be prepared using anti-receptor peptides or peptides containing terminal carboxyl groups based on known methods (for details, see Niman et al., Proc. Natl. Acad. Sci. USA, 80:4949-4953 (1983); Geysen et al., Proc. Natl. Acad. Sci. USA, 82:178-182 (1985); Lei et al., Biochemistry 34(20):6675-6688 (1995)). Typically, anti-receptor polypeptides or polypeptide analogs can be used alone or conjugated to a cross-linked immunogenic carrier as immunogens for preparing monoclonal antibodies against the anti-receptor polypeptides.
[0273] There are many other well-known methods for producing monoclonal antibodies as binding molecules of the present invention. Of these, the production of fully human antibodies has attracted particular attention. Phage display technology allows for affinity selection of fully human antibodies that specifically bind to known antigens from fully human antibody libraries. The literature provides detailed descriptions of the phage display technology itself, vector construction, and library screening. For details, see Dente et al., Gene. 148(1):7-13 (1994); Little et al., Biotechnol. Adv. 12(3):539-55 (1994); Clackson et al., Nature 352:264-628 (1991); and Huse et al., Science 246:1275-1281 (1989).
[0274] Monoclonal antibodies obtained from non-human species (e.g., mice) using hybridoma technology can be humanized to avoid human anti-mouse antibodies when administered to humans. Among these, well-known methods for antibody humanization include grafting and remodeling of complementarity-determining regions (CDRs). For details, see U.S. Patent Nos. 5,859,205 and 6,797,492; Liu et al., Immunol Rev. 222:9-27 (2008); Almagro et al., Front Biosci. 1;13:1619-33 (2008); Lazar et al., Mol Immunol. 44(8):1986-98 (2007); Li et al., Proc. Natl. Acad. Sci. USA. 103(10):3557-62 (2006). The disclosures of the above documents are incorporated by reference. Fully human antibodies can be prepared by immunizing transgenic mice, rabbits, monkeys, or other mammals that possess large portions of human immunoglobulin light and heavy chains. Examples of such mice include the Xenomouse (Abgenix, Inc.), HuMab-Mouse (Medarex / BMS), and VelociMouse (Regeneron). For details, see U.S. Patent Nos. 6,596,541, 6,207,418, 6,150,584, 6,111,166, 6,075,181, 5,922,545, 5,661,016, 5,545,806, 5,436,149, and 5,569,825. In the course of human therapy, chimeric antibodies constructed by integrating mouse antibody variable region genes and human antibody constant region genes are much less immunogenic in humans than mouse antibodies (Kipriyanov et al., Mol Biotechnol. 26:39-60 (2004); Houdebine, Curr Opin Biotechnol. 13:625-9 (2002)), the disclosures of which are incorporated by reference. Furthermore, site-specific mutagenesis of antibody variable regions can improve antibody affinity and specificity (Brannigan et al., Nat Rev Mol Cell Biol. 3:964-70 (2002); Adams et al., J. Immunol Methods. 231:249-60 (1999)).The constant region of an antibody can be partially replaced to effectively enhance its affinity for immune effector cells, thereby enhancing its cytotoxic effect.
[0275] Immunospecific antibodies against malignant cell antigens can be obtained commercially or by several conventional techniques, such as chemical synthesis or recombinant expression techniques. Similarly, nucleotide sequences encoding immunospecific antibodies against malignant cell antigens can be obtained commercially from the GenBank database or other similar databases, from the literature, or by routine cloning and sequencing.
[0276] In addition to antibodies, polypeptides or proteins can also act as binding molecules, interacting with corresponding receptors or epitopes on the surface of target cells by binding, blocking, attacking, or other means. As long as these peptides or proteins can specifically bind to the epitope or its corresponding receptor, they do not need to belong to the immunoglobulin family. These polypeptides can also be isolated using techniques similar to phage display antibodies (Szardenings, J Recept Signal Transduct Res. 2003;23(4):307-49). Peptide fragments obtained from random peptide libraries have applications similar to antibodies and antibody fragments. Polypeptide or protein molecules maintain their antigen-binding specificity by connecting to several macromolecules or vehicles via binding molecules. These macromolecules include, but are not limited to, albumin, polymers, liposomes, nanoparticles, or dendrimers.
[0277] Antibodies that can be used to conjugate drugs using the conjugates of the present invention to treat cancer, autoimmune diseases, and infectious diseases include, but are not limited to, the following: 3F8 (anti-GD2 antibody), abagovomab (anti-CA-125 antibody), abciximab (anti-CD41 antibody (integrin α-IIb)), adalimumab (anti-TNF-α antibody), adalimumab (anti-EpCAM antibody, CD326), afelimomab (anti-TNF-α); afutuzumab (anti-CD20 antibody), alacizumab pegol (Alacizumab pegol) (anti-VEGFR2 antibody), ALD518 (anti-IL-6 antibody), alemtuzumab (also known as Campus, Mab Campus, anti-CD52 antibody), altumomab (anti-CEA antibody), anatumomab (anti-tag-72 antibody), anrukinzumab (IMA-638, anti-IL-13 antibody), apolizumab (anti-HLA-DR antibody), arcitumomab (anti-CEA antibody), acelizumab (anti-L -selectin (CD62L) antibody), Atlizumab (also known as Tocilizumab, Actemra, RoActemra, anti-IL-6 receptor antibody), Atorolimumab (anti-rhesus factor antibody), Bapineuzumab (anti-β-amyloid antibody), Basiliximab (anti-CD25 (IL-2 receptor α chain) antibody), Bavituximab ximab (anti-phosphatidylserine antibody), bectumomab (also known as LymphoScan, anti-CD22 antibody), belimumab (also known as BENLYSTA, LymphoStat-B, anti-BAFF antibody), benralizumab (anti-CD125 antibody), bertilimumab (anti-CCL11 (eotaxin-1) antibody), besilesomab (also known as Scintimun, anti-CEA-related antigen antibody), bevacizumab (also known as Avastin, anti-VEGF antibody), biciromab (also known as FibriScint, anti-fibrin II beta chain antibody), bivatuzumab (anti-CD44v6 antibody), blinatumomab (also known as BiTE, anti-CD19 antibody), brentuximab (cAC10, anti-CD30 TNFRSF8 antibody), Briakinumab (anti-IL-12, IL-23 antibody), Canakinumab (also known as Ilaris, anti-IL-1 antibody),Cantuzumab (also known as C242, anti-CanAg antibody), Capromab, Catumaxomab (also known as removab, anti-EpCAM, anti-CD3 antibody), CC49 (anti-TAG-72 antibody), Cedelizumab (anti-CD4 antibody), Certolizumab pegol (also known as CIMZIA, anti-TNF-α antibody), Cetuximab (also known as Erbitux, IMC-C225, anti-EGFR antibody), Sitatuzumab (anti-EpCAM antibody), Cixutumumab (anti-IGF-1 antibody), Clenoliximab (anti-CD 4 antibodies), clivatuzumab (anti-MUC1 antibody), conatumumab (anti-TRAIL-R2 antibody), CR6261 (anti-influenza A hemagglutinin antibody), dacetuzumab (anti-CD40 antibody), daclizumab (also known as Zenapax, anti-CD25C (IL-2 receptor alpha chain) antibody), daratumumab (anti-CD38 (cyclic ADP-ribose hydrolase) antibody), denosumab (also known as Prolia, anti-RANKL antibody), (anti-B-lymphoma cell antibody), Dorlimomab, Dorlixizumab, Ecromeximab (anti-GD3 ganglioside antibody), Eculizumab (also known as Soliris, anti-C5 antibody), Edobacomab (anti-endotoxin antibody), Edrecolomab (also known as Panorex, MAb17-A1, anti-EpCAM antibody), Efalizumab (also known as Raptiva, anti-LFA-1 (CD11a) antibody), Efungumab (also known as Mycograb, anti-Hsp90 antibody), Elotuzumab Elotuzumab (anti-SLAMF7 antibody), Elsilimomab (anti-IL-6 antibody), Enlimomab pegol (anti-ICAM-1 (CD54) antibody), Epitumomab (anti-episialin antibody), Epratuzumab (anti-CD22 antibody), Erlizumab (anti-ITGB2 (CD18) antibody), Ertumaxomab (also known as Rexomun, anti-HER2 / neu, CD3 antibody), Etaracizumab (also known as Abegrin, anti-integrin αvβ3),Exibirumab (anti-hepatitis B surface antigen antibody (HBs antibody)), Fanolesomab (also known as NeutroSpec, anti-CD15 antibody), Faralimomab (anti-interferon receptor antibody), Farletuzumab (anti-folate receptor 1 antibody), Felvizumab (antibody against respiratory syncytial virus), Fezakinumab (anti-IL-22 antibody), Figitumumab (anti-IGF-1 receptor antibody), Fontolizumab (anti-IFN-γ antibody), foravirumab (anti-rabies virus glycoprotein antibody), fresolimumab (anti-TGF-β antibody), galiximab (anti-CD80 antibody), gantenerumab (anti-β-amyloid antibody), gavilimomab (anti-CD147 (basigin) antibody), gemtuzumab (anti-CD33 antibody), girentuximab (anti-carbonic anhydrase 9 antibody), Glembatumumab (also known as CR011, anti-GPNMB antibody), Golimumab (also known as Simponi, anti-TNF-α antibody), Gomiliximab (anti-CD23C (IgE receptor) antibody), Ibalizumab (anti-CD4 antibody), Ibritumomab (anti-CD20 antibody), Igovomab (also known as Indimacis-125, anti-CA-125 antibody), Imciromab (also known as Myoscint , anti-cardiac myosin antibody), infliximab (also known as Remicade, anti-TNF-α antibody), intetumumab (anti-CD51 antibody), inolimomab (anti-CD25 (IL-2 receptor α chain) antibody), inotuzumab (anti-CD22 antibody), ipilimumab (anti-CD152 antibody), iratumumab (anti-CD30 (TNFRSF8) antibody), keliximab (anti-CD4 antibody), labetuzumab (also known as CEA-Cide, anti-CEA antibody),Lebrikizumab (anti-IL-13 antibody), Remalesomab (anti-NCA-90 (granulocyte antigen) antibody), Lerdelimumab (anti-TGFβ-2 antibody), Lexatumumab (anti-TRAIL-R2 antibody), Ribivirumab (anti-hepatitis B surface antigen antibody), Lintuzumab (anti-CD33 antibody), Lucatumumab (anti-CD40 antibody), Lumiliximab (anti-CD23 (IgE receptor) antibody), Mapatumumab (anti-TRAIL-R1 antibody), Maslimomab ( Anti-T cell receptor antibody), Matuzumab (anti-EGFR antibody), Mepolizumab (also known as Bosatria, anti-IL-5 antibody), Metelimumab (anti-TGFβ-1 antibody), Milatuzumab (anti-CD74 antibody), Minretumomab (anti-TAG-72 antibody), Mitumomab (also known as BEC-2, anti-ganglioside antibody-GD3), Morolimumab (anti-rhesus factor antibody), Motavizumab (also known as Numax, anti-RS virus antibody), Muromonab-CD3 (also known as Orthoclone OKT3, anti-CD3 antibody), Nacolomab (anti-C242 antibody), Naptumomab (anti-5T4 antibody), Natalizumab (also known as Tysabri, anti-integrin α4 antibody), Nebacumab (anti-endotoxin antibody), Necitumumab (anti-EGFR antibody), Nerelimomab (anti-TNF-α antibody), Nimotuzumab (also known as : Theracim, Theraloc, anti-EGFR antibody), nofetumomab, ocrelizumab (anti-CD20 antibody), odulimomab (also known as afolimomab, anti-LFA-1 (CD11a) antibody), ofatumumab (also known as Arzerra, anti-CD20 antibody), olaratumab (anti-PDGF-Rα antibody), omalizumab (also known as Xolair,Anti-IgEFc region antibody), Oportuzumab (anti-EpCAM antibody), Oregovomab (also known as OvaRex, anti-CA-125 antibody), Otelixizumab (anti-CD3 antibody), Pagibaximab (anti-LTA antibody), Palivizumab (also known as Synagis, Abbosynagis, anti-RS virus antibody), Panimumab (also known as Vectibix, ABX-EGF, anti-EGFR antibody), Panobaccumab (anti-Pseudomonas aeruginosa antibody), Pascolizumab (anti-IL-4 antibody), Pemtumomab (also known as Theragyn, anti-MUC1 antibody), Pertuzumab (also known as Omnitarg, 2C4, anti-HER2 / neu antibody), Pexelizumab (anti-C5 antibody), Pintumomab (anti-adenocarcinoma antigen antibody), Priliximab (anti-CD4 antibody), Pritumumab (anti-vimentin antibody), PRO140 (anti-CCR5 antibody), Racotumomab (ra cotumomab (also known as 1E10, anti-(N-glycolylneuraminic acid (NeuGc, NGNA)-ganglioside (GM3) antibody), rafivirumab (anti-rabies virus glycoprotein antibody), ramucirumab (anti-VEGFR2 antibody), ranibizumab (also known as Lucentis, anti-VEGF-A antibody), raxibacumab (anti-anthrax toxin, protective antigen antibody), regavirumab (anti-CMV glycoprotein B antibody), reslizumab lizumab (anti-IL-5 antibody), rilotumumab (anti-HGF antibody), rituximab (also known as MabThera, Rituxanmab, anti-CD20 antibody), robatumumab (anti-IGF-1 receptor antibody), rontalizumab (anti-IFN-α antibody), rovelizumab (also known as LeukArrest, anti-CD11, CD18 antibody), ruplizumab (also known as Antova, anti-CD154 (CD40L) antibody),Satumomab (anti-TAG-72 antibody), Sevirumab (anti-CMV antibody), Sibrotuzumab (anti-FAP antibody), Sifalimumab (anti-IFN-α antibody), Siltuximab (anti-IL-6 antibody), Siplizumab (anti-CD2 antibody), (Smart) MI95 (anti-CD33 antibody), Solanezumab (, Anti-β-amyloid antibody), Sonepcizumab (anti-sphingosine-1-phosphate antibody), Sontuzumab (anti-episialin antibody), Stamulumab (anti-myostatin antibody), Sulesomab (also known as LeukoScan, (anti-NCA-90 (granulocyte antigen) antibody)), Tacatuzumab (anti-α-fetoprotein antibody) Antibody to protein), tadocizumab (anti-integrin αIIbβ3 antibody), talizumab (anti-IgE antibody), tanezumab (anti-NGF antibody), taplitumomab (anti-CD19 antibody), tefibazumab (also known as Aurexis, anti-clumping factor A antibody), telimomab, tenatumomab natumomab (anti-tenascin C antibody), teneliximab (anti-CD40 antibody), teplizumab (anti-CD3 antibody), TGN1412 (anti-CD28 antibody) ), Ticilimumab (also known as Tremelimumab, anti-CTLA-4 antibody), Tigatuzumab (anti-TRAIL-R2 antibody), TNX-650 (anti-IL-13 antibody), Tocilizumab (Also known as Atlizumab, Actemra, RoActemra, (anti-IL-6 receptor antibody), Toralizumab (anti-CD154 (CD40L) antibody), Tositumomab (anti-CD20 antibody), Trastuzumab (also known as Herceptin, anti-HER2 / neu antibody), Tremelimumab (anti-CTLA-4 antibody), TucotuzumabCelmoleukin (anti-EpCAM antibody), Tuvirumab (anti-hepatitis B antibody), Urtoxazumab (anti-Escherichia coli antibody), Ustekinumab (also known as Stelara, anti-IL-12, IL-23 antibody), Vapaliximab (anti-AOC3 (VAP-1) antibody), Vedolizumab (anti-integrin α4β7 antibody), Veltuzumab (anti-CD20 antibody), Vepalimomab (anti-AOC3 (VAP-1) antibody), Visilizumab (also known as Nuvion, anti-CD3 antibody), Vitaxin (anti-angiogenic integrin avb3 antibody), Volociximab (anti-integrin Phospholipase α5β1), Votumumab (also known as HumaSPECT, anti-tumor antigen CTAA16.88 antibody), Zalutumumab (also known as HuMax-EGFr, (anti-EGFR antibody), Zanolimumab (also known as HuMax-CD4, anti-CD4 antibody), Ziralimumab (anti-CD147 (basic immunoglobulin) antibody), Zolimomab (anti-CD5 antibody), Etanercept (registered trademark "Enbrel"), Alefacept (registered trademark "Amevive"), Abatacept (registered trademark "Orencia"), Rilonacept (Arcalyst), 14F7 [anti-IRP-2 (iron regulatory protein 2) antibody], 14G2a (Nat.Cancer Inst.), J591 (anti-ganglioside GD2 antibody for melanoma and solid tumors, from Weill Cornell Medical School), J592 (anti-PSMA antibody for treating prostate cancer, from Weill Cornell Medical School), 225.28S [anti-HMW-MAA (high molecular weight melanoma-associated antigen) antibody for melanoma, from Sorin Radiofarmaci SRL (Milan, Italy)], COL-1 (anti-CEACAM3 antibody, CGM1, for colorectal and gastric cancer, from Nat. Cancer Inst.), CYT-356 (registered trademark "Oncoltad", prostate cancer), HNK20 (Ora VaxInc. for respiratory syncytial virus), ImmuRAIT (IMMUNOMEDICS for non-Hodgkin's lymphoma), Lym-1 (anti-HLA-DR10 antibody, Peregrine Pharm for oncology), MAK-195F [anti-TNF (tumor necrosis factor; TNFA, TNF-α; TNFSF2) antibody for sepsis and toxic shock from Abbott / Knoll], MEDI-500 [also known as T10B9, anti-CD3 antibody, TRαβ (T-cell receptor α / β) for graft-versus-host disease from MediImmune Inc.], RING SCAN [Neoprobe Corp. for breast cancer, colon cancer, and colorectal cancer)], Avicidin (anti-EPCAM (epithelial cell adhesion molecule) antibody), anti-TACSTD1 (tumor-associated calcium signal transducer 1) antibody, anti-GA733-2 (gastrointestinal tumor-associated protein 2) antibody, anti-EGP-2 (epithelial glycoprotein 2) antibody; anti-KSA antibody; KS1 / 4 antigen; M4S; tumor antigen 17-1A; CD326 for colon cancer, ovarian cancer, prostate cancer, and non-Hodgkin's lymphoma from NeoRx Corp.; LYMPHOCIDE (IMMUNOMEDICS, NJ), Smart ID10 (Protein Design Labs), Oncolym (Techniclone Inc, CA), Allomune (BioTransplant, CA), anti-VEGF antibody (Genentech, CA); CEAcide (Immunomedics, NJ), IMC-1C11 (ImClone Systems, NJ), and cetuximab (ImClone, NJ).
[0278] Other antibodies that function as binding ligands include, but are not limited to, antibodies against the following antigens: aminopeptidase N (CD13), annexin A1, B7-H3 (CD276, various cancers), CA125 (ovarian), CA15-3 (carcinoma), CA19-9 (carcinoma), L6 (carcinoma), Lewis Y (carcinoma), Lewis X (carcinoma), alpha-fetoprotein (carcinoma), CA242 (colorectal), placental alkaline phosphatase (carcinoma), prostate-specific antigen (prostate), prostatic acid phosphatase (prostate), epidermal growth factor (carcinoma), CD2 (Hodgkin's disease, NHL) lymphoma, multiple myeloma), CD3ε (T-cell lymphoma, lung cancer, breast cancer, gastric cancer, ovarian cancer, autoimmune diseases, malignant ascites), CD19 (B-cell malignancies), CD20 (non-Hodgkin's lymphoma), CD22 (leukemia, lymphoma, multiple myeloma, systemic lupus erythematosus), CD30 (Hodgkin's lymphoma), CD33 (leukemia, autoimmune diseases), CD38 (multiple myeloma), CD40 (lymphoma, multiple myeloma, leukemia (CLL)), CD51 (metastatic melanoma, sarcoma), CD52 (leukemia), CD56 (small cell lung cancer, ovarian cancer, Merkel cell carcinoma and liquid tumors, multiple myeloma) ), CD66e (cancer), CD70 (metastatic renal cell carcinoma and non-Hodgkin's lymphoma), CD74 (multiple myeloma), CD80 (lymphoma), CD98 (cancer), mucin (carcinoma), CD221 (solid tumor), CD227 (breast cancer, ovarian cancer), CD262 (non-small cell lung cancer and other cancers), CD309 (ovarian cancer), CD326 (solid tumor), CEACAM3 (colorectal cancer, gastric cancer), CEACAM5 (carcinoembryonic antigen; CEA, CD66e) (breast cancer, colorectal cancer and lung cancer), DLL4 (Δ-like-4), EGFR (epidermal growth factor receptor, various cancers), CTLA4 (melanoma), CXCR4 (CD184, hemoglobin, solid tumors), endoglin (CD105, solid tumors), EPCAM (epithelial cell adhesion molecule, bladder, head, neck, colon cancer, NHL prostate cancer, and ovarian cancer), ERBB2 (epidermal growth factor receptor 2; lung cancer, breast cancer, prostate cancer), FCGR1 (autoimmune disease), FOLR (folate receptor, ovarian cancer), GD2 ganglioside (cancer), G-28G (cell surface antigen glycolipid, melanoma), GD3 idiotype (cancer), heat shock protein (cancer), HER1 (lung cancer, gastric cancer), HER2 (breast cancer, lung cancer, and ovarian cancer), HLA-DR10 (NHL),HLA-DRB (NHL, B-cell leukemia), human chorionic gonadotropin (carcinoma), IGF1R (insulin-like growth factor-1 receptor, solid tumors, blood cancers), IL-2 receptor (interleukin-2 receptor, T-cell leukemia and lymphoma), IL-6R (interleukin-6 receptor, multiple myeloma, RA, Castleman's disease, IL6-dependent tumors), integrins (αVβ3, α5β1, α6β4, αIIβ3, α5β5, αVβ5 for various cancers), MAGE-1 ( carcinoma), MAGE-2 (carcinoma), MAGE-3 (carcinoma), MAGE-4 (carcinoma), anti-transferrin receptor (carcinoma), p97 (melanoma), MS4A1 (transmembrane 4-domain family A member 1, non-Hodgkin's B-cell lymphoma, leukemia), MUC1 or MUC1-KLH (breast cancer, ovarian cancer, cervical cancer, bronchial and gastrointestinal cancer), MUC16 (CA125) (ovarian cancer), CEA (colon), gp100 (melanoma), MART1 (melanoma), MPG (melanoma), MS4A1 (Transmembrane 4-domain family A member 1, small cell lung cancer, NHL), nucleolin, neuronal oncogene product (carcinoma), P21 (carcinoma), anti-(paratope of N-glycolylneuraminic acid (breast cancer, melanoma cancer), PLAP-like testicular alkaline phosphatase (ovarian cancer, testicular cancer), PSMA (prostate cancer), PSA (prostate), ROBO4, TAG72 (tumor-associated glycoprotein 72, leukemia (AML), gastric cancer, colorectal cancer, ovarian cancer), T cell transmembrane protein (cancer), Ti e (CD202b), TNFRSF10B (tumor necrosis factor receptor superfamily member 10B, cancer), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B, multiple myeloma, NHL, other cancers, RA and SLE), TPBG (trophoblast glycoprotein, renal cell carcinoma), TRAIL-R1 (TNF-related apoptosis ligand receptor 1, lymphoma, NHL, colorectal cancer, lung cancer), VCAM-1 (CD106, melanoma), VEGF, VEGF-A,VEGF-2 (CD309) (various cancers). Other tumor-associated antigens recognized by antibodies have been reported (Gerber, et al., mAbs 1:3, 247-253 (2009); Novellino et al., Cancer Immunol Immunother. 54 (3), 187-207 (2005); Franke et al., Cancer Biother Radiopharm. 2000, 15, 459-76). (See Gerber, et al., mAbs 1:3, 247-253 (2009); Novellino et al., Cancer Immunol Immunother. 54 (3), 187-207 (2005); Franke, et al., Cancer Biother Radiopharm. 2000, 15, 459-76).
[0279] The antibody-like protein is preferably an IgG antibody that can be directed against tumor cells, virus-infected cells, microorganism-infected cells, parasite-infected cells, autoimmune cells, activated cells, myeloid cells, activated T cells, B cells, or melanocytes. More specifically, the antibody can be any agent / molecule that can bind to any one of the following antigens or receptors: CD1, CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD12w, CD14, CD15, CD16, CD16a, CD16b, CDw17, CD18, CD19, CD2 0, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD32a, CD32b, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD4 0, CD41, CD42, CD42a, CD42b, CD42c, CD42d, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD49c, CD49d, CD49f, CD50, CD51, CD52, CD 53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD60a, CD60b, CD60c, CD61, CD62E, CD62L, CD62P, CD63, CD64, CD65, CD65s, CD66, CD66a, C D66b, CD66c, CD66d, CD66e, CD66f, CD67, CD68, CD69, CD70, CD71, CD72, CD73, CD74, CD74, CD75, CD75s, CD76, CD77, CD78, CD79, CD79a, C D79b, CD80, CD81, CD82, CD83, CD84, CD85, CD85a, CD85b, CD85c, CD85d, CD85e, CD85f, CD85g, CD85g, CD85i, CD85j, CD85k, CD85m, CD86, CD87, CD88, CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD100, CD101, CD102, CD103, CD104, CD105, CD106, CD107,CD107a、CD107b、CD108、CD109、CD110、CD111、CD112、CD113、CD114、CD115、CD116、CD117、CD118、CD119、CD120a、CD120b、CD121、CD121a、CD121b、CD122、CD123、CD123a、CD124、CD125、CD126、CD127、CD128、CD129、CD130、CD131、CD132、CD133、CD134、CD135、CD136、CD137、CD138、CD139、CD140、CD140a、CD140b、CD141、CD142、CD143、CD144、CD145、CDw145、CD146、CD147、CD148、CD149、CD150、CD151、CD152、CD153、CD154、CD155、CD156a、CD156b、CD156c、CD156d、CD157、CD158、CD158a、CD158b1、CD158b2、CD158c、CD158d、CD158e1、CD158e2、CD158f2、CD158g、CD158h、CD158i、CD158j、CD158k、CD159、CD159a、CD159b、CD159c、CD160、CD161、CD162、CD163、CD164、CD165、CD166、CD167、CD167a、CD167b、CD168、CD169、CD170、CD171、CD172、CD172a、CD172b、CD172g、CD173、CD174、CD175、CD175s、CD176、CD177、CD178、CD179、CD179a、CD179b、CD180、CD181、CD182、CD183、CD184、CD185、CD186、CDw186、CD187、CD188、CD189、CD190、CD191、CD192、CD193、CD194、CD195、CD196、CD197、CD198、CDw198、CDw199、CD200、CD201、CD202(a,b)、CD203、CD203c、CD204、CD205、CD206、CD207、CD208、CD209、CD210、CDw210a、CDw210b、CD211、CD212、CD213、CD213a1、CD213a2、CD214、CD215、CD216、CD217、CD218、CDw218a、CD218、CD21b9、CD220、CD221、CD222、CD223、CD224、CD225、CD226、CD227、CD228、C D229、CD230、CD231、CD232、CD233、CD234、CD235a、CD235b、CD236、CD236R、C D238, CD239, CD240, CD240ce, CD240d, CD241, CD242, CD243, CD244, CD245, CD246, CD247, CD248, CD249, CD250, CD251, CD252, CD253, CD254, CD255, CD2 56、CD257、CD258、CD259、CD260、CD261、CD262、CD263、CD264、CD265、CD266、CD267、CD268、CD269、CD270、CD271、CD272、CD273、CD274、CD275、CD276、CD 277, CD278, CD279, CD281, CD282, CD283, CD284, CD285, CD286, CD287, CD288, CD289, CD290, CD291, CD292, CD293, CD294, CD295, CD296, CD297, CD298, C D299、CD300、CD300a、CD300b、CD300c、CD301、CD302、CD303、CD304、CD305、 CD306、CD307、CD307a、CD307b、CD307c、CD307d、CD307e、CD307f、CD308、CD3 09、CD310、CD311、CD312、CD313、CD314、CD315、CD316、CD317、CD318、CD319 、CD320、CD321、CD322、CD323、CD324、CD325、CD326、CD327、CD328、CD329、CD 330、CD331、CD332、CD333、CD334、CD335、CD336、CD337、CD338、CD339、CD34 0、CD341、CD342、CD343、CD344、CD345、CD346、CD347、CD348、CD349、CD350、C D351、CD352、CD353、CD354、CD355、CD356、CD357、CD358、CD359、CD360、CD361、CD362、CD363、CD364、CD365、CD366、CD367、CD368、CD369、CD370、CD371、CD372, CD373, CD374, CD375, CD376, CD377, CD378, CD379, CD381, CD382, CD383, CD384, CD385, CD386, CD387, CD388, CD389, CRIPTO, CRIPTO, CR, CR1, CRGF, CRIPTO, CXCR5, LY64, TDGF1, 4-1BB, APO2, ASLG659, BMPR1B, 4-1BB, 5AC, 5T4 (trophoblast glycoprotein, TPBG, 5T4, Wnt activation inhibitor 1 or WA IF1), adenocarcinoma antigen, AGS-5, AGS-22M6, activin receptor-like kinase 1, AFP, AKAP-4, ALK, α integrin, αvβ6, aminopeptidase N, amyloid beta, androgen receptor, angiopoietin 2, angiopoietin 3, annexin A1, anthrax toxin protective antigen, anti-transferrin receptor, AOC3 (VAP-1), B7-H3, anthrax, BAFF (B-cell activating factor), BCMA, B-lymphoma cells, bcr-abl, bombesin, BORIS, C5, C2 42 antigen, CA125 (carbohydrate antigen 125, MUC16), CA-IX (or CAIX, carbonic anhydrase 9), CALLA, CanAg, canine IL31, carbonic anhydrase IX, cardiac myosin, CCL11 (CC motif chemokine 11), CCR4 (CC chemokine receptor type 4, CD194), CCR5, CD3E (epsilon), CEA (carcinoembryonic antigen), CEACAM3, CEACAM5 (carcinoembryonic antigen), CFD (factor D), Ch4D5, cholecystokinin 2 (CCK2R), CLDN18 (cloudy claudin-18), CLDN18.1 (claudin-18.1), CLDN18.2 (claudin-18.2), clumping factor A, cMet, CRIPTO, FCSF1R (colony-stimulating factor 1 receptor, CD115), CSF2 (colony-stimulating factor 2, granulocyte-macrophage colony-stimulating factor (GM-CSF)), CSP4, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CTAA16.88 tumor antigen, CXCR4, CXC chemokine receptor type 4, cADP-ribose hydrolase, Cyclin B1, CYP1B1, cytomegalovirus, cytomegalovirus glycoprotein B, dabigatran, DLL3 (delta-like ligand 3), DLL4 (delta-like ligand 4),DPP4 (dipeptidyl peptidase 4), DR5 (death receptor 5), Escherichia coli Shiga toxin type 1, Escherichia coli Shiga toxin type 2, ED-B, EGFL7 (EGF-like domain containing protein 7), EGFR, EGFRII, EGFRvIII, endoglin, endothelin B receptor, endotoxin, EpCAM (epithelial cell adhesion molecule), EphA2, episialin, ERBB2 (epidermal growth factor receptor 2), ERBB3, ERG (TMPRS S2ETS fusion gene), Escherichia coli, ETV6-AML, FAP (fibroblast activation protein α), fibroblast surface antigen, FCGR1, α-fetoprotein, fibrin II, β chain, fibronectin ectodomain B, FOLR (folate receptor), folate receptor α, folate hydrolase, respiratory syncytial virus Fos-related antigen 1F protein, Frizzled receptor, fucosyl GM1, GD2 ganglioside, G-28 (cell surface glycolipid antigen), GD3 idiotype, GloboH, glypican 3, N-glycolylneuraminic acid, GM3, GMCSF receptor α chain, growth differentiation factor, GP100, GPNMB (transmembrane protein NMB), GUCY2C (guanylate cyclase 2C, guanylate cyclase C (GC-C), intestinal guanylate cyclase, guanylate cyclase-C receptor, heat-stable enterotoxin receptor (hSTAR)), heat shock protein, hemocyte Agglutinins, hepatitis B surface antigen, hepatitis B virus, HER1 (human epidermal growth factor receptor 1), HER2, HER2 / neu, HER3 (ERBB-3), IgG4, HGF / SF (stem cell growth factor / scatter factor), HHGFR, HIV-1, histone complex, HLA-DR (human leukocyte antigen), HLA-DR10, HLA-DRB, HMWMAA, human chorionic gonadotropin, HNGF, human scatter factor receptor kinase, HPV E6 / E7, Hsp90, hTERT, ICAM-1 (intercellular adhesion molecule 1), idiotype, IGF1R (IGF-1, insulin-like growth factor 1 receptor), IGF-1 receptor, IFN-γ, influenza hemagglutinin, IgE, IgE Fc region, IGF-1 receptor, interleukins (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-17A, IL-18, IL-19,IL-20, IL-21, IL-22, IL-23, IL-27, or IL-28), IL-31RA, ILGF2 (insulin-like growth factor 2), integrin (α4, α, IIIb β3, αvβ3, α4β7, α5β1, α6β4 , α7β7, αIIβ3, α5β5, αvβ5), interferon-γ-inducible protein, ITAGA2, ITGB2, KIR2D, Kappa Ig, LCK, Le, legumain, Lewis-Y antigen, LFA-1 (lymphocyte function-associated antigen 1, CD11a), LHRH, LINGO-1, lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT-1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGEA1, MAGEA3, MAGE4, MART1, MCP-1, MIF (macrophage migration inhibitory factor or glycosylation inhibitory factor (GIF)), MS4A1 (transmembrane 4 domain subfamily A member 1), MSLN (mesothelin), MUC1 (mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM), MUC1-KLH, MUC16 (CA125), MCP1 (monocyte chemoattractant protein 1), MelanA / MART1, ML-IAP, MPG, MS4A1 (transmembrane 4 domain subfamily A), MYCN, myelin-associated glycoprotein, myostatin, NA17, NARP-1, NCA-90 (granulocyte antigen), Nectin-4 (ASG-22ME), NGF, neuronal apoptosis-regulating proteinase 1, NOGO-A, Notch receptor, nucleolin, Neu oncogene product, NY-BR-1, NY-ESO-1, OX-40, OxLDL (oxidized low-density lipoprotein), OY-TES1, P21, non-mutant p53, P9 7, Page 4, PAP, anti-(N-glycolylneuraminic acid) paratope, PAX3, PAX5, PCSK9, PDCD1 (PD-1, programmed cell death protein 1), PDGF-Rα (platelet-derived growth factor receptor α), PDGFR-β, PDL-1, PLAC1, PLAP-like testicular alkaline phosphatase, platelet-derived growth factor receptor β, sodium phosphate cotransporter, PMEL17, polysialic acid, proteinase 3 (PR1), prostate cancer, PS (phosphatidylserine), prostate cancer cells, Pseudomonas aeruginosa, PSMA, PSA, PSCA, rabies virus glycoprotein, RHD (Rh polypeptide 1 (RhPI)), rhesus factor, RANKL, PhoC,Ras mutant, RGS5, ROBO4, respiratory syncytial virus, RON, ROR1, sarcoma metastatic breakpoint, SART3, sclerostin, SLAMF7 (SLAM family member 7), selectin P, SDC1 (syndecan 1), sLe(a), somatomedin C, SIP (sphingosine-1-phosphate), somatostatin, sperm protein 17, SSX2, STEAP1 (six-transmembrane epithelial antigen of the prostate 1), STEAP2, STn, TAG-72 (tumor-associated glycoprotein 72), survivin, T cell receptor, T cell transmembrane protein, TEM1 (tumor epithelial marker 1), TENB2, tenascin-C (TN-C), TGF-α, TGF-β (transforming growth factor beta), TGF-β1, TGF-β2 (transforming growth factor beta 2), Tie (CD202b), Tie2, TIM-1 (CDX- 014), TN, TNF, TNF-α, TNFRSF8, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B), TPBG (trophoblast glycoprotein), TRAIL-R1 (tumor necrosis-inducing ligand receptor 1), TRAILR2 (death receptor 5 (DR5)), tumor-associated calcium signal transducer 2, tumor-specific glycosylation of MUC1, TWEAK receptor, TYRP1 (glycoprotein 75), TRP-1 (Trop1), TRP-2 (Trop2), tyrosinase, VCAM-1, VEGF, VEGF-A, VEGF-2, VEGFR-1, VEGFR2, or cells expressing vimentin, WT1, XAGE1, or any insulin growth factor receptor, or any epidermal growth factor receptor.
[0280] In another specific embodiment, the antibody-drug conjugates of the invention are used for targeted cancer therapy, including, but not limited to, adrenocortical carcinoma, anal cancer, bladder cancer, brain tumors (adult, brainstem glioma, childhood, cerebellar astrocytoma, cerebral astrocytoma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal and pineal tumor, visual pathway and hypothalamic glioma), breast cancer, carcinoid tumor, gastrointestinal, carcinoma of unknown primary, cervical carcinoma, colorectal carcinoma, endometrial cancer, esophageal cancer, extrahepatic bile duct cancer, and Ewing's family of tumors. Tumor (PNET), extracranial malignant germ cell tumor, eye cancer, intraocular melanoma, gallbladder cancer, gastric cancer (stomach), germ cell tumor, extragonadal, gestational trophoblastic tumor, head and neck cancer, hypopharyngeal cancer, pancreatic islet cell carcinoma, kidney cancer (renal cell carcinoma), laryngeal carcinoma, leukemia (acute lymphoblastic, acute myeloid, chronic lymphocytic, chronic myeloid, hairy cell), lip and oral cancer, liver cancer, lung cancer (non-small cell, small cell, lymphoma (AIDS-related, central nervous system, skin T-cell) alveolar sarcoma, Hodgkin's disease, non-Hodgkin's disease, malignant mesothelioma, melanoma, Merkel cell carcinoma, metastatic squamous neck cancer of unknown primary site, multiple myeloma and other plasma cell neoplasms, mycosis fungoides, myelodysplastic syndrome, myeloproliferative syndrome, nasopharyngeal cancer, neuroblastoma, oral cancer, pharyngeal cancer, osteosarcoma, ovarian cancer (epithelial, germ cell tumor, low malignant potential tumor), pancreatic cancer (exocrine gland, islet cell carcinoma), paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer , pheochromocytoma cancer, pituitary cancer, plasmacytoma, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell carcinoma (kidney cancer), renal pelvis and ureter (transitional cell), salivary gland cancer, Sezary syndrome, skin cancer, skin cancer (cutaneous T-cell lymphoma, Kaposi's sarcoma, melanoma), small intestine cancer, soft tissue sarcoma, stomach cancer, testicular cancer, thymoma (malignant), thyroid cancer, urethral cancer, uterine cancer (sarcoma), abnormal cancers of children, vaginal cancer, vulvar cancer, Wilms' tumor.
[0281] In another specific embodiment, the antibody-drug conjugates of the invention are used in accordance with compositions and methods for the treatment or prevention of autoimmune diseases, including, but not limited to, autoimmune achlorhydric chronic active hepatitis, acute disseminated encephalomyelitis, acute hemorrhagic leukoencephalitis, Addison's disease, agammaglobulinemia, alopecia areata, amyotrophic lateral sclerosis, ankylosing spondylitis, anti-GMB / TBM nephritis, antiphospholipid syndrome, antisynthetase syndrome, arthritis, atopic allergy, atopic dermatitis, autoimmune aplastic anemia, autoimmune cardiomyopathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, and autoimmune peripheral nervous system disease. Autoimmune pancreatitis, multiple autoimmune endocrinopathy types I, II, and III, autoimmune progesterone dermatitis, autoimmune thrombocytopenic purpura, autoimmune uveitis, Barlow's disease / Barlow's concentric sclerosis, Behçet's disease, Berger's disease, Bickerstaff's encephalitis, Blau syndrome, bullous pemphigoid, Castleman's disease, Chagas' disease, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, chronic relapsing multifocal osteomyelitis, chronic Lyme disease, chronic obstructive pulmonary disease, allergic granulomatous vasculitis, cicatricial pemphigoid , celiac disease, Cogan's syndrome, cold agglutinin disease, complement component C2 deficiency, cephalic arteritis, CREST syndrome, Crohn's disease (idiopathic inflammatory bowel disease), Cushing's syndrome, cutaneous leukocytoclastic vasculitis, malignant atrophic papulosis, painful adiposity, dermatitis herpetiformis, dermatomyositis, type 1 diabetes, diffuse cutaneous scleroderma, myocardial infarction, discoid lupus erythematosus, eczema, endometriosis, enthesitis-associated arthritis, eosinophilic fasciitis, epidermolysis bullosa acquisita, erythema nodosum, idiopathic mixed cryoglobulinemia, Evans syndrome, fibrodysplasia ossificans progressiva, fibromyalgia, fibromyositis, Fibrotic alveolitis, gastritis, gastrointestinal pemphigoid, giant cell arteritis, glomerulonephritis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's encephalopathy, Hashimoto's thyroiditis, hemolytic anemia, allergic purpura, herpes gestationis, hidradenitis suppurativa, Hughes' syndrome (antiphospholipid antibody syndrome), hypogammaglobulinemia, idiopathic inflammatory demyelinating disease, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (autoimmune thrombocytopenic purpura), IgA nephropathy (Berger's disease), inclusion body myositis, inflammatory demyelinating polyneuropathy, interstitial cystitis, irritable bowel syndrome,Juvenile idiopathic arthritis, juvenile rheumatoid arthritis, mucocutaneous lymph node syndrome, Lambert-Eaton myasthenic syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, linear immunoglobulin A disease (LAD), Lou Gehrig's disease (amyotrophic lateral sclerosis), lupus-like hepatitis, lupus erythematosus, Blau syndrome, Meniere's disease, microscopic polyangiitis, Miller-Fisher syndrome, mixed connective tissue disease, scleroderma, Mucha-Jakob disease, Muckle-Wells syndrome, multiple myeloma, multiple myeloma Sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (Devic's disease), neuromuscular diseases, ocular cicatricial pemphigoid, opsoclonus-myoclonus syndrome, Ord's thyroiditis, relapsing rheumatism, Panda syndrome (childhood autoimmune neuropsychiatric disorder complicated by streptococcal infection), tumor-associated cerebellar degeneration, paroxysmal nocturnal hemoglobinuria, Parry-Romberg syndrome, Parsonage-Georgia syndrome, pars planus inflammation, pemphigus, pemphigus vulgaris, pernicious anemia, perivenous encephalomyelitis, POEM S syndrome, polyarteritis nodosa, polymyalgia rheumatica, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, progressive inflammatory neuropathy, psoriasis, psoriatic arthritis, pyoderma gangrenosum, pure red cell aplastic anemia, Rasmussen's encephalitis, Raynaud's disease, relapsing polychondritis, Reiter's syndrome, restless legs syndrome, retroperitoneal fibrosis, rheumatoid arthritis, rheumatic fever, sarcoidosis, schizophrenia, Schmidt's syndrome, Schnitzler's syndrome, scleritis, scleroderma, Sjogren's syndrome syndrome, spondyloarthropathy, sticky blood syndrome, Still's disease, stiff-man syndrome, subacute bacterial endocarditis, Susac syndrome, acute febrile neutrophilic dermatosis, Sydenham chorea, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis (giant cell arteritis), Tolosa-Hunt syndrome, transverse myelitis, ulcerative colitis (idiopathic inflammatory bowel disease), undifferentiated connective tissue disease, undifferentiated spondyloarthropathy, vasculitis, vitiligo, Wegener's granulomatosis, Wilson's syndrome, and Westcott-Aldrich syndrome.
[0282] In another specific example, the antibody-drug conjugates of the present invention for the treatment or prevention of autoimmune diseases include, but are not limited to, anti-elastin antibodies; Abys anti-epithelial cell antibodies; anti-basement membrane type IV collagen protein antibodies; anti-nuclear antibodies; anti-double-stranded DNA antibodies, anti-single-stranded DNA antibodies, anti-cardiolipin antibodies IgM, IgG; anti-celiac antibodies; anti-phospholipid antibodies IgK, IgG; anti-SM antibodies; anti-mitochondrial antibodies; thyroid antibodies; microsomal antibodies, T cell antibodies; thyroglobulin antibodies, anti-scleroderma-70 antibodies (AntiSCL-70); anti-Jones antibodies ( Anti-Jo), anti-U1RNP antibody (Anti-U1RNP); anti-La / SSB antibody; anti-SSA antibody; anti-SSB antibody; anti-parietal cell antibody; anti-histone antibody; anti-RNP antibody; C-ANCA; P-ANCA; anti-centromere antibody; anti-fibrin antibody, anti-GBM antibody, anti-ganglioside antibody; anti-desmosomal glycoprotein 3 core antibody (anti-Desmogein3); anti-p62 antibody; anti-sp100 antibody; anti-mitochondrial (M2) antibody; rheumatoid factor antibody; anti-MCV antibody; anti-topoisomerase antibody; and anti-neutrophil cytoplasmic (cANCA) antibody.
[0283] In a preferred embodiment, the binding molecule used in the conjugate of the invention is capable of binding to a receptor or receptor complex expressed by activated lymphocytes associated with autoimmune disease. The receptor or receptor complex may be, for example, a member of the immunoglobulin gene superfamily (e.g., CD2, CD3, CD4, CD8, CD19, CD20, CD22, CD28, CD30, CD33, CD37, CD38, CD56, CD70, CD79, CD90, CD125, CD147, CD152 / CTLA-4, PD-1, or ICOS), the TNF receptor superfamily (e.g., CD27, CD40, CD95), or a receptor complex expressed by activated lymphocytes associated with autoimmune disease. / Fas, CD134 / OX40, CD137 / 4-1BB, INF-R1, TNFR-2, RANK, TACI, BCMA, osteoprotegerin, Apo2 / TRAIL-R1, TRAIL-R2, TRAIL-R3, TRAIL-R4, and APO-3), integrins, cytokine receptors, chemokine receptors, major histocompatibility proteins, lectins (C-type, S-type, or I-type), or complement regulatory proteins.
[0284] In another specific embodiment, useful cell-binding ligands immunospecific for viral or microbial antigens are humanized or human monoclonal antibodies. As used herein, the term "viral antigen" includes, but is not limited to, any viral peptide, polypeptide protein (e.g., HIV gp120, HIV nef, RSV F glycoprotein, influenza virus neuraminidase, influenza virus hemagglutinin, HTLV tax, herpes simplex virus glycoproteins (e.g., gB, gC, gD, and gE), and hepatitis B surface antigen) that can elicit an immune response. As used herein, the term "microbial antigen" includes, but is not limited to, any microbial peptide, polypeptide, protein, saccharide, polysaccharide, or lipid molecule (e.g., bacterial, fungal, pathogenic protozoan, or yeast polypeptide (e.g., LPS and capsular polysaccharide 5 / 8)) that can elicit an immune response. Examples of antibodies useful for treating viral or microbial infections include, but are not limited to, palivizumab (a humanized anti-respiratory syncytial virus monoclonal antibody used to treat RVS infections), PRO542 (a CD4 fusion antibody used to treat HIV infections), Ostavir (a human antibody used to treat hepatitis B virus), PROTVIR (a humanized IgG1 antibody used to treat cytomegalovirus), and anti-LPS antibodies.
[0285] The antibody-drug conjugates of the invention can be used to treat infectious diseases, including, but not limited to, Acinetobacter infection, actinomycosis, African sleeping sickness (African trypanosomiasis), AIDS (acquired immunodeficiency syndrome), amebiasis, Anaplasmosis, Bacillus anthracis, bacterial tuberculosis infection, Argentine hemorrhagic fever, ascariasis, aspergillosis, astrovirus infection, babesiosis, Bacillus cereus infection, bacterial pneumonia, bacterial vaginosis, Bacteroides infection, Balantidiosis, Strongyloides bailidis infection, BK virus infection, black sand mites, Blastocystis hominis infection, Blastomyces cerevisiae, Bolivian hemorrhagic fever, and Borrelia spp. botulism (and infant botulism), Brazilian hemorrhagic fever, brucellosis, Burkholderia infection, Buruli ulcer, Calicivirus infection (norovirus, sapovirus), Campylobacter infection, Candida infection (candidiasis, thrush), cat scratch disease, cellulitis, Chagas disease (American trypanosomiasis), chancroid, chickenpox, Clostridium difficile, pneumonia, cholera, chromomycosis, liver fluke disease, Clostridium difficile infection, coccidioidomycosis, Colorado tick fever, colds (acute viral nasopharyngitis, acute rhinitis), Creutzfeldt-Jakob disease, Crimean-Congo hemorrhagic fever, Cryptococcus, Cryptosporidium, cutaneous larval migration, Cyclospora infection, cysticercosis, cytomegalovirus infection, dengue fever, dientamebiasis, diphtheria, diphyllobothriasis, dracunculiasis, Ebola hemorrhagic fever, hydatid disease, ehrlichiosis, pinworms (pinworm infection), enterococcal infection, enterovirus infection, typhus, erythema infectiosum (fifth disease), acute exanthema in children, trematopoietinosis, fluke thrombosis, fatal familial insomnia, filariasis, food poisoning caused by Clostridium perfringens, non-parasitic diseases Live amoeba infection, Fusobacterium infection, gas gangrene (Clostridium myonecrosis), diotrichosis, Gerstmann-Straussler-Scheinker syndrome, Giardiasis, glanders, gnathostomiasis, gonorrhea, inguinal granuloma (donovanosis), group A streptococcal infection, group B streptococcal infection, Haemophilus influenzae infection, hand, foot and mouth disease (HFMD), hantavirus pulmonary syndrome, Helicobacter pylori infection, hemolytic uremic syndrome, hemorrhagic fever with renal syndrome, hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpes simplex, histoplasmosis, hookworm infection,Human Balkan virus infection, human ehrlichiosis Evans, human granulocytic anaplasmosis, human metapneumovirus infection, human monocytic ehrlichiosis, human papillomavirus infection, human parainfluenza virus infection, microtaeniasis, influenza, isosporosis, Kawasaki disease, mononucleosis, Mycobacterium kikuchii infection, kuru, Lassa fever, Legionnaires' disease, Legionnaires' disease, leishmaniasis, leprosy, leptospirosis, listeriosis, Lyme disease, lymphatic filariasis, lymphocytic choriomeningeal disease Infection, malaria, Marburg hemorrhagic fever, measles, melioidosis (Whitmore's disease), meningitis, meningococcal disease, metagonism, microsporidiosis, molluscum contagiosum, mumps, typhus (endemic typhus), mycoplasma pneumonia, mycetoma, myiasis, neonatal conjunctivitis (ophthalmia neonatorum), Creutzfeldt-Jakob disease (vCJD, nvCJD), nocardiosis, onchocerciasis (blinding filariasis), paracoccidioidomycosis (South American blastomycosis), paragonimiasis, pasteurellosis, head lice (head lice), body lice (body lice), pubic lice (pubic lice) Crarbice, pelvic inflammatory disease, whooping cough, plague, pneumococcal infection, Pneumococcal pneumonia, Pneumocystis carinii pneumonia, pneumonia, polio, Prevotella infection, PAME, progressive multifocal leukoencephalopathy, psittacosis, Q fever, rabies, rat bite fever, respiratory syncytial virus infection, rhinovirus infection, rickettsial infection, Rift Valley fever, Rocky Mountain spotted fever, rotavirus infection, rubella, salmonellosis, SARS (severe acute respiratory syndrome), scabies, schistosomiasis, sepsis, diarrhea (dysentery), shingles (Herpes zoster), smallpox, sporozoites These include: lice, staphylococcal food poisoning, staphylococcal infection, nematodes, syphilis, tapeworm disease, tetanus (openis), Barber's sitch, tinea manubriata, pityriasis nigricans, tinea pedis, tinea unguium, tinea versicolor, toxocariasis (ocular larva migrans), toxocariasis (visceral larva migrans), toxoplasmosis, Trichinella spiralis, trichomoniasis, cryptobiosis (whipworm infection), pulmonary tuberculosis, tularemia, urea-digesting Mycoplasma infection, Venezuelan equine encephalitis, Venezuelan hemorrhagic fever, viral pneumonia, West Nile fever, rhizobium spp., Mycobacterium pseudotuberculosis, yersiniosis, yellow fever, and zygomycosis.
[0286] The cell-binding molecules, more preferably antibodies as described herein, include those directed against pathogenic strains, including but not limited to Acinetobacter baumannii, Actiomyces israelii, Actinomyces odontolyticus, Propionibacterium propionicus, Trypanosoma brucei, HIV (human immunodeficiency virus), Entamoeba histolytica, Anaplasma spp., Bacillus anthracis, and Arcanobacterium haemolyticum. icum), Junin virus, Roundworms, Aspergillus, Astroviridae, Babesia, Bacillus cereus, Multiplex bacteria, Bacteroides, Colonic pouch ciliates, Roundworm of Bayley, Strongyloides, BK virus, Piedraia hortae, Blastocystis hominis, Dermatitis ulcerans, Macupo virus, Borrelia, Clostridium botulinum, Sabia, Brucella, Burkholderia cepacia and other Burkholderia species, Mycobacterium ulcerans, Caliciviridae, Campylobacter , usually Candida albicans and other Candida species, Bartonella henselae, Group A Streptococcus and Staphylococcus, Trypanosoma cruzi, Haemophilus ducreyi, Varicella-zoster virus (VZV), Chlamydia trachomatis, Chlamydia pneumoniae, Vibrio cholerae, Fonsecae pedrosoi, Clonorchiasis, Clostridium difficile, Coccidioides immitis, Coccidioides posadaci, Colorado tick fever virus, rhinovirus, coronavirus, Creutzfeldt-Jakob disease prion, Crimean-Congo hemorrhagic fever virus, Cryptococcus neoformans, Cryptosporidium spp., Cat hookworm, Co-parasites, Cyclospora, Taenia solium, Cytomegalovirus, Dengue virus (DEN-1, DEN-2, DEN-3 and DEN-4) - Flavivirus, Dictyonamoeba, Corynebacterium diphtheriae, Diphyllobothrix spp., Dracunculus medinensis, Ebola virus, Echinococcus spp., Ehrlichia spp., Pinworms, Enterococcus spp., Enterovirus spp., Rickettsia typhi, Parvovirus B19,Human herpesvirus 6, human herpesvirus 7, Fluke, Fasciola hepatica and Fasciola gigantica, FFI prion, Filarioidea, Clostridium perfringens, Fusobacterium, Clostridium perfringens, other Clostridium species, Geotrichum candidum, GSS prion, Giardia lamblia, Burkholderia mallei, Gnathostoma nematode, Gnathostoma spp., Neisseria gonorrhoeae, Bordetella granulomatosis, Streptococcus pyogenes, Streptococcus agalactiae, Haemophilus influenzae, enteric viruses, most Coxsackie A viruses, enteric virus 71, Sin Nombre virus , Helicobacter pylori, Escherichia coli O158:H7, Bunyaviridae, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, Herpes simplex virus type 1, Herpes simplex virus type 2, Histoplasma capsulatum, Oncocystis obliterans, American hookworm, Haemophilus influenzae, Boca human virus, Ehrlichiaewingii, Anaplasma phagocytophilum, Human metapneumovirus, Ehrlichia chaffeensis, Human papillomavirus, Human parainfluenza virus Viruses such as hamster ovarian tapeworm, taenia diminuta, Epstein-Barr virus, Orthomyxoviridae, Isospora belli, Kingella kingae, Klebsiella pneumoniae, Klebsiella otsena, Klebsiella rhinoscleromotis, Coulour pneumonitis, Lassa fever virus, Legionella pneumophila, Leishmania, Mycobacterium leprae and Mycobacterium lepromatosis epromatosis), Leptospira, Listeria, Borreliosis and other Borrelia species, Wuchereria bancrofti and Brugia malayi, Lymphocytic choriomeningitis virus (LCMV), Plasmodium, Marburg virus, Measles virus, Burkholderia pseudomallei, Neisseria meningitidis, Fluke yokogawai, Microsporidia, Molluscum contagiosum virus (MCV), Mumps virus, Rickettsia typhi, Mycoplasma pneumoniae, various bacteria (actinomycetoma) and fungi (mycosis fungi),Parasitic fly larvae of Diptera, Chlamydia trachomatis and Neisseria gonorrhoeae, vCJD prion, Nocardia asteroides and other Nocardia species, Onchocerciasis volvulus, Blastomyces brasiliensis, Paragonimus and other Paragonimus species, Pasteurella spp., head lice, body lice, Phthirus pubis, Bordetella pertussis, Yersinia pestis, Streptococcus pneumoniae, Pneumocystis cysticercosis, poliovirus, Prevotella spp., Naegleria ameba, JC virus, Chlamydia psittacosis, Coxiella burnetii, rabies virus, bead-chain E. coli and rat-bite fever virus Pirochetes, Respiratory Respiratory Syncytial Virus, Rhinosporidium sayberi, Rhinovirus, Rickettsia spp., Rickettsia mites, Rift Valley fever virus, Rocky Mountain spotted fever rickettsia, Rotavirus, Rubella virus, Salmonella spp., Atypical pneumonia coronavirus, Scabies mites, Schistosoma spp., Shigella spp., Varicella zoster virus, Variola major or minor, Sporothrix schenckii, Staphylococcus spp., Staphylococcus aureus, Streptococcus pyogenes, Strongyloides stercoralis, Syphilis spirochetes, Cestode spp., Clostridium tetani, Ringworm, Trichophyton tonsurans, Tinea pedis, Epidermophyton floccosum, Tinea rubra Fungi and Trichophyton mentagrophytes, Trichophyton rubrum, Holtea werneckii, Ringworm, Malassezia spp., Roundworms canis and cat roundworms, Toxoplasma gondii, Trichinella spiralis, Trichomonas vaginalis, Trichuris trichiura, Mycobacterium tuberculosis, Tula hot Francis bacteria, Ureaplasma urealyticum, Venezuelan equine encephalitis virus, Vibrio cholerae, Guanarito virus, West Nile virus, Trichosporum spp., Mycobacterium pseudotuberculosis, Yersinia enterocolitica, Yellow fever virus, Mucorales (mucormycosis) and Entomophthora spp. (Entomophthora infection), Pseudomonas aeruginosa, Campylobacter fetus (Vibrio), Aeromonas bacteria, Edwardsiella spp., Tarda, Plague Bacteria, Shigella dysenteriae, Shigella sonnei, Salmonella typhimurium, Treponema pertenue, Treponema carateneum, Fensenburgdorferi, Borrelia burgdorferi, Leptospira hemorrhagic jaundice, Pneumocystis carinii, Brucella abortus, Brucella abortus, Malta fever, Mycoplasma spp., Rickettsia typhi, Rickettsia tsutsugamushi, Chlamydia spp., pathogenic fungi (Aspergillus fumigatus, Candida albicans, Histoplasma capsulatum); protozoa (Entamoeba histolytica, Trichomonas vaginalis, Trichomonas venoides, Trypanosoma gambiens,Trypanosoma brucei rhodesiense, Leishmania donovani, Leishmania tropicalis, Leishmania brasiliensis, Pneumocystis carinii pneumoniae, Plasmodium vivax, Plasmodium falciparum, malignant malaria); or helminths (Schistosoma japonicum, Schistosoma mansoni, Schistosoma haematobium, and hookworms).
[0287] Other antibodies as cell-binding ligands for use in the present invention for the treatment of viral diseases include, but are not limited to, antibodies against antigens of pathogenic viruses, examples of which include, but are not limited to, Poxyiridae, Herpesviridae, Adenoviridae, Papovaviridae, Enteroviridae, Picornaviridae, Parvoviridae, Reoviridae, Retroviridae, influenza virus, parainfluenza virus, mumps, measles, respiratory syncytial virus, and the like. Viruses, rubella, arboviruses, rhabdoviruses, arenaviruses, non-A / non-B hepatitis viruses, rhinoviruses, coronaviruses, rotaviruses, tumor viruses [e.g., HBV (hepatocellular carcinoma), HPV (cervical cancer, anal cancer), Kaposi's sarcoma-associated herpesvirus (Kaposi's sarcoma), EB virus (nasopharyngeal carcinoma, Burkitt's lymphoma, primary central nervous system lymphoma), MCPyV (Merkel cell carcinoma), SV40 (simian virus 40), HCV (hepatocellular carcinoma), HTLV-I (adult T-cell leukemia / lymphoma)]; immune diseases caused by viruses: [e.g., human immunodeficiency virus (AIDS)], CNS viruses: [e.g., JCV (progressive multifocal leukoencephalopathy), MeV (subacute sclerosing panencephalitis), LCV (lymphocytic choriomeningitis), arboviral encephalitis, Orthomyxoviridae (presumed) (encephalitis lethargica), RV (rabies), vesicular stomatitis, herpesvirus meningitis, Ramsay-Hunt syndrome type II; poliovirus (acute poliomyelitis, post-polio syndrome), HTLV-I (tropical spastic paraparesis)]; cytomegalovirus (CMV retinitis, HSV (herpetic keratitis)); cardiovascular disease viruses [e.g., Respiratory system / acute nasopharyngitis / viral pneumonia: [EB virus (EBV infection / infectious mononucleosis), cytomegalovirus, SARS coronavirus (severe acute respiratory syndrome), Orthomyxoviridae: influenza virus A / B / C (influenza / avian influenza), paramyxovirus: human parainfluenza virus (parainfluenza), RSV (human respiratory syncytial virus), hMPV]; digestive system viruses [MuV (mumps), cytomegalovirus (CMV esophagitis);These include pathogenic viral diseases such as adenovirus (adenovirus infection); rotavirus, norovirus, astrovirus, coronavirus, HBV (hepatitis B virus), CBV, HAV (hepatitis A virus), HCV (hepatitis C virus), HDV (hepatitis D virus), HEV (hepatitis E virus), and HGV (hepatitis G virus); and urogenital viruses (e.g., BK virus, MuV (mumps)).
[0288] According to a further object, the present invention also relates to a pharmaceutical composition for treating cancer, infectious diseases, or autoimmune diseases, comprising the conjugate of the present invention together with a pharmaceutically acceptable carrier, diluent, or excipient. Methods for treating cancer, infectious diseases, and autoimmune diseases can be performed in vitro, in vivo, or ex vivo. An example of in vitro therapy includes cell culture treatment to kill all cells except for desired variants that do not express the target antigen, or to kill variants that express undesired antigens. An example of ex vivo therapy includes treatment of hematopoietic stem cells (HSCs) prior to transplantation (HSCT) and their return to the same patient to kill diseased or malignant cells. For example, clinical ex vivo treatments for removing cancer or lymphocyte cells from bone marrow prior to autologous transplantation in the treatment of cancer and autoimmune diseases, or for removing T cells and other lymphocytes from allogeneic bone marrow or tissue prior to transplantation to prevent graft-versus-host disease, can be performed as follows: After bone marrow cells are obtained from a patient or other individual, they are cultured at 37°C for 15 minutes to approximately 48 hours in serum-containing medium containing the conjugate of the present invention at a concentration ranging from approximately 1 pM to 0.1 mM. The exact concentration conditions and culture time (= dose) can be easily determined by an experienced clinician. After culture, the bone marrow cells are washed with serum-containing medium and returned to the body by known methods, such as intravenous injection. If the patient is undergoing other treatments (e.g., ablative chemotherapy or total body irradiation) between bone marrow cell acquisition and reinfusion treatment, the processed bone marrow cells are cryopreserved in liquid nitrogen using standard medical equipment.
[0289] Prescription and Application
[0290] The conjugates of the present application are suitable for formulation into liquids or for lyophilization and subsequent reconstitution into liquid formulations. The conjugate in a liquid formulation or in a formulated lyophilized powder may comprise 0.01% to 99% by weight of the major component in the formulation. Generally, pre-lyophilized liquid formulations containing the conjugate active ingredient at a concentration of 0.1 g / L to 300 g / L for delivery to patients without high levels of antibody aggregation may contain one or more polyols (e.g., sugars), a buffer having a pH of 4.5 to 7.5, surfactants (e.g., polysorbate 20 or 80), antioxidants (e.g., ascorbic acid and / or methionine), tonicity agents (e.g., mannitol, sorbitol, or NaCl), chelating agents such as EDTA, metal complexes (e.g., Zn-protein complexes), biodegradable polymers such as polyesters, preservatives (e.g., benzyl alcohol), and / or free amino acids.
[0291] Buffers suitable for use in the formulation include, but are not limited to, organic acid salts such as sodium, potassium, ammonium, or trihydroxyethylamino salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid; Tris, tromethamine hydrochloride, sulfate, or phosphate buffers. Additionally, amino acid cationic components can also be used as buffers. Examples of such amino acid components include, but are not limited to, arginine, glycine, glycylglycine, and histidine. Arginine buffers include arginine acetate, arginine chloride, arginine phosphate, arginine sulfate, arginine succinate, and the like. In one embodiment, the arginine buffer is arginine acetate. Examples of histidine buffers include histidine chloride-arginine chloride, histidine acetate-arginine acetate, histidine phosphate-arginine phosphate, histidine sulfate-arginine sulfate, histidine succinate-arginine succinate, and the like. The pH of the buffer formulation is 4.5 to 7.5, preferably about 4.5 to about 6.5, and more preferably about 5.0 to about 6.2. In some embodiments, the concentration of the organic acid salt in the buffer is about 10 mM to about 500 mM.
[0292] "Polyols," optionally included in formulations, are substances with multiple hydroxyl groups. Polyols can be used as stabilizing excipients and / or isotonicity agents in both liquid and lyophilized formulations. Polyols can protect biopharmaceuticals from physical and chemical degradation pathways. Preferentially excluded cosolvents increase the effective surface tension of the solvent at the protein interface, thereby ensuring that the most energetically favorable structural conformation is the one with the smallest surface area. Polyols include sugars (reducing and nonreducing sugars), sugar alcohols, and sugar acids. "Reducing sugars" contain a hemiacetal group that can reduce metal ions or covalently react with lysine and other amino groups in proteins, while "nonreducing sugars" lack these properties of reducing sugars. Examples of reducing sugars are fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose, and glucose. Nonreducing sugars include sucrose, trehalose, sorbose, melezitose, and raffinose. The sugar alcohol is selected from mannitol, xylitol, erythritol, maltitol, lactitol, erythritol, threitol, sorbitol, and glycerol. Sugar acids include L-gluconate and its metal salts. The polyol content in the liquid formulation or the resulting lyophilized solid can be 0.0% to 20% by weight. Preferably, a non-reducing sugar, sucrose or trehalose, at a concentration of about 0.1% to 15% is selected in the formulation, with trehalose being preferred over sucrose due to its solution stability.
[0293] Surfactants optionally included in the formulation include polysorbates (such as polysorbate 20, polysorbate 40, polysorbate 65, polysorbate 80, polysorbate 81, and polysorbate 85), poloxamers (such as poloxamer 188, poly(ethylene oxide)-poly(propylene oxide), poloxamer 407, and polyethylene-polypropylene glycol); Triton; sodium dodecyl sulfate (SDS); sodium lauryl sulfate; sodium octyl glycoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl betaine; The surfactant may be selected from the group consisting of propyl, linoleamidopropyl, myristamidopropyl, palmimidopropyl, or isostearamidopropyl betaine (e.g., lauramidopropyl); myristamidopropyl, palmidopropyl, or isostearamidopropyl dimethylamine; sodium methyl cocoyl or sodium methyl oleyl taurate; dodecyl betaine, dodecyl dimethylamine oxide, cocamidopropyl betaine, and cocoamphoglycinate, the "MONAQUAT" (trademark) series (e.g., isostearyl ethylimidonium ethosulfate); polyethyl glycol, polypropylene glycol, and ethylene and propylene glycol copolymers (e.g., Pluronics, PF68, etc.). Suitable surfactants are polyoxyethylene sorbitan fatty acid esters, such as polysorbate 20, 40, 60, or 80 (Tween 20, 40, 60, or 80). The concentration of surfactant in the formulation ranges from 0.0% to about 2.0% by weight. In certain embodiments, the concentration of surfactant is from about 0.01% to about 0.2%. In one embodiment, the concentration of surfactant is about 0.02%.
[0294] A "preservative" optionally included in the formulation is a compound that substantially reduces bacterial activity. Examples of potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl groups are long-chain compounds), and benzethonium chloride. Other types of preservatives include aromatic alcohols such as phenol, butyl, and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol. The preservative content in the liquid formulation or the prepared lyophilized powder can be 0.0% to 5.0% by weight. In one embodiment, the preservative herein is benzyl alcohol.
[0295] Suitable free amino acids for use as tonicity or osmolality adjusters in bulk materials or formulations include, but are not limited to, arginine, cystine, glycine, lysine, histidine, ornithine, isoleucine, leucine, alanine, glycerol, glutamic acid, or aspartic acid. Basic amino acids, i.e., arginine, lysine, and / or histidine, are preferred. When histidine is included in a composition, it can function as both a buffer and a free amino acid; however, when a histidine buffer is used, a non-histidine free amino acid, e.g., histidine buffer and lysine, are typically included. Amino acids may be D- and / or L-, but are usually L-forms. Amino acids may be present as any stable salt, e.g., hydrochloride salts such as arginine-HCl. The amino acid content in a liquid formulation or prepared lyophilized powder can range from 0.0% to 30% by weight.
[0296] The antioxidant in the formulation can optionally be selected from methionine, glutathione, cysteine, cystine, or ascorbic acid at a concentration of up to about 5 mg / ml in the liquid formulation or 0.0 to 5.0 wt% in the formulated lyophilized powder. The formulation can optionally include a metal chelator, such as EDTA or EGTA, at a concentration of up to about 2 mM in the liquid formulation or 0.0 to 0.3% in the formulated lyophilized powder.
[0297] The final formulation can be adjusted to a desired pH with a buffer adjuster (e.g., acids such as HCl, H2SO4, acetic acid, H3PO4, citric acid, etc., or bases such as NaOH, KOH, NH4OH, ethanolamine, diethanolamine, or triethanolamine, sodium phosphate, potassium phosphate, trisodium citrate, or tromethamine). The formulation must be controlled to be "isotonic," meaning that the formulation has essentially the same osmotic pressure as human blood. Isotonic formulations generally have an osmotic pressure of approximately 250-350 mOsm. Isotonicity can be measured, for example, using a vapor pressure or ice-type osmometer. Isotonicity agents are selected from mannitol, sorbitol, sodium acetate, potassium chloride, sodium phosphate, potassium phosphate, trisodium citrate, or NaCl. Generally, both the buffer salt and the isotonicity agent can account for up to 30% by weight of the formulation.
[0298] Other excipients that may be useful in either the liquid or lyophilized formulations of the patent application include, for example, fucose, cellobiose, maltotriose, melibiose, octulose, ribose, xylitol, arginine, histidine, glycine, alanine, methionine, glutamic acid, lysine, imidazole, glycylglycine, mannosylglycerate, Triton X-100, Pluoronic F-127, cellulose, cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin, dextran (10, 40, or 70 kD), polydextrose, maltodextrin, ficoll, gelatin, hydroxypropyl methacrylate, sodium phosphate, potassium phosphate, ZnCl2, zinc, zinc oxide, sodium citrate, trisodium citrate, tromethamine, copper, fibronectin, heparin, human serum albumin, protamine, glycerin, glycerol, EDTA, metacresol, benzyl alcohol, phenol, polyhydric alcohols, or hydrogenated forms of carbohydrates having a carbonyl group reduced to a primary or secondary hydroxyl group.
[0299] Other contemplated excipients that may be utilized in the aqueous pharmaceutical compositions of the patent application include, for example, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, lipids such as phospholipids or fatty acids, steroids such as cholesterol, protein excipients such as serum albumin (human serum albumin), recombinant human albumin, gelatin, casein, salt-forming counterions such as sodium, etc. These and additional known pharmaceutical excipients and / or additives suitable for use in the formulations of the present invention are described in, for example, "The Handbook of Pharmaceutical Excipients, 4 th edition, Rowe et al., Eds., American Pharmaceuticals Association (2003); and Remington: The Science and Practice of Pharmacy, 21 thedition, Gennaro, Ed., Lippincott Williams & Wilkins (2005).”
[0300] Pharmaceutical containers or containers are used to hold pharmaceutical formulations of any of the conjugates of the patent application. The containers may be vials, bottles, prefilled syringes, prefilled syringes, or autoinjector syringes. Liquid formulations can be freeze-dried or drum-dried into cake or powder form in borosilicate or soda-lime glass vials. Solid powders can also be prepared by efficient spray drying and then packaged in vials or pharmaceutical containers for storage and distribution.
[0301] In a further embodiment, the present invention provides a method for preparing a formulation, comprising the steps of: (a) lyophilizing a formulation comprising a conjugate, excipients, and a buffer system; and (b) reconstituting the lyophilized mixture of step (a) in a reconstitution medium such that the reconstituted formulation is stable. The formulation of step (a) may further comprise a stabilizer and one or more excipients selected from the group including bulking agents, salts, surfactants, and preservatives described above. The reconstitution medium may be any of several diluted organic acids or water, i.e., sterile water or bacteriostatic water for injection (BWFI). The reconstitution medium may be selected from the group consisting of water, i.e., sterile water, bacteriostatic water for injection (BWFI), or acetic acid, propionic acid, succinic acid, sodium chloride, magnesium chloride, an acidic solution of sodium chloride, an acidic solution of magnesium chloride, and an acidic solution of arginine, in an amount of about 10 to about 250 mM.
[0302] Liquid pharmaceutical formulations of the present conjugates must exhibit various predefined properties. One of the main concerns for liquid pharmaceuticals is stability, as proteins / antibodies tend to form soluble and insoluble aggregates during manufacturing and storage. Furthermore, various chemical reactions (e.g., deamination, oxidation, clipping, isomerization) can occur in solution, leading to increased levels of degradation products and loss of biological activity. Preferably, the conjugates in liquid or lyophilized formulations should exhibit a shelf life of greater than 6 months at 25°C. More preferably, the conjugates, either in liquid or lyophilized formulations, should exhibit a shelf life of greater than 12 months at 25°C. Most preferably, liquid formulations should exhibit a shelf life of approximately 24-36 months at 2-8°C, and lyophilized formulations should exhibit a shelf life of up to approximately 60 months at 2-8°C. Both liquid and lyophilized formulations should exhibit a shelf life of at least 2 years at -20°C or -70°C.
[0303] In some embodiments, the formulation is stable after freezing (e.g., at -20°C or -70°C) and thawing, e.g., after one, two, or three freeze-thaw cycles. Stability can be qualitatively and / or quantitatively assessed by a variety of methods, including assessment of drug / antibody (protein) ratio and aggregate formation (e.g., using ultraviolet light, size-exclusion chromatography, turbidity measurements, and visual inspection); assessment of charge heterogeneity using cation-exchange chromatography, electric focusing, or capillary zone electrophoresis (e.g., image capillary); amino- or carboxyl-terminal sequence analysis; mass spectrometry, or matrix-assisted laser desorption / ionization / time-of-flight mass spectrometry (MALDI / TOF MS), or HPLC-MS / MS; SDS-PAGE analysis to compare antibody reduction or integrity; peptide map (e.g., trypsin or lysine-carbon) analysis; and assessment of antibody biological activity or antigen-binding function. The instability can include any one or more of aggregation, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomerization), shearing / hydrolysis / cleavage (e.g., hinge rupture), succinimide formation, unpaired cysteine, N-terminal extension, C-terminal processing, and catabolic glycosylation.
[0304] A stable conjugate should also "retain its biological activity" in the pharmaceutical formulation, e.g., the biological activity of the conjugate at a particular time, e.g., 12 months, should be within about 20%, preferably within about 10% (within the error of the assay) of the biological activity at the time the pharmaceutical formulation was prepared, as determined by, e.g., antigen binding assays and / or in vitro cytotoxicity assays.
[0305] For in vivo clinical applications, the conjugates of the present invention may be provided in the form of a solution or a lyophilized solid that can be redissolved in sterile water for injection. Examples of suitable conjugate administration methods are as follows: The conjugate is administered intravenously as a bolus injection daily, weekly, every two weeks, every three weeks, every four weeks, or once a month for 8 to 54 weeks. The bolus dose is dissolved in 50 to 1000 mL of saline, to which human serum albumin can optionally be added (e.g., 0.5 to 1 mL of concentrated human serum albumin solution at 100 mg / mL). The drug dosage is approximately 50 μg to 20 mg / kg body weight per week, administered intravenously (each injection ranging from 10 μg to 200 mg / kg). After 4 to 54 weeks of treatment, patients can receive a second course of treatment. The exact treatment method, including the route of administration, excipients, diluents, dosage, and treatment duration, can be determined by an experienced surgeon.
[0306] Examples of treating diseases by selectively killing cell populations by in vivo or ex vivo methods include any type of cancer, autoimmune diseases, transplant rejection, and infectious diseases (including viral, bacterial, or parasitic).
[0307] The amount of conjugate required to achieve a desired biological effect will vary depending on many factors, including the chemical properties, potency and bioavailability of the conjugate, the type of disease, the patient's race, the patient's pathological condition, the route of administration, and all factors that determine the required dosage, delivery and regimen.
[0308] In general terms, the conjugates of the present invention may be formulated for parenteral administration by dissolving them in a physiological buffer solution to a concentration of 0.1 to 10% w / v. Typical dosage ranges are 1 μg / kg body weight to 0.1 g / kg body weight daily, weekly, biweekly, triweekly, or monthly, with preferred dosage ranges being 0.01 mg / kg body weight to 25 mg / kg body weight weekly, biweekly, triweekly, or monthly. The preferred drug dosage may depend appropriately on variables such as the type and extent of progression of the disease or disorder, the overall health of the individual patient, the relative biological activity of the selected drug, the compound dosage form, the mode of administration (intravenous, intramuscular, or other), the pharmacokinetic properties of the drug in the selected mode of administration, and the administration rate (single injection or continuous infusion) and schedule (frequency of administration within a given period of time).
[0309] The conjugates of the present invention can be administered in unit doses, where "unit dose" refers to a single dose administered to a single patient, and can be used in simple and convenient packaging while maintaining a physically and chemically stable unit dosage, either as the active conjugate itself or as a pharmaceutically acceptable composition, as described below. Therefore, typical daily / weekly / biweekly / monthly total dose ranges are 0.01 to 100 mg / kg. As a general guideline, unit doses for humans range from 1 to 3,000 mg per day, week, biweekly, triweekly, or monthly. Preferably, the unit dose range is 1 mg to 500 mg administered one to four times per month, and more preferably 1 mg to 100 mg administered once per week, once every two weeks, or once every three weeks. The conjugates provided herein can be prepared by adding one or more pharmaceutically acceptable excipients to a pharmaceutical composition. The unit dosage of the drug can be administered orally as a tablet, simple capsule, or soft capsule; intranasally as a powder, nasal drops, or aerosol; or dermal administration as, for example, an ointment, cream, lotion, gel, or spray or a skin patch. The composition can be conveniently administered in unit dosage form and can be prepared by any method known in the pharmaceutical arts, for example, as described in Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005.
[0310] Preferred formulations include pharmaceutical compositions in which the compounds of the present invention are formulated for oral or parenteral administration. For example, oral dosage forms such as tablets, pills, powders, capsules, and lozenges can contain one or more of the following ingredients or other compounds with similar properties: binders such as microcrystalline cellulose or gum tragacanth; diluents such as starch or lactose; dispersing agents such as starch and cellulose derivatives; lubricants such as magnesium stearate; glidants such as colloidal silica; sweeteners such as sucrose or saccharin; and flavoring agents such as peppermint or methyl salicylate. Capsules can be prepared in hard or soft form by mixing gelatin, optionally mixed with a plasticizer, as can starch capsules. Furthermore, dosage units can contain various different materials, such as sugar coatings, shellac, or enteric coatings, to modify their physical form. Other oral dosage forms, such as syrups or elixirs, can contain sweeteners, preservatives, pigments, colorings, and flavorings. Additionally, the active compound can be processed and formulated differently to produce fast-dissolving, sustained-release, or extended-release dosage forms, preferably dual-mode. A preferred tablet formulation contains a mixture of lactose, cornstarch, magnesium silicate, croscarmellose sodium, povidone, magnesium stearate, or talc, or a combination thereof.
[0311] Liquid preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Liquid preparations may contain binders, buffers, preservatives, chelating agents, sweeteners, flavorings, and coloring agents. Non-aqueous solvents include alcohol, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and organic acid esters such as ethyl oleate. Aqueous carriers include mixtures of water and ethanol, buffers, and saline. In particular, biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers, or polyoxyethylene / polyoxypropylene copolymers can be used as materials to control the release of active compounds. Vehicles for intravenous administration include fluid and nutrient replenishers and Ringer's dextrose-based electrolyte replenishers. Other possible parenteral delivery systems for these active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
[0312] Other alternative administration methods include inhalants, including dry powders, aerosols, and drops. Inhalants may be, for example, aqueous solutions containing polyoxyethylene-9-lauryl ether, glycocholate, deoxycholate, or oily solutions for administration in the form of nasal drops or as gels for intranasal application. Formulations for buccal administration, such as tablets or lozenges, may contain flavorings such as sucrose or gum arabic and other additives such as glycocholate. Formulations suitable for rectal administration are preferably given as unit-dose suppositories, for example, containing a solid base such as cocoa butter and may contain salicylic acid. Topical formulations for the skin are preferably in the form of ointments, creams, lotions, pastes, gels, sprays, aerosols, or oils. Bases include petrolatum, lanolin, polyethylene glycols, and alcohols, as well as mixtures thereof. Formulations suitable for transdermal administration can be given as discrete patches and may be lipophilic emulsions or buffered aqueous solutions, dissolved or dispersed in a polymer or adhesive.
[0313] In yet another embodiment, a pharmaceutical composition comprising a therapeutically effective amount of a conjugate of Formula (V), (VI), or (VII), or any conjugate described throughout this patent, is administered simultaneously with another drug, such as a chemotherapeutic agent, radiation therapy, immunotherapy, autoimmune disease treatment, anti-infective, or other antibody-drug conjugate, to achieve a synergistic effect. In another specific embodiment, the synergistic drug or radiation therapy can be administered prior to or following administration of the conjugate of the invention, and in some aspects is administered prior to or following the conjugate of the invention by at least 1 hour, 12 hours, 1 day, 1 week, 2 weeks, 3 weeks, 1 month, or even several months.
[0314] The synergist is preferably selected from one or several of the following drugs: abatacept, abiraterone acetate, abraxane, acetaminophen / hydrocodone, acalabrutinib, aducanumab, adalimumab, ADXS31-142, ADXS-HER2, afatinib dimaleate, aldesleukin, alectinib, alemtuzumab, alitretinoin, adotrastuzumab emtansine, amphetamine / dextroamphetamine, anastrozole, aripiprazole, anthracyclines, aripiprazole, atazanavir, atezolizumab, atorvastatin, avelumab, axicabtagene Ciloleucel, axitinib, belinostat, live BCG, izumab, bexarotene, blinatumomab, bortezomib, bosutinib, brentuximab vedotin, brigatinib, budesonide, budesonide / formoterol, buprenorphine, cabazitaxel, cabozantinib, capmatinib, capecitabine, carfilzomib, chimeric antigen receptor-modified T (CAR-T) cells, celecoxib, ceritinib, cetuximab, chidamide, cyclosporine, cinacalcet, crizotinib, cobimetinib, Cosentyx, crizotinib, CTL01 9. Dabigatran, dabrafenib, dacarbazine, daclizumab, dacomitinib, daptomycin, daratumumab, darbepoetin alfa, darunavir, dasatinib, denileukin diftitox, denosumab, Depakote, dexlansoprazole, methylphenidate, dexamethasone, dinutuximab, doxycycline, duloxetine, duvelisib, DurvalUmab, elotuzumab, emtricitabine / rilpivirine / tenofovir, disoproxil fumarate, emtricitabine / tenofovir / efavirenz, enoxaparin, ensartinib, enzalutamide, epoetin alfa, erlotinib, esomeprazole, eszopiclone, everolimus, exemestane, everolimus, exenatide ER, ezetimibe, ezetimibe / simvastatin, fenofibrate, filgrastim, fingolimod, fluticasone propionate, fluticasone / salmeterol, fulvestrant, Gadiva, gefitinib, glatiramer, goserelin acetate, icotinib, imatinib, ibritumomabTiuxetan, ibrutinib, idelarib, ifosfamide, infliximab, imiquimod, Immucyst, immune BCG, iniparib, insulin aspart, insulin detemir, insulin glargine, insulin lispro, interferon alpha, interferon alpha 1b, interferon alpha 2a, interferon alpha 2b, interferon beta, interferon beta 1a, interferon beta 1b, interferon gamma 1a, iapatinib, ipilimumab, ipratropium bromide / salbutamoate oxal, ixazomib, Kanuma, lanreotide acetate, lenalidomide, lenaliamide, lenvatinib mesylate, letrozole, levothyroxine, lidocaine, linezolid, liraglutide, examfetamine, LN-144, lorlatinib, memantine, methylphenidate, metoprolol, mekinist, melicitabine / rilpivirine / tenofovir, modafinil, mometasone, misidac-C, necitumumab, neratinib, nilotinib, niraparib, nivolumab, ofatumumab, obinutuzumab, ora Paribu, olmesartan, olmesartan / hydrochlorothiazide, omalizumab, omega-3 fatty acid ethyl ester, oncoline, oseltamivir, osimertinib, oxycodone, palbociclib, palivizumab, panitumumab, panobinostat, pazopanib, pembrolizumab, PD-1 antibody, PD-L1 antibody, pemetrexed, pertuzumab, pneumococcal conjugate vaccine, pomalidomide, poziotinib, pregabalin, proscavax, propranolol, quetiapine, rabeprazole, radium chloride Mu223, raloxifene, raltegravir, ramucirumab, ranibizumab, regorafenib, rituximab, rivaroxaban, romidepsin, rosuvastatin, ruxolitinib phosphate, salbutamol, savolitinib, semaglutide, sildenafil, siltuximab, sipuleucel-T, sitagliptin, sitagliptin / metformin, solifenacin, solanezumab, sonidegib, sorafenib, sunitinib, tacrolimus, taclimus, tadalafil, tamoxifen, tafinlar, talimogene laherparepvec, talazoparib, telaprolevib, IR / emtricitabine, tenofovirDisoproxil fumarate, testosterone gel, thalidomide, TICE BCG, tiotropium bromide, tisagenluclucel, toremifene, trametinib, trastuzumab, trastuzumab deruxtecan, trabectedin (ecteinascidin 743), trametinib, tremelimumab, trifluridine / tipiracil, tretinoin, ustekinumab, valsartan, veliparib, vandetanib, vemurafenib, venetoclax, vorinostat, difluaflibercept, zostavax, and analogs, derivatives, pharmaceutically acceptable salts, carriers, diluents, or excipients thereof, or combinations thereof.
[0315] The drugs / cytotoxic agents used in the conjugates of this patent can be any analogs and / or derivatives of the drugs / molecules described in this patent. One skilled in the art of drugs / cytotoxic agents will readily understand that each of the drugs / cytotoxic agents described herein can be modified in such a way that the resulting compound still retains the specificity and / or activity of the starting compound. One skilled in the art will also understand that many of these compounds can be used in place of the drugs / cytotoxic agents described herein. Thus, the drugs / cytotoxic agents of the present invention include analogs and derivatives of the compounds described herein.
[0316] According to a further object, the present invention also relates to a process for preparing the conjugates of the present invention. The compounds and processes of the present invention can be prepared in many ways well known to those skilled in the art. The camptothecin analogs used in the conjugates can be synthesized, for example, by application or adaptation of the methods described below, or variations thereof as would be understood by those skilled in the art. Appropriate modifications and substitutions will be readily apparent to those skilled in the art and are well known or readily obtainable by those skilled in the art from the scientific literature. In particular, such methods are described in R.C. Larock, Comprehensive Organic Transformations, 2 nd Edition, Wiley-VCH Publishers, 1999.
[0317] In the synthesis of the cytotoxic agents of the present invention, desired reactive functional groups in the final product, such as hydroxy, amino, imino, thio, or carboxy groups, may be protected as necessary to avoid undesired participation in the reaction. Conventional protecting groups can be used according to standard practice; see, for example, P.G. Wuts and T.W. Greene, "Greene's Protective Groups in Organic Synthesis," Wiley-Interscience, 4th edition (2006). Depending on the reaction, it may be carried out in the presence of a base or acid or in a suitable solvent. There are no particular limitations on the nature of the base, acid, or solvent used in this reaction; bases, acids, and solvents conventionally used in this type of reaction can be used as long as they do not adversely affect other parts of the molecule. This reaction can be carried out over a wide temperature range. Generally, temperatures between -80°C and 150°C (more preferably, about room temperature to 100°C) are considered suitable. The reaction time may also vary significantly depending on many factors, particularly the reaction temperature and the nature of the reagents. However, a period of 3 to 20 hours is usually sufficient, so long as the reaction is effective under the preferred conditions described above.
[0318] The post-treatment of the reaction can be carried out by a conventional method. For example, the reaction product can be recovered by distilling the solvent from the reaction mixture, or, if necessary, after distilling the solvent from the reaction mixture, the residue can be poured into water, followed by extraction with a water-immiscible organic solvent and evaporation of the solvent from the extract. Furthermore, if necessary, the product can be further purified by various known techniques, such as recrystallization, reprecipitation, or various chromatographic techniques, particularly column chromatography or thin-layer chromatography.
[0319] The method of the present invention is further illustrated, but not limited, by the following examples. All references cited herein and in the following examples are expressly incorporated by reference in their entirety. [Example]
[0320] The following examples further illustrate the present invention but are not intended to limit the scope of the present application. Unless otherwise specified, the cell lines described in the following examples were maintained in culture media based on conditions specified by the American Type Culture Collection (ATCC), the German Collection of Microbial Cell Cultures (DMSZ), Braunschweig, Germany, or the Shanghai Institute of Cell Culture, Chinese Academy of Sciences. Unless otherwise specified, all cell culture reagents were provided by Invitrogen. All anhydrous solvents were commercially available and stored in nitrogen-sealed bottles. PEG compounds were purchased from Biomatrik Inc., Jiaxing, China. Some compounds, unless otherwise referenced in synthesis, were provided by Chinese contract research organizations (CROs) (e.g., Wuxi Apptec, Haoyuan Chemexpress, Raybow Pharma). Experimental animals were purchased from the National Resource Center of Model Mice via GemPharmatech Co., Ltd. (Najin, China) and Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). T-DM1 was purchased from Roche via a pharmacy in Hong Kong, China. All other reagents and solvents were purchased according to the highest standards and used without further purification. Preparative HPLC separations were performed on a Varain PreStar HPLC. HPLC analysis was performed on an Agilent 1260. Mass spectral data were acquired on a Waters Xwvo QTOF equipped with a Waters Acquity UPLC separation module and an Acquity TUV detector. NMR spectra were recorded on a Zhongke-niujin WNMR-I 400 MHz instrument at the Department of Chemistry, Zhejiang University of Technology. Chemical shifts (δ) are in parts per million (ppm) and are referenced to tetramethylsilane at 0.00. Coupling constants (J) are in Hz. Elemental analysis of C, H, and / or N was provided by the Department of Chemistry, Zhejiang University of Technology and performed on an Elementar UNICUBE. Quantitative analysis of metal atoms was performed on an Agilent ICPOES 730 ICP-MS.
[0321] Example 1: Synthesis of zinc propan-2-amine chloride complex (Z-01) [ka]
[0322] Zinc chloride (6.0 g, 44.03 mmol) was dissolved in 50 mL of methanol and cooled to approximately 5°C in an ice-water bath. Propan-2-amine (10.4 g, 176.11 mmol) dissolved in 60 mL of methanol was added dropwise to the zinc chloride methanol solution, maintaining the solution temperature below 5°C. A white solid slowly precipitated during the addition of the amine solution. After the addition, the solution was warmed to room temperature and slowly stirred overnight to precipitate more white solid. 200 mL of ethyl acetate was then added to the mixture, and the mixture was stirred for an additional 10 minutes. The resulting white solid was filtered, washed with methanol, and then dried under vacuum to give 8.9 g of zinc propan-2-amine chloride complex as an off-white solid (79.4% yield). 1 HNMR (400MHz, DMSO-d6): δ = 3.61 (s, 4H), 3.12-3.06 (m, 2H), 1.12 (d, J=6.3Hz, 12H). Elemental analysis, calculated: C, 28.32; H, 7.13; N, 11.01; measured: C, 28.08; H, 7.10; N, 11.20;
[0323] Example 2: Synthesis of zinc ethanolamine chloride complex (Z-02) [ka]
[0324] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and ethanolamine (10.8 g, 176.11 mmol), to give 8.2 g of zinc ethanolamine chloride complex as an off-white solid (72.6% yield). 1H NMR (400 MHz, DMSO) δ 3.77 (s, 2H), 3.50 (t, J = 5.6Hz, 2H), 2.69 (t, J=5.7Hz, 2H). Elemental analysis, calculated: C, 18.59; H, 5.46; N, 10.84; measured: C, 18.25; H, 5.02; N, 10.30.
[0325] Example 3: Synthesis of zinc diethanolamine chloride complex (Z-03) [ka]
[0326] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and diethanolamine (18.5 g, 176.11 mmol), to give 12.2 g of zinc diethanolamine chloride complex as an off-white solid (80.4% yield). 1 H NMR (400 MHz, DMSO) δ 4.60 (s, 2H), 3.59 (m, 8H), 3.35 (m, 4H), 2.72 (s, 8H). Elemental analysis, calculated: C, 27.73; H, 6.40; N, 8.08; measured: C, 27.25; H, 6.05; N, 7.80;
[0327] Example 4: Synthesis of zinc homopiperazine chloride complex (Z-04) [ka]
[0328] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and piperazine (15.2 g, 176.11 mmol), to give 9.2 g of zinc homopiperazine chloride complex as an off-white solid (73.6% yield). 1H NMR (400 MHz, DMSO) δ 4.34 (s, 2H), 3.01-2.85 (m, 8H), 1.87-1.75 (m, 2H). Elemental analysis, calculated: N, 11.85; measured: N, 11.50.
[0329] Example 5: Synthesis of zinc piperazine chloride complex (Z-05) [ka]
[0330] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and piperazine (15.2 g, 176.11 mmol), to give 7.6 g of zinc piperazine chloride complex as an off-white solid (94.0% yield). 1 H NMR (400 MHz, DMSO) δ 2.73 (s, 8H). Elemental analysis, calculated: C, 21.60; H, 4.53; N, 12.59; measured: C, 21.10; H, 4.69; N, 12.30;
[0331] Example 6: Synthesis of zinc o-phenylenediamine chloride complex (Z-06) [ka]
[0332] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and o-phenylenediamine (19.1 g, 176.11 mmol), to give 9.5 g of o-phenylenediamine zinc chloride complex as an off-white solid (88.3% yield). 1 HNMR (400MHz, DMSO-d6): δ= 6.55-6.51 (m, 2H), 6.43-6.39 (m, 2H), 4.43 (s, 4H). Elemental analysis, calculated: C, 29.48; H, 3.30; N, 11.46; measured: C, 29.70; H, 3.63; N, 11.30.
[0333] Example 7: Synthesis of zinc propylenediamine chloride complex (Z-07) [ka]
[0334] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and propylenediamine (13.0 g, 176.11 mmol), to give 8.1 g of zinc propylenediamine chloride complex as an off-white solid (87.4% yield). 1 H NMR (400 MHz, DMSO) δ 3.93 (s, 2H), 3.82 (s, 2H), 2.86-2.66 (m, 2H), 2.24 (s, 1H), 1.09 (d, J=6.5Hz, 3H)). Elemental analysis, calculated value: C3H 10 Cl2N2Zn (207.95): C, 17.12; H, 4.79; Cl, 33.70; N, 13.31; Zn, 31.07.
[0335] Example 8: Synthesis of zinc 1,2-cyclohexanediamine chloride complex (Z-08) [ka]
[0336] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and 1,2-cyclohexanediamine (20.1 g, 176.11 mmol), to give 8.5 g of zinc 1,2-cyclohexanediamine chloride complex as an off-white solid (77.7% yield). 1 H NMR (400 MHz, DMSO) δ 3.89 (s, 4H), 2.27-2.11 (m, 2H), 1.65 (d, J=9.9Hz, 2H), 1.59-1.45 (m, 2H), 1.32-1.26 (m, 2H), 1.19-1.14 (m, 2H). Elemental analysis, calculated value: C6H 14Cl2N2Zn (247.98): N, 11.18; Zn, 26.10; Measured: N, 10.88; Zn, 25.95.
[0337] Example 9: Synthesis of zinc methylamine chloride complex (Z-09) [ka]
[0338] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and methylamine hydrochloride (20.1 g, 176.11 mmol), to give 9.5 g of zinc methylamine chloride complex as an off-white solid (94.0% yield). 1 H NMR (400 MHz, DMSO) δ 7.71 (s, 6H), 2.37 (d, J=3.6Hz, 6H). Elemental analysis, calculated value: C2H 10 Cl2N2Zn (195.95): N, 14.12; Zn, 32.95; Measured: N, 13.96; Zn, 32.82.
[0339] Example 10: Synthesis of zinc ethylamine chloride complex (Z-10) [ka]
[0340] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and ethylamine solution (19.9 g, 176.11 mmol, 40% wt), to give 8.3 g of zinc ethylamine chloride complex as an off-white solid (84.0% yield). 1 H NMR (400 MHz, DMSO) δ 3.76-3.50 (m, 4H), 2.66 (q, J=7.2Hz, 4H), 1.10 (t, J=7.2Hz, 6H). Elemental analysis, calculated value: C4H 14Cl2N2Zn (223.98): N, 12.37; Zn, 28.87; Measured: N, 12.08; Zn, 28.72.
[0341] Example 11: Synthesis of zinc 2-methylpropane-1,2-diamine chloride complex (Z-11) [ka]
[0342] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and 2-methylpropane-1,2-diamine (15.5 g, 176.11 mmol), to give 7.8 g of zinc 2-methylpropane-1,2-diamine chloride complex as an off-white solid (79.6% yield). 1 H NMR (400 MHz, DMSO) δ 4.02 (s, 2H), 3.78 (s, 2H), 2.43 (d, J=5.6Hz, 2H), 1.12 (s, 6H). Elemental analysis, calculated value: C4H 12 Cl2N2Zn (221.97): N, 12.48; Zn, 28.80; Measured: N, 12.35; Zn, 28.58.
[0343] Example 12: Synthesis of zinc (3R,4S)-tetrahydrofuran-3,4-diamine chloride complex (Z-12) [ka]
[0344] The procedure was the same as in Example 1, starting from zinc chloride (2.0 g, 14.68 mmol) and (3R,4S)-tetrahydrofuran-3,4-diamine (5.1 g, 29.35 mmol), to give 3.8 g of zinc (3R,4S)-tetrahydrofuran-3,4-diamine chloride complex as an off-white solid (83.7% yield). 1H NMR (400 MHz, DMSO) δ 8.82 (s, 6H), 4.07-3.83 (m, 6H). Elemental analysis, calculated value: C4H 10 Cl2N2OZn (235.95) Zn, 27.42; N, 12.48; Measured: N, 12.30; Zn, 27.26.
[0345] Example 13: Synthesis of zinc pyrrolidine chloride complex (Z-13) [ka]
[0346] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and pyrrolidine (15.5 g, 176.11 mmol), to give 11.0 g of zinc chloride pyrrolidine complex as an off-white solid (90.4% yield). 1 H NMR (400 MHz, DMSO) δ 4.46 (s, 2H), 2.85 (t, J=6.2Hz, 8H), 1.81-1.65 (m, 8H). Elemental analysis, calculated value: C8H 18 Cl2N2Zn (276.01): N, 10.06; Zn, 23.47; Measured: N, 9.88; Zn, 23.59.
[0347] Example 14: Synthesis of zinc N-methylimidazole chloride complex (Z-14) [ka]
[0348] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and N-methylimidazole (14.5 g, 176.11 mmol), to give 10.0 g of zinc homopiperazine chloride complex as an off-white solid (90.4% yield). 1H NMR (400 MHz, DMSO) δ 8.09 (s, 2H), 7.39 (d, J=1.4Hz, 2H), 7.06 (t, J=1.3Hz, 2H), 3.77 (s, 6H). Elemental analysis, calculated value: C8H 12 Cl2N4Zn (297.97): N, 18.64; Zn, 21.76; Measured: N, 18.40; Zn, 21.58.
[0349] Example 15: Synthesis of zinc piperidine chloride complex (Z-15) [ka]
[0350] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and piperidine (15.0 g, 176.11 mmol), to give 10.5 g of zinc chloride piperidine complex as an off-white solid (77.8% yield). 1 H NMR (400 MHz, DMSO) δ 4.00 (s, 2H), 2.80 (t, J=4.6Hz, 8H), 1.61-1.45 (m, 12H). Elemental analysis, calculated value: C 10 H 22 Cl2N2Zn (304.04): N, 9.14; Zn, 21.33; Measured: N, 8.83; Zn, 21.50.
[0351] Example 16: Synthesis of zinc pyridine chloride complex (Z-16) [ka]
[0352] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and pyridine (13.9 g, 176.11 mmol), to give 9.5 g of zinc pyridine chloride complex as an off-white solid (73.2% yield). 1H NMR (400 MHz, DMSO) δ 8.61 (dt, J=4.4, 1.7 Hz, 4H), 7.94-7.86 (m, 2H), 7.49 (ddd, J=7.6, 4.4, 1.5 Hz, 4H). Elemental analysis, calculated value: C 10 H 10 Cl2N2Zn (291.95): N, 9.51; Zn, 22.20; Measured: N, 9.35, Zn, 21.90.
[0353] Example 17: Synthesis of zinc 2-methylpyridine chloride complex (Z-17) [ka]
[0354] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and 2-methylpyridine (16.1 g, 176.11 mmol), to give 11.3 g of zinc 2-methylpyridine chloride complex as an off-white solid (79.6% yield). 1 H NMR (400 MHz, DMSO) δ 8.48 (ddd, J=5.0, 1.9, 0.9 Hz, 2H), 7.72 (td, J=7.7, 1.9Hz, 2H), 7.29 (d, J=7.8Hz, 2H) ), 7.22 (ddd, J=7.7, 5.4, 1.2Hz, 2H), 2.50 (s, 6H). Elemental analysis, calculated value: C 12 H 14 Cl2N2Zn (319.98): N, 8.69; Zn, 20.27; Measured: N, 8.35, Zn, 20.12.
[0355] Example 18: Synthesis of zinc 6-methylpyridin-2-amine chloride complex (Z-18) [ka]
[0356] The procedure was the same as in Example 1, starting with zinc chloride (4.0 g, 29.35 mmol) and 6-methylpyridin-2-amine (12.7 g, 117.41 mmol), to give 2.3 g of zinc 6-methylpyridin-2-amine chloride complex as an off-white solid (32.0% yield). 1 H NMR (400 MHz, DMSO) δ 7.25 (dd, J=8.2, 7.2Hz, 1H), 6.34 (d, J=7.2Hz, 1H), 6.23 (d, J=8.2Hz, 1H), 5.75 (s, 2H), 2.23 (s, 3H). Elemental analysis, calculated: C6H8Cl2N2Zn (241.94): N, 11.46; Zn, 26.75; measured: N, 11.25, Zn, 26.48.
[0357] Example 19: Synthesis of zinc morpholine chloride complex (Z-19) [ka]
[0358] The procedure was the same as in Example 1, starting with zinc chloride (6.0 g, 44.03 mmol) and morpholine (15.2 g, 176.11 mmol), to give 8.1 g of zinc morpholine chloride complex as an off-white solid (89.5% yield). 1 H NMR (400 MHz, DMSO) δ 3.64-3.59 (m, 8H), 2.79 (dd, J=5.6, 4.0Hz, 8H). Chemical formula: C8H 18 Cl2N2O2Zn; exact mass: 308.0037; elemental analysis N, 9.02; Zn, 21.05; found: N, 8.81; Zn, 20.75.
[0359] Example 20: Synthesis of zinc methylpiperazine chloride complex (Z-20) [ka]
[0360] The procedure was the same as in Example 1, starting with zinc chloride (4.0 g, 29.35 mmol) and methylpiperazine (11.8 g, 117.41 mmol), to give 8.1 g of zinc methylpiperazine chloride complex as an off-white solid (82.5% yield). 1 H NMR (400 MHz, DMSO) δ 2.81 (t, J=5.0Hz, 8H), 2.37 (s, 8H), 2.15 (s, 6H). Chemical formula: C 10 H 24 Cl2N4Zn; Exact mass: 334.0669; Elemental analysis: N, 16.64; Zn, 19.42; Found: N, 16.80; Zn, 18.98.
[0361] Example 21: Synthesis of zinc pyridin-2-ylmethanamine chloride complex (Z-21) [ka]
[0362] The procedure was the same as in Example 1, starting with zinc chloride (4.0 g, 29.35 mmol) and pyridin-2-ylmethanamine (12.7 g, 117.41 mmol), to give 6.2 g of zinc pyridin-2-ylmethanamine chloride complex as an off-white solid (86.8% yield). 1 H NMR (400 MHz, DMSO) δ8.55 (dt, J=5.2, 1.4Hz, 1H), 7.99 (td, J=7.7, 1.7Hz, 1H), 7.58-7.53 (m, 1H), 7.51 (ddd), J=7.5, 5.2, 1.2Hz, 1H), 4.09 (s, 2H), 4.06 (s, 2H). Chemical formula: C 12 H 16 Cl2N4Zn; Exact mass: 350.0043; Elemental analysis: N, 15.89; Zn, 18.54; Found: N, 16.21; Zn, 18.72.
[0363] Example 22: Synthesis of zinc 4-methylthiazole chloride complex (Z-22) [ka]
[0364] The procedure was the same as in Example 1, starting with zinc chloride (4.0 g, 29.35 mmol) and 4-methylthiazole (11.6 g, 117.41 mmol), to give 6.5 g of zinc 4-methylthiazole chloride complex as an off-white solid (66.2% yield). 1 H NMR (400 MHz, DMSO) δ9.02 (d, J=2.0Hz, 2H), 7.33 (dt, J=2.0, 1.0Hz, 2H), 2.43 (d, J =1.0Hz, 6H).
[0365] Example 23: Synthesis of zinc 4-methylbenzene-1,2-diamine chloride complex (Z-23) [ka]
[0366] The procedure was the same as in Example 1, starting with zinc chloride (4.0 g, 29.35 mmol) and 4-methylbenzene-1,2-diamine (14.3 g, 117.41 mmol), to give 5.8 g of zinc 4-methylbenzene-1,2-diamine chloride complex as an off-white solid (77.0% yield). 1 H NMR (400 MHz, DMSO) δ6.42 (d, J=7.7Hz, 1H), 6.36 (d, J=2.0Hz, 1H), 6.21 (dd, J=7.7, 2.0Hz, 1H), 4.30 (s, 4H), 2.08 (s, 3H). Chemical formula: C7H 10 Cl2N2Zn; Exact mass: 255.9513; Elemental analysis: N, 10.84; Zn, 25.30; Found: N, 10.42; Zn, 25.73.
[0367] Example 24. Synthesis of zinc butane-2,3-diamine chloride complex (Z-24) [ka]
[0368] The procedure was the same as in Example 1, starting with zinc chloride (800 mg, 5.87 mmol) and butane-2,3-diamine (939.2 mg, 5.87 mmol), to give 1.90 g of zinc butane-2,3-diamine chloride complex as an off-white solid (87.1% yield). 1 H NMR (400 MHz, DMSO) δ 8.61 (s, 5H), 3.54-3.47 (m, 2H), 1.29 (d, J=6.5Hz, 6H).
[0369] Example 25: Synthesis of zinc oxazole chloride complex (Z-25) [ka]
[0370] The ...
Claims
1. A method for homogeneous conjugation comprising the steps of: (a) providing an effective amount of a transition metal cation-amino chelate / complex (M(NR 1 R 2 R 3 ) m1 m2+ 2. Incubating an antibody or antibody-like protein, in particular an IgG antibody, in a buffered system in the presence of 0.1% glycerol and a reducing agent; (b) adding an effective amount of a conjugate or payload / conjugate conjugate having a thiol-reactive group (e.g., a drug containing a maleimide terminus) to react with the thiol group generated in step (a); and (c) optionally adding an effective amount of an oxidizing agent (e.g., dehydroascorbic acid) to reoxidize any unreacted sulfhydryl groups; (d) and then purifying the resulting conjugate; (e) optional step (c) above can be replaced by the addition of an effective amount of cystine or a related disulfide compound to quench any unreacted reducing agent, while an effective amount of cysteine or a related sulfhydryl compound can be added to quench excess conjugation of a linker or linker / payload conjugate containing a thiol reactive group to generate cysteine, or an effective amount of cysteine or a related sulfhydryl compound can be added to quench excess linker or linker / payload conjugate molecules; The transition metal cation-amino chelate / complex has the formula M(NR 1 R 2 R 3 ) m1 m2+ where: M is Zn 2+ , Cu 2+ , Fe 2+ , Cd 2+ , Ni 2+ , Cr 2+ , Cr 3+ , Ti 2+ , Ti 3+ , Co 2+ , Mn 2+ , Mn 3+ , Ag + , and Hg 2+ Selected from: R 1 , R 2 and R 3 are each independently 1 -C 8 Alkyl, C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 -C 8 selected from aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; m1 is 1, 2, 3, 4, 5, 6, 7, or 8; m2 is 1, 2, 3, 4, 5, or 6; In addition, N.R. 1 , R 2 and / or R 3 may themselves form a heterocycle, a carbocycle, a heterobicycle, or a carbobicycle; 1 R 2 R 3 ) m1 can form dimers, trimers, tetramers, pentamers, or hexamers, and these polymers are N, R 1 , R 2 and / or R 3 are covalently bonded between The reducing agent is an organic phosphine, and the amount used is 1.0 to 20 equivalents per mole of protein; The oxidizing agent added in step (c) is DHAA, Fe 3+ , I 2 , Cu 2+ , Mn 3+ , MnO 2 , or Fe 3+ / I - The concentration of the oxidizing agent used in the reaction solution is 0.02 mM to 1.0 mM, or 1-100 equivalents per mole of protein; the transition metal cation-amino chelate / complex M(NR 1 R 2 R 3 ) m1 m2+ is at a concentration of 0.01 mM to 1.0 mM, or 0.5-20 equivalents per mole of protein; The pH of the conjugation reaction is usually about 5.0 to 8.0, preferably about 5.5 to 7.5; as a co-solvent, up to 30% of a water-miscible organic solvent selected from DMA, DMF, ethanol, methanol, acetone, acetonitrile, THF, isopropyl alcohol, dioxane, propylene glycol, or ethylene glycol can be added to the aqueous buffer solution; The optimum temperature for the conjugation reaction is usually about -5°C to 40°C, preferably about 0°C to 37°C; more preferably about 2°C to 8°C; the optimum reaction time for the conjugation reaction is about 15 minutes to about 48 hours, preferably 30 minutes to 16 hours; The conjugate can be purified by Sephadex G25 or Sephacryl S300 column gel filtration, adsorption chromatography, ion (cation or anion) exchange chromatography, or dialysis (ultrafiltration or ultrafiltration (UF) and / or diafiltration (DF); The drug / antibody-like protein (antibody) ratio (DAR) of the conjugates can also be measured by UV in the wavelength range of 240-380 nm, hydrophobic interaction chromatography (HIC-HPLC), capillary electrophoresis (CE), and / or LC-MS, CE-MS, or LC-MS / MS.
2. The transition metal cation amino chelate compound according to claim 1 is selected from the following: Zn(NH 2 CH 3 ) 2 2+ , Zn(NH 2 CH 2 CH 3 ) 2 2+ , Zn(NH 2 CH 2 CH 2 CH 3 ) 2 2+ , Zn(NH 2 CH (CH 3 ) 2 ) 2 2+ , Zn(NH 2 C (CH 3 ) 3 ) 2 2+ , Zn(NH 2 CH 2 C (CH 3 ) 3 ) 2 2+ , Zn(NH(CH 3 ) 2 ) 2 2+ , Zn(NH(CH 2 CH 3 ) 2 ) 2 2+ , Zn(NH(CH(CH 3 ) 2 ) 2 ) 2 2+ , Zn(NH(C(CH 3 ) 3 ) 2 ) 2 2+ , Zn(NH(CH(CH 2 CH3) 2 ) 2 ) 2 2+ , Zn(NH(CH 2 C (CH 3 ) 3 ) 2 ) 2 2+ Zn(NH(CH 2 C(CH 2 CH 3 ) 3 ) 2 ) 2 2+ Zn(NH(CH 2 CH 2 C(CH 3 ) 3 ) 2 ) 2 2+ Zn(NH 2 CH 2 CH 2 OH) 2 2+ Zn(NH(CH 2 CH 2 OH) 2 ) 2 2+ Zn(N(CH 2 CH 2 OH) 3 ) 2 2+ Zn(NH 2 CH 2 COOH) 2 2+ Zn(NH 2 CH 2 P. 2 ) 2 2+ Zn(NH 2 CH 2 COOCH 3 ) 2 2+ Zn(NH 2 CH 2 COOCH 2 CH 3 ) 2 2+ Zn(NH 2 CH 2 P.S. 3 ) 3 ) 2 2+ Zn(NH 2 CH 2 P.S. 3 ) 2 ) 2 2+ Zn(NH 2 CH 2 CH 2 COOH) 2 2+ Zn(NH(CH 2 COOH) 2 ) 2 2+ Zn(N(CH 2 CH 2 COOH) 3 ) 2 2+ Zn(NH 2 CH 3 ) 4 2+ Zn(NH 2 CH 2 CH 3 ) 4 2+ Zn(NH 2 CH 2 CH 2 CH 3 ) 4 2+ Zn(NH 2 CH(CH 3 ) 2 ) 4 2+ Zn(NH 2 C(CH 3 ) 3 ) 4 2+ Zn(NH 2 CH 2 C(CH 3 ) 3 ) 4 2+ Zn(NH(CH 3 ) 2 ) 4 2+ Zn(NH(CH 2 CH 3 ) 2 ) 4 2+ Zn(NH(CH(CH 3 ) 2 ) 2 ) 4 2+ Zn(NH(C(CH 3 ) 3 ) 2 ) 4 2+ Zn(NH(CH(CH 2 CH 3 ) 2 ) 2 ) 4 2+ Zn(NH(CH 2 C(CH 3 ) 3 ) 2 ) 4 2+ Zn(NH(CH 2 C(CH 2 CH 3 ) 3 ) 2 ) 4 2+ Zn(NH(CH 2 CH 2 C(CH 3 ) 3 ) 2 ) 4 2+ Zn(NH 2 CH 2 CH 2 OH) 4 2+ Zn(NH(CH 2 CH 2 OH) 2 ) 4 2+ Zn(N(CH 2 CH 2 OH) 3 ) 4 2+ Zn(NH 2 CH 2 COOH) 4 2+ Zn(NH 2 CH 2 P. 2 ) 4 2+ Zn(NH 2 CH 2 COOCH 3 ) 4 2+ Zn(NH 2 CH 2 COOCH 2 CH 3 ) 4 2+ Zn(NH 2 CH 2 P.S. 3 ) 3 ) 4 2+ Zn(NH 2 CH 2 P.S. 3 ) 2 ) 4 2+ Zn(NH 2 CH 2 CH 2 COOH) 4 2+ Zn(NH(CH 2 COOH) 2 ) 4 2+ Zn(N(CH 2 CH 2 COOH) 3 ) 4 2+ 、 【Chemistry 1】 【change】 All of the complex cations are Cl - , Br - , I - , SO 4 2- , HSO 4 - , NO 3 - , PO 4 3- , HPO 4 2- , H 2 PO 4 - , CO 3 2- , HCO 3 - , HCOO - , CH 3 COO - , F 3 CCOO - , Cl 3 CCOO - , FCH 2 COO - , ClCH 2 COO - , F 2 CHCOO - , Cl 2 CHCOO - , BF 4 - , SO 3 2- , HSO 3 - , CH 3 SO 3 - , C 6 H 5 CH 2 SO 3 - , C 6 H 5 SO 3 - , C 6 H 5 COO - , C 6 H 5 CH 2 COO - , C 6 F 5 O - , C 6 H 4 (OH)COO - , C 6 H 2 F 3 O - , C 6 H 4 (NO 2 ) O - , and C 6 H 2 (NO 2 ) 3 O - may be formed as a salt with an anion selected from The concentration of the transition metal cation-amino complex in the reaction solution is 0.5 to 20 equivalents per mole of protein, and is selected from ethanol, methanol, propanol, propanediol, DMA, DMSO, THF, or CH 3 CN may be added to the reaction solution together with a water-miscible organic solvent selected from the group consisting of toluene, ...
3. The organophosphine reducing agent of claim 1 is tris(hydroxypropyl)-phosphine (P(CH 2 CH 2 CH 2 O.H. 3 ), P(CH 2 CH 3 ) 3 , P(CH 2 CH 2 CH 3 ) 3 , P(CH 2 CH 2 -CH 2 CH 3 ) 3 , P(CH(CH 3 ) 2 ) 3 , P(CH 2 CH=CH 2 ) 3 , P(CH 2 CH 2 C.N. 3 , P(CH(CH 3 ) 2 ) 2 (CH 2 CH 2 N.H. 2 ), P(CH 2 CH 2 CONH 2 ) 3 , P(CH 2 CH 2 CONHC 3 ) 3 , P(CH 2 CH 2 CH 2 NHCOCH 3 ) 3 , NaB(CN)H 3 , (C 6 H 11 ) 2 P (CH 2 ) 4 P (C 6 H 11 ) 2 , (C 6 H 11 ) 2 P (CH 2 ) 3 P-(C 6 H 11 ) 2 , dicyclohexyl(ethyl)phosphine, bis[2-(di-tert-butylphosphine)ethyl]amine, tricyclohexylphosphine, 1,2-ethyldiylbis[dicyclohexyl]-phosphine, bis[2-(dicyclohexylphosphine)ethyl]amine, tris[2-(diphenylphosphine)ethyl]-phosphine ([(C 6 H 5 ) 2 P.C.H. 2 CH 2 ] 3 P), triphenylphosphine, sulfonated triphenylphosphine (2-(diphenylphosphine)benzenesulfonic acid (diPPBS), 3-(diphenylphosphine))benzenesulfonic acid, 4-(diphenylphosphinyl)benzenesulfonic acid, 3,3′,3″-phosphoryltribenzenesulfonic acid); preferably, the reducing agent is selected from TECP or P(CH 2 CH 2 CH 2 O.H. 3 and more preferably selected from TECP; and the reducing agent used in the reaction solution in step (A) has a concentration of 0.02 mM-1.0 mM or 1.0-20.0 molar equivalents of protein in the reaction solution; preferably, the reducing agent is used in an amount of 2.0-4.0 molar equivalents of protein.
4. The buffer of choice for carrying out the selective reduction according to claim 1 is selected from PBS, Mes, Bis-Tris, Bis-Tris propane, Pipes, Aces, Mopso, Bes, Mops, Hepes, Tes, Pipps, Dipso, Tapso, Heppso, Tris-up, Tris-HCl, Tricine, Hepps, Gly-Gly, Bicine, Taps, Hepee, acetate, histidine, citrate, MES, borate, or any two, three or four of these. the pH of the buffer solution is 4.0-9.0, preferably 5.0-7.5, more preferably 5.5-7.5; the concentration of the buffer solution during the reaction is 0.02-1.0M, preferably 20-100mM; as a co-solvent, up to 30% of an organic solvent miscible with water selected from DMA, DMF, ethanol, methanol, acetone, acetonitrile, THF, isopropyl alcohol, dioxane, propylene glycol, or ethylene glycol can be added to the aqueous buffer solution.
5. The drug / conjugate conjugate of claim 1 is represented by formula (I), (II), or (III): 【Chemistry 2】 During the ceremony, Lv 1 and Lv 2 are thiol reactive groups and are independently selected from: 【Chemistry 3】 【change】 【change】 【change】 【change】 During the ceremony, X 1 ' and X 2 ' are independently F, Cl, Br, I, OTf, OMs, OC 6 H 4 (NO 2 ), O.C. 6 H 3 (NO 2 ) 2 , O.C. 6 F 5 , O.C. 6 H.F. 4 , or Lv 3 is; 2 is O, NH, N(R 1 ), or C.H. 2 is; R 3 and R 5 are independently H, R 1 , aromatic, heteroaromatic, or aromatic group, and one or several H atoms are independently selected from -R 1 , -halogen, -OR 1 , -SR 1 , -NR 1 R 2 , -NO 2 , -S(O)R 1 , -S(O) 2 R 1 , or -COOR 1 is replaced by; 3 and Lv 3 ' is independently a leaving group selected from F, Cl, Br, I, nitrophenoxyl, N-hydroxysuccinimide (NHS), phenoxyl, benzenethiol, dinitrophenoxyl, pentafluorophenoxyl, tetrafluorophenoxyl, difluorophenoxyl, monofluorophenoxyl, pentachlorophenoxyl, triflate, imidazole, dichlorophenoxyl, tetrachlorophenoxyl, 1-hydroxybenzotriazole, tosylate, mesylate, 2-ethyl-5-phenylisoxazolium-3'-sulfonate, anhydrides formed with themselves or other anhydrides, acetyl anhydride, formyl anhydride, or an intermediate molecule generated with a condensation reagent for a peptide coupling reaction or a Mitsunobu reaction; In formula (II) and formula (III), 【Chemistry 4】 can be selected from: 【Chemistry 5】 【change】 【change】 【change】 【change】 In the formula, Lv 3 , Lv 3 ', X 1 ', and X 2 ' is as above; the bond in the middle of two atoms 【Chemistry 6】 means that it can bond to either of the two atoms; L 1 and L 2 are the same or different, and each independently represents O, NH, S, NHNH, N(R 3 ), N(R 3 ) N (R 3 '), or the formula (OCH 2 CH 2 ) p OR 3 , (OCH 2 CH (CH 3 )) p OR 3 , NH(CH 2 CH 2 O) p OR 3 , NH(CH 2 CH (CH 3 ) O) pR3 p OR 3 , N[(CH 2 CH 2 O) p R 3 ][(CH 2 CH 2 O) p’ R 3’ ], (OCH 2 CH 2 ) p COOR 3 , or C.H. 2 CH 2 (O.C.H. 2 CH 2 ) p COOR 3 where p and p′ are independently an integer selected from 0 to about 1000, or a combination thereof; 1 -C 8 Alkyl; C 2 -C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 -C 8 aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; 3 and R 3’ are independently H, C 1 -C 8 Alkyl; C 2 -C 8 heteroalkyl, alkylcycloalkyl, aryl of heterocycloalkyl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, or amide having 1 to 8 carbon atoms; or 1 to 8 natural or unnatural amino acids as described in the definitions; or a group of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 0 to about 1000, or a combination thereof; L 1 Or L 2 may contain self-immolative or non-self-immolative moieties, peptidyl units, hydrazone bonds, disulfide, ester, oxime, amide, or thioether bonds, said self-immolative units including aromatic compounds electronically similar to para-aminobenzylcarbamoyl (PAB) groups, including 2-aminoimidazole-5-methanol derivatives, heterocyclic PAB analogs, β-glucuronides, and ortho- or para-aminobenzyl acetals; The self-immolative linker moiety has any of the following structures: 【Chemistry 7】 In the formula, ( * Atoms labeled with X are points of attachment to additional spacers, releasable linker units, cytotoxic agents, and / or cell binding molecules (CBAs); 1 , Y 1 , Z 2 , and Z 3 is independently NH, O or S; Z 1 is independently H, NH, O, or S; v is 0 or 1; U 1 are independently H, OH, C 1 -C 6 Alkyl, (OCH 2 CH 2 ) n ,F,Cl,Br,I,OR 5 , S.R. 5 , N.R. 5 R 5’ , N=NR 5 , N=R 5 , N.R. 5 R 5’ , NO 2 , SOR 5 R 5’ , S.O. 2 R 5 , S.O. 3 R 5 , OSO 3 R 5 , P.R. 5 R 5’ , P.O.R. 5 R 5’ , P.O. 2 R 5 R 5’ , OPO (OR 5 ) (OR 5’ ), or OCH 2 PO (OR 5 ) (OR 5’ ) in which R 5 and R 5’ is as defined above; preferably R 5 and R 5’ are independently H, C 1 -C 8 Alkyl; C 2 -C 8 Alkenyl, alkynyl, heteroalkyl; 3 -C 8 aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl; or a medicinal cationic salt; The non-self-immolative linker moiety has any of the following structures: 【Chemistry 8】 【change】 In the formula, ( * ) are atoms marked with an additional spacer R 1 , a releasable linker unit, a cytotoxic agent, and / or a point of attachment to a binding molecule; X 1 , Y 1 , U 1 , R 5 , R 5’ is as defined above; r is 0 to 100; m and n are independently 0 to 6; L 1 Or L 2 may be comprised of one or more linker moieties which are 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP"), valine-citrulline ("val-cit" or "vc"), alanine-phenylalanine ("ala-phe" or "af"), p-aminobenzyloxycarbonyl ("PAB"), 4-thiopentanoic acid ("SPP"), 4-(N-maleimidomethyl)cyclohexane-1 carboxylate ("MCC"), (4-acetyl)aminobenzoic acid ("SIAB"), 4-thiobutyric acid (SPDB), 4-thio-2-hydroxysulfonylbutyric acid (2-sulfo-SPDB), or a natural or unnatural peptide having from 1 to 8 natural or unnatural amino acid units. L 1 Or L 2 may be a releasable conjugate. The term releasable conjugate refers to a conjugate that includes at least one bond that can be broken down under physiological conditions, such as pH-labile, acid-labile, base-labile, oxidatively labile, metabolically labile, biochemically labile, or enzymatically labile. Physiological conditions that cause the breakdown of such bonds do not necessarily include biological or metabolic processes, but may instead include standard chemical reactions, such as hydrolysis or substitution reactions, e.g., disulfide bond exchange reactions with intracellular thiols such as glutathione, which is abundant in the millimolar range in endosomes, which have a lower pH than the cytosolic pH, and / or in malignant cells. The releasable connector (L 1 Or L 2 Examples of -(CR) 5 R 6 ) m (A) r (CR) 7 R 8 ) n (OCH) 2 CH 2 ) t -、-(CR 5 R 6 ) m (CR) 7 R 8 ) n (A) r (OCH) 2 CH 2 ) t -、-(A]) r -(CR) 5 R 6 ) m (CR) 7 R 8 ) n (OCH) 2 CH 2 ) t -、-(CR 5 R 6 ) m (CR) 7 R 8 ) n (OCH) 2 CH 2 ) r (A) t -、-(CR 5 R 6 ) m -(CR) 7 =CR 8 )(CR 9 R 10 ) n (A) t (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (NR) 11 CON t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (A) t (NR) 11 CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (O) (A) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (OCNR) 7 )(Aa) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (C) (A) t -(CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m (NR) 11 CON t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-(CR 5 R 6 ) m -(O・)(Aq) t (CR) 9 R 10 ) n -(OCH 2 CH 2 ) r -、-(CR 5 R 6 ) m (OCNR 7 ) (Aa) t (CR 9 R 10 ) n (O.C.H. 2 CH 2 ) r -, - (CR 5 R 6 ) m (CO) (Aa) t (CR 9 R 10 ) n (O.C.H. 2 CH 2 ) r -, - (CR 5 R 6 ) m -phenyl-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) m -furyl-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) m -oxazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) m -Thiazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) t -Thienyl-(CO)(CR 7 R 8 ) n -, - (CR 5 R 6 ) t -imidazolyl-(CO)(CR 7 R 8 ) n -, - (CR 5 R 6 ) t -Morpholino-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) t -piperazino-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) t -N-methylpiperazine-(CO)(Aa) t (CR 7 R 8 ) n -, - (CR 5 R 6 ) m -(Aa) t Phenyl-, -(CR 5 R 6 ) m -(Aa) t Frill-,-(CR 5 R 6 ) m -Oxazolyl (Aa) t -, - (CR 5 R 6 ) m -Thiazolyl (Aa) t -, - (CR 5 R 6 ) m -Thienyl (Aa) t -, - (CR 5 R 6 ) m -Imidazolyl (Aa) t -, - (CR 5 R 6 ) m -Morpholino-(Aa) t -, - (CR 5 R 6 ) m -Piperazino- (Aa) t -, - (CR 5 R 6 ) m -N-methylpiperazino- (Aa) t -, -K(CR 5 R 6 ) m (A) r (CR) 7 R 8 ) n (OCH) 2 CH 2 ) t -、-K(CR 5 R 6 ) m (CR) 7 R 8 ) n (A) r (OCH) 2 CH 2 ) t -、-K(Aa) r (CR) 5 R 6 ) m (CR) 7 R 8 ) n (OCH) 2 CH 2 ) t -、-K(CR 5 R 6 ) m (CR) 7 R 8 ) n (OCH) 2 CH 2 ) r (A) t -、-K(CR 5 R 6 ) m (CR) 7 =R 8 )(CR 9 R 10 ) n (A) t (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (NR) 11 CON t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (A) t (NR) 11 CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (O) (A) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (OCNR) 7 )(Aa) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (C) (A) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (NR) 11 CON t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (O) (A) t (CR) 9 R 10 ) n (OCH) 2 CH 2 ) r -、-K(CR 5 R 6 ) m (OCNR 7 ) (Aa) t (CR 9 R 10 ) n (O.C.H. 2 CH 2 ) r -, -K(CR 5 R 6 ) m (CO) (Aa) t (CR 9 R 10 ) n (O.C.H. 2 CH 2 ) r -, -K(CR 5 R 6 ) m -phenyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -furyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -oxazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -Thiazolyl-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -Thienyl-(CO)(CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -imidazolyl-(CO)(CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -Morpholino-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -piperazino-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) t -N-methylpiperazine-(CO)(Aa) t (CR 7 R 8 ) n -, -K(CR 5 R 6 ) m -(Aa) t Phenyl-, -K(CR 5 R 6 ) m -(Aa) t Frill-, -K (CR 5 R 6 ) m -Oxazolyl (Aa) t -, -K(CR 5 R 6 ) m -Thiazolyl (Aa) t -, -K(CR 5 R 6 ) m -Thienyl (Aa) t -, -K(CR 5 R 6 ) m -Imidazolyl (Aa) t -, -K(CR 5 R 6 ) m -Morpholino-(Aa) t -, -K(CR 5 R 6 ) m -Piperazino- (Aa) t G-, -K (CR 5 R 6 ) m -N-methylpiperazino- (Aa) t ; In the formula, m, Aa, m, n, R 3 , R 4 , and R 5 are defined above; t and r are independently 0 to 100; R 6 , R 7 , and R 8 are independently H; halide; C 1 ~C 8 selected from alkyl, aryl, alkenyl, alkynyl, ether, ester, amine, or amide; 1 R 2 , C.F. 3 , OR 1 , aryl, heterocycle, S(O)R 1 , S.O. 2 R 1 , -CO 2 H, -SO 3 H, -OR 1 , -CO 2 R 1 , -CONR 1 , -PO 2 R 1 R 12 , -PO 3 H or P(O)R 1 R 2 R 3’ K is optionally substituted with NR 1 , -SS-, -C(=O)-, -C(=O)NH-, -C(=O)O-, -C=NH-O-, -C=N-NH-, -C(=O)NH-NH-, O, S, Se, B, or C 3 ~C 6 It is a heteroaromatic ring. The connector L 1 and L 2 The structure may be the following structures or combinations thereof: 【Chemistry 9】 【change】 【change】 【change】 【change】 【change】 【change】 X 2 , X 3 , X 4 , X 5 , or X 6 are independently NH, NHNH; N(R 12 );N(R 12 ) N (R 12’ );O;S;C 1 ~C 6 Alkyl; C 2 ~C 6 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; CH 2 OR 12 , C.H. 2 S.R. 12 , C.H. 2 NHR 12 or 1 to 8 amino acids; 12 and R 12’ are independently H; C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, or amide having 1 to 8 carbon atoms; or a group of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 0 to about 100; or a combination thereof; Furthermore, L 1 , L 2 , X 1 , X 2 , X 3 , X 1’ , X 2’ , and X 3’ may each independently be absent; E 1 Lv 1 and Lv 2 is a linking group connecting two thiol-reactive groups of E 1 , CH, CH 2 , NH, NHNH, N(R 3 ), N(R 3 ) N (R 3’ ), N=N, N-N, P, P(=O), S, Si, C 2 ~C 8 Alkyl, heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; a peptide comprising 1 to 4 units of an amino acid, preferably aspartic acid, glutamic acid, arginine, histidine, lysine, serine, threonine, asparagine, glutamine, cysteine, selenocysteine, tyrosine, phenylalanine, glycine, proline, tryptophan, alanine; or any of the following structures: 【Chemistry 10】 【change】 D is a cytotoxic agent, a therapeutic agent, an immunotherapeutic short antibody-like protein, or a functional molecule for enhancing the binding or stability of a cell-binding antibody-like protein agent, a cell surface receptor binding ligand, an antibody fragment, an siRNA, or a DNA molecule, preferably selected from: 1) Chemotherapeutic agents: a) alkylating agents selected from the group consisting of: nitrogen mustards: chlorambucil, chlornaphazine, cyclophosphamide, dacarbazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, mannomustine, mitobronitol, melphalan, mitolactol, pipobroman, nobembitine, phenesterine, prednimustine, thiotepa, trofosfamide, uracil mustard; CC-1065 and synthetic analogs of adozelesin, carzelesin and bizeresin; duocarmycin and its synthetic analogs KW-2189 and CBI-TMI; benzodiazepine dimers or pyrrolobenzodiazepine (PBD) dimers, tomaymycin dimers, indolinobenzodiazepine dimers. benzodiazepines, imidazobenzothiadiazepine dimers, or oxazolidinobenzodiazepine dimers; nitrosourea compounds including carmustine, lomustine, chlorozotocin, fotemustine, nimustine, ranimustine; alkylsulfonates including busulfan, treosulfan, improsulfan, and piposulfan; triazenes or dacarbazines; platinum-containing compounds including carboplatin, cisplatin, and oxaliplatin; aziridines, benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramine, trimethylolomelamine; b) plant alkaloids selected from the group consisting of: vinca alkaloids including vincristine, vinblastine, vindesine, vinorelbine, navelbine; taxoids including paclitaxel and docetaxel and analogs thereof; maytansinoids including DM1, DM2, DM3, DM4, DM5, DM6, DM7, maytansine, ansamitocins and analogs thereof; cryptophycins including the cryptophycin 1 and cryptophycin 8 groups; epothilones, eleutherobin, discodermolide, bryostatins, dolostatins, auristatins, tubulysins, cephalostatins; pancratistatin; sarcodictiin; spongistatin; c) DNA topoisomerase inhibitors selected from: epipodophyllins, including 9-aminocamptothecin, camptothecin, crisnatol, daunomycin, etoposide, etoposide phosphate, irinotecan, mitoxantrone, novantrone, retinoic acid (retinols), teniposide, topotecan, 9-nitrocamptothecin or RFS2000; and mitomycins and their analogs; d) Antimetabolites: {[Antifolates: (DHFR inhibitors: including methotrexate, trimetrexate, denopterin, pteropterin, aminopterin (4-aminopteroic acid), or other folate analogs); IMP dehydrogenase inhibitors (including mycophenolic acid, tiazofurin, ribavirin, EICAR); Ribonucleotide reductase inhibitors (including hydroxyurea, deferoxamine)]; [Pyrimidine analogs: uracil uridine analogs (including ancitabine, azacitidine, 6-azauridine, capecitabine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, 5-fluorouracil, floxuridine, raltitrexed); cytosine analogs: (including cytarabine, cytosine arabinoside, fludarabine); purine analogs: (including azathioprine, fludarabine, mercaptopurine, thiamiprine, thioguanine); folic acid supplements such as folinic acid}; e) Hormonal Therapy: Receptor Antagonists: [Antiestrogens: (including megestrol, raloxifene, tamoxifen); LHRH Agonists: (including goserelin, leuprolide acetate); Antiandrogens: (including bicalutamide, flutamide, calsterone, dromostanolone propionate, epithiostanol, goserelin, leuprolide, mepitiostane, nilutamide, testolactone, trilostane, and other similar androgen inhibitors. retinoids / deltoid: [vitamin D3 analogs: (including CB1093, EB1089, KH1060, cholecalciferol, ergocalciferol); photodynamic therapy agents: (including verteporfin, phthalocyanines, photosensitizer Pc4, demethoxyhypocrelin A); cytokines: (including interferon alpha, interferon gamma, tumor necrosis factor (TNF), TNF domain-containing human proteins)]}; f) Kinase inhibitors: selected from the group consisting of BIBW2992 (anti-EGFR / Erb2), imatinib, gefitinib, pegaptanib, sorafenib, dasatinib, sunitinib, erlotinib, nilotinib, lapatinib, axitinib, pazopanib, vandetanib, E7080 (anti-VEGFR2), mubritinib, ponatinib, bafetinib, bosutinib, cabozantinib, vismodegib, iniparib, ruxolitinib, CYT387, axitinib, tivozanib, sorafenib, bevacizumab, cetuximab, trastuzumab, ranibizumab, panitumumab, ispinesib; g) a poly(ADP-ribose)polymerase (PARP) inhibitor selected from the group consisting of olaparib, niraparib, iniparib, talazoparib, veliparib, CEP9722 (Cephalon), E7016 (Eisai), BGB-290 (Beigene), or 3-aminobenzamide; h) enediyne antibiotics (selected from the calicheamicins, calicheamicin gamma 1, delta 1, alpha 1, or beta 1; dynemicins including dynemicin A and deoxydynemicin; esperamicin, kedarcidin, C-1027, maduropeptin, or neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomycins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin; chromomycins, dactinomycin, daunomycin, Antibiotics selected from rubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin, epirubicin, eribulin, esorubicin, idarubicin, marcelomycin, nitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potofilomycin, puromycin, queramycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; i) Polyketides (acetogenins), bullatacin and bullatacinone; gemcitabine, epoxomicins and carfilzomib, bortezomib, thalidomide, lenalidomide, pomalidomide, tosedostat, zybrestat, PLX4032, STA-9090, Stimuvax, allovectin-7, zygeva, probenge, elvoy, isoprenylation inhibitors and lovastatin, dopaminergic neurotoxins and 1-methyl-4-phenyl Pyridine ion, cell cycle inhibitors (including staurosporine), actinomycins (including actinomycin D and dactinomycin), amanitins, bleomycins (including bleomycin A2, bleomycin B2, and peplomycin), anthracyclines (including daunorubicin, doxorubicin (adriamycin), idarubicin, epirubicin, pirarubicin, and zorubicin), mitoxantrone, MDR inhibitors or verapamil, Ca 2+ ATP inhibitors or thapsigargin, histone deacetylase inhibitors (including vorinostat, romidepsin, panobinostat, valproic acid, mocetinostat (MGCD0103), belinostat, PCI-24781, entinostat, SB939, resminostat, gibinostat, AR-42, CUDC-101, sulforaphane, trichostatin A); thapsigargin, celecoxib, glitazones, epigallocatechin gallate, disulfiram, salinosporamide A, anti-adrenal drugs (selected from the group consisting of aminoglutethimide, mitotane, trilostanca); aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; arabinoside, bestravsil; bisanto len; edatrexate; defofamine; demecolcine; diaziquone; elfornitine (DFMO), elfomitine; elliptinium acetate; etocurside, gallium nitrate, gacytosine, hydroxyurea; ibandronate, lentinan; lonidamine; mitoguazone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllic acid; 2-ethylhydrazide; procarbazine; PSK (registered trademark); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2''-trichlorotriethylamine; trichothecenes (including T2 toxin, verrucarin A, roridin A, and anguidine); urethane, siRNA, antisense medicines, nucleases; 2) Anti-autoimmune disease drugs: cyclosporine, cyclosporine A, aminocaproic acid, azathioprine, bromocriptine, chlorambucil, chloroquine, cyclophosphamide, corticoids (including amcinonide, betamethasone, budesonide, hydrocortisone, flunisolide, fluticasone propionate, fluocortolone danazol, dexamethasone, triamcinolone acetonide, and beclomethasone dipropionate), DHEA, etanercept, hydroxychloroquine, infliximab, meloxicam, methotrexate, mofetil, mycophenolic acid, prednisone, sirolimus, and tacrolimus; 3) Anti-infectives, including but not limited to: a) Aminoglycosides: amikacin, astromycin, gentamicin (netilmicin, sisomicin, isepamicin), hygromycin B, kanamycin (amikacin, arbekacin, bekanamycin, dibekacin, tobramycin), neomycin (framycin, paromomycin, ribostamycin), netilmicin, spectinomycin, streptomycin, tobramycin, verdamycin; b) Amphenicols: azidamphenicol, chloramphenicol, florfenicol, thiamphenicol; c) Ansamycins: geldanamycin, herbimycin; d) Carbapenems: biapenem, doripenem, ertapenem, imipenem, cilastatin, meropenem, panipenem; e) Cephalosporins: carbacephems (loracarbef), cephacetrile, cefaclor, cephradine, cefadroxil, cephalonium, cephaloridine, cephalothin or cephalothin, cephalexin, cephaloglycin, cefamandole, cephapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefbuperazone, cefcapene, cefdaloxime, cefepime, cefminox, cefoxitin, cefprozil, cefroxadine, ceftezole, cefuroxime, cefixime, cefdinir, cefditoren, cefepime, Fetameth, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefozopran, cephalexin, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefprozil, cefquinome, cefsulodin, ceftazidime, cefteram, ceftibuten, ceftiolene, ceftizoxime, ceftobiprol, ceftriaxone, cefuroxime, cefuzonam, cephamycins (including cefoxitin, cefotetan, cefmetazole), oxacephems (flomoxef, latamoxef); f) Glycopeptides: bleomycin, vancomycin (including oritavancin, telavancin), teicoplanin (dalbavancin), ramoplanin; g) Glycylcyclines: Tigecycline; h) β-lactamase inhibitors: penams (sulbactam, tazobactam), clavams (clavulanic acid); i) Lincosamides: clindamycin, lincomycin; j) Lipopeptides: daptomycin, A54145, calcium-dependent antibiotic (CDA); k) Macrolides: azithromycin, cethromycin, clarithromycin, dirithromycin, erythromycin, flurithromycin, josamycin, ketolides (telithromycin, cethromycin), midecamycin, miokamicin, oleandomycin, rifamycin (rifampicin, rifampin, rifabutin, rifapentine), rokitamycin, roxithromycin, spectinomycin, spiramycin, tacrolimus (FK506), troleandomycin, telithromycin; l) Monobactams: aztreonam, tigemonam; m) Oxazolidinones: Linezolid; n) Penicillins: amoxicillin, ampicillin, pivampicillin, hetacillin, bacampicillin, methampicillin, talampicillin, azidocillin, azlocillin, benzylpenicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, clometocillin, procaine benzylpenicillin, carbenicillin (carindacillin), cloxacillin, dicloxacillin, epicillin, flucloxacillin, mecillinam (pivmecillinam), mezlocillin, methicillin, nafcillin, oxacillin, penamecillin, penicillin, phenethicillin, phenoxymethylpenicillin, piperacillin, propicillin, sulbenicillin, temocillin, ticarcillin; o) Polypeptides: bacitracin, colistin, polymyxin B; p) quinolones: alatrofloxacin, balofloxacin, ciprofloxacin, clinafloxacin, danofloxacin, difloxacin, enoxacin, enrofloxacin, floxin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, canotrovafloxacin, levofloxacin, lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, orbifloxacin, ofloxacin, pefloxacin, trovafloxacin, grepafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, trovafloxacin; q) Streptogramins: pristinamycin, quinupristin / dalfopristin; r) Sulfonamides: mafenide, prontosil, sulfacetamide, sulfamethizole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, trimethoprim-sulfamethoxazole (co-trimoxazole); s) Steroidal antibacterial agents: fusidic acid, etc.; t) Tetracyclines: doxycycline, chlortetracycline, clomocycline, demeclocycline, lymecycline, meclocycline, methacycline, minocycline, oxytetracycline, penimepicycline, rolitetracycline, tetracycline, glycylcycline (such as tigecycline); u) Other antibiotics: annonacin, arsphenamine, bactoprenol inhibitors (bacitracin), DADAL / AR inhibitors (cycloserine), dictyostatin, discodermolide, eleutherobin, epothilone, ethambutol, etoposide, faropenem, fusidic acid, furazolidone, isoniazid, laulimalide, metronidazole, mupirocin, mycolactone, NAM synthesis inhibitors (fosfomycin), nitrofurantoin, paclitaxel, platensimycin, pyrazinamide, quinupristin / dalfopristin, rifampicin (rifampin), tazobactamcinidazole, uvaricin; 4) Antiviral drugs: a) Entry / fusion inhibitors: aplaviroc, maraviroc, vicriviroc, gp41 (enfuvirtide), PRO140, CD4 (ibalizumab); b) Integrase inhibitors: raltegravir, elvitegravir, globoidnan A; c) Maturation inhibitors: Bevirimat, Vivecon; d) Neuraminidase inhibitors: oseltamivir, zanamivir, peramivir; e) Nucleosides and Nucleotides: Abacavir, Acyclovir, Adefovir, Amdoxovir, Apricitabine, Brivudine, Cidofovir, Clevudine, Dexerbucitabine, Didanosine (DDI), Elvucitabine, Emtricitabine (FTC), Entecavir, Famciclovir, Fluorouracil (5-FU), 3'-Fluoro substituted 2',3'-deoxynucleoside analogues (e.g., 3'-Fluoro-2',3'-dideoxythymidine (FLT) and 3'-Fluoro-2',3'-deoxythymidine (FLT), 3'-Fluoro-2',3'-deoxy-3'-pyridin ... dideoxyguanosine (FLG), fomivirsen, ganciclovir, idoxuridine, lamivudine (3TC), L-nucleosides (e.g., including the group consisting of β-L-thymidine and β-L-2'-deoxycytidine), penciclovir, rasvir, ribavirin, stampidine, stavudinecet (d4T), taribavirin (viramidine), telbivudine, tenofovir, trifluridine, valacyclovir, valganciclovir, zalcitabine (ddC), zidovudine (AZT); f) Non-nucleosides: amantadine, ateviridine, capravirine, diarylpyrimidines (etravirine, rilpivirine), delavirdine, docosanol, emivirine, efavirenz, foscarnet (phosphorylformate), imiquimod, interferon alpha, loviride, rhodenosine, methisazone, nevirapine, NOV-205, peginterferon alpha, podophyllotoxin, rifampicin, rimantadine, resiquimod (R-848), tromantadine; g) Protease inhibitors: amprenavir, atazanavir, boceprevir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, pleconaril, ritonavir, saquinavir, telaprevir (VX-950), tipranavir; h) Other antivirals: abzyme, arbidol, calanolide A, ceragenin, cyanovirin-N, diarylpyrimidine, epigallocatechin gallate (EGCG), foscarnet, griffithsin, taribavirin (viramidine), hydroxyurea, KP-1461, miltefosine, pleconaril, portmanteau inhibitors, ribavirin, seliciclib; (5) The drugs used in the conjugates prepared according to the present invention also include radioisotopes. Examples of radioisotopes (radionuclides) are: 3 H. 11 C. 14 C. 18 F. 32 P. 35 S. 64 Cu, 68 G.A. 86 Y. 99 Tc, 111 In, 123 I, 124 I, 125 I, 131 I, 133 Xe, 177 Lu, 211 At, or 213 Bi; (6) Pharmaceutically acceptable salts, acids, or derivatives of any of the above drugs.
6. Thiol groups in the antibody or antibody-like protein produced by the method of claim 1 are independently reacted, simultaneously or sequentially, with a drug / conjugate of formula (I), (II), or (III) to form a conjugate of formula (V), (VI), or (VII) as shown below: 【Chemistry 11】 During the ceremony, n is 1 to 20; n' is 1 to 10; preferably, n is 1 to 8 and n' is 1 to 4; more preferably, n is 2 to 4 and n' is 1 to 2; D 1 , D 2 , L 1 , L 2 , and E 1 is the same as defined above; S (sulfur) is generated by the reduction of a specific disulfide bond in an antibody or antibody-like protein under the conditions of the method of the present invention; mAb is an antibody or antibody-like protein; Lv 1’ and Lv 2’ is a thiol in the mAb, the thiol being Lv of the structure defined in claim 5; 1 and Lv 2 is a group obtained by reacting with Lv 1’ and Lv 2’ independently have the structure: 【Chemistry 12】 In the formula, X 2’ and R 3 has the same definition as in claim 5; In formula (VI) and formula (VII), 【Chemistry 13】 can independently be selected from: 【Chemistry 14】 【change】 【change】 【change】 In the formula, R 1 , R 2 , and X 2 has the same definition as above; mAb is an antibody or antibody-like protein, preferably said conjugate specifically binds to a thiol between the heavy and light chains of said antibody.
7. In the conjugation process, a thiol group in the antibody or antibody-like protein produced by the method of claim 1 is conjugated to a condensation compound represented by the following formula (VIII), (IX), or (X) and independently a drug D 1 And / or D 2 simultaneously or sequentially to form a conjugate of formula (V), (VI), or (VII): 【Chemistry 15】 During the ceremony, L 1 , L 2 , E 1 , Lv 1 , and Lv 2 is defined as above for formula (I), (II), and (III); 1 And / or D 2 The condensation reaction with can be carried out in a separate reaction pot; Lv 5 and Lv 6 is independently selected from: 【Chemistry 16】 【change】 During the ceremony, X1' is F, Cl, Br, I, OTs (tosylate), OTf (triflate), OMs (mesylate), OC 6 H 4 (NO 2 ), O.C. 6 H 3 (NO 2 ) 2 , O.C. 6 F 5 , O.C. 6 H.F. 4 , or Lv 3 is; 2’ is O, NH, N(R 1 ), or C.H. 2 is; R 3 and R 5 are independently H, R 1 , aromatic, heteroaromatic, or one or several H atoms are independently -R 1 , -halogen, -OR 1 , -SR 1 , -NR 1 R 2 , -NO 2 , -S(O)R 1 , -S(O) 2 R 1 , or -COOR 1 Lv is an aromatic group substituted by 3 and Lv 3’ are independently a leaving group selected from F, Cl, Br, I, nitrophenoxyl; N-hydroxysuccinimide (NHS); phenoxyl; benzenethiol, dinitrophenoxyl; pentafluorophenoxyl; tetrafluorophenoxyl; difluorophenoxyl; monofluorophenoxyl; pentachlorophenoxyl; triflate; imidazole; dichlorophenoxyl; tetrachlorophenoxyl; 1-hydroxybenzotriazole; tosylate; mesylate; 2-ethyl-5-phenylisoxazolium-3′-sulfonate, anhydrides formed with themselves or with other anhydrides selected from acetyl anhydride and formyl anhydride, or intermediate molecules generated with condensation reagents for peptide coupling reactions or Mitsunobu reactions; 1 Or Lv 2 and the thiol in the antibody or antibody-like protein, the functional group Lv 5 And / or Lv 6 can also react with thiols in cytotoxic agents.
8. In the conjugation method, a thiol group in the antibody or antibody-like protein produced by the method of claim 1 is reacted simultaneously or independently sequentially with the formula (VIII), (IX), or (X) shown in claim 7 to form the following formula (XI), (XII), or (XIII), and then a drug D is added to the reaction mixture. 1 Or D 2 to form a conjugate of formula (V), (VI), or (VII): 【Chemistry 17】 In the formula, Lv 5 , Lv 6 , L 1 , L 2 , E 1 , Lv 1’ , Lv 2’ , mAb, n, and n' are as defined above.
9. The drug D according to claim 6, 7 or 8 1 and D. 2 are chromophore molecules capable of absorbing UV light, fluorescent light, IR light, near-IR light, visible light; xanthophores, erythrophores, iridophores, leucophores, melanophores, cereophores; a class or subclass of fluorescent molecules, which are fluorescent chemicals that re-emit light with light; a class or subclass of visual light sensitive molecules; a class or subclass of light emitting molecules; a class or subclass of luminescent molecules; and a class or subclass of luciferin compounds. Thus, the conjugates can be used to detect, monitor, or study the interaction of the cell binding molecule with a target cell; Chromophore molecules include the following non-proteinaceous organic fluorophores: xanthene derivatives (including fluorescein, rhodamine, Oregon Green, eosin, and Texas Red); cyanine derivatives (including cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, and merocyanine); squalene derivatives and ring-substituted squaraines (including Seta, SeTau, and Square dyes); naphthalene derivatives (including dansyl and prodan derivatives); coumarin derivatives; oxadiazole derivatives (including pyridyloxazole, nitrobenzoxadiazole, and benzoxadiazole); anthracene derivatives (including anthraquinones, including DRAQ5, DRAQ7, and CyTRAK Orange); pyrene derivatives (cascade blue); oxazine derivatives (including Nile red, Nile blue, cresyl violet, oxazine 170); acridine derivatives (including proflavine, acridine orange, acridine yellow). Arylmethine derivatives (including auramine, crystal violet, and malachite green). Selected from tetrapyrrole derivatives (including porphines, phthalocyanines, bilirubins); The chromophore molecules can be selected from analogs and derivatives of the following fluorophore compounds: CF dyes, DRAQ and CyTRAK probes, BODIPY, Alexa Fluor, DyLight Fluor, Atto and Trancey, FluoProbes, Abberior dyes, DY and MegaStokes dyes, SulfoCy dyes, HiLyte Fluor, Seta, SeTau and Square dyes, Quasar and Cal. Flour dyes, SureLight dyes (APC, RPEPerCP, phycobilisome), APC, APCXL, RPE, BPE, allophycocyanin (APC), aminocoumarin, APC-Cy7 conjugates, BODIPY-FL, Cascade Blue, Cy2, Cy3, Cy3.5, Cy3B, Cy5, Cy5.5, Cy7, fluorescein, FluorX, hydroxycoumarin, Lissamine rhodamine B, Lucifer Yellow, methoxycoumarin, NBD, Pacific Blue, Pacific Orange, PE-Cy5 conjugate, PE-Cy7 conjugate, PerCP, R-Phycoerythrin (PE), Red613, Seta-555-azide, Seta-555-DBCO, Seta-555-NHS, Seta-580-NHS, Seta-680-NHS, Seta-780-NHS, Seta-APC-780, Seta-PerCP-680, Seta-R-PE-670, SeTau380-NHS, SeTau405-maleimide, SeTau405-NHS, SeTau425-NHS, SeTau647-NHS, Texas Red, TRITC, T ruRed, X-rhodamine, 7-AAD (7-aminoactinomycin D, CG selective), acridine orange, chromomycin A3, CyTRAK orange (red excitation dark), DAPI, DRAQ5, DRAQ7, ethidium bromide, Hoechst 33258, Hoechst 33342, LDS751, mithramycin, propidium iodide (PI), SYTOX blue, SYTOX green, SYTOX orange, thiazole orange, TO-PRO: cyanine monomer, TOTO-1, TO-PRO-1, TOTO-3, TO-PRO-3, YOYO-1, YO-1;Fluorescent dyes including the following compounds or their derivatives: DCFH (2′7′-dichlorodihydro-fluorescein, oxidized form), DHR (dihydrorhodamine 123, oxidized form, photocatalytic oxidation), Fluo-3 (AM ester, pH>6), Fluo-4 (AM ester, pH 7.2), Indo-1 (AM ester, low / high calcium (Ca; 2+ )), SNARF (pH 6 / 9), Allophycocyanin (APC), AmCyan1 (tetramer, Clontech), AsRed2 (tetramer, Clontech), Azami Green (monomer), Azurite, B-Phycoerythrin (BPE), Cerulean, CyPet, DsRed monomer (Clontech), DsRed2 ("RFP"), EBFP, EBFP2, ECFP, EGFP (weak dimer), Emerald (weak dimer), EYFP (weak dimer), GFP (S65A mutant), GFP (S65C mutant), GFP (S65L mutant), GFP (S65T mutant), GFP (Y66F mutant), GFP (Y66H mutant), GFP (Y66W mutant), GFP uv , HcRed1, J-Red, Katyusha, Kusabira Orange (monomer, MBL), mCFP, mCherry, mCitrine, Midriishi Cyan (dimer, MBL), mKate (TagFP635, monomer), mKeima-Red (monomer), mKO, mOrange, mPlum, mRaspberry, mRFP1 (monomer), mStrawberry, mTFP1, mTurquoise2, P3 (phycobilisome complex), Peridinin Chlorophyll (PerCP), R-phycoerythrin (RPE), T-Sapphire, TagCFP (dimer), TagGFP (dimer), TagRFP (dimer), TagYFP (dimer), tdTomato (tandem dimer), Topaz, TurboFP602 (dimer), TurboFP635 (dimer), TurboGFP (dimer), TurboRFP (dimer), TurboYFP635 (dimer), Venus, native GFP, YPet, Zs Green 1 (tetramer), Zs Yellow 1 (tetramer), and derivatives thereof.
10. The drug D according to claim 5 1 and D. 2 may independently be a polyalkylene glycol selected from poly(ethylene glycol) (PEG), poly(propylene glycol), and copolymers of ethylene oxide and propylene oxide; particularly preferred is PEG, and more particularly preferred is monofunctionally activated hydroxyPEG (e.g., hydroxyPEG activated at one end, including hydroxyPEG-monocarboxylic acid, hydroxyPEG-monoaldehyde, hydroxyPEG-monoamine, hydroxyPEG-monohydrazide, hydroxyPEG-monocarbazide, hydroxyPEG-monoiodoacetamide, hydroxyPEG-monomaleimide, hydroxyPEG-orthopyridine disulfide, hydroxyPEG-monoxime, hydroxyPEG-monophenylcarbonate, hydroxyPEG-monophenylglyoxal, hydroxyPEG-monothiazolidine-2-thione, hydroxyPEG-monothioester, hydroxyPEG-monothiol, hydroxyPEG-monotriazine, and hydroxyPEG-monovinylsulfone). The polyalkylene glycol has a molecular weight of about 10 Daltons to about 200 kDa, and the conjugate can be used to extend the half-life of the antibody or antibody-like protein molecule when administered to a mammal.
11. The drug D according to claim 6, 7 or 8 1 and D. 2 are selected from the group consisting of tubulysin and its analogues, maytansine and its analogues, taxanes and its analogues, CC-1065 and its analogues, daunorubicin or doxorubicin and its analogues, amatoxin and its analogues, benzodiazepine dimers (dimers of pyrrolobenzodiazepines (PBD), tomaymycin, anthramycin, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidinobenzodiazepines) and their analogues, calicheamicin and enediyne antibiotic analogues, actinomycin, and its analogs, azaserine and its analogs, bleomycin and its analogs, epirubicin and its analogs, tamoxifen and its analogs, idarubicin and its analogs, dolastatins and its analogs, auristatins (including monomethylauristatin (MMAE), MMAF, auristatin PYE, auristatin TP, auristatin 2-AQ, 6-AQ, EB (AEB), and EFP (AEFP)) and their analogs, combretastatins, duocarmycins and their analogs, camptothecins and and analogs thereof, geldanamycin and analogs thereof, methotrexate and analogs thereof, thiotepa and analogs thereof, vindesine and analogs thereof, vincristine and analogs thereof, hemiasterin and analogs thereof, nazmamide and analogs thereof, spliceostatin, pladienolide, microginin and analogs thereof, radiosumin and analogs thereof, alterobactin and analogs thereof, microsclerodermin and analogs thereof, theonellamide and analogs thereof, esperama isin and its analogs, PNU-159682 and its analogs, protein kinase inhibitors, MEK inhibitors, KSP inhibitors, nicotinamide phosphoribosyltransferase (NAMPT) inhibitors, immunotoxins, specific cell receptor agonists, cell stimulatory or intracellular signaling molecules, one or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA), as well as stereoisomers, equivalents, analogs, or derivatives of the above-mentioned drugs; (a) Tubulysin and its analogs, or derivatives having one or more isotopes, or pharma- ceutically acceptable salts, hydrates, or hydrated salts, or polymorphic crystal structures, or optical isomers, racemates, diastereomers, or enantiomers thereof, having the following formula (IV): 【Chemistry 18】 During the ceremony, 【Chemistry 19】 is independent, L 1 And / or L 2 is a binding site that binds to; R 1 , R 2 , R 3 , and R 4 are independently H, C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl or heterocycle; C 3 ~C 8 Ar is aryl, Ar-alkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl; or R 1 R 2 , R 1 R 3 , R 2 R 3 , R 3 R 4 , R 5 R 6 , R 11 R 12 , or R 13 R 14 form a 3- to 7-membered carbocyclic, cycloalkyl, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system; L 1 Or L 2 When independently or simultaneously bound to R 1 and R 2 may be independently absent; R 5 , R 6 , R 8 , R 10 , and R 11 are independently H or C 1 ~C 4 alkyl or heteroalkyl; R 7 are independently H, R 14 , -R 14 C(=O)X 1 R 15 or -R 14 X 1 R 15 is; 1 is O, S, SS, NH, CH 2 , or NR 14 is; R 9 is H, OH, -O-, =O, -OR 14 , -OC(=O)R 14 , -OC(=O)NHR 14 -, -OC(=O)R 14 SSR 15 -, OP (=O) (OR 14 )-, -OC(=O)NR 14 R 15 ,OP(=O)(OR 14 ), or OR 14 OP(=O)(OR 15 ) selected from R 11 are independently H, R 1 , -R 14 C(=O)R 16 , -R 1 X 2 R 2 , -R 1 C(=O)X 2 wherein X 2 are -O-, -S-, -NH-, -N(R 2 ) -, -O-R 1 -, -S-R 1 -, -S(=O)-R 1 -, or -NHR 2 is; R 12 is R 1 , -OH, -SH, -NH 2 , N.H., N.H. 2 , -NH(R 15 ), -OR 15 , -R 15 C.O.R. 16 , -R 15 COOR 16 , -R 15 C(O)NH 2 , -R 15 C(O)NHR 17 , -SR 16 , R 15 S(=O)R 16 , -R 15 P(=O)(OR 17 ) 2 , -R 15 OP(=O)(OR 17 ) 2 , -CH 2 OP(=O)(OR 17 ) 2 , -R 15 SO 2 R 17 , -R 15 X 2 R 16 , -R 15 C(=O)X 2 wherein X 2 is -O-, OH, SH, -S-, NH 2 , -NH-, -N(R 15 ) -, -O-R 15 -, -S-R 15 -, -S(=O)-R 15 -, CH 2 or -NHR 15 - is; R 13 and R 14 are independently H, O, S, NH, N(R 15 ), NHNH, -OH, -SH, -NH 2 , N.H., N.H. 2 , -NH(R 15 ), -OR 15 , CO, -COX 2 , -COX 2 R 16 , R 17 ,F,Cl,Br,I,SR 16 , N.R. 16 R 17 , N=NR 16 , N=R 16 , NO 2 , S.O.R. 16 R 17 , S.O. 2 R 16 , S.O. 3 R 16 , OSO 3 R 16 , P.R. 16 R 17 , P.O.R. 16 R 17 , P.O. 2 R 16 R 17 , OP(O)(OR 17 ) 2 , O.C.H. 2 OP(O)(OR 17 ) 2 , O.C.(O)R 17 ,OC(O)OP(O)(OR 17 ) 2 , PO(OR 16 ) (OR 17 ), OP(O)(OR 17 ) OP (O) (OR 17 ) 2 , O.C.(O)N.R. 17 -O-(C 4 ~C 12 Glycoside), -N-(C 4 ~C 12 Glycoside); C 1 ~C 8 Alkyl, heteroalkyl; 2 ~C 8 Alkenyl, alkynyl, heteroalkyl, heterocycloalkyl; 3 ~C 8 Aryl, Ar-alkyl, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, or an ester, ether, or amide having 2 to 8 carbon atoms; or a peptide containing 1 to 8 amino acids (NH(Aa) 1~8 Or CO(Aa) 1~8 (N-terminus or C-terminus (Aa) r , r=1 to 8 identical or different amino acid sequences), or 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 0 to about 1000, or a combination of the above groups; X 2 is O, S, SS, NH, CH 2 , O.H., S.H., and N.H. 2 , CHR 1 , or N.R. 1 It is. R 15 , R 16 , and R 17 are independently H, C 1 ~C 8 Alkyl, heteroalkyl; 2 ~C 8 Alkenyl, alkynyl, heteroalkyl, heterocycloalkyl; 3 ~C 8 Aryl, Ar-alkyl, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl, alkylcarbonyl, or Na + , K + , Cs + , Li + , Ca 2+ , Mg + , Zn 2+ , N + (R 1 ) (R 2 ) (R 3 ) (R 4 ), or HN + (C 2 H 5 O.H. 3 It is salt; Y 1 and Y 2 is independently N or CH; q is 0 or 1; when q=0, Y 3 does not exist, and Y 4 , Y 5 , Y 6 , and Y 7 are independently CH, N, NH, O, S, or N(R1), so that Y 2 , Y 4 , Y 5 , Y 6 , and Y 7 form a heteroaromatic ring of furan, pyrrole, thiophene, thiazole, oxazole, imidazole, pyrazole, triazole, tetrazole, thiadiazole; when q=1, Y 3 , Y 4 , Y 5 , Y 6 , and Y 7 are independently CH or N, so that Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , and Y 7 forms an aromatic ring in benzene, pyridine, pyridazine, pyrimidine, pyrazine, triazine, tetrazine, or pentazine; In particular, tubulysin analogs have the structure shown below: 【Chemistry 20】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 During the ceremony, R 20 is H;C 1 ~C 8 A linear or branched alkyl or heteroalkyl group of 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 or a carboxylate, ester, ether, or amide having 1 to 8 carbon atoms; or an amino acid having 1 to 8 carbon atoms; or a group represented by the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 0 to about 1000; or 20 is absent and the oxygen atom forms a ketone, or a combination of the above; Z 2 and Z 3 are independently H, OH, NH 2 , O, NH, COOH, COO, C(O), C(O), C(O)NH, C(O)NH 2 , R 18 , O.C.H. 2 OP(O)(OR 18 ) 2 ,OC(O)OP(O)(OR 18 ) 2 , OPO (OR 18 ) 2 , NHPO (OR 18 ) 2 , OP(O)(OR 18 ) OP (O) (OR 18 ) 2 , O.C.(O)R 18 , O.C.(O)N.R. 18 , OSO 2 (OR 18 ), O-(C 4 ~C 12 -glycoside), C 1 ~C 8 Linear or branched alkyl or heteroalkyl of C 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ) is; R 17 and R 18 are independently H, linear or branched alkyl or heteroalkyl, C 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ) is; R 19 is H, OH, NH 2 , OSO 2 (OR 18 ), X.H.H. 2 OP(O)(OR 18 ) 2 , XPO(OR 18 ) 2 ,XC(O)OP(O)(OR 18 ) 2 , XC(O)R 18 , XC(O)NHR 18 , C 1 ~C 8 Alkyl or carboxylate; C 2 ~C 8 Alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 aryl or alkylcarbonyl; or a pharmaceutical salt; X is O, S, NH, NHNH, or CH 2 is; R 7 is the same as defined above; Bonding sites in formulae (IV-01) to (IV-79) 【Chemistry 21】 is the same as the binding site described in formula (IV). (b) calicheamicin and related enediyne antibiotics having the formula: 【Chemical 22】 During the ceremony, 【change】 L 1 Or L 2 This is the binding site for (c) maytansinoids or derivatives thereof represented by the following formula: 【Chemistry 23】 (d) Camptothecin (CPT) or a derivative thereof represented by the following formula: 【Chemistry 24】 During the ceremony, R 1 , R 2 , and R 4 are independently H, F, Cl, Br, CN, NO 2 , C 1 ~C 8 Alkyl; O-C 1 ~C 8 Alkyl; NH-C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 Aryl, Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; or an ester, ether, amide, carbonate, urea, or carbamate having 2 to 8 carbon atoms; R 3 is H, OH, NH 2 , C 1 ~C 8 Alkyl; O-C 1 ~C 8 Alkyl; NH-C 1 ~C 8 Alkyl; C 2 ~C 8 heteroalkyl, alkylcycloalkyl, heterocycloalkyl; or an ester, ether, amide, carbonate, urea, or carbamate having from 2 to 8 carbon atoms; Or, R 1 R 2 , R 2 R 3 , and R 3 R 4 independently form a 5-7 membered carbocyclic, heterocyclic, heterocycloalkyl, aromatic, or heteroaromatic ring system; 【Chemistry 25】 is an intramolecular site to which L1 or L2 can bind. Said camptothecin (CPT) or a derivative thereof, or one or more isotopes of chemical elements, or a pharma- ceutically acceptable salt, hydrate or hydrated salt, or a polymorphic crystal structure of these compounds, or an optical isomer, racemate, diastereomer or enantiomer, in particular has the following formula: 【Chemistry 26】 【change】 【change】 【change】 During the ceremony, 【Chemical 27】 Is L 1 Or L 2 is the binding site for P 1 is H, OH, NH 2 , COOH, C(O)NH 2 , O.C.H. 2 OP(O)(OR 18 ) 2 ,OC(O)OP(O)(OR 18 ) 2 , OPO (OR 18 ) 2 , NHPO (OR 18 ) 2 , O.C.(O)R 18 , OP(O)(OR 18 ) OP (O) (OR 18 ) 2 , O.C.(O)N.R. 18 , O C (O) N (C 2 H 4 ) 2 NCH 3 , OSO 2 (OR 18 ), O-(C 4 -C 12 -glycoside), OC(O)N(C 2 H 4 ) 2 CH 2 N (C 2 H 4 ) 2 CH 3 , O-(C 1 ~C 8 (straight-chain or branched alkyl) 1 ~C 8 Linear or branched alkyl or heteroalkyl of C 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Ar-alkyl, heterocycle, carbocycle, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ); R 17 and R 18 are independently H, linear or branched alkyl or heteroalkyl; C 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; 17 ), carbamates (-C(O)NR 17 R 18 ) is; R 1 and R 2 are independently H; O-C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl, alkylcycloalkyl, heterocycloalkyl; C 3 ~C 8 Ar-aryl, Ar-aralkyl. (e) a combretastatin which may have the formula: 【Chemistry 28】 (f) a taxane having the formula: 【Chemical 29】 During the ceremony, 【Chemistry 30】 L 1 Or L 2 Ar and Ar' are independently aryl or heteroaryl. (g) Anthracyclines having the formula: 【Chemistry 31】 【change】 (h) the vinca alkaloid is selected from vinblastine, vincristine, vindesine, leurosine, vinorelbine, catharanthine, vindoline, vincaminol, vineridine, minovincine, methoxyminovincine, minovincine, vincadifformine, desoxyvincaminol, vincamazine, vincamine, vinpocetine, and vinbrunin and has the formula: 【Chemistry 32】 【change】 (i) dolastatin and peptide analogs and derivatives thereof are selected from dolastatin 10, dolastatin E (AE), dolastatin EB (AEB), dolastatin EFP (AEFP), MMAD (monomethylauristatin D or monomethylauristatin 10), MMAF (monomethylauristatin F or N-methylvaline-valine-dolaisoleucine-dolaproine-phenylalanine), MMAE (monomethylauristatin E or N-methylvaline-valine-dolaisoleucine-dolaproine-norephedrine), 5-benzoylvaleric acid-AE ester (AEVB), auristatin F phenylenediamine (AFP), having the formula: or one or more isotopes of chemical elements, or a pharma- ceutically acceptable salt, hydrate or hydrated salt, or a polymorphic crystal structure of these compounds, or an optical isomer, racemate, diastereomer, or enantiomer; 【Chemical 33】 【change】 During the ceremony, R 1 , R 2 , R 3 , R 4 , and R 5 are independently H; C 1 ~C 8 a linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, amide, amine, heterocycloalkyl, or acyloxylamine of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 1 to about 5000; 1 R 2 , R 2 R 3 , R 1 R 3 , or R 3 R 4 may be taken together to form a 3-8 membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; X 3 is H, CH 3 , or X 1’ R 1’ wherein X 1’ is NH, N(CH 3 ), NHNH, O, or S; R 1’ is H or C 1 -C 8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxylamine; R 3’ is H or C 1 -C 6 is a straight or branched alkyl group; Z 3’ H, COOR 1 , N.H. 2 , N.H.R. 1 , OR 1 , C.O.N.R. 1 , NHCOR 1 , O.C.O.R. 1 , OP(O)(OM 1 ) (O.M. 2 ), O.C.H. 2 OP(O)(OM 1 ) (O.M. 2 ), OSO 3 M 1 , R 1 , O-glycosides (glucosides, galactosides, mannosides, glucuronosides / glucuronides, allosides, fructosides, etc.), NH-glycosides, S-glycosides, or CH 2 - is a glycoside; M 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , N.R. 1 R 2 R 3 It is. Y 1 and Y 2 is a connection site (which binds independently to L1 and / or L2) 【Chemical 34】 and independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 or a connection site 【Chemistry 35】 If not bonded to OH, NH 2 , N.H.N.H. 2 , N.H.R. 5 , SH, C(O)OH, C(O)NH 2 , OC(O)NH 2 , OC(O)OH, NHC(O)NH 2 , NHC(O)SH, OC(O)NH(R 1 ), N(R 1 )C(O)NH(R 2 ), C(O)NHNHC(O)OH, and C(O)NHR 1 is; R 12 は、OH、NH 2 、NHR 1 NHNH 2 、NHNHCOOH、O-R 1 -COOH、NH-R 1 -COOH、NH-(Aa) n COOH, O(CH 2 CH 2 O) p CH 2 CH 2 Hmm, Hmm 2 CH 2 O) p CH 2 CH 2 NH 2 NH(CH 2 CH 2 O) p CH 2 CH 2 NH 2 NR 1 R 1’ 、NHOH、NHOR 1 O(CH 2 CH 2 O) p CH 2 CH 2 COOH, NH(CH 2 CH 2 O) p CH 2 CH 2 COOH、NH-Ar-COOH、NH-Ar-NH 2 O(CH 2 CH 2 O) p CH 2 CH 2 P.S. 3 H,NH(CH 2 CH 2 O) p CH 2 CH 2 P.S. 3 H 1 -NHSO 3 H 1 -NHSO 3 H、O(CH 2 CH 2 O) p CH 2 CH 2 NHPO 3 H 2 、NH(CH 2 CH 2 O) p CH 2 CH 2 NHPO 3 H 2 、OR 1 、R 1 -NHPO 3 H 2 、R 1 -OPO 3 H 2 、O(CH 2 CH 2 O) p CH 2 CH 2 OPO 3 H 2 、OR 1 -NHPO 3 H 2 、NH-R 1 -NHPO 3 H 2 、NH(CH 2 CH 2 NH) p CH 2 CH 2 NH 2 、NH(CH 2 CH 2 S) p CH 2 CH 2 NH 2 、NH(CH 2 CH 2 NH) p CH 2 CH 2 OH、NH(CH 2 CH 2 S) p CH 2 CH 2 OH、NH-R 1 -NH 2 、或NH(CH 2 CH 2 O) p CH 2 CH 2 NHPO 3 H 2 where Aa is 1 to 8 identical or different amino acids; p is 1 to 5000; R 1 , R 2 , R 3 , R 4 , R 5 , R 5’ , Z 1 , Z 2 , and n are as defined above. (j) Hemiasterlin and its analogs having the following formula: 【Chemical Formula 36】 During the ceremony, R 1 , R 2 , R 3 , R 4 , and R 5 are independently H; C 1 ~C 8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester, ether, amide, amine, heterocycloalkyl, or acyloxylamine; or a peptide containing 1 to 8 amino acids, or a peptide of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 1 to about 5000; 2 R 3 can form a 3-8 membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group. (k) Eribulin, having the formula: 【Chemical 37】 (l) Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors having the following formulas NP01, NP02, NP03, NP04, NP05, NP06, NP07, NP08, and NP09, or one or more isotopes of chemical elements, or pharma- ceutically acceptable salts, hydrates, or hydrated salts, or polymorphic crystal structures of these compounds, or optical isomers, racemates, diastereomers, or enantiomers: 【Chemical 38】 During the ceremony, 【Chemical Formula 39】 is the same as above; X 5 is F, Cl, Br, I, OH, OR 1 , R 1 , O.P.O. 3 H 2 , OSO 3 H, N.H.R. 1 , O.C.O.R. 1 , NHCOR 1 It is. (m) Benzodiazepine dimers and analogs thereof having the formula PB01, PB02, PB03, PB04, PB05, PB06, PB07, PB08, PB09, PB10, PB11, PB12, PB13, PB14, PB15, and PB16, or one or more isotopes of chemical elements, or pharma- ceutically acceptable salts, hydrates, or hydrated salts, or polymorphic crystal structures of these compounds, or optical isomers, racemates, diastereomers, or enantiomers: 【Chemistry 40】 【change】 【change】 During the ceremony, X 1 , X 2 , Y 1 , and Y 2 are independently O, N, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), CH, C(O)NHNHC(O), and C(O)NR 1 is; R 1 , R 2 , R 3 , R 1’ , R 2’ , and R 3’ are independently H; F; Cl; =O; =S; OH; SH; C 1 -C 8 Linear or branched alkyl, aryl, alkenyl, heteroaryl, heteroalkyl, alkylcycloalkyl, ester (COOR 5 or -OC(O)R 5 ), ester (OR 5 ), amide (CONR 5 ), carbamates (OCONR 5 ), amine (NHR 5 , N.R. 5 R 5’ ), heterocycloalkyl, or acyloxylamine (-C(O)NHOH, -ONHC(O)R 5 ); or a peptide comprising 1 to 20 natural or unnatural amino acids, or a peptide of the formula (OCH 2 CH 2 ) p Or (OCH 2 CH (CH 3 )) p where p is an integer from 1 to about 1000; 1 R 2 , R 2 R 3 , R 1 R 3 , R 1’ R 2’ , R 2’ R 3’ , or R 1’ R 3’ can independently form a 3-8 membered ring of an alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; X 3 and Y 3 are independently N, NH, CH, or CR 1 or X 3 and Y 3 Any one of may be absent; R 4 , R 5 , R 6 , R 12 , and R 12’ are independently H, OH, NH 2 , NH(CH 3 ), N.H.N.H. 2 , COOH, SH, OZ 3 , S.Z. 3 , F, Cl, or C 1 -C 8 Linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxylamine; X 6 are CH, C(O), N, P(O)NH, P(O)NR 1 , CHC(O)NH,C 1 ~C 8 a straight or branched alkyl or heteroalkyl of 3 ~C 8 Aryl, heteroaryl, alkylcycloalkyl, acyloxy, alkylaryl, alkylaryloxy, alkylarylamino, or Aa (amino acid, preferably selected from Lys, Phe, Asp, Glu, Ser, Thr, His, Cys, Tyr, Trp, Gln, Asn, Arg); Z 3 is H, OP(O)(OM 1 ) (O.M. 2 ), O.C.H. 2 OP(O)(OM 1 ) (O.M. 2 ), OSO 3 M 1 , or O-glycosides (glucosides, galactosides, mannosides, glucuronosides / glucuronides, allosides, fructosides, etc.), NH-glycosides, S-glycosides, or CH 2 - is a glycoside; M 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , N.R. 1 R 2 R 3 is; 【Chemistry 41】 is the same as the definition above. (n) CC-1065 analogs and doucarmycin analogs having structures of formulas CC01, CC02, CC03, CC04, CC05, CC06, and CC07: 【Chemistry 42】 【change】 During the ceremony, X 1 , X 2 , Y 1 , and Y 2 is the connection site 【Chemistry 43】 and independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 or a connection site 【Chemistry 44】 If not bonded to OH, NH 2 , N.H.N.H. 2 , N.H.R. 1 , SH, C(O)OH, C(O)NH 2 , OC(O)NH 2 , OC(O)OH, NHC(O)NH 2 , NHC(O)SH, OC(O)NH(R 1 ), N(R 1 )C(O)NH(R 2 ), C(O)NHNHC(O)OH, and C(O)NHR 1 is; Z 3 , H, PO (OM 1 ) (O.M. 2 ), S.O. 3 M 1 , C.H. 2 PO (OM 1 ) (O.M. 2 ), C.H. 3 N (CH 2 CH 2 ) 2 NC(O)-, O(CH 2 CH 2 ) 2 N-C(O)-, R 1 or a glycoside; R 1 , R 2 , R 3 , M. 1 , M. 2 , and n are as defined above. (o) Amatoxin and its analogs, or isotopic substitutions of one or more chemical elements, or pharma- ceutically acceptable salts, hydrates, or hydrated salts, or polycrystalline structures of these compounds, or optical isomers, racemates, diastereomers, or enantiomers, having the following formulae Am01, Am02, and Am03: 【Chemistry 45】 During the ceremony, X 1 and Y 1 are independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), C.H. 2 , CHNH, CH 2 O, C(O)NHNHC(O), and C(O)NR 1 is; R 7 , R 8 , and R 9 are independently H, OH, OR 1 , N.H. 2 , N.H.R. 1 , C 1 ~C 6 Alkyl, or lacking; Y 2 , O, O 2 , N.R. 1 , NH, or absent; R 10 is CH 2 , O., N.H., N.R. 1 , NHC(O), NHC(O)NH, NHC(O)O, OC(O)O, C(O), OC(O), OC(O)(NR 1 ), (NR 1 ) C(O)(NR 1 ), C(O)R 1 , or lacking; R 11 は、OH、NH 2 、NHR 1 NHNH 2 、NHNHCOOH、O-R 1 -COOH、NH-R 1 -COOH、NH-(Aa) r COOH, O(CH 2 CH 2 O) p CH 2 CH 2 Hmm, Hmm 2 CH 2 O) p CH 2 CH 2 NH 2 NH(CH 2 CH 2 O) p CH 2 CH 2 NH 2 NR 1 R 2 O(CH 2 CH 2 O) p CH 2 CH 2 -COOH, A. 2 CH 2 O) p CH 2 CH 2 COOH、NH-Ar-COOH、NH-Ar-NH 2 O(CH 2 CH 2 O) p CH 2 CH 2 -NHSO 3 H,NH(CH 2 CH 2 O) p CH 2 CH 2 P.S. 3 H 1 -NHSO 3 H 1 -NHSO 3 H、O(CH 2 CH 2 O) p -CH 2 CH 2 P. 3 H 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 N.H.P.O. 3 H 2 , OR 1 , R 1 -NHPO 3 H 2 , R 1 -OPO 3 H 2 , O(CH 2 CH 2 O) p CH 2 CH 2 O.P.O. 3 H 2 , OR 1 -NHPO 3 H 2 , N.H.-R. 1 -NHPO 3 H 2 , or NH(CH 2 CH 2 O) p CH 2 -CH 2 N.H.P.O. 3 H 2 where: (Aa) r is 1 to 8 amino acids; n and m 1 is independently 1 to 20; p is 1 to 5000; R 1 , R 2 , Ar, and 【Chemistry 46】 is the same as the definition above. (p) The spliceostatins and pladienolides are spliceostatin A, FR901464, and (2S,3Z)-5-{[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,4R,5R,7S)-7-(2-hydrazinyl-2-oxoethyl)-4-hydroxy-1,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-1-yl-1}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate, pladienolide B, pladienolide D, and E7107, which have the core structure of Sp-01: 【Chemistry 47】 (q) Protein kinase inhibitors include PK01 to PK40 having the following structures: adavosertib, afatinib, axitinib, bafitinib, bosutinib, cometinib, crizotinib, cabozantinib, dasatinib, entrex erlotinib, erdafitinib, erlotinib, fostatinib, gefitinib, ibrutinib, imatinib, lapatinib, lenvatinib, and movitinib. ib, pazopanib, ponatinib, ponatinib, revastinib, regorafenib, ruxolitinib, sorafenib, sunitinib, SU6656, tofacitinib, vandervemurafenib, entrectinib, palbociclib, ribociclib, aveciclib, dacomitinib, neratinib, rociletinib (CO-1686), osimertinib, AZD3759, nazatinib (EGF816): 【Chemistry 48】 【change】 【change】 【change】 【change】 【change】 During the ceremony, Z 5 and Z 5’ are independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), and C(O)NR 1 R is selected from 1 and R 2 is the same as the definition above. (r) MEK inhibitors selected from PD0325901, selumetinib (AZD6244), cobimetinib (XL518), lefatinib, trametinib (GSK1120212), pimasertib, binimetinib (MEK162), AZD8330, RO4987655, RO5126766, WX-554, E6201, GDC-0623, PD-325901, and TAK-733, preferably having the structure: 【Chemistry 49】 During the ceremony, Z 5 is O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2) , C(O)NHNHC(O), and C(O)NR 1 R is selected from 1 and R 2 is the same as the definition above. (s) The protease inhibitor is selected from carfilzomib, clindamycin, retapamulin, and indibulin, and preferably has the following structure: 【Chemistry 50】 (t) the immunotoxin is selected from diphtheria toxin (DT), cholera toxin (CT), trichosanthin (TCS), dianthin, Pseudomonas exotoxin A (ETA), erythrogenic toxin, diphtheria toxin, AB toxin, type III exotoxin, prohemolysin, and apihemolysin; (u) The cell receptor agonist or cell stimulating molecule is selected from the following: folic acid derivatives; glutamic acid urea derivatives; somatostatin and its analogs (selected from the group consisting of octreotide (sandostatin) and lanreotide (somatilin)); aromatic sulfonamides; pituitary adenylate cyclase activating peptide (PACAP) (PAC1); vasoactive intestinal peptide (VIP / PACAP) (VPAC1, VPAC2); melanocyte stimulating hormone (α-MSH); cholecystokinin (CCK) / gastrin receptor agonist, bombesin (Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 Neurotensin receptor ligands (NTR1, NTR2, NTR3), substance P (NK1 receptor) ligands; neuropeptide Y (Y1-Y6); homing peptides including RGD (Arg-Gly-Asp), NGR (Asn-Gly-Arg), dimeric and multimeric cyclic RGD peptides (cRGDfV), TAASGVRSMH, and LTLRWVGLMS (chondroitin sulfate proteoglycan NG2 receptor ligand), and F3 peptide; cell membrane permeable peptides Peptides (CPPs); peptide hormones, luteinizing hormone releasing hormone (LHRH) agonists and antagonists, and gonadotropin releasing hormone (GnRH) agonists that act by targeting follicle stimulating hormone (FSH) and luteinizing hormone (LH) as well as testosterone production, such as buserelin (Pyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-NHEt), gonadorelin (Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 ), goserelin (Pyr-His-Trp-Ser-)Tyr-D-Ser(OtBu)-Leu-Arg-Pro-AzGly-NH 2 ), histrelin (Pyr-His-Trp-Ser-Tyr-D-His(N-benzyl)-Leu-Arg-Pro-NHEt), leuprolide (Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt), nafarelin (Pyr-His-Trp-Ser-Tyr-2Nal-Leu-Arg-Pro-Gly-NH 2 ), Triptorelin (Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH 2 ), nafarelin, deslorelin, abarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-(N-Me)Tyr-D-Asn-Leu-isopropylLys-Pro-DAla-NH 2 ), Cetrorelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH 2 ), degarelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-4-aminoPhe(L-hydroorotyl)-D-4-aminoPhe(carbamoyl)-Leu-isopropylLys-Pro-D-Ala-NH 2 ), and ganirelix (Ac-D-2Nal-D-4-chloroPhe-D-3-(3-pyridyl)Ala-Ser-Tyr-D-(N9,N10-diethyl)-homoArg-Leu-(N9,N10-diethyl)-homoArg-Pro-D-Ala-NH 2 ); pattern recognition receptors (PRRs) selected from Toll-like receptor (TLR) ligands, C-type lectins, and Nodlike receptor (NLR) ligands; calcitonin receptor agonists; integrin receptors and their receptor subtypes (α V β 1 , α V β 3 , α V β 5 , α V β 6 , α 6 β 4 , α 7 β 1 , α L β 2 , α IIb β 3 agonists (selected from the group consisting of GRGDSPK, cyclo(RGDfV)(L1) and its derivatives [cyclo(-N(Me)R-GDfV), cyclo(R-Sar-DfV), cyclo(RG-N(Me)D-fV), cyclo(RGD-N(Me)f-V), cyclo(RGDf-N(Me)V-)(cilengitide)]; anticalins (derivatives of lipocalin); adnectins (tenth FN3 (fibronectin)); designed ankyrin repeat proteins (DARPins); avimers; EGF receptor or VEGF receptor agonists; Specific small molecules of cell receptor agonists are selected from the following: LB01 (folic acid), LB02 (PMSA ligand), LB03 (PMSA ligand), LB04 (PMSA ligand), LB05 (somatostatin), LB06 (somatostatin), LB07 (octreotide, somatostatin analog), LB08 (ramareotide, somatostatin analog), LB09 (vapreotide (sambar), somatostatin analog), LB10 (CAI), LB11 (CAI), LB12 (CAI), LB13 (CAI), LB14 (CAI), LB15 (CAI), LB16 (CAI), LB17 (CAI), LB18 (CAI), LB19 (CAI), LB20 (CAI), LB21 (CAI), LB22 (CAI), LB23 (CAI), LB24 (CAI), LB25 (CAI), LB26 (CAI), LB27 (CAI), LB28 (CAI), LB29 (CAI), LB30 (CAI), LB31 (CAI), LB32 (CAI), LB33 (CAI), LB34 (CAI), LB35 (CAI), LB36 (CAI), LB37 (CAI), LB38 (CAI), LB39 (CAI), LB40 (CAI), LB41 (CAI), LB42 (CAI), LB43 (CAI), LB44 (CAI), LB45 (CAI), LB46 (CAI), LB47 (CAI), LB48 (CAI), LB49 (CAI), LB50 (CAI), LB51 (CAI), LB52 (CAI), LB53 (CAI), LB54 (CAI), LB55 (CAI), LB56 (CAI), LB57 (CAI), LB5 X ligand), LB11 (CAIX ligand), LB12 (gastrin releasing peptide receptor (GRPr), MBA), LB13 (luteinizing hormone releasing hormone (LH-RH) ligand and GnRH), LB14 (luteinizing hormone releasing hormone (LH-RH) and GnRH ligand), LB15 (GnRH antagonist, abarelix), LB16 (cobalamin, vitamin B12 analog), LB17 (cobalamin, vitamin B12 analog), LB18 (α v β 3 for integrin receptors), LB19 (heterobivalent peptide ligand for VEGF receptors), LB20 (neuromedin B), LB21 (bombesin for G protein-coupled receptors), LB22 (TLR for Toll-like receptors), 2 ), LB23 (for androgen receptor), LB24 (α v Cilengitide / cyclo(-RGDfV-) for integrin receptors), LB23 (fludrocortisone), LB25 (rifabutin analog), LB26 (rifabutin analog), LB27 (rifabutin analog), LB28 (fludrocortisone), LB29 (dexamethasone), LB30 (fluticasone propionate), LB31 (beclomethasone dipropionate), LB32 (triamcinolone acetonide), LB33 (prednisone), LB34 (prednisolone), LB35 (methylprednisolone), LB36 (betamethasone), LB37 (irinotecan analog), LB3 8 (crizotinib analog), LB39 (bortezomib analog), LB40 (carfilzomib analog), LB41 (carfilzomib analog), LB42 (leuprolide analog), LB43 (triptorelin analog), LB44 (clindamycin), LB45 (liraglutide analog), LB46 (semaglutide analog), LB47 (retapamulin analog), LB48 (indibulin analog), LB49 (vinblastine analog), LB50 (lixisenatide analog), LB51 (osimertinib analog), LB52 (nucleoside analog), LB53 (erlotinib analog), or LB54 (lapatinib analog); 【Chemistry 51】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 In the formula, X 4 and Y 1 are independently O, NH, NHNH, NR 1 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), C.H. 2 , C(O)NHNHC(O), and C(O)NR 1 It is. (v) one or more of DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), and PIWI-interacting RNA (piRNA) conjugated to an antibody or antibody-like protein by the methods of the invention, and having the following structure: 【Chemistry 52】 【Chemistry 53】 is the attachment site for the side chain linker of this patent; 【Chemical 54】 is a single or double strand of DNA, RNA, mRNA, siRNA, miRNA, or piRNA; X 1 and Y is independently O, NH, NHNH, NR 1 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 1 ), C.H. 2 , C(O)NHNHC(O), and C(O)NR 1 It is.
12. The antibody or antibody-like protein of claim 1, 6 or 8 is selected from: (A) the group consisting of probodies, nanobodies, peptides, polymeric micelles, liposomes, lipoprotein-based drug carriers, nanoparticle drug carriers, dendrimers, and the above molecules or particles conjugated to or coated with cell-binding ligands, or combinations thereof; (B) a full-length antibody (polyclonal antibody, monoclonal antibody, dimer, multimer), a multispecific antibody (selected from a bispecific antibody, a trispecific antibody, or a tetraspecific antibody); a single-chain antibody, an antibody fragment that binds to a target cell, a monoclonal antibody, a single-chain monoclonal antibody, a monoclonal antibody fragment that binds to a target cell, a chimeric antibody, a chimeric antibody fragment that binds to a target cell, a domain antibody, a domain antibody fragment that binds to a target cell, a resurfaced antibody, a single-chain resurfaced antibody, a resurfaced antibody fragment that binds to a target cell, a humanized antibody or a resurfaced humanized antibody, a single-chain humanized antibody, or a target cell-specific antibody. humanized antibody fragments, anti-idiotypic (anti-Id) antibodies, CDR binding, dimers, trimers, tetramers, miniantibodies, probodies, probody fragments, small immunity proteins (SIPs), lymphokine antibody-like proteins, hormone antibody-like proteins, growth factor antibody-like proteins, colony stimulating factor antibody-like proteins, nutrient transport antibody-like proteins, high molecular weight antibody-like proteins, fusion antibody-like proteins, kinase inhibitor antibody-like proteins, gene targeted antibody-like proteins, nanoparticle coated antibody-like proteins, or polymers modified with antibodies or large molecular weight antibody-like proteins; (C) The group consisting of IgG antibodies capable of targeting tumor cells, virus-infected cells, microbial-infected cells, parasite-infected cells, autoimmune disease cells, activated tumor cells, bone marrow cells, activated T cells, affected B cells, or melanocytes, or non-normal cells expressing any of the following antigens or receptors: CD1, CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD1 2w, CD14, CD15, CD16, CD16a, CD16b, CDw17, CD18, CD19, CD20, CD21, CD22, C D23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD32a, CD32b, CD 33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD42a, CD42b, CD 42c, CD42d, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD49c, CD49d , CD49f, CD50, CD51, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60, CD60a, CD60b, CD60c, CD61, CD62E, CD62L, CD62P, CD63, CD64, CD65, CD65s, CD66, CD66a, CD66b, CD66c, CD66d, CD66e, CD66f, CD67, CD68, CD69, CD70, C D71, CD72, CD73, CD74, CD74, CD75, CD75s, CD76, CD77, CD78, CD79, CD79a, CD 79b, CD80, CD81, CD82, CD83, CD84, CD85, CD85a, CD85b, CD85c, CD85d, CD85 e, CD85f, CD85g, CD85g, CD85i, CD85j, CD85k, CD85m, CD86, CD87, CD88, CD89 , CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD100, CD101 , CD102, CD103, CD104, CD105, CD106, CD107, CD107a, CD107b, CD108, CD109,CD110、CD111、CD112、CD113、CD114、CD115、CD116、CD117、CD118、CD119、CD120a、CD120b、CD121、CD121a、CD121b、CD122、CD123、CD123a、CD124、CD125、CD126、CD127、CD128、CD129、CD130、CD131、CD132、CD133、CD134、CD135、CD136、CD137、CD138、CD139、CD140、CD140a、CD140b、CD141、CD142、CD143、CD144、CD145、CDw145、CD146、CD147、CD148、CD149、CD150、CD151、CD152、CD153、CD154、CD155、CD156a、CD156b、CD156c、CD156d、CD157、CD158、CD158a、CD158b1、CD158b2、CD158c、CD158d、CD158e1、CD158e2、CD158f2、CD158g、CD158h、CD158i、CD158j、CD158k、CD159、CD159a、CD159b、CD159c、CD160、CD161、CD162、CD163、CD164、CD165、CD166、CD167、CD167a、CD167b、CD168、CD169、CD170、CD171、CD172、CD172a、CD172b、CD172g、CD173、CD174、CD175、CD175s、CD176、CD177、CD178、CD179、CD179a、CD179b、CD180、CD181、CD182、CD183、CD184、CD185、CD186、CDw186、CD187、CD188、CD189、CD190、CD191、CD192、CD193、CD194、CD195、CD196、CD197、CD198、CDw198、CDw199、CD200、CD201、CD202(a,b)、CD203、CD203c、CD204、CD205、CD206、CD207、CD208、CD209、CD210、CDw210a、CDw210b、CD211、CD212、CD213、CD213a1、CD213a2、CD214、CD215、CD216、CD217、CD218、CDw218a、CD218、CD21b9、CD220、CD221、CD222、<h2 style=";text-align:left;direction:ltr">CD223、CD224、CD225、CD226、CD227、C D228、CD229、CD230、CD231、CD232、CD 2333、CD234、CD235a、CD235b、CD236、CD236R、CD238、CD239、CD240、CD240ce 、CD240d、CD241、CD242、CD243、CD244 、CD245、CD246、CD247、CD248、CD249、 CD250、CD251、CD252、CD253、CD254、C D255、CD256、CD257、CD258、CD259、CD2 50、CD261、CD262、CD263、CD264、CD265、CD266、CD267、CD268、CD269、CD270 、CD271、CD272、CD273、CD274、CD275、 CD276、CD277、CD278、CD279、CD281、CD 282、CD283、CD284、CD285、CD286、CD2 87、CD288、CD289、CD290、CD291、CD29 2、CD293、CD294、CD295、CD296、CD297、CD298、CD299、CD300、CD300a、CD300b 、CD300c、CD301、CD302、CD303、CD304 、CD305、CD306、CD307、CD307a、CD307 b、CD307c、CD307d、CD307e、CD307f、C D308、CD309、CD310、CD311、CD312、CD3 13、CD314、CD315、CD316、CD317、CD318、CD319、CD320、CD321、CD322、CD323 、CD324、CD325、CD326、CD327、CD328、 CD329、CD330、CD331、CD332、CD333、CD 3344、CD335、CD336、CD337、CD338、CD339、CD340、CD341、CD342、CD343、CD34 4、CD345、CD346、CD347、CD348、CD349 、CD350、CD351、CD352、CD353、CD354、C D355、CD356、CD357、CD358、CD359、CD 360、CD361、CD362、CD363、CD364、CD3 55、CD366、CD367、CD368、CD369、CD370、CD371、CD372、CD373、CD374、CD375、CD376, CD377, CD378, CD379, CD381, CD382, CD383, CD384, CD385, CD386, CD387, CD388, CD389, CRIPTO, CRIPTO, CR, CR1, CRGF, CRIPTO, CXCR5, LY64, TDGF1, 4-1BB, APO2, ASLG659, BMPR1B, 4-1BB, 5AC, 5T4 (trophoblast glycoprotein, TPBG, 5T4, Wnt activation inhibitor 1 or WAIF1), adenocarcinoma antigen, AGS-5, AG S-22M6, activin receptor-like kinase 1, AFP, AKAP-4, ALK, α integrin, αvβ6, aminopeptidase N, amyloid β, androgen receptor, angiopoietin 2, angiopoietin 3, annexin A1, anthrax toxin protective antigen, anti-transferrin receptor, AOC3 (VAP-1), B7-H3, anthrax, BAFF (B-cell activating factor), BCMA, B-lymphoma cells, bcr-abl, bombesin, BORIS, C5, C242 antigen, CA125 (anthrax) Hydrate antigen 125, MUC16), CA-IX (or CAIX, carbonic anhydrase 9), CALLA, CanAg, canine IL31, carbonic anhydrase IX, cardiac myosin, CCL11 (C-C motif chemokine 11), CCR4 (CC chemokine receptor type 4, CD194), CCR5, CD3E (epsilon), CEA (carcinoembryonic antigen), CEACAM3, CEACAM5 (carcinoembryonic antigen), CFD (factor D), Ch4D5, cholecystokinin 2 (CCK2R), CLDN18 (claudin-18) , CLDN18.1 (claudin-18.1), CLDN18.2 (claudin-18.2), clumping factor A, cMet, CRIPTO, FCSF1R (colony-stimulating factor 1 receptor, CD115), CSF2 (colony-stimulating factor 2, granulocyte-macrophage colony-stimulating factor (GM-CSF)), CSP4, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CTAA16.88 tumor antigen, CXCR4, CXC chemokine receptor type 4, cADP ribose hydrolase, Cyclin B1, CYP1B1, cytomegalovirus, cytomegalovirus glycoprotein B, dabigatran, DLL3 (delta-like ligand 3), DLL4 (delta-like ligand 4), DPP4 (dipeptidyl peptidase 4),DR5 (death receptor 5), E. coli Shiga toxin type 1, E. coli Shiga toxin type 2, ED-B, EGFL7 (EGF-like domain containing protein 7), EGFR, EGFRII, EGFRvIII, endoglin, endothelin B receptor, endotoxin, EpCAM (epithelial cell adhesion molecule), EphA2, episialin, ERBB2 (epidermal growth factor receptor 2), ERBB3, ERG (TMPRSS2ETS fusion gene), E. coli , ETV6-AML, FAP (fibroblast activation protein α), fibroblast surface antigen, FCGR1, α-fetoprotein, fibrin II, β chain, fibronectin ectodomain B, FOLR (folate receptor), folate receptor α, folate hydrolase, respiratory syncytial virus Fos-related antigen 1F protein, Frizzled receptor, fucosyl GM1, GD2 ganglioside, G-28 (cell surface glycolipid antigen), GD3 idiotype Type, GloboH, Glypican 3, N-glycolylneuraminic acid, GM3, GMCSF receptor α chain, growth differentiation factor, GP100, GPNMB (transmembrane protein NMB), GUCY2C (guanylate cyclase 2C, guanylate cyclase C (GC-C), intestinal guanylate cyclase, guanylate cyclase-C receptor, heat-stable enterotoxin receptor (hSTAR)), heat shock protein, hemagglutinin, B Hepatitis surface antigen, Hepatitis B virus, HER1 (human epidermal growth factor receptor 1), HER2, HER2 / neu, HER3 (ERBB-3), IgG4, HGF / SF (stem cell growth factor / scatter factor), HHGFR, HIV-1, histone complex, HLA-DR (human leukocyte antigen), HLA-DR10, HLA-DRB, HMWMAA, human chorionic gonadotropin, HNGF, human scatter factor receptor kinase, HPV E6 / E7, Hsp90, hTERT, ICAM-1 (intercellular adhesion molecule 1), idiotype, IGF1R (IGF-1, insulin-like growth factor 1 receptor), IGHE, IFN-γ, influenza hemagglutinin, IgE, IgE Fc region, IGHE, interleukins (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-6R, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-17A, IL-18, IL-19, IL-20, IL-21, IL-22,IL-23, IL-27, or IL-28), IL-31RA, ILGF2 (insulin-like growth factor 2), integrin (α4, α, IIIb β 3 , αvβ3, α 4 β 7 , α5β1, α6β4, α7β7, αIIβ3, α5β5, αvβ5), interface Long-gamma-induced protein, ITAGA2, ITGB2, KIR2D, Kappa Ig, LCK, Le, legumain, Lewis-Y antigen, LFA-1 (lymphocyte function-associated antigen 1, CD11a), LHRH, LINGO-1, lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT-1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGEA1, MAGEA3, MAGE4, MART1, MCP-1, MIF (macrophage migration inhibitory factor or glycosylation inhibitory factor (GIF)), MS4A1 (transmembrane 4 domain subfamily A member 1), MSLN (mesothelin), MUC1 (mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM)), MUC1-KLH, MUC16 (CA125), MCP1 (monocyte chemotactic protein 1), MelanA / MART1, ML-IAP, MPG, MS4A1 (transmembrane 4 domain subfamily A), MYCN, myelin-associated glycoprotein, myostatin, NA17, NARP-1, NCA-90 (granulocyte antigen), Nectin-4 (ASG-22ME), NGF, neuronal apoptosis-regulating proteinase 1, NOGO-A, Notch receptor, nucleolin, Neu oncogene product, NY-BR-1, NY-ESO-1, OX-40, OxLDL (oxidized low density lipoprotein), OY-TES1, P21, non-mutant p53, P9 7, Page 4, PAP, anti-(N-glycolylneuraminic acid) paratope, PAX3, PAX5, PCSK9, PDCD1 (PD-1, programmed cell death protein 1), PDGF-Rα, (platelet-derived growth factor receptor α), PDGFR-β, PDL-1, PLAC1, PLAP-like testicular alkaline phosphatase, platelet-derived growth factor receptor β, sodium phosphate cotransporter, PMEL17, polysialic acid, proteinase 3 (PR1), prostate cancer, PS (phosphatidylserine), prostate cancer cells, Pseudomonas aeruginosa, PSMA, PSA, PSCA, rabies virus glycoprotein, RHD (Rh polypeptide 1 (RhPI)), Rhesus factor, RANKL, PhoC,Ras mutants, RGS5, ROBO4, respiratory syncytial virus, RON, ROR1, sarcoma metastasis breakpoint, SART3, sclerostin, SLAMF7 (SLAM family member 7), selectin P, SDC1 (syndecan 1), sLe(a), somatomedin C, SIP (sphingosine-1-phosphate), somatostatin, sperm protein 17, SSX2, STEAP1 (six-transmembrane epithelial of the prostate 1) antigen), STEAP2, STn, TAG-72 (tumor-associated glycoprotein 72), survivin, T cell receptor, T cell transmembrane protein, TEM1 (tumor epithelial marker 1), TENB2, tenascin-C (TN-C), TGF-α, TGF-β (transforming growth factor beta), TGF-β1, TGF-β2 (transforming growth factor beta 2), Tie (CD202b), Tie2, TIM-1 (CDX-014), TN, TNF, TNF-α, TNFRSF8, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), TNFRSF13B (tumor necrosis factor receptor superfamily member 13B), TPBG (trophoblast glycoprotein), TRAIL-R1 (tumor necrosis-inducing ligand receptor 1), TRAILR2 (death receptor 5 (DR5)), tumor-associated calcium signaling Transducer 2, tumor-specific glycosylation of MUC1, TWEAK receptor, TYRP1 (glycoprotein 75), TRP-1 (Trop1), TRP-2 (Trop2), tyrosinase, VCAM-1, VEGF, VEGF-A, VEGF-2, VEGFR-1, VEGFR2, or vimentin, WT1, XAGE1, or any insulin growth factor receptor, or any epidermal growth factor receptor.
13. More than 75% of the drugs are specifically conjugated to the disulfide bond site between the heavy chains of the antibody and have the following structures: a001-a233, C-009, C-020, C-025, C-027, C-031, C-037, C-038, C-039, C-043, C-046, C-052, C-056, C-059, C-063, C-066, C-071, C-079, C-084, C-087, C-093, C-096, C-102, C-109, C-111, C-118, C-123, C-133, C-143 , C-155, C-168, C-172, C-182, C-186, C-198, C-203, C-208, C-214, C-215, C-216, C-217, C-218, C-226, C-227, C-231, C-237, C-249, C -259, C-260, C-261, C-325, C-326, C-327, C-328, C-329, C-330, C331, C-332, C-333, C-334, C-335, C-353, C-363, C-371, C-378, C-379 , C-380, C-381, C-384, C-385, C-386, C-387, C-397, C-400, C-403, C-406, C-408a, C-408b, C-408c, C-408d, C-408e, C-408f, C-410a, C-410b, C-410c, C-412a, C-412b, C-412c, C-413a, C-413b, C-413c, C-413d, C-416a, C-416b, C-416c, C-416d, C-422a, C-422b, C-422c 8. The conjugate of claim 6, wherein the conjugate is C-422d, C-425a, C-425b, C-425c, C-425d, C-428a, C-428b, C-428c, C-428d, C-431a, C-431b, C-431c, C-431d; or derivatives of these compounds containing one or more isotopes, pharma- ceutically acceptable salts, hydrates, or hydrated salts of these compounds; or polymorphic crystal structures of these compounds; or optical isomers, racemates, diastereomers, or enantiomers of these compounds: 【Chemistry 55】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 During the ceremony, p, p 1 , p 2 , and p 3 are independently 0 to 100; m, m 1 , and m 2 is independently 0 to 20; n is 1 to 10; P 1 is H, OH, NH 2 , COOH, C(O)NH 2 , O.C.H. 2 OP(O)(OR 18 ) 2 ,OC(O)OP(O)(OR 18 ) 2 , OPO (OR 18 ) 2 , NHPO (OR 18 ) 2 , O.C.(O)R 18 , OP(O)(OR 18 ) OP (O) (OR 18 ) 2 , O.C.(O)N.R. 18 , O C (O) N (C 2 H 4 ) 2 NCH 3 , OSO 2 (OR 18 ), O-(C 4 -C 12 -glycosides), OC(O)N(C 2 H 4 ) 2 CH 2 N (C 2 H 4 ) 2 CH 3 , O-(C 1 ~C 8 (linear or branched alkyl) of 1 ~C 8 A linear or branched alkyl or heteroalkyl group of 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 linear or branched aryl, arylalkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ); R 17 and R 18 are independently H, linear or branched alkyl, or heteroalkyl; C 2 ~C 8 Straight-chain or branched alkenyl, alkynyl, alkylcycloalkyl, heterocycloalkyl; 3 ~C 8 linear or branched aryl, arylalkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, heteroaryl; carbonate (-C(O)OR 17 ), carbamates (-C(O)NR 17 R 18 ) is; R 1 , R 2 , R 3 , R 1’ , R 2’ , R 3’ , and R 4 are independently H, C 1 ~C 8 Alkyl; C 2 ~C 8 Heteroalkyl or heterocyclic ring; 3 ~C 8 R is an aryl, arylalkyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, heteroalkylcycloalkyl, carbocycle, or alkylcarbonyl; or R 1 and R 2 , R 1 and R 3 , R 2 and R 3 , R 3 and R 4 , R 1’ and R 2’ , R 1’ and R 3’ , or R 2’ and R 3’ form a 3- to 7-membered carbocyclic, cycloalkyl, heterocyclic, heterocycloalkyl, aromatic or heteroaromatic ring system; R 4 , R 5 , R 5’ , and R 6 are independently H, C 1 ~C 8 Linear or branched alkyl of C 3 ~C 8 or (Ar)r, where r=1-6 (amino acids or peptides having the same or different amino acid sequences); R 7 , R 8 , and R 9 are independently H, OH, OR 1 , N.H. 2 , N.H.R. 1 , C 1 -C 6 is or lacks alkyl; R 10 is CH 2 , O., N.H., N.R. 1 , NHC(O), NHC(O)NH, NHC(O)O, OC(O)O, C(O), OC(O), OC(O)(NR 1 ), (NR 1 ) C(O)(NR 1 ), C(O)R 1 Being or lacking; R 11 は、OH、NH 2 、NHR 1 NHNH 2 、NHNHCOOH、O-R 1 -COOH、NH-R 1 -COOH, NH-(Aa)rCOOH, O(CH 2 CH 2 O) p CH 2 CH 2 Hmm, Hmm 2 CH 2 O) p CH 2 CH 2 NH 2 NH(CH 2 CH 2 O) p CH 2 CH 2 NH 2 NR 1 R 2 O(CH 2 CH 2 O) p CH 2 CH 2 -COOH, A. 2 CH 2 O) p CH 2 CH 2 COOH、NH-Ar-COOH、NH-Ar-NH 2 O(CH 2 CH 2 O) p CH 2 CH 2 -NHSO 3 H,NH(CH 2 CH 2 O) p CH 2 CH 2 P.S. 3 H 1 -NHSO 3 H 1 -NHSO 3 H、O(CH 2 CH 2 O) p -CH 2 CH 2 P. 3 H 2 , NH(CH 2 CH 2 O) p CH 2 CH 2 N.H.P.O. 3 H 2 , OR 1 , R 1 -NHPO 3 H 2 , R 1 -OPO 3 H 2 , O(CH 2 CH 2 O) p CH 2 CH 2 O.P.O. 3 H 2 , OR 1 -NHPO 3 H 2 , N.H.-R. 1 -NHPO 3 H 2 , or NH(CH 2 CH 2 O) p CH 2 -CH 2 N.H.P.O. 3 H 2 where (Aa)r is 1 to 8 amino acids; n and m 1 is independently 1 to 20; p is 1 to 1000; R 1 , R 2 and Ar is as defined earlier in this application; 【Chemistry 56】 has the same definition as above; R 12 and R 12’ are independently H, ═O, OR 1 , N.H. 2 , NH(CH 3 ), N.H.N.H. 2 , COOH, SH, OZ 3 , S.Z. 3 , F, Cl, or C 1 ~C 8 linear or branched alkyl of 3 ~C 8 Aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxyamine; R 25 , R 26 , and R 25’ are independently H, Ac, R 1 , C(O)NHR 1 , C(O)R 1 , R 1 COOH, R 1 COOR 2 , R 1 OR 2 , R 1 CONHR 2 , C.H. 2 OAc, CH 2 NHAc, R 1 N.H. 2 , N.R. 1 R 2 , N + R 1 R 2 R 3 , C.H. 2 CONH (CH 2 ) q1 COOH, CH 2 CONH (CH 2 ) q1 COOR 1 , C.H. 2 CONH (CH 2 ) q1 N + R 1 R 2 R 3 or (Aa)r; X 1 , X 2 , X 4 , Y 1 , and Y 2 is the binding site 【Chemistry 57】 When bonded to, independently, O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C.H. 2 , CHNH, CH 2 O, C(O)NHNHC(O), OCH 2 C 6 H 4 NH, NHCH 2 C 6 H 4 N.H., S.C.H. 2 C 6 H 4 NH and C(O)NR 1 or a binding site 【Chemistry 58】 When not bonded to OH, NH 2 , N.H.N.H. 2 , N.H.R. 1 , SH, C(O)OH, C(O)NH 2 , OC(O)NH 2 , OC(O)OH, NHC(O)NH 2 , NHC(O)SH, OC(O)NH(R 1 ), N(R 1 )C(O)NH(R 2 ), C(O)NHNHC(O)OH, and C(O)NHR 1 and when bonded to S, Y 2 , O, O 2 , N.R. 1 , NH, or may be absent; X 3 and Y 3 are independently N, NH, CH, CH 2 , or C.R. 1 or X 3 and Y 3 One of the following may be missing; R 1 is C 1 ~C 8 Linear or branched alkyl, heteroalkyl; 3 ~C 8 Aryl, heteroaryl, alkylcycloalkyl, acyloxy, alkylaryl, alkylaryloxy, alkylarylamino, alkylarylthiol; (Ar)r, r=1-6 (amino acids or peptides having the same or different amino acid sequences); X 3 is H, CH 3 , or X 1’ R 1’ And X 1’ is NH, N(CH 3 ), NHNH, O, or S; R 1’ is H, C 1 ~C 8 Linear or branched alkyl of C 3 ~C 8 Aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, acyloxyamine; Z 3’ H, COOR 1 , N.H. 2 , N.H.R. 1 , OR 1 , C.O.N.R. 1 , NHCOR 1 , O.C.O.R. 1 , OP(O)(OM 1 ) (O.M. 2 ), O.C.H. 2 OP(O)(OM 1 ) (O.M. 2 ), OSO 3 M 1 , R 1 , or O-glycosides (glucosides, galactosides, mannosides, glucuronosides / glucuronides, allosides, fructosides, etc.), NH-glycosides, S-glycosides, or CH 2 - is a glycoside; M 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , or NR 1 R 2 R 3 is; Z 3 is OP(O)(OM 1 ) (O.M. 2 ), O.C.H. 2 OP(O)(OM 1 ) (O.M. 2 ), OSO 3 M 1 , P(O)(O.M 1 ) (O.M. 2 ), S.O. 3 M 1 , C.H. 2 P(O)(O.M. 1 ) (O.M. 2 ), C.H. 3 N (CH 2 CH 2 ) 2 NC(O)O-, O(CH 2 CH 2 ) 2 NC(O)O-,R 1 , or O-glycosides (glucosides, galactosides, mannosides, glucuronosides / glucuronides, allosides, fructosides, etc.), NH-glycosides, S-glycosides, or CH 2 - is a glycoside; M 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , or NR 1 R 2 R 3 is; X 5 is F, Cl, Br, I, OH, OR 1 , R 1 , O.P.O. 3 H 2 , OSO3H, NHR 1 , O.C.O.R. 1 , NHCOR 1 , CN, or OCH 2 OP(O)(OM 1 ) (O.M. 2 ) is; Y 5 is NH, NHNH, NR 1 , O, OCH 2 C 6 H 4 NH, NHCH 2 C 6 H 4 N.H., S.C.H. 2 C 6 H 4 N.H., R. 1 , (Ar) r, r=1-6 (amino acids or peptides having the same or different amino acid sequences); X 6 and Y 6 are independently CH, C(O), N, P(O)NH, P(O)NR 1 , CHC(O)NH,C 1 ~C 8 or a straight or branched alkyl of C 3 ~C 8 aryl, heteroaryl, alkylcycloalkyl, acyloxy, alkylaryl, alkylaryloxy, alkylarylamino, or Aa (amino acids, preferably Lys, Phe, Asp, Glu, Ser, Thr, His, Cys, Tyr, Trp, Gln, Asn, Arg); Z 5 and Z 5’ are independently O, NH, NHNH, NR 5 , S, C(O)O, C(O)NH, OC(O)NH, OC(O)O, NHC(O)O, NHC(O)NH, NHC(O)S, OC(O)N(R 1 ), N(R 1 ) C(O)N(R 2 ), C(O)NHNHC(O), or C(O)NR 1 Selected from: X 8 is O, S, NH, NHNH, NHR 1 , S.R. 12 , S.S.R. 12 , SSCH (CH 3 ) R 1 , SSC(CH 3 ) 2 R 1 , or R 1 is; In the formula, R 1 , R 2 , and R 3 are independently H, C, unless otherwise defined in the structural formula. 1 ~C 8 Linear or branched alkyl of C 3 ~C 8 is an aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, or acyloxyamine of the formula: Lv 1 is the same as the leaving group defined above, preferably F, Cl, Br, I, OTs, OMS, OC 6 H 3 (NO 2 ) 2 , O.C. 6 F 5 , O.C. 6 H 4 (NO 2 ), O.C. 6 C 5 Selected from: M 1 and M. 2 are independently H, Na, K, Ca, Mg, NH 4 , or NR 1 R 2 R 3 It is.
14. 10. The drug / conjugate conjugate of claim 1 or 5, having the following structure and wherein greater than 75% of the drug is specifically conjugated to the disulfide bond site between the heavy and light chains of the antibody; or a derivative of these compounds containing one or more isotopes, a pharma- ceutically acceptable salt, hydrate, or hydrated salt of these compounds; or a polymorphic crystal structure of these compounds; or an optical isomer, racemate, diastereomer, or enantiomer of these compounds: 【Chemistry 59】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 In the formula, m, m 1 , m 2 , n, P 1 , R 1 , R 2 , R 3 , R 4 , R 1’ , R 2’ , R 3’ , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 12 , R 12’ , R 25 , R 26 , R 25’ , X 1 , X 2 , X 3 , X 5 , X 6 , Y 1 , Y 2 , Y 6 , Z 3 , Z 5 , p, p 1 , p 2 , p 3 , q 1 , q 2 , Lv 1 , Aa, (Aa)r, Ar, and mAb have the same definitions as in claim 13.
15. The tumor cells of claim 12 are selected from the group consisting of lymphoma cells, myeloma cells, renal cells, breast cancer cells, prostate cancer cells, ovarian cancer cells, colon cancer cells, gastric cancer cells, squamous cell carcinoma cells, small cell lung cancer cells, non-small cell lung cancer cells, testicular cancer cells, malignant cells, or any cells that grow and divide unregulated and promote a cancer-causing pace.
16. 17. A pharmaceutical composition for the treatment or prevention of cancer, an autoimmune disease, or an infectious disease, comprising a therapeutically effective amount of a specific conjugate according to any one of claims 6 or 13 and a pharma- ceutically acceptable salt, carrier, diluent, or excipient, or a combination of said conjugates.
17. 17. The pharmaceutical composition of claim 16, which is a liquid formulation or a lyophilized solid / powder formulation, comprising, by weight 0.01% to 99% of one or more conjugates according to any of claims 6 or 13; Polyol 0.0% to 20.0%; 0.0% to 2.0% of one or more surfactants; 0.0% to 5.0% of one or more preservatives; 0.0% to 30% of one or more amino acids; 0.0% to 5.0% of one or more antioxidants; 0.0% to 0.3% of one or more metal chelating agents; 0.0% to 30.0% of one or more buffer salts to adjust the pH of the formulation to 4.5 to 7.5; and one or more tonicity agents, 0.0% to 30.0%, to adjust the osmolality to between about 250 and 350 mOsm after reconstitution for administration to a patient; The polyol is selected from fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose, glucose, sucrose, trehalose, sorbose, melezitose, raffinose, mannitol, xylitol, erythritol, maltitol, lactitol, erythritol, sorbitol, glycerol, or L-gluconate and its metal salts; The surfactant may be polysorbate 20, polysorbate 40, polysorbate 65, polysorbate 80, polysorbate 81, or polysorbate 85, poloxamer, poly(ethylene oxide)-poly(propylene oxide), polyethylene-polypropylene, Triton; sodium dodecyl sulfate (SDS), sodium lauryl sulfate; sodium octyl glucoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamide propyl- myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyl oleyl-taurate; dodecyl betaine, dodecyl dimethylamine oxide, cocamidopropyl betaine, and cocoamphoglycinate; or isostearyl ethylimidonium ethosulfate; polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol; The preservative is selected from benzyl alcohol, octadecyl dimethyl benzyl ammonium chloride, hexatonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, or m-cresol; The amino acids are selected from arginine, cystine, glycine, lysine, histidine, ornithine, isoleucine, leucine, alanine, glycine, glutamic acid, or aspartic acid; The antioxidant is selected from ascorbic acid, glutathione, cystine, or methionine; The chelating agent is selected from EDTA or EGTA; The buffer salt is selected from sodium, potassium, ammonium, or trihydroxyethylamino salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetate, or phthalic acid; tris or tromethamine hydrochloride, phosphate, or sulfate; anionic acetate, chloride, phosphate, sulfate, or succinate of arginine, glycine, glycylglycine, or histidine; The pharmaceutical composition, wherein the isotonicity agent is selected from mannitol, sorbitol, sodium acetate, potassium chloride, sodium phosphate, potassium phosphate, trisodium citrate, or sodium chloride.
18. 18. The pharmaceutical composition according to claim 16 or 17, which is filled in a vial, a bottle, a pre-filled syringe, or a pre-filled autoinjector syringe in liquid or lyophilized solid form.
19. 18. A specific conjugate according to claim 6 or 13, or a form of a pharmaceutical composition according to claim 16 or 17, having in vitro, in vivo or ex vivo cell killing activity.
20. 18. The pharmaceutical composition of claim 16 or 17, administered simultaneously with a chemotherapeutic agent, a radiotherapy, an immunotherapeutic agent, an autoimmune disease agent, an anti-infective agent, or other conjugate for synergistically treating or preventing cancer, an autoimmune disease, or an infectious disease.
21. The synergist according to claim 20 is selected from one or several of the following drugs: abatacept, abiraterone acetate, abraxane, acetaminophen / hydrocodone, acalabrutinib, aducanumab, adalimumab, ADXS31-142, ADXS-HER2, afatinib dimaleate, aldesleukin, alectinib, alemtuzumab, alitretinoin, adotrastuzumab emtansine, amphetamine / dextroamphetamine, anastrozole, aripiprazole, anthracycline, aripiprazole, atazanavir, atezolizumab, atorvastatin, avelumab, axicabtagene. Ciloreucel, axitinib, belinostat, live BCG, zumab, bexarotene, blinatumomab, bortezomib, bosutinib, brentuximab vedotin, brigatinib, budesonide, budesonide / formoterol, buprenorphine, cabazitaxel, cabozantinib, capmatinib, capecitabine, carfilzomib, chimeric antigen receptor modified T (CAR-T) cells, celecoxib, ceritinib, cetuximab, chidamide, cyclosporine, cinacalcet, crizotinib, cobimetinib, cosentyx, crizotinib, CTL01 9. Dabigatran, dabrafenib, dacarbazine, daclizumab, dacomitinib, daptomycin, daratumumab, darbepoetin alfa, darunavir, dasatinib, denileukin diftitox, denosumab, depakote, dexlansoprazole, methylphenidate, dexamethasone, dinutuximab, doxycycline, duloxetine, duvelisib, durval Umab, elotuzumab, emtricitabine / rilpivirine / tenofovir, disoproxil fumarate, emtricitabine / tenofovir / efavirenz, enoxaparin, ensartinib, enzalutamide, epoetin alfa, erlotinib, esomeprazole, eszopiclone, everolimus, exemestane, everolimus, exenatide ER, ezetimibe, ezetimibe / simvastatin, fenofibrate, filgrastim, fingolimod, fluticasone propionate, fluticasone / salmeterol, fulvestrant, gaziva, gefitinib, glatiramer, goserelin acetate, icotinib, imatinib, ibritumomabTiuxetan, ibrutinib, idelarib, ifosfamide, infliximab, imiquimod, immucyst, immune BCG, iniparib, insulin aspart, insulin detemir, insulin glargine, insulin lispro, interferon alpha, interferon alpha 1b, interferon alpha 2a, interferon alpha 2b, interferon beta, interferon beta 1a, interferon beta 1b, interferon gamma 1a, iapatinib, ipilimumab, ipratropium bromide / salbutamo oxal, ixazomib, Kanuma, lanreotide acetate, lenalidomide, lenalidomide, lenvatinib mesylate, letrozole, levothyroxine, lidocaine, linezolid, liraglutide, examfetamine, LN-144, lorlatinib, memantine, methylphenidate, metoprolol, mekinist, melicitabine / rilpivirine / tenofovir, modafinil, mometasone, misidac-C, necitumumab, neratinib, nilotinib, niraparib, nivolumab, ofatumumab, obinutuzumab, ora Paribu, olmesartan, olmesartan / hydrochlorothiazide, omalizumab, omega-3 fatty acid ethyl ester, oncoline, oseltamivir, osimertinib, oxycodone, palbociclib, palivizumab, panitumumab, panobinostat, pazopanib, pembrolizumab, PD-1 antibody, PD-L1 antibody, pemetrexed, pertuzumab, pneumococcal conjugate vaccine, pomalidomide, poziotinib, pregabalin, proskavax, propranolol, quetiapine, rabeprazole, radium chloride M223, raloxifene, raltegravir, ramucirumab, ranibizumab, regorafenib, rituximab, rivaroxaban, romidepsin, rosuvastatin, ruxolitinib phosphate, salbutamol, savolitinib, semaglutide, sildenafil, siltuximab, sipulcel-T, sitagliptin, sitagliptin / metformin, solifenacin, solanezumab, sonidegib, sorafenib, sunitinib, tacrolimus, taclimus, tadalafil, tamoxifen, tafinlar, talimogene laherparepvec, talazoparib, telaporebrib, IR / emtricitabine, tenofovirDisoproxil fumarate, testosterone gel, thalidomide, TICE BCG, tiotropium bromide, tisagencleucel, toremifene, trametinib, trastuzumab, trastuzumab deruxtecan, trabectedin (ecteinascidin 743), trametinib, tremelimumab, trifluridine / tipiracil, tretinoin, ustekinumab, valsartan, veliparib, vandetanib, vemurafenib, venetoclax, vorinostat, dibuaflibercept, zostavax, and analogs, derivatives, pharma- ceutically acceptable salts, carriers, diluents or excipients thereof, or combinations thereof.
Citation Information
Patent Citations
Preparation process of compounds useful as SGLT2 inhibitors
JP2014510776A
Symmetrical hyperbranched silicone-modified polymerizable compound and preparation method modularizing same
WO2014141578A1
Process for preparing antibody-drug conjugates with improved homogeneity
WO2020164561A1
Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system
US20100184135A1
Aldehyde-Tagged Protein-Based Drug Carriers and Methods of Use
US20100210543A1
